82_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 1_CD Presentation_NN of_IN the_DT financial_JJ statements_NNS Additional_JJ information_NN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN US_NNP generally_RB accepted_VBD accounting_NN principles_NNS US_NNP GAAP_NNP is_VBZ included_VBN Description_NN of_IN business_NN in_IN the_DT Notes_NNS to_TO the_DT Financial_NNP statements_NNS ._.
In_IN Note_NN 37_CD a_DT statement_NN of_IN GlaxoSmithKline_NNP is_VBZ a_DT major_JJ global_JJ healthcare_NN group_NN which_WDT is_VBZ differences_NNS ,_, and_CC a_DT reconciliation_NN of_IN net_JJ income_NN and_CC shareholders_NNS engaged_VBN in_IN the_DT creation_NN and_CC discovery_NN ,_, development_NN ,_, manufacture_NN equity_NN ,_, between_IN UK_NNP and_CC US_NNP GAAP_NNP are_VBP provided_VBN ,_, and_CC the_DT principal_NN and_CC marketing_NN of_IN pharmaceutical_JJ products_NNS including_VBG vaccines_NNS ,_, Financial_NNP statements_NNS are_VBP presented_VBN in_IN accordance_NN with_IN US_NNP GAAP_NNP over-the-counter_JJ OTC_NNP medicines_NNS and_CC health-related_JJ consumer_NN and_CC in_IN a_DT US_NNP GAAP_NNP format_NN ._.
GlaxoSmithKlines_NNS principal_JJ pharmaceutical_JJ products_NNS include_VBP medicines_NNS in_IN the_DT following_VBG therapeutic_JJ areas_NNS :_: Merger_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP plc_NN central_JJ nervous_JJ system_NN ,_, respiratory_JJ ,_, anti-virals_NNS ,_, anti-bacterials_NNS ,_, GlaxoSmithKline_NNP plc_NN acquired_VBD Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP metabolic_JJ and_CC gastro-intestinal_JJ ,_, vaccines_NNS ,_, oncology_NN and_CC emesis_NN ,_, Beecham_NNP plc_NN by_IN way_NN of_IN a_DT scheme_NN of_IN arrangement_NN for_IN the_DT merger_NN of_IN cardiovascular_JJ and_CC arthritis_NNS ._.
the_DT two_CD companies_NNS which_WDT became_VBD effective_JJ on_IN 27th_JJ December_NNP 2000_CD ._.
Financial_JJ period_NN Under_IN UK_NNP GAAP_NNP the_DT Financial_NNP statements_NNS of_IN GlaxoSmithKline_NNP plc_NN These_DT Financial_NNP statements_NNS cover_VBP the_DT financial_JJ year_NN from_IN are_VBP prepared_VBN as_IN a_DT merger_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP 1st_CD January_NNP to_TO 31st_VB December_NNP 2002_CD ,_, with_IN comparative_JJ gures_NNS for_IN Beecham_NNP plc._NN ._.
The_DT comparative_JJ gures_NNS for_IN the_DT year_NN to_TO the_DT financial_JJ years_NNS from_IN 1st_CD January_NNP to_TO 31st_VB December_NNP 2001_CD and_CC 31st_CD December_NNP 2000_CD therefore_RB include_VBP the_DT results_NNS of_IN Glaxo_NNP 1st_CD January_NNP to_TO 31st_VB December_NNP 2000_CD ._.
Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP plc._NN ._.
Under_IN US_NNP GAAP_NNP the_DT Financial_NNP statements_NNS of_IN GlaxoSmithKline_NNP plc_NNP Composition_NNP of_IN the_DT Group_NNP are_VBP prepared_JJ as_IN an_DT acquisition_NN of_IN SmithKline_NNP Beecham_NNP plc_NN by_IN A_DT list_NN of_IN the_DT subsidiary_NN and_CC associated_VBN undertakings_NNS which_WDT ,_, in_IN the_DT Glaxo_NNP Wellcome_NNP plc_NN at_IN 27th_JJ December_NNP 2000_CD ._.
Accordingly_RB the_DT opinion_NN of_IN the_DT Directors_NNS ,_, principally_RB affected_VBD the_DT amount_NN of_IN profit_NN results_NNS of_IN SmithKline_NNP Beecham_NNP for_IN all_DT periods_NNS prior_RB to_TO that_DT date_NN are_VBP or_CC the_DT net_JJ assets_NNS of_IN the_DT Group_NNP is_VBZ given_VBN in_IN Principal_NN Group_NNP not_RB consolidated_JJ ._.
Presentation_NN of_IN statement_NN of_IN profit_NN and_CC loss_NN Composition_NN of_IN financial_JJ statements_NNS A_DT columnar_NN presentation_NN has_VBZ been_VBN adopted_VBN in_IN the_DT statement_NN of_IN The_DT consolidated_JJ financial_JJ statements_NNS are_VBP drawn_VBN up_RP in_IN accordance_NN profit_NN and_CC loss_NN in_IN order_NN to_TO illustrate_VB underlying_VBG business_NN performance_NN with_IN UK_NNP generally_RB accepted_VBD accounting_NN principles_NNS UK_NNP GAAP_NNP and_CC as_IN this_DT is_VBZ the_DT primary_JJ measure_NN used_VBN by_IN management_NN ._.
For_IN this_DT with_IN UK_NNP accounting_NN presentation_NN ._.
purpose_NN certain_JJ items_NNS are_VBP identied_JJ separately_RB and_CC are_VBP excluded_VBN The_DT Financial_NNP statements_NNS comprise_VBP :_: from_IN business_NN performance_NN ._.
These_DT comprise_VBP :_: merger_NN and_CC integration_NN items_NNS ,_, including_VBG product_NN divestments_NNS :_: costs_NNS relating_VBG to_TO previously_RB Consolidated_NNP statement_NN of_IN profit_NN and_CC loss_NN announced_VBD manufacturing_NN and_CC other_JJ restructuring_NN ,_, and_CC the_DT effect_NN Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS of_IN disposals_NNS of_IN subsidiaries_NNS ._.
Consolidated_NNP statement_NN of_IN cash_NN ow_NN Consolidated_NNP balance_NN sheet_NN Trading_NN profit_NN reects_VBZ sales_NNS less_RBR :_: cost_NN of_IN sales_NNS ,_, comprising_VBG costs_NNS Reconciliation_NNP of_IN movements_NNS in_IN equity_NN shareholders_NNS funds_NNS of_IN manufacture_NN and_CC external_JJ royalties_NNS :_: selling_NN ,_, general_JJ and_CC Company_NN balance_NN sheet_NN administrative_JJ expenditure_NN ,_, comprising_VBG the_DT costs_NNS of_IN selling_NN ,_, Notes_NNP to_TO the_DT financial_JJ statements_NNS ._.
distribution_NN and_CC medical_JJ support_NN of_IN currently_RB marketed_VBN products_NNS and_CC the_DT costs_NNS of_IN administration_NN :_: and_CC the_DT costs_NNS of_IN research_NN and_CC As_IN permitted_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT development_NN to_TO create_VB future_JJ products_NNS for_IN sale_NN ._.
profit_NN and_CC loss_NN account_NN of_IN the_DT company_NN is_VBZ not_RB presented_VBN ._.
The_DT consolidated_JJ statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Accounting_NNP convention_NN includes_VBZ :_: The_DT Financial_NNP statements_NNS have_VBP been_VBN prepared_VBN using_VBG the_DT historical_JJ cost_NN convention_NN ._.
the_DT realized_VBN profit_NN attributable_JJ to_TO shareholders_NNS as_IN reected_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN Accounting_NN standards_NNS the_DT unrealised_JJ gain_NN or_CC loss_NN in_IN the_DT value_NN of_IN the_DT Groups_NNS overseas_RB The_DT Financial_NNP statements_NNS comply_VBP with_IN all_DT applicable_JJ UK_NNP accounting_NN net_JJ assets_NNS ,_, less_JJR related_JJ foreign_JJ currency_NN borrowings_NNS ,_, attributable_JJ standards_NNS ._.
to_TO currency_NN movements_NNS over_IN the_DT period_NN ._.
The_DT reconciliation_NN of_IN movements_NNS in_IN equity_NN shareholders_NNS funds_NNS Accounting_NNP principles_NNS and_CC policies_NNS comprises_VBZ the_DT items_NNS contributing_VBG to_TO the_DT increase_NN or_CC decrease_NN over_IN The_DT preparation_NN of_IN Financial_NNP statements_NNS in_IN conformity_NN with_IN generally_RB the_DT period_NN in_IN shareholders_NNS funds_NNS ._.
Such_JJ items_NNS include_VBP :_: accepted_VBN accounting_NN principles_NNS requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN the_DT total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT period_NN assets_NNS and_CC liabilities_NNS and_CC disclosure_NN of_IN contingent_JJ assets_NNS and_CC dividends_NNS paid_VBN and_CC proposed_VBN liabilities_NNS at_IN the_DT date_NN of_IN the_DT Financial_NNP statements_NNS and_CC the_DT reported_VBN the_DT proceeds_NNS of_IN shares_NNS issued_VBN during_IN the_DT period_NN amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
the_DT cost_NN of_IN shares_NNS purchased_VBN for_IN cancellation_NN under_IN the_DT Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
share_NN buy-back_NN program_NN changes_NNS to_TO goodwill_NN ,_, arising_VBG on_IN acquisitions_NNS prior_RB to_TO The_DT Financial_NNP statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN 1st_CD January_NNP 1998_CD ,_, which_WDT has_VBZ been_VBN set_VBN directly_RB against_IN reserves_NNS ._.
the_DT companys_NNS accounting_VBG policies_NNS approved_VBN by_IN the_DT Board_NNP and_CC described_VBN in_IN Note_NN 2_CD ._.
The_DT company_NN has_VBZ implemented_VBN one_CD new_JJ Financial_NNP Reporting_NNP Standard_NNP in_IN 2002_CD as_IN described_VBN in_IN Note_NN 3_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 83_CD 2_CD Accounting_NN policies_NNS Foreign_JJ currency_NN transactions_NNS Foreign_JJ currency_NN transactions_NNS by_IN Group_NNP companies_NNS are_VBP booked_VBN Consolidation_NN in_IN local_JJ currency_NN at_IN the_DT exchange_NN rate_NN ruling_NN on_IN the_DT date_NN of_IN The_DT consolidated_JJ Financial_NNP statements_NNS include_VBP :_: transaction_NN ,_, or_CC at_IN the_DT forward_JJ rate_NN if_IN hedged_VBN by_IN a_DT forward_RB the_DT assets_NNS and_CC liabilities_NNS ,_, and_CC the_DT results_NNS and_CC cash_NN ow_NN ,_, of_IN the_DT exchange_NN contract_NN ._.
Foreign_JJ currency_NN assets_NNS and_CC liabilities_NNS are_VBP company_NN and_CC its_PRP$ subsidiary_NN undertakings_NNS ,_, including_VBG Employee_NNP translated_VBN into_IN local_JJ currency_NN at_IN rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT Share_NN Ownership_NN Trusts_VBZ ESOTs_NNS balance_NN sheet_NN date_NN ,_, or_CC at_IN the_DT forward_JJ rate_NN ._.
Exchange_NNP differences_NNS the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS and_CC results_NNS of_IN joint_JJ ventures_NNS are_VBP included_VBN in_IN trading_NN profit_NN ._.
Revenue_NN The_DT Financial_NNP statements_NNS of_IN undertakings_NNS consolidated_VBN are_VBP made_VBN Revenue_NN is_VBZ recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN when_WRB goods_NNS up_IN to_TO 31st_CD December_NNP ._.
or_CC services_NNS are_VBP supplied_VBN to_TO external_JJ customers_NNS against_IN orders_NNS Undertakings_NNS in_IN which_WDT the_DT Group_NNP has_VBZ a_DT material_NN interest_NN are_VBP received_VBN ._.
Turnover_NN represents_VBZ the_DT net_JJ invoice_NN value_NN ,_, after_IN the_DT accounted_VBN for_IN as_IN subsidiaries_NNS where_WRB the_DT Group_NNP exercises_VBZ dominant_JJ deduction_NN of_IN discounts_NNS given_VBN at_IN the_DT point_NN of_IN sale_NN ,_, of_IN products_NNS inuence_NN ,_, as_IN joint_JJ ventures_NNS where_WRB the_DT Group_NNP exercises_VBZ joint_JJ control_NN despatched_VBD to_TO ,_, or_CC available_JJ for_IN collection_NN by_IN ,_, customers_NNS ,_, less_JJR and_CC as_IN associates_NNS where_WRB the_DT Group_NNP can_MD exercise_VB significant_JJ accruals_NNS for_IN estimated_JJ future_JJ rebates_NNS and_CC returns_NNS ._.
ESOTs_NNS are_VBP accounted_VBN for_IN as_IN subsidiaries_NNS on_IN the_DT grounds_NNS and_CC other_JJ sales_NNS taxes_NNS are_VBP excluded_VBN from_IN revenue_NN ._.
that_IN the_DT Group_NNP has_VBZ fide_NN facto_JJ control_NN ._.
Expenditure_NN Interests_NNS acquired_VBN in_IN undertakings_NNS are_VBP consolidated_VBN from_IN the_DT Expenditure_NN is_VBZ recognized_VBN in_IN respect_NN of_IN goods_NNS and_CC services_NNS received_VBN effective_JJ date_NN of_IN acquisition_NN and_CC interests_NNS sold_VBN are_VBP consolidated_VBN when_WRB supplied_VBN in_IN accordance_NN with_IN contractual_JJ terms_NNS ._.
Provision_NNP is_VBZ up_RB to_TO the_DT date_NN of_IN disposal_NN ._.
made_VBN when_WRB an_DT obligation_NN exists_VBZ for_IN a_DT future_JJ liability_NN in_IN respect_NN of_IN a_DT Transactions_NNS and_CC balances_NNS between_IN subsidiary_NN undertakings_NNS are_VBP past_JJ event_NN and_CC where_WRB the_DT amount_NN of_IN the_DT obligation_NN can_MD be_VB reliably_RB eliminated_VBN :_: no_DT profit_NN is_VBZ taken_VBN on_IN sales_NNS between_IN subsidiary_NN estimated_VBN ._.
Advertising_NNP expenditure_NN is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN undertakings_NNS or_CC sales_NNS to_TO joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS account_VBP as_IN incurred_VBN ._.
Shipment_NN costs_NNS on_IN inter-company_JJ transfers_NNS are_VBP until_IN the_DT products_NNS are_VBP sold_VBN to_TO customers_NNS outside_IN the_DT Group_NNP ._.
charged_VBN to_TO cost_NN of_IN sales_NNS :_: distribution_NN costs_NNS on_IN sales_NNS to_TO customers_NNS are_VBP included_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenditure_NN ._.
Goodwill_NN arising_VBG on_IN the_DT acquisition_NN of_IN interests_NNS in_IN subsidiary_NN Restructuring_NN costs_NNS are_VBP recognized_VBN in_IN respect_NN of_IN the_DT direct_JJ undertakings_NNS ,_, joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS ,_, expenditures_NNS of_IN a_DT business_NN reorganisation_NN where_WRB the_DT plans_NNS are_VBP representing_VBG the_DT excess_NN of_IN the_DT purchase_NN consideration_NN over_IN the_DT sufciently_RB detailed_JJ and_CC well_RB advanced_VBD ,_, and_CC where_WRB appropriate_JJ Groups_NNS share_NN of_IN the_DT separable_JJ net_JJ assets_NNS acquired_VBN ,_, is_VBZ capitalized_VBN communication_NN to_TO those_DT affected_VBN has_VBZ been_VBN undertaken_VBN at_IN the_DT as_IN a_DT separate_JJ item_NN in_IN the_DT case_NN of_IN subsidiary_NN undertakings_NNS and_CC as_IN balance_NN sheet_NN date_NN ._.
part_NN of_IN the_DT cost_NN of_IN investment_NN in_IN the_DT case_NN of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS ._.
Goodwill_NN is_VBZ denominated_VBN in_IN the_DT currency_NN Research_NN and_CC development_NN in_IN which_WDT the_DT acquisition_NN is_VBZ made_VBN and_CC nanced_VBN ._.
In_IN the_DT case_NN of_IN Research_NNP and_CC development_NN expenditure_NN is_VBZ charged_VBN to_TO the_DT profit_NN acquisitions_NNS prior_RB to_TO 1998_CD ,_, goodwill_NN was_VBD written_VBN off_RP against_IN and_CC loss_NN account_NN in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
Tangible_JJ reserves_NNS :_: on_IN a_DT subsequent_JJ disposal_NN of_IN assets_NNS from_IN such_JJ acquisitions_NNS ,_, xed_VBD assets_NNS used_VBN for_IN research_NN and_CC development_NN are_VBP depreciated_VBN in_IN any_DT related_JJ goodwill_NN is_VBZ removed_VBN from_IN consolidated_JJ reserves_NNS and_CC accordance_NN with_IN the_DT Groups_NNS policy_NN ._.
charged_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
The_DT Groups_NNS interests_NNS in_IN its_PRP$ joint_JJ ventures_NNS are_VBP accounted_VBN for_IN using_VBG Environmental_JJ expenditure_NN the_DT gross_JJ equity_NN method_NN ._.
The_DT Groups_NNS interests_NNS in_IN its_PRP$ associated_VBN Environmental_NNP expenditure_NN related_VBN to_TO existing_VBG conditions_NNS resulting_VBG undertakings_NNS are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ._.
from_IN past_JJ or_CC current_JJ operations_NNS and_CC from_IN which_WDT no_DT current_JJ or_CC future_JJ benefit_NN is_VBZ discernible_JJ is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN Deferred_VBN taxation_NN relief_NN on_IN unrealised_JJ intra-Group_JJ profit_NN is_VBZ account_NN ._.
The_DT Group_NNP determines_VBZ its_PRP$ liability_NN on_IN a_DT site-by-site_JJ basis_NN accounted_VBD for_IN only_RB to_TO the_DT extent_NN that_IN it_PRP is_VBZ considered_VBN recoverable_JJ ._.
and_CC records_NNS a_DT liability_NN at_IN the_DT time_NN when_WRB it_PRP is_VBZ probable_JJ and_CC can_MD be_VB Assets_NNS and_CC liabilities_NNS of_IN overseas_JJ subsidiary_NN and_CC associated_VBN reasonably_RB estimated_VBN ._.
This_DT liability_NN includes_VBZ the_DT Groups_NNS own_VBP portion_NN undertakings_NNS and_CC joint_JJ ventures_NNS including_VBG related_JJ goodwill_NN ,_, are_VBP of_IN the_DT costs_NNS and_CC also_RB a_DT portion_NN of_IN other_JJ potentially_RB responsible_JJ translated_VBN into_IN sterling_NN at_IN rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT balance_NN parties_NNS costs_NNS when_WRB it_PRP is_VBZ probable_JJ that_IN they_PRP will_MD not_RB be_VB able_JJ to_TO satisfy_VB sheet_NN date_NN ._.
The_DT results_NNS and_CC cash_NN ows_NNS of_IN overseas_JJ subsidiary_NN and_CC their_PRP$ respective_JJ shares_NNS of_IN the_DT clean-up_JJ obligation_NN ._.
When_WRB recoveries_NNS associated_VBN undertakings_NNS and_CC joint_JJ ventures_NNS are_VBP translated_VBN into_IN of_IN reimbursements_NNS are_VBP virtually_RB certain_JJ they_PRP are_VBP recorded_VBN as_IN assets_NNS ._.
sterling_NN using_VBG average_JJ rates_NNS of_IN exchange_NN ._.
Exchange_NNP adjustments_NNS arising_VBG when_WRB the_DT opening_NN net_JJ assets_NNS and_CC the_DT profits_NNS for_IN the_DT year_NN Legal_NNP and_CC other_JJ disputes_NNS retained_VBN by_IN overseas_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS and_CC Provision_NNP is_VBZ made_VBN for_IN the_DT anticipated_JJ settlement_NN costs_NNS and_CC legal_JJ and_CC joint_JJ ventures_NNS are_VBP translated_VBN into_IN sterling_NN ,_, less_JJR exchange_NN differences_NNS other_JJ expenses_NNS associated_VBN with_IN claims_NNS received_VBN and_CC legal_JJ and_CC other_JJ arising_VBG on_IN related_VBN foreign_JJ currency_NN borrowings_NNS ,_, are_VBP taken_VBN directly_RB disputes_NNS against_IN the_DT Group_NNP where_WRB a_DT reasonable_JJ estimate_NN can_MD be_VB to_TO reserves_NNS and_CC reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN made_VBN of_IN the_DT likely_JJ outcome_NN of_IN the_DT dispute_NN ._.
No_DT provision_NN is_VBZ made_VBN for_IN gains_NNS and_CC losses_NNS ._.
unasserted_JJ claims_NNS or_CC where_WRB an_DT obligation_NN exists_VBZ under_IN a_DT dispute_NN but_CC it_PRP is_VBZ not_RB possible_JJ to_TO make_VB a_DT reasonable_JJ estimate_NN ._.
Costs_NNS associated_VBN In_IN translating_VBG into_IN sterling_NN ,_, assets_NNS ,_, liabilities_NNS ,_, results_NNS and_CC cash_NN ows_NNS with_IN claims_NNS made_VBN by_IN the_DT Group_NNP against_IN third_JJ parties_NNS are_VBP charged_VBN to_TO of_IN overseas_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS and_CC joint_JJ ventures_NNS the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP are_VBP incurred_VBN ._.
reported_VBN in_IN currencies_NNS of_IN hyper-inationary_JJ economies_NNS ,_, adjustments_NNS are_VBP made_VBN to_TO reect_VB current_JJ price_NN levels_NNS ._.
Any_DT loss_NN on_IN net_JJ monetary_JJ assets_NNS is_VBZ charged_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
84_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 2_CD Accounting_NN policies_NNS continued_VBD Tangible_JJ xed_JJ assets_NNS Tangible_JJ xed_VBD assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provisions_NNS for_IN Pensions_NNS and_CC post-retirement_JJ benets_NNS depreciation_NN or_CC impairment_NN ._.
The_DT costs_NNS of_IN acquiring_VBG and_CC developing_VBG The_DT cost_NN of_IN providing_VBG pensions_NNS and_CC other_JJ employee_NN post-retirement_JJ computer_NN software_NN for_IN internal_JJ use_NN and_CC internet_NN sites_NNS for_IN external_JJ benets_NNS is_VBZ charged_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN on_IN a_DT use_NN are_VBP capitalized_VBN as_IN a_DT tangible_JJ xed_JJ asset_NN where_WRB the_DT software_NN or_CC systematic_JJ and_CC rational_JJ basis_NN ,_, based_VBN on_IN actuarial_JJ assumptions_NNS ,_, over_IN site_NN supports_VBZ a_DT significant_JJ business_NN system_NN and_CC the_DT expenditure_NN the_DT period_NN during_IN which_WDT benefit_NN is_VBZ derived_VBN from_IN employees_NNS services_NNS ._.
leads_NNS to_TO the_DT creation_NN of_IN a_DT durable_JJ asset_NN ._.
Any_DT difference_NN between_IN this_DT charge_NN and_CC the_DT contributions_NNS paid_VBN is_VBZ included_VBN as_IN an_DT asset_NN or_CC liability_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN ._.
Depreciation_NN is_VBZ calculated_VBN to_TO write_VB off_RP the_DT cost_NN of_IN tangible_JJ xed_JJ assets_NNS ,_, excluding_VBG freehold_JJ land_NN ,_, in_IN equal_JJ annual_JJ instalments_NNS over_IN Employee_NN share_NN plans_VBZ their_PRP$ expected_VBN useful_JJ lives_NNS ._.
The_DT normal_JJ expected_VBN useful_JJ lives_NNS of_IN the_DT Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO employees_NNS under_IN major_JJ categories_NNS of_IN tangible_JJ xed_JJ assets_NNS are_VBP reviewed_VBN annually_RB share_NN option_NN and_CC share_NN award_NN schemes_NNS ._.
In_IN respect_NN of_IN award_NN and_CC are_VBP :_: schemes_NNS and_CC certain_JJ share_NN option_NN grants_NNS ,_, the_DT company_NN provides_VBZ Freehold_NNP buildings_NNS 20_CD to_TO 50_CD years_NNS finance_NN to_TO ESOTs_NNS to_TO purchase_VB company_NN shares_NNS on_IN the_DT open_JJ market_NN Leasehold_NNP land_NN and_CC The_DT shorter_JJR of_IN lease_NN term_NN and_CC 50_CD to_TO meet_VB the_DT companys_NNS obligation_NN to_TO provide_VB shares_NNS when_WRB buildings_NNS years_NNS employees_NNS exercise_VBP their_PRP$ option_NN or_CC award_NN :_: any_DT excess_NN of_IN the_DT Plant_NN and_CC machinery_NN 10_CD to_TO 20_CD years_NNS purchase_NN price_NN of_IN the_DT shares_NNS above_IN the_DT exercise_NN price_NN of_IN the_DT options_NNS Fixtures_NNS and_CC equipment_NN 3_CD to_TO 10_CD years_NNS and_CC awards_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT ERP_NNP systems_NNS software_NN 7_CD years_NNS periods_NNS of_IN service_NN in_IN respect_NN of_IN which_WDT the_DT options_NNS and_CC awards_NNS are_VBP Other_JJ computer_NN software_NN 3_CD to_TO 5_CD years_NNS granted_VBN ._.
In_IN respect_NN of_IN other_JJ share_NN option_NN grants_NNS ,_, share_NN options_NNS when_WRB exercised_VBN are_VBP accounted_VBN for_IN as_IN share_NN issues_NNS at_IN exercise_NN price_NN ._.
ERP_NNP systems_NNS software_NN generally_RB involves_VBZ significant_JJ customisation_NN Additional_JJ employer_NN costs_NNS in_IN respect_NN of_IN options_NNS and_CC awards_NNS are_VBP prior_RB to_TO implementation_NN and_CC is_VBZ expected_VBN to_TO have_VB a_DT useful_JJ economic_JJ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT periods_NNS of_IN service_NN ._.
life_NN of_IN seven_CD years_NNS ,_, rather_RB than_IN the_DT maximum_JJ five_CD years_NNS of_IN other_JJ Costs_NNS of_IN running_VBG the_DT ESOTs_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN computer_NN software_NN ._.
Shares_NNS held_VBN by_IN the_DT ESOTs_NNS are_VBP accounted_VBN for_IN as_IN xed_JJ asset_NN On_IN disposal_NN of_IN a_DT tangible_JJ xed_JJ asset_NN ,_, the_DT cost_NN and_CC related_JJ investments_NNS held_VBN at_IN cost_NN less_JJR a_DT provision_NN to_TO recognize_VB any_DT shortfall_NN accumulated_VBN depreciation_NN are_VBP removed_VBN from_IN the_DT financial_JJ in_IN the_DT proceeds_NNS receivable_NN from_IN employees_NNS on_IN exercise_NN unless_IN there_EX statements_NNS and_CC the_DT net_JJ amount_NN ,_, less_JJR any_DT proceeds_NNS ,_, is_VBZ taken_VBN to_TO is_VBZ deemed_VBN to_TO be_VB a_DT permanent_JJ impairment_NN in_IN value_NN ._.
the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
Goodwill_NNP Leases_NNP Goodwill_NNP is_VBZ stated_VBN at_IN cost_NN less_JJR a_DT provision_NN for_IN amortisation_NN ._.
Leasing_NNP agreements_NNS which_WDT transfer_VBP to_TO the_DT Group_NNP substantially_RB all_DT Amortisation_NNP is_VBZ calculated_VBN to_TO write_VB off_RP the_DT cost_NN in_IN equal_JJ annual_JJ the_DT benets_NNS and_CC risks_NNS of_IN ownership_NN of_IN an_DT asset_NN are_VBP treated_VBN as_IN instalments_NNS over_IN its_PRP$ expected_VBN useful_JJ life_NN ._.
The_DT useful_JJ life_NN is_VBZ not_RB finance_VB leases_NNS ,_, as_IN if_IN the_DT asset_NN had_VBD been_VBN purchased_VBN outright_RB ._.
The_DT normally_RB expected_VBN to_TO exceed_VB 20_CD years_NNS ._.
assets_NNS are_VBP included_VBN in_IN tangible_JJ xed_JJ assets_NNS and_CC the_DT capital_NN element_NN of_IN the_DT leasing_NN commitments_NNS is_VBZ shown_VBN as_IN obligations_NNS under_IN finance_NN Intangible_NNP xed_VBD assets_NNS leases_NNS ._.
Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP depreciated_VBN over_IN the_DT Intangible_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR a_DT provision_NN for_IN amortisation_NN ._.
shorter_JJR of_IN the_DT lease_NN terms_NNS and_CC the_DT useful_JJ lives_NNS of_IN the_DT assets_NNS ._.
The_DT Acquired_VBN licences_NNS ,_, patents_NNS ,_, know-how_NN and_CC marketing_NN rights_NNS are_VBP interest_NN element_NN of_IN the_DT lease_NN rental_NN is_VBZ charged_VBN against_IN profit_NN ._.
amortised_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS in_IN equal_JJ instalments_NNS ,_, All_DT other_JJ leases_NNS are_VBP operating_VBG leases_NNS and_CC the_DT annual_JJ rentals_NNS are_VBP but_CC no_DT longer_JJR than_IN 15_CD years_NNS ._.
Items_NNS capitalized_VBN are_VBP restricted_VBN to_TO charged_VBN against_IN profit_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ._.
those_DT related_VBN to_TO specic_JJ compounds_NNS or_CC products_NNS which_WDT are_VBP being_VBG developed_VBN for_IN commercial_JJ applications_NNS ._.
The_DT estimated_VBN useful_JJ lives_NNS Impairment_NN of_IN xed_JJ assets_NNS for_IN determining_VBG the_DT amortisation_NN charge_NN are_VBP reviewed_VBN annually_RB ,_, The_DT carrying_VBG values_NNS of_IN xed_JJ assets_NNS are_VBP reviewed_VBN for_IN impairment_NN and_CC take_VB into_IN account_NN the_DT estimated_VBN time_NN it_PRP takes_VBZ to_TO bring_VB the_DT when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT assets_NNS might_MD be_VB impaired_VBN ._.
compounds_NNS or_CC products_NNS to_TO market_NN as_IN marketable_JJ products_NNS ._.
Any_DT provision_NN for_IN impairment_NN is_VBZ charged_VBN against_IN profit_NN in_IN the_DT year_NN Any_DT development_NN costs_NNS which_WDT are_VBP incurred_VBN by_IN the_DT Group_NNP and_CC concerned_JJ ._.
First_JJ year_NN impairment_NN reviews_NNS are_VBP conducted_VBN for_IN are_VBP associated_VBN with_IN an_DT acquired_VBN licence_NN ,_, patent_NN ,_, know-how_NN acquired_VBD goodwill_NN and_CC intangible_JJ assets_NNS ._.
Certain_JJ intangibles_NNS are_VBP or_CC marketing_NN rights_NNS are_VBP written_VBN off_RP to_TO the_DT profit_NN and_CC loss_NN account_NN considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN and_CC are_VBP therefore_RB not_RB when_WRB incurred_VBN ._.
Such_JJ intangibles_NNS are_VBP subject_JJ to_TO annual_JJ impairment_NN tests_NNS ._.
Impairment_NN is_VBZ determined_VBN by_IN reference_NN to_TO the_DT higher_JJR of_IN net_JJ Brands_NNS are_VBP valued_VBN independently_RB as_IN part_NN of_IN the_DT fair_JJ value_NN of_IN realisable_JJ value_NN and_CC value_NN in_IN use_NN ,_, which_WDT is_VBZ measured_VBN by_IN reference_NN businesses_NNS acquired_VBN from_IN third_JJ parties_NNS where_WRB the_DT brand_NN has_VBZ a_DT value_NN to_TO discounted_JJ future_JJ cash_NN ows_NNS ._.
The_DT value_NN of_IN shares_NNS held_VBN by_IN the_DT which_WDT is_VBZ substantial_JJ and_CC long-term_JJ and_CC where_WRB the_DT brands_NNS can_MD be_VB ESOTs_NNS is_VBZ reviewed_VBN quarterly_JJ to_TO determine_VB if_IN there_EX is_VBZ any_DT permanent_JJ sold_VBN separately_RB from_IN the_DT rest_NN of_IN the_DT businesses_NNS acquired_VBN ._.
are_VBP amortised_VBN over_IN the_DT estimated_VBN useful_JJ lives_NNS but_CC no_DT longer_JJR than_IN 20_CD years_NNS ,_, except_IN where_WRB the_DT end_NN of_IN the_DT useful_JJ economic_JJ life_NN of_IN the_DT Investments_NNPS in_IN joint_JJ ventures_NNS and_CC associates_NNS brand_NN can_MD not_RB be_VB foreseen_VBN ._.
Investments_NNP in_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS are_VBP Prior_RB to_TO 1998_CD ,_, acquired_VBN minor_JJ brands_NNS and_CC similar_JJ intangibles_NNS were_VBD carried_VBN in_IN the_DT consolidated_JJ balance_NN sheet_NN at_IN the_DT Groups_NNS share_VBP eliminated_VBN in_IN the_DT Group_NNP balance_NN sheet_NN against_IN reserves_NNS in_IN the_DT year_NN of_IN their_PRP$ net_JJ assets_NNS at_IN date_NN of_IN acquisition_NN and_CC of_IN their_PRP$ postof_JJ acquisition_NN ._.
acquisition_NN retained_VBD profits_NNS or_CC losses_NNS together_RB with_IN any_DT goodwill_NN arising_VBG on_IN the_DT acquisition_NN ,_, net_NN of_IN amortisation_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 85_CD 2_CD Accounting_NN policies_NNS continued_VBD Debt_NN instruments_NNS Debt_NN instruments_NNS are_VBP stated_VBN at_IN the_DT amount_NN of_IN net_JJ proceeds_NNS Stocks_NNS adjusted_VBN to_TO amortise_VB the_DT issue_NN cost_NN of_IN debt_NN evenly_RB over_IN the_DT term_NN Stocks_NNS are_VBP included_VBN in_IN the_DT financial_JJ statements_NNS at_IN the_DT lower_JJR of_IN cost_NN of_IN the_DT debt_NN ._.
including_VBG manufacturing_NN overheads_NNS ,_, where_WRB appropriate_JJ and_CC net_JJ realisable_JJ value_NN ._.
Cost_NN is_VBZ generally_RB determined_VBN on_IN a_DT first_JJ in_IN ,_, first_RB out_IN 3_CD New_JJ accounting_NN policies_NNS and_CC future_JJ requirements_NNS basis_NN ._.
The_DT Group_NNP has_VBZ implemented_VBN Financial_NNP Reporting_NNP Standard_NNP 19_CD Taxation_NNP Deferred_NNP Tax_NNP in_IN 2002_CD which_WDT requires_VBZ deferred_VBN tax_NN to_TO be_VB accounted_VBN The_DT Group_NNP accounts_NNS for_IN taxation_NN which_WDT is_VBZ deferred_VBN or_CC accelerated_VBN for_IN on_IN a_DT full_JJ provision_NN basis_NN ,_, rather_RB than_IN a_DT partial_JJ provision_NN basis_NN as_IN by_IN reason_NN of_IN timing_NN differences_NNS which_WDT have_VBP originated_VBN but_CC not_RB before_RB ._.
Comparative_JJ information_NN has_VBZ been_VBN restated_VBN as_RB necessary_JJ ._.
reversed_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Deferred_JJ tax_NN assets_NNS are_VBP only_RB The_DT effect_NN in_IN 2001_CD is_VBZ to_TO increase_VB the_DT business_NN performance_NN tax_NN recognized_VBN to_TO the_DT extent_NN that_IN they_PRP are_VBP considered_VBN recoverable_JJ charge_NN by_IN 8_CD million_CD 2000_CD 43_CD million_CD and_CC the_DT overall_JJ tax_NN charge_NN against_IN future_JJ taxable_JJ profits_NNS ._.
Deferred_JJ tax_NN on_IN the_DT retained_VBN earnings_NNS by_IN 6_CD million_CD 2000_CD 48_CD million_CD ._.
The_DT net_JJ deferred_VBN tax_NN asset_NN at_IN of_IN overseas_JJ subsidiaries_NNS is_VBZ only_RB provided_VBN when_WRB there_EX is_VBZ a_DT binding_JJ 31st_CD December_NNP 2001_CD has_VBZ been_VBN reduced_VBN by_IN 127_CD million_CD ._.
commitment_NN to_TO distribute_VB past_JJ earnings_NNS in_IN future_NN periods_NNS ._.
In_IN June_NNP 2002_CD ,_, the_DT Council_NNP of_IN the_DT European_NNP Union_NNP adopted_VBD a_DT Deferred_JJ tax_NN is_VBZ measured_VBN at_IN the_DT average_JJ tax_NN rates_NNS that_WDT are_VBP expected_VBN Regulation_NN requiring_VBG listed_VBN companies_NNS in_IN its_PRP$ Member_NNP States_NNPS to_TO to_TO apply_VB in_IN the_DT periods_NNS in_IN which_WDT the_DT timing_NN differences_NNS are_VBP expected_VBN prepare_VBP their_PRP$ consolidated_JJ financial_JJ statements_NNS in_IN accordance_NN with_IN to_TO reverse_VB ._.
Deferred_JJ tax_NN liabilities_NNS and_CC assets_NNS are_VBP not_RB discounted_VBN ._.
The_DT Group_NNP has_VBZ initiated_VBN a_DT project_NN to_TO plan_VB for_IN and_CC implement_VB the_DT conversion_NN from_IN Current_JJ asset_NN investments_NNS UK_NNP GAAP_NNP to_TO International_NNP Financial_NNP Reporting_NNP Standards_NNP IFRSs_NNP ._.
Current_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ The_DT first_JJ Annual_JJ Report_NNP prepared_VBN under_IN IFRSs_NNS will_MD be_VB that_IN for_IN the_DT realisable_JJ value_NN ._.
The_DT first_JJ financial_JJ results_NNS announcement_NN prepared_VBN in_IN accordance_NN with_IN IFRSs_NNS will_MD be_VB that_IN for_IN In_IN the_DT case_NN of_IN securities_NNS acquired_VBN at_IN a_DT significant_JJ premium_NN or_CC the_DT first_JJ quarter_NN of_IN 2005_CD ._.
discount_NN to_TO maturity_NN value_NN ,_, and_CC intended_VBN to_TO be_VB held_VBN to_TO redemption_NN ,_, cost_NN is_VBZ adjusted_VBN to_TO amortise_VB the_DT premium_NN or_CC discount_NN over_IN the_DT life_NN 4_CD Exchange_NNP rates_NNS to_TO maturity_NN of_IN the_DT security_NN ._.
Floating_VBG rate_NN bonds_NNS are_VBP stated_VBN at_IN cost_NN ._.
Interest_NN income_NN is_VBZ taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT The_DT Group_NNP uses_VBZ the_DT average_NN of_IN exchange_NN rates_NNS prevailing_VBG during_IN receivable_JJ basis_NN ._.
the_DT period_NN to_TO translate_VB the_DT results_NNS and_CC cash_NN ows_NNS of_IN overseas_JJ Group_NNP subsidiary_NN ,_, joint_JJ venture_NN and_CC associated_VBN undertakings_NNS into_IN sterling_JJ Equity_NN investments_NNS are_VBP included_VBN as_IN current_JJ assets_NNS when_WRB regarded_VBN and_CC period_NN end_NN rates_NNS to_TO translate_VB the_DT net_JJ assets_NNS of_IN those_DT as_IN available_JJ for_IN sale_NN ._.
The_DT currencies_NNS which_WDT most_RBS inuence_JJ these_DT translations_NNS ,_, and_CC the_DT relevant_JJ exchange_NN rates_NNS ,_, were_VBD :_: Derivative_JJ financial_JJ instruments_NNS The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS 2002 2001 2000_CD for_IN trading_NN purposes_NNS ._.
Average_JJ rates_NNS :_: Derivative_JJ financial_JJ instruments_NNS are_VBP used_VBN to_TO manage_VB exposure_NN to_TO US$_$ 1.50_CD 1.44_CD 1.52_CD market_NN risks_NNS from_IN treasury_NN operations_NNS ._.
The_DT principal_JJ derivative_JJ Euro_NNP 1.59_CD 1.61_CD 1.64_CD instruments_NNS are_VBP currency_NN swaps_NNS ,_, forward_RB exchange_NN contracts_NNS and_CC Yen_NNP 188.00_CD 175.00_CD 163.46_CD Period_NNP end_NN rates_NNS :_: interest_NN rate_NN swaps_NNS ._.
The_DT derivative_JJ contracts_NNS are_VBP treated_VBN from_IN US$_$ 1.61_CD 1.45_CD 1.49_CD inception_NN as_IN an_DT economic_JJ hedge_NN of_IN the_DT underlying_VBG financial_JJ Euro_NNP 1.54_CD 1.64_CD 1.61_CD instrument_NN ,_, with_IN matching_JJ accounting_NN treatment_NN and_CC cash_NN ows_NNS ._.
Yen_NNP 192.00_CD 190.00_CD 171.00_CD The_DT derivative_JJ contracts_NNS have_VBP high_JJ correlation_NN with_IN the_DT specic_JJ financial_JJ instrument_NN being_VBG hedged_VBN both_DT at_IN inception_NN and_CC throughout_IN the_DT hedge_JJ period_NN ._.
Derivative_JJ instruments_NNS no_RB longer_RB 5_CD Merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP designated_VBN as_IN hedges_NNS are_VBP restated_VBN at_IN market_NN value_NN and_CC any_DT future_JJ The_DT combination_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP plc_NN changes_NNS in_IN value_NN are_VBP taken_VBN directly_RB to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
was_VBD treated_VBN as_IN a_DT merger_NN at_IN 27th_JJ December_NNP 2000_CD under_IN UK_NNP GAAP_NNP ._.
Currency_NNP swaps_NNS and_CC forward_RB exchange_NN contracts_NNS used_VBN to_TO x_SYM the_DT Under_IN merger_NN accounting_NN ,_, the_DT shares_NNS issued_VBN by_IN GlaxoSmithKline_NNP plc_NN value_NN of_IN the_DT related_JJ asset_NN or_CC liability_NN in_IN the_DT contract_NN currency_NN and_CC to_TO acquire_VB Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP were_VBD accounted_VBN at_IN the_DT contract_NN rate_NN are_VBP accrued_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN for_IN at_IN par_NN and_CC no_DT share_NN premium_NN arose_VBD :_: the_DT shares_NNS acquired_VBN by_IN over_IN the_DT life_NN of_IN the_DT contract_NN ._.
Gains_NNS and_CC losses_NNS on_IN foreign_JJ exchange_NN GlaxoSmithKline_NNP in_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP were_VBD contracts_NNS designated_VBN as_IN hedges_NNS of_IN forecast_NN foreign_JJ exchange_NN similarly_RB accounted_VBD for_IN at_IN the_DT nominal_JJ value_NN of_IN the_DT shares_NNS issued_VBN ._.
transactions_NNS are_VBP deferred_VBN and_CC included_VBN in_IN the_DT measurement_NN of_IN the_DT In_IN the_DT consolidated_JJ Financial_NNP statements_NNS of_IN GlaxoSmithKline_NNP ,_, the_DT related_VBN foreign_JJ currency_NN transactions_NNS in_IN the_DT period_NN they_PRP occur_VBP ._.
results_NNS and_CC net_JJ assets_NNS of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP Gains_NNS and_CC losses_NNS on_IN balance_NN sheet_NN hedges_NNS are_VBP accrued_VBN and_CC are_VBP were_VBD combined_VBN ,_, at_IN their_PRP$ book_NN amounts_NNS ,_, subject_JJ to_TO alignment_VB taken_VBN directly_RB to_TO reserves_NNS ,_, except_IN that_DT forward_JJ premium_NN discounts_NNS adjustments_NNS ._.
are_VBP recognized_VBN as_IN interest_NN over_IN the_DT life_NN of_IN the_DT contracts_NNS ._.
In_IN view_NN of_IN the_DT proximity_NN of_IN the_DT merger_NN date_NN to_TO the_DT financial_JJ year_NN end_NN Interest_NN differentials_NNS under_IN interest_NN swap_NN agreements_NNS are_VBP recognized_VBN date_NN ,_, and_CC the_DT relative_JJ insignicance_NN of_IN any_DT business_NN activity_NN between_IN in_IN the_DT profit_NN and_CC loss_NN account_NN by_IN adjustment_NN of_IN interest_NN expense_NN 27th_JJ December_NNP 2000_CD and_CC 31st_CD December_NNP 2000_CD ,_, the_DT accounting_NN over_IN the_DT life_NN of_IN the_DT agreement_NN ._.
date_NN of_IN the_DT merger_NN was_VBD for_IN practical_JJ purposes_NNS taken_VBN as_IN 31st_CD December_NNP 2000_CD ._.
The_DT whole_NN of_IN the_DT profit_NN for_IN the_DT financial_JJ year_NN 2000_CD of_IN each_DT of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP plc_NN was_VBD deemed_VBN to_TO relate_VB to_TO the_DT period_NN prior_RB to_TO the_DT merger_NN date_NN ._.
86_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 6_CD Segment_NN information_NN An_DT analysis_NN of_IN turnover_NN ,_, profit_NN before_IN taxation_NN ,_, total_JJ assets_NNS ,_, net_JJ assets_NNS and_CC tangible_JJ xed_JJ assets_NNS by_IN business_NN and_CC geographical_JJ sector_NN are_VBP set_VBN out_RP below_IN ._.
The_DT business_NN sectors_NNS consist_VBP of_IN Pharmaceuticals_NNS prescription_NN pharmaceuticals_NNS and_CC vaccines_NNS and_CC Consumer_NN Healthcare_NNP oral_JJ care_NN ,_, OTC_NNP medicines_NNS and_CC nutritional_JJ healthcare_NN ._.
The_DT geographical_JJ sectors_NNS reect_VBP the_DT Groups_NNS most_RBS significant_JJ regional_JJ markets_NNS and_CC are_VBP consistent_JJ with_IN the_DT Groups_NNS regional_JJ market_NN management_NN reporting_VBG structure_NN ._.
Business_NNP sector_NN data_NN includes_VBZ an_DT allocation_NN of_IN corporate_JJ costs_NNS to_TO the_DT sector_NN ._.
There_EX are_VBP no_DT sales_NNS between_IN business_NN sectors_NNS ._.
The_DT Groups_NNS activities_NNS are_VBP organised_VBN on_IN a_DT global_JJ basis_NN ._.
The_DT geographical_JJ sector_NN gures_NNS are_VBP therefore_RB inuenced_VBN by_IN the_DT location_NN of_IN the_DT Groups_NNS operating_VBG resources_NNS ,_, in_IN particular_JJ manufacturing_NN and_CC research_NN ,_, and_CC by_IN variations_NNS over_IN time_NN in_IN intra-Group_JJ trading_NN and_CC funding_NN arrangements_NNS ._.
2001 2000 2002_CD restated_VBN restated_VBN Turnover_NN by_IN business_NN sector_NN m_NN m_FW m_FW Pharmaceuticals_NNPS 17,995_CD 17,205_CD 15,429_CD Consumer_NN Healthcare_NNP 3,217_CD 3,284_CD 2,650_CD External_NNP turnover_NN 21,212_CD 20,489_CD 18,079_CD profit_NN before_IN tax_NN by_IN business_NN sector_NN Pharmaceuticals_NNS 5,068_CD 4,302_CD 4,316_CD Consumer_NN Healthcare_NNP 483 432 413_CD Operating_NN profit_NN 5,551_CD 4,734_CD 4,729_CD Share_NN of_IN profits_NNS losses_NNS of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 75_CD 71_CD 57_CD profit_NN on_IN disposal_NN of_IN interest_NN in_IN associate_JJ 96_CD 144_CD profit_NN on_IN disposal_NN of_IN businesses_NNS 10_CD Product_NN divestments_VBZ 11_CD 296_CD 1,402_CD Merger_NNP transaction_NN costs_NNS 121_CD Net_JJ interest_NN payable_JJ 141_CD 88_CD 182_CD profit_NN before_IN taxation_NN 5,506_CD 4,517_CD 6,029_CD profit_NN before_IN taxation_NN 5,506_CD 4,517_CD 6,029_CD Taxation_NNP 1,461_CD 1,333_CD 1,747_CD Minority_NNP interests_NNS 110_CD 97_CD 120_CD Preference_NN share_NN dividends_NNS 20_CD 34_CD 56_CD Earnings_NNS 3,915_CD 3,053_CD 4,106_CD Total_JJ assets_NNS by_IN business_NN sector_NN Pharmaceuticals_NNS 18,608_CD 18,495_CD Consumer_NN Healthcare_NNP 3,719_CD 3,848_CD Total_JJ assets_NNS 22,327_CD 22,343_CD Net_JJ assets_NNS by_IN business_NN sector_NN Pharmaceuticals_NNS 5,720_CD 6,573_CD Consumer_NN Healthcare_NNP 1,668_CD 1,679_CD Net_JJ assets_NNS 7,388_CD 8,252_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 87_CD 6_CD Segment_NN information_NN continued_VBD 2001 2000 2002_CD restated_VBN restated_VBN Turnover_NN by_IN location_NN of_IN subsidiary_NN undertaking_NN m_NN m_FW m_FW USA_NNP 11,096_CD 10,517_CD 8,850_CD Europe_NNP 10,423_CD 10,704_CD 9,970_CD International_NNP 6,824_CD 7,540_CD 5,112_CD Gross_NNP turnover_NN 28,343_CD 28,761_CD 23,932_CD USA_NNP 168 327 297_CD Europe_NNP 3,873_CD 4,372_CD 4,294_CD International_NNP 3,090_CD 3,573_CD 1,262_CD Inter-segment_NN turnover_NN 7,131_CD 8,272_CD 5,853_CD USA_NNP 10,928_CD 10,190_CD 8,553_CD Europe_NNP 6,550_CD 6,332_CD 5,676_CD International_NNP 3,734_CD 3,967_CD 3,850_CD External_NNP turnover_NN 21,212_CD 20,489_CD 18,079_CD Turnover_NN by_IN location_NN of_IN customer_NN USA_NNP 10,807_CD 10,087_CD 8,554_CD Europe_NNP 6,064_CD 5,855_CD 5,264_CD International_NNP 4,341_CD 4,547_CD 4,261_CD External_NNP turnover_NN 21,212_CD 20,489_CD 18,079_CD profit_NN before_IN tax_NN by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 2,117_CD 934_CD 1,190_CD Europe_NNP 2,490_CD 2,580_CD 2,586_CD International_NNP 944_CD 1,220_CD 953_CD Operating_NN profit_NN 5,551_CD 4,734_CD 4,729_CD Share_NN of_IN profits_NNS losses_NNS of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 75_CD 71_CD 57_CD profit_NN on_IN disposal_NN of_IN interest_NN in_IN associate_JJ 96_CD 144_CD profit_NN on_IN disposal_NN of_IN businesses_NNS 10_CD Product_NN divestments_VBZ 11_CD 296_CD 1,402_CD Merger_NNP transaction_NN costs_NNS 121_CD Net_JJ interest_NN payable_JJ 141_CD 88_CD 182_CD profit_NN before_IN taxation_NN 5,506_CD 4,517_CD 6,029_CD profit_NN before_IN taxation_NN 5,506_CD 4,517_CD 6,029_CD Taxation_NNP 1,461_CD 1,333_CD 1,747_CD Minority_NNP interests_NNS 110_CD 97_CD 120_CD Preference_NN share_NN dividends_NNS 20_CD 34_CD 56_CD Earnings_NNS 3,915_CD 3,053_CD 4,106_CD Total_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 4,455_CD 5,454_CD Europe_NNP 12,614_CD 10,831_CD International_NNP 2,950_CD 3,927_CD Total_JJ operating_VBG assets_NNS 20,019_CD 20,212_CD Cash_NN at_IN bank_NN and_CC liquid_JJ investments_NNS 2,308_CD 2,131_CD Total_JJ assets_NNS 22,327_CD 22,343_CD Net_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 376_CD 1,232_CD Europe_NNP 7,298_CD 6,524_CD International_NNP 2,049_CD 2,597_CD Net_NN operating_VBG assets_NNS 9,723_CD 10,353_CD Net_JJ debt_NN 2,335_CD 2,101_CD Net_JJ assets_NNS 7,388_CD 8,252_CD 88_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 6_CD Segment_NN information_NN continued_VBD 2002_CD 2001_CD Plant_NN ,_, Land_NNP and_CC equipment_NN Computer_NN Assets_NNS in_IN buildings_NNS and_CC vehicles_NNS software_NN construction_NN Total_JJ Total_JJ Tangible_JJ xed_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN m_NN m_FW m_FW m_FW m_FW m_FW USA_NNP 680_CD 379_CD 31_CD 322_CD 1,412_CD 1,536_CD Europe_NNP 1,700_CD 1,833_CD 118_CD 553_CD 4,204_CD 4,138_CD International_NNP 524_CD 370_CD 11_CD 128_CD 1,033_CD 1,171_CD Total_JJ 2,904_CD 2,582_CD 160_CD 1,003_CD 6,649_CD 6,845_CD UK_NNP segment_NN Information_NN is_VBZ given_VBN separately_RB in_IN respect_NN of_IN the_DT UK_NNP ,_, which_WDT ,_, although_IN included_VBN in_IN the_DT Groups_NNS Europe_NNP market_NN region_NN ,_, is_VBZ considered_VBN the_DT Groups_NNS home_NN segment_NN for_IN the_DT purposes_NNS of_IN segmental_JJ reporting_NN ._.
2001_CD 2002_CD restated_VBN 2000_CD m_FW m_FW m_FW Turnover_NN by_IN location_NN of_IN customer_NN 1,366_CD 1,328_CD 1,151_CD Gross_NNP turnover_NN 4,945_CD 5,388_CD 3,306_CD Inter-segment_NN turnover_NN 3,230_CD 3,753_CD 1,798_CD Turnover_NN by_IN location_NN of_IN subsidiary_NN 1,715_CD 1,635_CD 1,508_CD Operating_NN profit_NN 1,276_CD 1,772_CD 1,665_CD Total_JJ assets_NNS 8,846_CD 7,274_CD Net_NN operating_VBG assets_NNS 4,910_CD 4,514_CD 7_CD Merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC divested_JJ businesses_NNS Manufacturing_NNP and_CC other_JJ restructuring_NN costs_NNS were_VBD incurred_VBN by_IN GlaxoSmithKline_NNP during_IN 2002_CD and_CC 2001_CD in_IN implementation_NN of_IN previously_RB announced_VBN plans_NNS for_IN restructuring_NN of_IN manufacturing_NN and_CC other_JJ activities_NNS ._.
These_DT costs_NNS were_VBD also_RB incurred_VBN by_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP in_IN 2000_CD ._.
Merger_NN integration_NN costs_NNS relate_VBP to_TO the_DT integration_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP into_IN a_DT unied_JJ GlaxoSmithKline_NNP business_NN ._.
These_DT costs_NNS include_VBP consultancy_NN fees_NNS in_IN respect_NN of_IN integration_NN planning_NN ,_, severance_NN costs_NNS ,_, asset_NN write-offs_NNS ,_, costs_NNS related_VBN to_TO the_DT early_JJ vesting_NN or_CC lapse_NN of_IN performance_NN conditions_NNS on_IN share_NN options_NNS and_CC share_NN incentive_NN awards_NNS and_CC costs_NNS of_IN the_DT program_NN to_TO encourage_VB staff_NN to_TO convert_VB Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP share_NN options_NNS into_IN GlaxoSmithKline_NNP share_NN options_NNS ._.
Integration_NN costs_NNS were_VBD incurred_VBN in_IN 2002_CD and_CC 2001_CD relating_VBG to_TO the_DT integration_NN of_IN the_DT Block_NNP Drug_NNP businesses_NNS ._.
These_DT costs_NNS include_VBP professional_JJ fees_NNS ,_, severance_NN costs_NNS and_CC asset_NN write-offs_NNS ._.
Product_NN divestment_NN income_NN arising_VBG in_IN 2002_CD related_VBN to_TO the_DT nalisation_NN of_IN the_DT disposals_NNS of_IN Famvir_NNP ,_, Kytril_NNP and_CC other_JJ products_NNS required_VBN in_IN 2000_CD in_IN order_NN to_TO obtain_VB regulatory_JJ approval_NN for_IN the_DT merger_NN ._.
Merger_NN transaction_NN costs_NNS were_VBD incurred_VBN in_IN 2000_CD in_IN order_NN to_TO effect_VB the_DT merger_NN ._.
These_DT costs_NNS comprise_VBP the_DT fees_NNS and_CC expenses_NNS incurred_VBN in_IN preparing_VBG and_CC implementing_VBG the_DT scheme_NN of_IN arrangement_NN for_IN the_DT merger_NN ._.
The_DT disposal_NN of_IN businesses_NNS in_IN 2002_CD related_VBN to_TO the_DT nalisation_NN of_IN the_DT disposals_NNS of_IN Clinical_JJ Laboratories_NNPS and_CC Healthcare_NNP Services_NNPS in_IN 1999_CD ._.
The_DT disposal_NN of_IN businesses_NNS in_IN 2001_CD primarily_RB arose_VBD on_IN the_DT sale_NN of_IN Affymax_NNP ._.
It_PRP included_VBD a_DT 299_CD million_CD write_VB off_IN of_IN goodwill_NN which_WDT was_VBD previously_RB eliminated_VBN against_IN Group_NNP reserves_NNS ._.
The_DT disposal_NN of_IN businesses_NNS in_IN 2000_CD relates_VBZ to_TO the_DT disposal_NN of_IN Healthcare_NNP Services_NNPS in_IN 1999_CD ._.
Restructuring_NN costs_NNS were_VBD incurred_VBN in_IN Healthcare_NNP Services_NNPS before_IN its_PRP$ disposal_NN ._.
The_DT share_NN of_IN associate_NN in_IN 2000_CD related_VBN to_TO restructuring_VBG costs_NNS incurred_VBN by_IN Quest_NNP Diagnostics_NNPS ._.
RestrucDisposal_NNP of_IN Merger_NNP turing_VBG Block_NNP Drug_NNP subsidiaries_NNS Total_JJ 2002_CD m_FW m_FW m_FW m_FW m_FW Manufacturing_NNP and_CC other_JJ restructuring_NN 121_CD 121_CD Merger_NN integration_NN costs_NNS 851_CD 851_CD Block_NNP Drug_NNP integration_NN costs_NNS 60_CD 60_CD Effect_NN on_IN operating_NN profit_NN 851_CD 121_CD 60_CD 1,032_CD Product_NNP divestments_VBZ 11_CD 11_CD profit_NN on_IN disposal_NN of_IN businesses_NNS 10_CD 10_CD Effect_NN on_IN profit_NN before_IN tax_NN 840_CD 121_CD 60_CD 10_CD 1,011_CD Effect_NN on_IN taxation_NN operating_NN items_NNS 266_CD Effect_NN on_IN taxation_NN non-operating_JJ items_NNS 33_CD Effect_NN on_IN taxation_NN 299_CD Effect_NN on_IN earnings_NNS 712_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 89_CD 7_CD Merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC divested_JJ businesses_NNS continued_VBD RestrucDisposal_NNP of_IN Total_NNP Merger_NNP turing_VBG Block_NNP Drug_NNP subsidiaries_NNS restated_VBN 2001_CD m_FW m_FW m_FW m_FW m_FW Manufacturing_NNP and_CC other_JJ restructuring_NN 162_CD 162_CD Merger_NN integration_NN costs_NNS 1,069_CD 1,069_CD Block_NNP Drug_NNP integration_NN costs_NNS 125_CD 125_CD Effect_NN on_IN operating_NN profit_NN 1,069_CD 162_CD 125_CD 1,356_CD Loss_NN on_IN disposal_NN of_IN businesses_NNS 296_CD 296_CD Effect_NN on_IN profit_NN before_IN tax_NN 1,069_CD 162 125 296_CD 1,652_CD Effect_NN on_IN taxation_NN operating_NN items_NNS 355_CD Effect_NN on_IN taxation_NN non-operating_JJ items_NNS 33_CD Effect_NN on_IN taxation_NN 322_CD Effect_NN on_IN earnings_NNS 1,330_CD RestrucDisposal_NNP of_IN Total_NNP Merger_NNP turing_VBG Associate_NNP subsidiaries_NNS restated_VBN 2000_CD m_FW m_FW m_FW m_FW m_FW Manufacturing_NNP and_CC other_JJ restructuring_NN 171_CD 171_CD Merger_NN integration_NN costs_NNS 400_CD 400_CD Effect_NN on_IN operating_NN profit_NN 400 171 571_CD Share_NN of_IN associate_JJ 8_CD 8_CD Product_NNP divestments_NNS 1,416_CD 1,416_CD Merger_NNP transaction_NN costs_NNS 121_CD 121_CD Loss_NN on_IN disposal_NN of_IN business_NN 14_CD 14_CD Effect_NN on_IN profit_NN before_IN tax_NN 895_CD 171_CD 8_CD 14_CD 702_CD Effect_NN on_IN taxation_NN operating_NN items_NNS 120_CD Effect_NN on_IN taxation_NN non-operating_JJ items_NNS 370_CD Effect_NN on_IN taxation_NN 250_CD Effect_NN on_IN earnings_NNS 452_CD 8_CD Other_JJ operating_NN income_NN expense_NN 2002 2001 2000_CD m_FW m_FW m_FW Royalties_NNPS and_CC other_JJ income_NN 75_CD 34_CD 43_CD Other_JJ operating_NN expense_NN 209_CD 126_CD 58_CD 134_CD 92_CD 15_CD Income_NN from_IN equity_NN investments_NNS and_CC other_JJ disposals_NNS 23 129 289 111_CD 37_CD 274_CD Royalties_NNS and_CC other_JJ income_NN is_VBZ principally_RB a_DT core_NN of_IN recurring_VBG income_NN in_IN the_DT form_NN of_IN royalties_NNS from_IN the_DT out-licensing_NN of_IN intellectual_JJ property_NN ._.
Other_JJ operating_NN expense_NN comprises_VBZ non-recurring_JJ costs_NNS related_VBN to_TO product_NN liability_NN and_CC other_JJ claims_NNS and_CC other_JJ costs_NNS in_IN respect_NN of_IN product_NN withdrawals_NNS ._.
Income_NN from_IN equity_NN investments_NNS and_CC other_JJ disposals_NNS arises_VBZ from_IN equity_NN investment_NN sales_NNS and_CC equity_NN investment_NN write-downs_NNS due_JJ to_TO adverse_JJ market_NN conditions_NNS ,_, product_NN and_CC property_NN disposals_NNS ._.
90_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 9_CD Operating_NN profit_NN 2002 2001 2000_CD m_FW m_FW m_FW The_DT following_JJ items_NNS have_VBP been_VBN charged_VBN in_IN operating_NN profit_NN :_: Employee_NN costs_NNS Note_VBP 33_CD 4,940_CD 4,686_CD 4,487_CD Advertising_NN 688 696 652_CD Distribution_NN costs_NNS 281 272 260_CD Depreciation_NN of_IN tangible_JJ xed_JJ assets_NNS :_: Owned_JJ assets_NNS 760 758 733_CD Leased_JJ assets_NNS 4_CD 32_CD Amortisation_NNP of_IN goodwill_NN 12_CD 10_CD 11_CD Amortisation_NNP of_IN intangible_JJ xed_JJ assets_NNS 60_CD 40_CD 27_CD Exchange_NNP losses_NNS on_IN foreign_JJ currency_NN deposits_NNS loans_NNS 3_CD Operating_NN lease_NN rentals_NNS :_: Plant_NN and_CC machinery_NN 50_CD 41_CD 44_CD Land_NNP and_CC buildings_NNS 61_CD 70_CD 70_CD Audit_NNP fees_NNS 6.1_CD 7.2_CD 6.3_CD Fees_NNS to_TO auditors_NNS for_IN other_JJ work_NN :_: Auditors_NNS UK_NNP rm_VBD 5.2_CD 13.1_CD 9.4_CD Auditors_NNS overseas_RB rms_VBZ 9.6_CD 22.6_CD 15.3_CD Analysis_NN of_IN fees_NNS to_TO auditors_NNS for_IN other_JJ work_NN :_: Non-statutory_JJ assurance_NN services_NNS 1.8_CD 1.6_CD Tax_NNP advisory_JJ services_NNS 4.2_CD 5.9_CD Merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP 6.0_CD 14.6_CD Other_JJ services_NNS 2.8_CD 13.6_CD Included_VBN within_IN audit_NN fees_NNS above_IN is_VBZ a_DT fee_NN of_IN 10,000_CD 2001_CD 10,000_CD ,_, 2000_CD 10,000_CD relating_VBG to_TO the_DT company_NN audit_NN of_IN GlaxoSmithKline_NNP plc._NNP ._.
Included_VBN within_IN fees_NNS to_TO auditors_NNS for_IN other_JJ work_NN are_VBP amounts_NNS of_IN 6.0_CD million_CD 2001_CD 17.4_CD million_CD paid_VBN to_TO the_DT auditors_NNS management_NN consulting_NN practice_NN ,_, which_WDT was_VBD sold_VBN by_IN them_PRP in_IN 2002_CD ._.
10_CD Joint_NNP ventures_NNS and_CC associated_VBN undertakings_NNS 2002 2001 2000_CD m_FW m_FW m_FW Associated_NNP undertakings_NNS :_: Share_NN of_IN profits_NNS of_IN Quest_NNP Diagnostics_NNPS Inc._NNP 94_CD 79_CD 64_CD Share_NN of_IN losses_NNS of_IN other_JJ associated_VBN undertakings_NNS 1_CD 1_CD Amortisation_NNP of_IN goodwill_NN 6_CD 7_CD 7_CD 88_CD 71_CD 56_CD Share_NN of_IN losses_NNS profits_NNS of_IN joint_JJ ventures_NNS 13_CD 1_CD 75_CD 71_CD 57_CD Share_NN of_IN turnover_NN of_IN joint_JJ ventures_NNS 8_CD 88_CD Sales_NNS to_TO joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 7_CD 11_CD 15_CD 11_CD Net_JJ interest_NN payable_JJ 2002 2001 2000_CD m_FW m_FW m_FW Interest_NN payable_JJ On_IN bank_NN loans_NNS and_CC overdrafts_NNS 6_CD 26_CD 45_CD On_IN other_JJ loans_NNS 198 169 271_CD In_IN respect_NN of_IN finance_NN leases_NNS 2_CD 3_CD 1_CD 206 198 317_CD Share_NN of_IN interest_NN payable_JJ of_IN associate_JJ 8_CD 19 23 214 217_CD 340_CD Investment_NN income_NN Interest_NN income_NN 71 129 159_CD Realised_VBN gains_NNS 2_CD Provision_NNP for_IN market_NN value_NN adjustments_NNS 1_CD 73 129 158 141_CD 88_CD 182_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 91_CD 12_CD Taxation_NNP 2001 2000 2002_CD restated_VBN restated_VBN Taxation_NNP charge_NN based_VBN on_IN profits_NNS for_IN the_DT period_NN m_NN m_FW m_FW UK_NNP corporation_NN tax_NN at_IN the_DT UK_NNP statutory_JJ rate_NN 479 838 928_CD Less_RBR double_JJ taxation_NN relief_NN 117 351 384 362_CD 487_CD 544_CD Overseas_JJ taxation_NN 1,036_CD 876_CD 1,242_CD Deferred_JJ taxation_NN 29_CD 53_CD 55_CD 1,427_CD 1,310_CD 1,731_CD Share_NN of_IN taxation_NN charge_NN of_IN associates_NNS 34_CD 23_CD 16_CD 1,461_CD 1,333_CD 1,747_CD 2001_CD 2000_CD Reconciliation_NNP of_IN the_DT current_JJ taxation_NN rate_NN on_IN Group_NNP profits_NNS 2002_CD restated_VBN restated_VBN %_NN %_NN %_NN UK_NNP statutory_JJ rate_NN of_IN taxation_NN 30.0_CD 30.0_CD 30.0_CD Overseas_JJ taxes_NNS 0.1_CD 1.1_CD 2.2_CD Average_NNP Group_NNP tax_NN rate_NN 30.1_CD 28.9_CD 32.2_CD Effect_NN of_IN special_JJ tax_NN status_NN in_IN manufacturing_VBG locations_NNS 3.9_CD 3.7_CD 3.2_CD Share_NN option_NN deductions_NNS in_IN the_DT USA_NNP 0.2_CD 1.1_CD 0.8_CD Merger_NNP and_CC restructuring_VBG costs_NNS 0.7_CD 5.4_CD 0.2_CD R&D_NNP credits_NNS not_RB previously_RB recognized_VBN 1.2_CD 0.9_CD 1.1_CD Other_JJ permanent_JJ differences_NNS 0.8_CD 0.4_CD 1.4_CD Capital_NN allowances_NNS in_IN excess_NN of_IN depreciation_NN 0.5_CD 0.2_CD Intra-Group_NNP profit_NN 1.3_CD 1.3_CD 1.2_CD Reversing_VBG timing_NN differences_NNS on_IN tax_NN losses_NNS 2.5_CD 0.2_CD Other_JJ timing_NN differences_NNS 2.3_CD 3.9_CD 2.5_CD Prior_RB year_NN items_NNS 2.4_CD 0.7_CD Current_JJ tax_NN rate_NN on_IN ordinary_JJ activities_NNS 25.4_CD 30.2_CD 29.6_CD Capital_NN allowances_NNS in_IN excess_NN of_IN depreciation_NN 0.5_CD 0.2_CD Intra-Group_NNP profit_NN 1.3_CD 1.3_CD 1.2_CD Reversing_VBG timing_NN differences_NNS on_IN tax_NN losses_NNS 2.5_CD 0.2_CD Other_JJ timing_NN differences_NNS 2.3_CD 3.9_CD 2.5_CD Share_NN of_IN associates_NNS taxation_NN 0.6_CD 0.5_CD 0.3_CD Prior_RB year_NN items_NNS 3.6_CD 1.5_CD Tax_NNP rate_NN on_IN ordinary_JJ activities_NNS 26.5_CD 29.5_CD 29.0_CD The_DT Group_NNP operates_VBZ in_IN countries_NNS where_WRB the_DT tax_NN rate_NN differs_VBZ to_TO the_DT UK_NNP rate_NN ._.
The_DT standard_JJ rate_NN of_IN tax_NN for_IN the_DT Group_NNP has_VBZ been_VBN estimated_VBN by_IN aggregating_VBG the_DT local_JJ standard_JJ tax_NN rates_NNS and_CC weighting_NN these_DT in_IN proportion_NN to_TO accounting_VBG profits_NNS ._.
profits_NNS arising_VBG from_IN manufacturing_VBG operations_NNS in_IN Singapore_NNP ,_, Puerto_NNP Rico_NNP and_CC Ireland_NNP are_VBP taxed_VBN at_IN reduced_JJ rates_NNS ._.
The_DT effect_NN of_IN this_DT reduction_NN in_IN the_DT taxation_NN charge_NN increased_VBD earnings_NNS per_IN share_NN by_IN 3.6_CD p_NN in_IN 2002_CD ,_, 2.7_CD p_NN in_IN 2001_CD and_CC by_IN 3.2_CD p_NN in_IN 2000_CD ._.
The_DT integrated_JJ nature_NN of_IN the_DT Groups_NNS worldwide_JJ operations_NNS ,_, involving_VBG significant_JJ investment_NN in_IN research_NN and_CC strategic_JJ manufacture_NN at_IN a_DT limited_JJ number_NN of_IN locations_NNS ,_, with_IN consequential_JJ cross-border_JJ supply_NN routes_NNS into_IN numerous_JJ end-markets_NNS ,_, gives_VBZ rise_NN to_TO complexity_NN and_CC delay_NN in_IN negotiations_NNS with_IN revenue_NN authorities_NNS as_IN to_TO the_DT profits_NNS on_IN which_WDT individual_JJ Group_NNP companies_NNS are_VBP liable_JJ to_TO tax_NN ._.
Disagreements_NNS with_IN ,_, and_CC between_IN ,_, revenue_NN authorities_NNS as_IN to_TO intra-Group_JJ transactions_NNS ,_, in_IN particular_JJ the_DT price_NN at_IN which_WDT goods_NNS should_MD be_VB transferred_VBN between_IN Group_NNP companies_NNS in_IN different_JJ tax_NN jurisdictions_NNS ,_, can_MD produce_VB conicting_VBG claims_NNS from_IN revenue_NN authorities_NNS as_IN to_TO the_DT profits_NNS that_WDT fall_VBP to_TO be_VB taxed_VBN in_IN individual_JJ territories_NNS ._.
Resolution_NN of_IN such_JJ issues_NNS is_VBZ a_DT continuing_VBG fact-of-life_NN for_IN GlaxoSmithKline_NNP ._.
In_IN the_DT USA_NNP ,_, for_IN a_DT number_NN of_IN years_NNS ,_, GlaxoSmithKline_NNP has_VBZ had_VBN significant_JJ open_JJ issues_NNS relating_VBG to_TO transfer_VB pricing_NN ._.
These_DT issues_NNS affect_VBP all_DT years_NNS from_IN 1989_CD to_TO the_DT present_JJ and_CC concern_NN a_DT number_NN of_IN products_NNS ,_, although_IN the_DT most_RBS significant_JJ relates_VBZ to_TO the_DT success_NN of_IN Zantac_NNP ,_, in_IN respect_NN of_IN which_WDT the_DT claims_NNS of_IN the_DT US_NNP Internal_NNP Revenue_NNP Service_NNP IRS_NNP substantially_RB exceed_VBP the_DT Groups_NNS estimation_NN of_IN its_PRP$ taxation_NN liabilities_NNS ._.
The_DT IRS_NNP claims_NNS ,_, which_WDT are_VBP not_RB completely_RB quantied_VBN ,_, continue_VBP to_TO be_VB the_DT subject_NN of_IN discussions_NNS between_IN the_DT US_NNP and_CC UK_NNP tax_NN authorities_NNS under_IN the_DT competent_JJ authority_NN provisions_NNS of_IN the_DT double_JJ tax_NN convention_NN between_IN the_DT two_CD countries_NNS ._.
Within_IN these_DT discussions_NNS there_EX is_VBZ a_DT wide_JJ variation_NN between_IN the_DT views_NNS of_IN the_DT US_NNP and_CC UK_NNP tax_NN authorities_NNS and_CC ,_, exceptionally_RB ,_, they_PRP may_MD be_VB unable_JJ to_TO reach_VB agreement_NN to_TO settle_VB the_DT dispute_NN ._.
In_IN the_DT event_NN of_IN the_DT UK_NNP and_CC US_NNP tax_NN authorities_NNS not_RB reaching_VBG agreement_NN ,_, the_DT matter_NN may_MD have_VB to_TO be_VB resolved_VBN by_IN litigation_NN ._.
GlaxoSmithKline_NNP uses_VBZ the_DT best_JJS advice_NN in_IN determining_VBG its_PRP$ transfer_NN pricing_NN methodology_NN and_CC in_IN seeking_VBG to_TO manage_VB transfer_NN pricing_NN issues_NNS to_TO a_DT satisfactory_JJ conclusion_NN and_CC ,_, on_IN the_DT basis_NN of_IN external_JJ professional_JJ advice_NN ,_, continues_VBZ to_TO believe_VB that_IN it_PRP has_VBZ made_VBN adequate_JJ provision_NN for_IN the_DT liabilities_NNS likely_JJ to_TO arise_VB from_IN open_JJ assessments_NNS ._.
92_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 12_CD Taxation_NNP continued_VBD Except_IN as_IN shown_VBN in_IN these_DT Financial_NNP statements_NNS ,_, no_DT provision_NN has_VBZ been_VBN made_VBN for_IN taxation_NN which_WDT would_MD arise_VB on_IN the_DT distribution_NN of_IN profits_NNS retained_VBN by_IN overseas_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS ,_, on_IN the_DT grounds_NNS that_IN no_DT remittance_NN of_IN profit_NN retained_VBN at_IN 31st_CD December_NNP 2002_CD is_VBZ required_VBN in_IN such_JJ a_DT way_NN that_IN incremental_JJ tax_NN will_MD arise_VB ._.
At_IN 31st_CD December_NNP 2002_CD ,_, the_DT Group_NNP had_VBD corporate_JJ tax_NN losses_NNS of_IN approximately_RB 69_CD million_CD and_CC capital_NN losses_NNS estimated_VBN to_TO be_VB in_IN excess_NN of_IN 9_CD billion_CD which_WDT are_VBP not_RB recognized_VBN as_IN deferred_JJ tax_NN assets_NNS because_IN there_EX is_VBZ insufficient_JJ evidence_NN that_IN these_DT losses_NNS will_MD be_VB used_VBN ._.
Current_JJ Deferred_NNP Deferred_NNP tax_NN creditor_NN tax_NN debtor_NN tax_NN provision_NN Tax_NNP balances_NNS m_VBP m_FW m_FW At_IN 1st_CD January_NNP 2002_CD as_IN previously_RB reported_VBN 1,672_CD 871_CD Prior_RB year_NN adjustment_NN 426_CD 553_CD At_IN 1st_CD January_NNP 2002_CD as_IN restated_VBN 1,672_CD 1,297_CD 553_CD Exchange_NNP adjustments_NNS 103_CD 79_CD 12_CD Charge_NNP to_TO profit_VB and_CC loss_NN account_NN 1,398_CD 15_CD 14_CD Cash_NN paid_VBN 1,633_CD Other_JJ movements_NNS 115 170 163_CD At_IN 31st_CD December_NNP 2002_CD 1,449_CD 1,373_CD 742 2001 2002_CD restated_VBN Deferred_JJ taxation_NN asset_NN liability_NN m_NN m_NN Accelerated_VBD capital_NN allowances_NNS 710_CD 691_CD Stock_NNP valuation_NN adjustment_NN 113_CD 113_CD Intra-Group_JJ profit_NN 487_CD 375_CD Product_NNP and_CC business_NN disposals_NNS 125_CD 161_CD Pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS 190_CD 298_CD Tax_NNP losses_NNS 93_CD 97_CD Legal_NNP and_CC other_JJ disputes_NNS 124_CD 25_CD Manufacturing_NNP restructuring_NN 52_CD 71_CD Other_JJ net_JJ timing_NN differences_NNS 633 843 631 744_CD Of_IN the_DT above_JJ categories_NNS of_IN provided_VBN deferred_VBN taxation_NN ,_, stock_NN valuation_NN adjustments_NNS ,_, intra-Group_JJ profit_NN and_CC other_JJ timing_NN differences_NNS are_VBP current_JJ ._.
All_DT deferred_VBN taxation_NN movements_NNS arise_VBP from_IN the_DT origination_NN and_CC reversal_NN of_IN timing_NN differences_NNS ._.
The_DT Group_NNP has_VBZ implemented_VBN the_DT new_JJ Financial_NNP Reporting_NNP Standard_NNP ,_, FRS_NNP 19_CD Deferred_NNP Tax_NNP ,_, in_IN 2002_CD ,_, which_WDT requires_VBZ deferred_VBN tax_NN to_TO be_VB accounted_VBN for_IN on_IN a_DT full_JJ provision_NN basis_NN rather_RB than_IN a_DT partial_JJ provision_NN basis_NN as_IN before_RB ._.
For_IN the_DT full_JJ year_NN 2001_CD the_DT business_NN performance_NN tax_NN charge_NN is_VBZ increased_VBN by_IN 8_CD million_CD ,_, and_CC the_DT total_JJ tax_NN charge_NN by_IN 6_CD million_CD ._.
The_DT net_JJ deferred_VBN tax_NN asset_NN at_IN 31st_CD December_NNP 2001_CD has_VBZ been_VBN reduced_VBN by_IN 127_CD million_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 93_CD 13_CD Earnings_NNS per_IN share_NN 2001 2000 2002_CD restated_VBN restated_VBN p_JJ pp_NN Basic_JJ earnings_NNS per_IN share_NN 66.2_CD 50.3_CD 67.7_CD Adjustment_NNP for_IN merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC disposal_NN of_IN subsidiaries_NNS :_: Merger_NN integration_NN and_CC transaction_NN costs_NNS 10.8_CD 13.0_CD 6.8_CD Product_NNP divestments_NNS 16.8_CD Restructuring_NN costs_NNS 1.5_CD 2.0_CD 2.2_CD Block_NNP Drug_NNP integration_NN costs_VBZ 0.7_CD 1.6_CD Disposal_NNP of_IN businesses_NNS 0.9_CD 5.4_CD 0.2_CD Associates_NNP 0.1_CD Adjusted_VBN earnings_NNS per_IN share_NN 78.3_CD 72.3_CD 60.2_CD Diluted_VBN earnings_NNS per_IN share_NN 66.0_CD 49.9_CD 66.9_CD Basic_JJ and_CC adjusted_JJ earnings_NNS per_IN share_NN have_VBP been_VBN calculated_VBN by_IN dividing_VBG the_DT profit_NN attributable_JJ to_TO shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN during_IN the_DT period_NN ._.
The_DT numbers_NNS used_VBN in_IN calculating_VBG basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN are_VBP reconciled_VBN below_IN ._.
To_TO illustrate_VB business_NN performance_NN ,_, which_WDT is_VBZ the_DT primary_JJ performance_NN measure_NN used_VBN by_IN management_NN ,_, adjusted_VBN earnings_NNS and_CC adjusted_VBN earnings_NNS per_IN share_NN are_VBP presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposal_NN of_IN businesses_NNS ._.
Management_NNP believes_VBZ that_IN exclusion_NN of_IN these_DT non-recurring_JJ items_NNS provides_VBZ a_DT better_JJR comparison_NN of_IN business_NN performance_NN for_IN the_DT periods_NNS presented_VBN ._.
Accordingly_RB this_DT information_NN is_VBZ provided_VBN as_IN a_DT supplement_NN to_TO that_DT contained_VBN in_IN the_DT consolidated_JJ statement_NN of_IN profit_NN and_CC loss_NN on_IN pages_NNS 76_CD and_CC 77_CD prepared_JJ in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
Basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN include_VBP these_DT non-recurring_JJ items_NNS ._.
Net_JJ profit_NN for_IN the_DT period_NN attributable_JJ to_TO shareholders_NNS m_VBP m_FW m_FW Earnings_NNS basic_JJ and_CC diluted_JJ 3,915_CD 3,053_CD 4,106_CD Adjustments_NNS for_IN merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC disposal_NN of_IN subsidiaries_NNS 712_CD 1,330_CD 452_CD Adjusted_VBN earnings_NNS 4,627_CD 4,383_CD 3,654_CD Weighted_VBN average_JJ number_NN of_IN shares_NNS in_IN issue_NN millions_NNS millions_NNS millions_NNS Basic_JJ and_CC adjusted_JJ 5,912_CD 6,064_CD 6,065_CD Dilution_NN for_IN share_NN options_NNS 22_CD 52_CD 69_CD Diluted_NNP 5,934_CD 6,116_CD 6,134_CD Shares_NNS held_VBN by_IN the_DT Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS ESOT_NNP are_VBP excluded_VBN ._.
The_DT trustees_NNS have_VBP waived_VBN their_PRP$ rights_NNS to_TO dividends_NNS on_IN the_DT shares_NNS held_VBN by_IN the_DT ESOTs_NNS ._.
94_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 14_CD Dividends_NNPS 2002_CD 2001_CD m_NN m_NN GlaxoSmithKline_NNP plc_NN :_: First_NNP interim_JJ 535_CD 546_CD Second_JJ interim_JJ 530_CD 546_CD Third_NNP interim_JJ 527_CD 546_CD Fourth_JJ interim_JJ 754_CD 718_CD 2,346_CD 2,356_CD 2000_CD m_NN Glaxo_NNP Wellcome_NNP plc_NN :_: Interim_NNP 538_CD Second_JJ interim_JJ 827_CD Final_JJ 1,365_CD SmithKline_NNP Beecham_NNP plc_NN :_: First_NNP interim_JJ 162_CD Second_JJ interim_JJ 162_CD Third_JJ interim_JJ 163_CD Fourth_JJ interim_JJ 245_CD 732_CD 2,097_CD 2002_CD 2001_CD Dividends_NNPS per_IN share_NN p_NN p_VBP GlaxoSmithKline_NNP plc_NN :_: First_NNP interim_JJ 9_CD 9_CD Second_JJ interim_JJ 9_CD 9_CD Third_NNP interim_JJ 9_CD 9_CD Fourth_JJ interim_JJ 13_CD 12_CD 40_CD 39_CD 2000_CD p_NN Glaxo_NNP Wellcome_NNP plc_SYM -_: per_IN Glaxo_NNP Wellcome_NNP share_NN :_: Interim_NNP 15_CD Second_JJ interim_JJ 23_CD Final_JJ 38_CD The_DT equivalent_JJ dividend_NN per_IN GlaxoSmithKline_NNP share_NN is_VBZ the_DT same_JJ as_IN the_DT dividend_NN per_IN Glaxo_NNP Wellcome_NNP share_NN ._.
SmithKline_NNP Beecham_NNP plc_NN per_IN SmithKline_NNP Beecham_NNP share_NN :_: First_NNP interim_JJ 3.0_CD Second_JJ interim_JJ 3.0_CD Third_JJ interim_JJ 3.0_CD Fourth_JJ interim_JJ 4.5_CD 13.5_CD SmithKline_NNP Beecham_NNP plc_NN equivalent_JJ dividend_NN per_IN GlaxoSmithKline_NNP share_NN :_: First_NNP interim_JJ 6.59_CD Second_JJ interim_JJ 6.59_CD Third_JJ interim_JJ 6.59_CD Fourth_JJ interim_JJ 9.89_CD 29.66_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 95_CD 15_CD Goodwill_NNP Total_NNP m_VBD Cost_NN at_IN 1st_CD January_NNP 2002_CD 210_CD Exchange_NNP adjustments_NNS 17_CD Additions_NNS Note_VBP 31_CD 23_CD Cost_NN at_IN 31st_CD December_NNP 2002_CD 216_CD Amortisation_NNP at_IN 1st_CD January_NNP 2002_CD 36_CD Exchange_NNP adjustments_NNS 3_CD Provision_NNP for_IN the_DT year_NN 12_CD Amortisation_NNP at_IN 31st_CD December_NNP 2002_CD 45_CD Net_JJ book_NN value_NN at_IN 1st_CD January_NNP 2002_CD 174_CD Net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2002_CD 171_CD Licences_NNPS ,_, 16_CD Intangible_JJ assets_NNS patents_NNS ,_, etc._FW ._.
Brands_NNP Total_NNP m_FW m_FW m_FW Cost_NN at_IN 1st_CD January_NNP 2002_CD 597_CD 1,266_CD 1,863_CD Exchange_NNP adjustments_NNS 27_CD 94_CD 121_CD Additions_NNS 182_CD 182_CD Acquisition_NNP of_IN businesses_NNS 4_CD 4_CD Assets_NNS written_VBN off_RP 44_CD 10_CD 54_CD Cost_NN at_IN 31st_CD December_NNP 2002_CD 712_CD 1,162_CD 1,874_CD Amortisation_NNP at_IN 1st_CD January_NNP 2002 119 119_CD Exchange_NNP adjustments_NNS 5_CD 5_CD Provision_NNP for_IN the_DT year_NN 60_CD 60_CD Assets_NNS written_VBN off_RP 12_CD 12_CD Amortisation_NNP at_IN 31st_CD December_NNP 2002 162 162_CD Impairment_NN at_IN 1st_CD January_NNP 2002_CD 46_CD 25_CD 71_CD Exchange_NNP adjustments_NNS 3_CD 3_CD Impairment_NN loss_NN 4_CD 4_CD Impairment_NN at_IN 31st_CD December_NNP 2002_CD 53_CD 22_CD 75_CD Net_JJ book_NN value_NN at_IN 1st_CD January_NNP 2002_CD 432_CD 1,241_CD 1,673_CD Net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2002_CD 497_CD 1,140_CD 1,637_CD The_DT licences_NNS and_CC patents_NNS acquired_VBN in_IN the_DT year_NN relate_VBP to_TO the_DT acquisition_NN of_IN various_JJ compound_NN rights_NNS and_CC other_JJ research_NN based_VBN agreements_NNS see_VBP Note_NN 26_CD ._.
Brands_NNP largely_RB comprise_VBP a_DT portfolio_NN of_IN Sterling_NN products_NNS such_JJ as_IN Panadol_NNP ,_, Solpadeine_NNP and_CC Hedex_NNP and_CC the_DT Block_NNP Drug_NN products_NNS such_JJ as_IN Sensodyne_NNP ,_, Polident_NNP and_CC Poligrip_NNP ._.
Each_DT of_IN these_DT is_VBZ considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN given_VBN the_DT strength_NN and_CC durability_NN of_IN the_DT brand_NN and_CC the_DT level_NN of_IN marketing_NN support_NN ._.
Accordingly_RB ,_, they_PRP are_VBP not_RB amortised_VBN ._.
The_DT valuation_NN of_IN each_DT Sterling_NN brand_NN is_VBZ reviewed_VBN annually_RB using_VBG a_DT 10_CD year_NN cash_NN ow_NN forecast_NN as_IN this_DT was_VBD the_DT basis_NN for_IN the_DT original_JJ independent_JJ assessment_NN when_WRB they_PRP were_VBD acquired_VBN in_IN 1994_CD and_CC a_DT post-tax_JJ discount_NN rate_NN of_IN eight_CD per_IN cent_NN ._.
The_DT valuation_NN of_IN each_DT Block_NNP Drug_NNP brand_NN is_VBZ also_RB reviewed_VBN annually_RB using_VBG a_DT five_CD year_NN cash_NN ow_NN forecast_NN and_CC a_DT post-tax_JJ discount_NN rate_NN of_IN eight_CD per_IN cent_NN ._.
96_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS Plant_NN ,_, Land_NNP and_CC equipment_NN Computer_NN Assets_NNS in_IN 17_CD Tangible_JJ xed_JJ assets_NNS buildings_NNS and_CC vehicles_NNS software_NN construction_NN Total_JJ m_NN m_FW m_FW m_FW m_FW Cost_NN at_IN 1st_CD January_NNP 2002_CD 3,903_CD 6,821_CD 300_CD 1,212_CD 12,236_CD Exchange_NNP adjustments_NNS 154_CD 207_CD 5_CD 48_CD 414_CD Additions_NNPS 68_CD 350_CD 36_CD 573_CD 1,027_CD Acquisitions_NNS 57_CD 1_CD 13_CD Disposals_NNPS 69_CD 387_CD 8_CD 15_CD 479_CD Reclassications_NNPS 557_CD 130_CD 9_CD 696_CD Cost_NN at_IN 31st_CD December_NNP 2002_CD 4,310_CD 6,714_CD 332_CD 1,027_CD 12,383_CD Depreciation_NN at_IN 1st_CD January_NNP 2002_CD 1,011_CD 4,002_CD 95_CD 5,108_CD Exchange_NNP adjustments_NNS 41_CD 129_CD 3_CD 173_CD Provision_NNP for_IN the_DT year_NN 155_CD 555_CD 54_CD 764_CD Disposals_NNS 9_CD 305_CD 5_CD 319_CD Reclassications_NNPS 142_CD 173_CD 31_CD Depreciation_NN at_IN 31st_CD December_NNP 2002_CD 1,258_CD 3,950_CD 172_CD 5,380_CD Impairment_NN at_IN 1st_CD January_NNP 2002 147 112_CD 24_CD 283_CD Exchange_NNP 12_CD 7_CD 19_CD Impairment_NN loss_NN 29_CD 73_CD 102_CD Disposals_NNPS 11_CD 1_CD 12_CD Reclassications_NNS 5_CD 5_CD Impairment_NN at_IN 31st_CD December_NNP 2002 148 182_CD 24_CD 354_CD Net_JJ book_NN value_NN at_IN 1st_CD January_NNP 2002_CD 2,745_CD 2,707_CD 205_CD 1,188_CD 6,845_CD Net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2002_CD 2,904_CD 2,582_CD 160_CD 1,003_CD 6,649_CD The_DT net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2002_CD of_IN the_DT Groups_NNS land_NN and_CC buildings_NNS comprises_VBZ freehold_NN properties_NNS 2,699_CD million_CD at_IN 1st_CD January_NNP 2002_CD 2,516_CD million_CD ,_, properties_NNS with_IN leases_NNS of_IN 50_CD years_NNS or_CC more_JJR 135_CD million_CD at_IN 1st_CD January_NNP 2002_CD 157_CD million_CD and_CC properties_NNS with_IN leases_NNS of_IN less_JJR than_IN 50_CD years_NNS 70_CD million_CD at_IN 1st_CD January_NNP 2002_CD 72_CD million_CD ._.
Included_VBN in_IN plant_NN ,_, equipment_NN and_CC vehicles_NNS at_IN 31st_CD December_NNP 2002_CD are_VBP leased_VBN assets_NNS with_IN a_DT cost_NN of_IN 6_CD million_CD at_IN 1st_CD January_NNP 2002_CD 23_CD million_CD ,_, accumulated_VBN depreciation_NN of_IN 4_CD million_CD at_IN 1st_CD January_NNP 2002_CD 14_CD million_CD and_CC a_DT net_JJ book_NN value_NN of_IN 2_CD million_CD at_IN 1st_CD January_NNP 2002_CD 9_CD million_CD ._.
The_DT impairment_NN loss_NN principally_RB relates_VBZ to_TO reductions_NNS in_IN forecast_NN cash_NN ows_VBZ resulting_VBG from_IN decisions_NNS to_TO close_VB manufacturing_NN facilities_NNS and_CC has_VBZ been_VBN measured_VBN by_IN reference_NN to_TO value_NN in_IN use_NN ,_, typically_RB using_VBG a_DT discount_NN rate_NN of_IN eight_CD per_IN cent_NN ._.
Joint_NNP Associated_NNP Equity_NNP Own_NNP 18_CD Fixed_JJ asset_NN investments_NNS ventures_NNS undertakings_NNS investments_NNS shares_NNS Total_JJ m_NN m_FW m_FW m_FW m_FW At_IN 1st_CD January_NNP 2002 32 127 133_CD 2,936_CD 3,228_CD Exchange_NNP adjustments_NNS 2_CD 15_CD 16_CD 33_CD Additions_NNS 539_CD 44_CD Charge_NNP for_IN the_DT year_NN 51_CD 51_CD Impairment_NN 19_CD 19_CD Transfers_NNPS 5_CD 8_CD 13_CD Disposals_NNS 4_CD 59_CD 63_CD Retained_VBN profit_NN for_IN the_DT year_NN 13_CD 47_CD 34_CD Goodwill_NNP amortisation_NN 6_CD 6_CD At_IN 31st_CD December_NNP 2002 17 153 125_CD 2,826_CD 3,121_CD Investments_NNP in_IN joint_JJ ventures_NNS comprise_VBP 19_CD million_CD share_NN of_IN gross_JJ assets_NNS 2001_CD 33_CD million_CD and_CC 2_CD million_CD share_NN of_IN gross_JJ liabilities_NNS 2001_CD 1_CD million_CD ._.
The_DT principal_NN associated_VBN undertaking_NN is_VBZ Quest_NNP Diagnostics_NNPS ,_, Inc._NNP a_DT US_NNP clinical_JJ laboratory_NN business_NN listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
The_DT investment_NN has_VBZ a_DT book_NN value_NN at_IN 31st_CD December_NNP 2002_CD of_IN 129_CD million_CD 2001_CD 98_CD million_CD and_CC a_DT market_NN value_NN of_IN 782_CD million_CD 2001_CD 1,094_CD million_CD ._.
At_IN 31st_CD December_NNP 2002_CD ,_, the_DT Group_NNP owned_VBD 23_CD per_IN cent_NN of_IN Quest_NNP 2001_CD 23_CD per_IN cent_NN ._.
This_DT holding_NN was_VBD reduced_VBN to_TO 21_CD per_IN cent_NN in_IN February_NNP 2003_CD following_VBG Quests_NNP acquisition_NN of_IN Unilab_NNP Corporation_NNP ._.
The_DT book_NN value_NN includes_VBZ goodwill_NN which_WDT is_VBZ being_VBG amortised_VBN over_IN 20_CD years_NNS :_: the_DT amortisation_NN charge_NN for_IN 2002_CD was_VBD 6_CD million_CD ._.
The_DT goodwill_NN at_IN 31st_CD December_NNP 2002_CD amounts_NNS to_TO 101_CD million_CD 2001_CD 118_CD million_CD ._.
Goodwill_NN of_IN 115_CD million_CD which_WDT relates_VBZ to_TO the_DT continuing_VBG Group_NNP interest_NN in_IN Clinical_NNP Laboratories_NNP assets_NNS attributed_VBD to_TO Quest_NNP ,_, remains_VBZ eliminated_VBN against_IN Group_NNP reserves_NNS ._.
Equity_NNP investments_NNS comprise_VBP listed_VBN investments_NNS of_IN 7_CD million_CD 2001_CD 8_CD million_CD and_CC unlisted_JJ investments_NNS of_IN 118_CD million_CD 2001_CD 125_CD million_CD ._.
The_DT market_NN value_NN of_IN listed_VBN investments_NNS was_VBD 11_CD million_CD 2001_CD 8_CD million_CD ._.
Investments_NNP in_IN own_JJ shares_NNS consist_VBP of_IN shares_NNS held_VBN by_IN Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS see_VBP Note_NN 34_CD ._.
The_DT market_NN value_NN of_IN own_JJ shares_NNS at_IN 31st_CD December_NNP 2002_CD was_VBD 2,161_CD million_CD 2001_CD 3,229_CD million_CD ._.
This_DT valuation_NN shortfall_NN is_VBZ not_RB considered_VBN to_TO represent_VB a_DT permanent_JJ diminution_NN in_IN value_NN in_IN the_DT context_NN of_IN the_DT length_NN of_IN the_DT future_JJ period_NN over_IN which_WDT the_DT related_JJ share_NN options_NNS may_MD be_VB exercised_VBN ._.
Accordingly_RB no_DT provision_NN has_VBZ been_VBN made_VBN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 97_CD 19_CD Equity_NN investments_NNS Total_JJ m_NN At_IN 1st_CD January_NNP 2002_CD 185_CD Exchange_NNP adjustments_NNS 4_CD Additions_NNPS 43_CD Transfer_NN from_IN xed_JJ asset_NN investments_NNS 6_CD Impairment_NN 55_CD Disposals_NNPS 14_CD At_IN 31st_CD December_NNP 2002_CD 161_CD Equity_NN investments_NNS include_VBP listed_VBN investments_NNS of_IN 125_CD million_CD 2001_CD 185_CD million_CD ._.
The_DT market_NN value_NN of_IN listed_VBN investments_NNS was_VBD 232_CD million_CD 2001_CD 531_CD million_CD ._.
20_CD Stocks_NNS 2002_CD 2001_CD m_NN m_NN Raw_NNP materials_NNS and_CC consumables_NNS 508_CD 565_CD Work_NN in_IN progress_NN 673_CD 808_CD Finished_VBN goods_NNS 899_CD 717_CD 2,080_CD 2,090_CD 21_CD Debtors_NNS 2001_CD 2002_CD restated_VBN m_NN m_NN Amounts_NNS due_JJ within_IN one_CD year_NN Trade_NNP debtors_NNS 3,515_CD 3,628_CD Other_JJ debtors_NNS 569_CD 575_CD Prepaid_JJ pension_NN contributions_NNS 257_CD 11_CD Other_JJ prepayments_NNS and_CC accrued_VBN income_NN 178_CD 177_CD Amounts_NNS due_JJ after_IN one_CD year_NN Other_JJ debtors_NNS 294_CD 320_CD Prepayments_NNS and_CC accrued_VBN income_NN 14_CD 9_CD Deferred_VBN taxation_NN Note_NN 12_CD 1,373_CD 1,297_CD 6,200_CD 6,017_CD Debtors_NNS include_VBP trading_NN balances_NNS of_IN nil_NN 2001_CD 2_CD million_CD due_JJ from_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS ._.
22_CD Other_JJ creditors_NNS 2002_CD 2001_CD m_NN m_NN Amounts_NNS due_JJ within_IN one_CD year_NN Trade_NNP creditors_NNS 715_CD 760_CD Taxation_NNP Note_NN 12_CD 1,449_CD 1,672_CD Social_NNP security_NN 87_CD 123_CD Other_JJ creditors_NNS 429_CD 345_CD Accruals_NNPS and_CC deferred_JJ income_NN 3,285_CD 3,142_CD Dividends_NNS payable_JJ 1,292_CD 1,264_CD 7,257_CD 7,306_CD Amounts_NNS due_JJ after_IN one_CD year_NN Other_JJ creditors_NNS 113_CD 58_CD Accruals_NNS and_CC deferred_JJ income_NN 93 132 206 190_CD Accruals_NNS include_VBP obligations_NNS for_IN wages_NNS and_CC salaries_NNS of_IN 557_CD million_CD 2001_CD 617_CD million_CD ._.
98_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS Pensions_NNS and_CC other_JJ Legal_JJ 23_CD Provisions_NNS for_IN post-retirement_JJ Manufacturing_NNP Merger_NNP and_CC other_JJ Deferred_NNP Other_JJ liabilities_NNS and_CC charges_NNS benets_NNS restructuring_VBG integration_NN disputes_NNS taxation_NN provisions_NNS Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW m_FW At_IN 1st_CD January_NNP 2002_CD as_IN previously_RB reported_VBN 1,022_CD 126 240 227 195_CD 1,810_CD Prior_RB year_NN adjustment_NN Note_VB 12 553 553_CD At_IN 1st_CD January_NNP 2002_CD as_IN restated_VBN 1,022_CD 126 240 227 553_CD 195_CD 2,363_CD Exchange_NNP adjustments_NNS 69_CD 2_CD 8_CD 44_CD 12_CD 12_CD 123_CD Charge_NNP for_IN the_DT year_NN 198 32 379 304_CD 14_CD 4_CD 931_CD Applied_NNP 335_CD 52_CD 203_CD 72_CD 17_CD 679_CD Reclassications_NNS and_CC other_JJ movements_NNS 105_CD 1_CD 5_CD 92_CD 163_CD 13_CD 341_CD At_IN 31st_CD December_NNP 2002 921 103 403_CD 507 742 157_CD 2,833_CD In_IN December_NNP 2002_CD ,_, the_DT Group_NNP made_VBD special_JJ cash_NN contributions_NNS totalling_VBG 320_CD million_CD into_IN the_DT UK_NNP ,_, US_NNP and_CC German_JJ pension_NN schemes_NNS ._.
The_DT contributions_NNS relating_VBG to_TO the_DT US_NNP and_CC German_JJ pension_NN schemes_NNS are_VBP included_VBN within_IN the_DT amounts_NNS applied_VBD to_TO the_DT provision_NN above_IN :_: the_DT contribution_NN relating_VBG to_TO the_DT UK_NNP pension_NN scheme_NN has_VBZ increased_VBN the_DT prepayment_NN amount_NN shown_VBN under_IN debtors_NNS in_IN Note_NN 21_CD ._.
The_DT Group_NNP has_VBZ recognized_VBN costs_NNS in_IN 2002_CD in_IN respect_NN of_IN plans_NNS for_IN manufacturing_NN and_CC other_JJ restructuring_NN initiated_VBN in_IN 1998_CD ,_, 1999_CD and_CC in_IN 2001_CD following_VBG the_DT merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP and_CC acquisition_NN of_IN Block_NNP Drug_NNP ._.
These_DT plans_NNS are_VBP largely_RB to_TO be_VB completed_VBN during_IN 2003_CD ._.
Costs_NNS recognized_VBD as_IN a_DT provision_NN ,_, principally_RB in_IN respect_NN of_IN identied_JJ severances_NNS at_IN sites_NNS where_WRB it_PRP has_VBZ been_VBN announced_VBN that_IN manufacturing_VBG activities_NNS will_MD cease_VB ,_, are_VBP expected_VBN to_TO be_VB incurred_VBN mainly_RB in_IN 2003_CD ._.
Costs_NNS of_IN asset_NN write-downs_NNS have_VBP been_VBN recognized_VBN as_IN an_DT impairment_NN of_IN xed_JJ assets_NNS ._.
The_DT Group_NNP has_VBZ recognized_VBN costs_NNS in_IN 2001_CD and_CC 2002_CD in_IN respect_NN of_IN plans_NNS for_IN the_DT integration_NN of_IN the_DT Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP businesses_NNS ._.
Additional_JJ costs_NNS will_MD be_VB incurred_VBN as_IN implementation_NN of_IN the_DT integration_NN following_VBG the_DT merger_NN continues_VBZ ._.
Costs_NNS recognized_VBD as_IN a_DT provision_NN in_IN respect_NN of_IN identied_JJ severances_NNS are_VBP expected_VBN to_TO be_VB incurred_VBN in_IN 2003_CD ,_, and_CC in_IN respect_NN of_IN the_DT program_NN to_TO encourage_VB staff_NN to_TO convert_VB Glaxo_NNP Wellcome_NNP or_CC SmithKline_NNP Beecham_NNP share_NN options_NNS into_IN GlaxoSmithKline_NNP share_NN options_NNS when_WRB employees_NNS exercise_VBP these_DT options_NNS ._.
Provisions_NNS for_IN legal_JJ and_CC other_JJ disputes_NNS and_CC other_JJ matters_NNS include_VBP amounts_NNS relating_VBG to_TO US_NNP anti-trust_NN ,_, product_NN liability_NN ,_, contract_NN terminations_NNS ,_, self-insurance_NN ,_, environmental_JJ clean-up_JJ and_CC property_NN rental_NN ._.
The_DT companys_NNS Directors_NNS ,_, having_VBG taken_VBN legal_JJ advice_NN ,_, have_VBP established_VBN provisions_NNS after_IN taking_VBG into_IN account_NN insurance_NN and_CC other_JJ agreements_NNS and_CC having_VBG regard_NN to_TO the_DT relevant_JJ facts_NNS and_CC circumstances_NNS of_IN each_DT matter_NN and_CC in_IN accordance_NN with_IN accounting_NN requirements_NNS ._.
No_DT provisions_NNS have_VBP been_VBN made_VBN for_IN unasserted_JJ claims_NNS ._.
The_DT ultimate_JJ liability_NN for_IN such_JJ matters_NNS may_MD vary_VB from_IN the_DT amounts_NNS provided_VBN and_CC is_VBZ dependent_JJ upon_IN the_DT outcome_NN of_IN litigation_NN proceedings_NNS ,_, investigations_NNS and_CC possible_JJ settlement_NN negotiations_NNS ._.
GlaxoSmithKline_NNP is_VBZ involved_VBN in_IN a_DT number_NN of_IN legal_JJ and_CC other_JJ disputes_NNS including_VBG notication_NN of_IN possible_JJ claims_NNS where_WRB ,_, because_IN of_IN the_DT early_JJ stage_NN of_IN the_DT matter_NN ,_, no_DT reliable_JJ estimate_NN of_IN the_DT outcome_NN can_MD be_VB made_VBN ._.
Accordingly_RB no_DT provision_NN has_VBZ been_VBN recorded_VBN for_IN these_DT matters_NNS or_CC any_DT unasserted_JJ claims_NNS ._.
It_PRP is_VBZ in_IN the_DT nature_NN of_IN the_DT Groups_NNS business_NN that_IN a_DT number_NN of_IN these_DT matters_NNS may_MD be_VB the_DT subject_NN of_IN negotiation_NN and_CC litigation_NN over_IN several_JJ years_NNS ._.
The_DT largest_JJS individual_JJ amounts_NNS provided_VBN are_VBP expected_VBN to_TO be_VB settled_VBN within_IN two_CD years_NNS ._.
For_IN a_DT discussion_NN of_IN litigation_NN issues_NNS ,_, refer_VBP to_TO Legal_NNP proceedings_NNS in_IN Note_NN 30_CD ._.
24_CD Contingent_JJ liabilities_NNS Contingent_JJ liabilities_NNS ,_, comprising_VBG guarantees_NNS ,_, discounted_VBD bills_NNS and_CC other_JJ items_NNS arising_VBG in_IN the_DT normal_JJ course_NN of_IN business_NN ,_, amounted_VBD at_IN 31st_CD December_NNP 2002_CD to_TO 138_CD million_CD 2001_CD 90_CD million_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 99_CD 25_CD Net_JJ debt_NN 2002_CD 2001_CD m_NN m_NN Liquid_NN investments_NNS 1,256_CD 1,415_CD Cash_NN at_IN bank_NN 1,052_CD 716_CD 2,308_CD 2,131_CD Loans_NNPS and_CC overdrafts_NNS due_JJ within_IN one_CD year_NN :_: Bank_NNP loans_NNS and_CC overdrafts_NNS 263_CD 307_CD Commercial_JJ paper_NN 1,284_CD 1,269_CD Eurobonds_NNS and_CC Medium-Term_JJ notes_NNS 542_CD Obligations_NNS under_IN finance_NN leases_NNS 1_CD 2_CD Other_JJ loans_NNS 3_CD 4_CD 1,551_CD 2,124_CD Loans_NNS due_JJ after_IN one_CD year_NN :_: Bank_NNP loans_NNS 3_CD 11_CD Eurobonds_NNS ,_, Medium-Term_JJ notes_NNS and_CC private_JJ nancing_NN 3,054_CD 2,059_CD Loan_NNP Stock_NNP 14_CD 16_CD Obligations_NNS under_IN finance_NN leases_NNS 12_CD 12_CD Other_JJ loans_NNS 9_CD 10_CD 3,092_CD 2,108_CD Net_JJ debt_NN 2,335_CD 2,101_CD At_IN the_DT balance_NN sheet_NN date_NN the_DT Groups_NNS liquid_JJ investments_NNS had_VBD an_DT aggregate_JJ market_NN value_NN of_IN 1,264_CD million_CD 2001_CD 1,418_CD million_CD ._.
Loans_NNS and_CC overdrafts_NNS due_JJ within_IN one_CD year_NN Commercial_JJ paper_NN comprises_VBZ a_DT US$_$ 10_CD billion_CD program_NN ,_, of_IN which_WDT 1,284_CD million_CD was_VBD in_IN issue_NN at_IN 31st_CD December_NNP 2002_CD at_IN 31st_CD December_NNP 2001_CD 1,269_CD million_CD ,_, backed_VBD up_RP by_IN committed_JJ facilities_NNS of_IN 364_CD days_NNS duration_NN of_IN 872_CD million_CD ,_, renewable_JJ annually_RB ,_, and_CC liquid_JJ investments_NNS of_IN 787_CD million_CD ._.
The_DT weighted_JJ average_JJ interest_NN rate_NN on_IN commercial_JJ paper_NN borrowings_NNS at_IN 31st_CD December_NNP 2002_CD was_VBD 1.3_CD per_IN cent_NN ._.
Loans_NNS due_JJ after_IN one_CD year_NN In_IN 2002_CD ,_, a_DT 500_CD million_CD ,_, 4.875_CD per_IN cent_NN coupon_NN bond_NN and_CC two_CD ,_, US_NNP dollar_NN denominated_VBD ,_, oating_VBG rate_NN bonds_NNS totalling_VBG $_$ 495_CD million_CD were_VBD issued_VBN under_IN the_DT European_JJ Medium_NNP Term_NNP Note_NN program_NN ._.
The_DT Group_NNP also_RB raised_VBD $_$ 500_CD million_CD of_IN oating_NN rate_NN debt_NN through_IN a_DT private_JJ nancing_NN arrangement_NN ._.
This_DT may_MD be_VB redeemed_VBN by_IN the_DT Group_NNP at_IN any_DT time_NN and_CC ,_, in_IN particular_JJ ,_, in_IN the_DT event_NN of_IN any_DT accelerating_VBG event_NN that_WDT would_MD increase_VB the_DT cost_NN of_IN funding_NN for_IN the_DT Group_NNP ._.
Loans_NNS due_JJ after_IN one_CD year_NN are_VBP repayable_JJ over_IN various_JJ periods_NNS as_IN follows_VBZ :_: 2002_CD 2001_CD m_NN m_NN Between_IN one_CD and_CC two_CD years_NNS 423_CD 11_CD Between_IN two_CD and_CC three_CD years_NNS 563_CD 116_CD Between_IN three_CD and_CC four_CD years_NNS 311_CD 140_CD Between_IN four_CD and_CC five_CD years_NNS 2_CD 843_CD After_IN five_CD years_NNS 1,793_CD 998_CD 3,092_CD 2,108_CD The_DT loans_NNS repayable_JJ after_IN five_CD years_NNS carry_VBP interest_NN at_IN effective_JJ rates_NNS between_IN 4.9_CD per_IN cent_NN and_CC 5.3_CD per_IN cent_NN ._.
The_DT repayment_NN dates_NNS range_VBP from_IN 2008_CD to_TO 2033_CD ._.
100_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 25_CD Net_JJ debt_NN continued_VBD Secured_JJ loans_NNS Loans_NNS amounting_VBG to_TO 13_CD million_CD 2001_CD 13_CD million_CD are_VBP secured_VBN by_IN charges_NNS on_IN xed_VBN and_CC current_JJ assets_NNS ._.
2002_CD 2001_CD Finance_NNP lease_NN obligations_NNS m_VBP m_FW Rental_JJ payments_NNS due_JJ within_IN one_CD year_NN 1_CD 2_CD Rental_JJ payments_NNS due_JJ between_IN one_CD and_CC two_CD years_NNS 2_CD 2_CD Rental_JJ payments_NNS due_JJ between_IN two_CD and_CC three_CD years_NNS 1_CD 1_CD Rental_JJ payments_NNS due_JJ between_IN three_CD and_CC four_CD years_NNS 1_CD 1_CD Rental_JJ payments_NNS due_JJ between_IN four_CD and_CC five_CD years_NNS 1_CD 1_CD Rental_JJ payments_NNS due_JJ after_IN five_CD years_NNS 7_CD 7_CD Total_JJ finance_NN lease_NN obligations_NNS 13_CD 14_CD Financial_NNP instruments_NNS Further_JJ information_NN is_VBZ given_VBN in_IN Note_NN 32_CD ._.
26_CD Commitments_NNS 2002_CD 2001_CD Capital_NNP commitments_NNS m_VBP m_FW Contracted_VBN for_IN but_CC not_RB provided_VBN in_IN the_DT financial_JJ statements_NNS Intangible_NNP xed_VBD assets_NNS 1,410_CD 1,103_CD Tangible_JJ xed_JJ assets_NNS 382_CD 298_CD 1,792_CD 1,401_CD A_DT number_NN of_IN commitments_NNS were_VBD made_VBN in_IN 2002_CD under_IN licensing_NN and_CC other_JJ agreements_NNS ,_, principally_RB with_IN elbion_NN AG_NNP ,_, Adolor_NNP Corporation_NNP ,_, Theravance_NNP ,_, Inc._NNP and_CC Unigene_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Payments_NNS become_VBP due_JJ if_IN future_JJ milestones_NNS are_VBP achieved_VBN ._.
As_IN some_DT of_IN these_DT agreements_NNS relate_VBP to_TO compounds_NNS in_IN the_DT early_JJ stages_NNS of_IN development_NN ,_, milestone_NN payments_NNS will_MD continue_VB for_IN a_DT number_NN of_IN years_NNS if_IN the_DT compounds_NNS move_VBP successfully_RB through_IN the_DT development_NN process_NN ._.
Generally_RB the_DT closer_RBR the_DT product_NN is_VBZ to_TO marketing_VBG approval_NN the_DT greater_JJR the_DT possibility_NN of_IN success_NN ._.
The_DT Group_NNP also_RB has_VBZ other_JJ commitments_NNS of_IN 162_CD million_CD relating_VBG to_TO other_JJ payments_NNS to_TO be_VB made_VBN under_IN licences_NNS and_CC other_JJ alliances_NNS ,_, principally_RB to_TO Exelixis_NNP Inc._NNP 2002_CD 2001_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS for_IN the_DT next_JJ year_NN m_FW m_FW Operating_NN leases_NNS on_IN land_NN and_CC buildings_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 10_CD 5_CD Between_IN one_CD and_CC five_CD years_NNS 47_CD 18_CD After_IN five_CD years_NNS 56_CD 51_CD 113_CD 74_CD Operating_NN leases_NNS on_IN plant_NN ,_, equipment_NN and_CC vehicles_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 7_CD 4_CD Between_IN one_CD and_CC five_CD years_NNS 47_CD 27_CD After_IN five_CD years_NNS 1_CD 55_CD 31_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS in_IN future_JJ years_NNS 2003 168 105 2004_CD 97_CD 89_CD 2005_CD 80_CD 79_CD 2006_CD 59_CD 69_CD 2007_CD 49_CD 59_CD 2008_CD and_CC thereafter_RB 249 241 702 642_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 101_CD Share_NN premium_NN Ordinary_NNP Shares_NNP of_IN 25p_JJ each_DT Redeemable_JJ preference_NN shares_NNS of_IN 1_CD each_DT 27_CD Share_NN capital_NN and_CC share_NN premium_NN account_NN account_NN Number_NNP m_NNP Number_NNP m_FW m_FW Share_NN capital_NN authorised_VBN At_IN 31st_CD December_NNP 2001_CD 10,000,000,000_CD 2,500_CD At_IN 31st_CD December_NNP 2002_CD 10,000,000,000_CD 2,500_CD Share_NN capital_NN issued_VBN and_CC fully_RB paid_VBN At_IN 1st_CD January_NNP 2001_CD 50,000_CD 6,225,662,174_CD 1,556_CD 30_CD Share_NN capital_NN redeemed_VBN at_IN par_JJ 50,000_CD Share_NN capital_NN issued_VBN under_IN share_NN option_NN schemes_NNS 17,878,815_CD 4_CD 140_CD Share_NN capital_NN purchased_VBN and_CC canceled_VBN 70,575,000_CD 17_CD At_IN 31st_CD December_NNP 2001_CD 6,172,965,989_CD 1,543_CD 170_CD Share_NN capital_NN issued_VBN under_IN share_NN option_NN schemes_NNS 7,049,394_CD 2_CD 54_CD Share_NN capital_NN purchased_VBN and_CC canceled_VBN 155,749,038_CD 39_CD At_IN 31st_CD December_NNP 2002_CD 6,024,266,345_CD 1,506_CD 224_CD Number_NN 000_CD Number_NN of_IN shares_NNS issuable_JJ under_IN outstanding_JJ options_NNS Note_VBP 34_CD At_IN 31st_CD December_NNP 2001_CD 155,078_CD At_IN 31st_CD December_NNP 2002_CD 217,953_CD Number_NN of_IN unissued_JJ shares_NNS not_RB under_IN option_NN At_IN 31st_CD December_NNP 2001_CD 3,671,956_CD At_IN 31st_CD December_NNP 2002_CD 3,757,781_CD The_DT redeemable_JJ preference_NN shares_NNS were_VBD redeemed_VBN by_IN the_DT company_NN on_IN 31st_CD August_NNP 2001_CD ._.
The_DT nominal_JJ amount_NN of_IN these_DT redeemable_JJ preference_NN shares_NNS was_VBD converted_VBN into_IN 200,000_CD ordinary_JJ shares_NNS of_IN 25_CD pence_NN each_DT resulting_VBG in_IN authorised_JJ share_NN capital_NN at_IN 31st_CD December_NNP 2001_CD of_IN 10_CD billion_CD ordinary_JJ shares_NNS of_IN 25_CD pence_NN each_DT ._.
In_IN October_NNP 2002_CD ,_, GlaxoSmithKline_NNP commenced_VBD a_DT new_JJ 4_CD billion_CD share_NN buy-back_JJ program_NN ._.
This_DT follows_VBZ the_DT completion_NN of_IN the_DT 4_CD billion_CD buy-back_NN program_NN announced_VBN in_IN 2001_CD ._.
A_DT total_NN of_IN 2,220_CD million_CD was_VBD spent_VBN in_IN 2002_CD of_IN which_WDT 219_CD million_CD relates_VBZ to_TO the_DT new_JJ buy-back_NN program_NN ._.
The_DT exact_JJ amount_NN and_CC timing_NN of_IN future_JJ purchases_NNS will_MD be_VB determined_VBN by_IN the_DT Group_NNP and_CC is_VBZ dependent_JJ on_IN market_NN conditions_NNS and_CC other_JJ factors_NNS ._.
In_IN the_DT period_NN 1st_CD January_NNP 2003_CD to_TO 3rd_CD March_NNP 2003_CD a_DT further_JJ 9,350,000_CD shares_NNS had_VBD been_VBN purchased_VBN and_CC canceled_VBN at_IN a_DT cost_NN of_IN 105_CD million_CD ._.
For_IN details_NNS of_IN substantial_JJ shareholdings_NNS refer_VBP to_TO Substantial_NNP shareholdings_NNS on_IN page_NN 155_CD ._.
28_CD Non-equity_JJ minority_NN interests_NNS SmithKline_NNP Beecham_NNP Holdings_NNP Corporation_NNP SBH_NNP Corp_NNP ,_, a_DT subsidiary_NN incorporated_VBN in_IN Delaware_NNP ,_, USA_NNP ,_, has_VBZ in_IN issue_NN $_$ 500_CD million_CD of_IN Flexible_NNP Auction_NNP Market_NNP Preferred_NNP Stock_NNP Flex_NNP AMPS_NNP ,_, comprising_VBG 5,000_CD shares_NNS of_IN $_$ 100,000_CD each_DT ,_, issued_VBN in_IN six_CD series_NN ._.
The_DT dividend_NN on_IN half_NN of_IN these_DT shares_NNS was_VBD xed_VBN on_IN issuance_NN in_IN 1996_CD for_IN a_DT seven_CD year_NN period_NN ._.
The_DT dividend_NN on_IN the_DT other_JJ half_NN was_VBD xed_VBN for_IN a_DT five_CD year_NN period_NN which_WDT ended_VBD during_IN 2001_CD and_CC now_RB varies_VBZ ,_, predominately_RB with_IN prevailing_VBG interest_NN rates_NNS ,_, and_CC is_VBZ set_VBN every_DT seven_CD weeks_NNS at_IN an_DT auction_NN at_IN which_WDT the_DT shares_NNS are_VBP also_RB traded_VBN ._.
SBH_NNP Corp_NNP also_RB has_VBZ in_IN issue_NN $_$ 400_CD million_CD of_IN Auction_NNP Rate_NNP Preference_NNP Stock_NNP ARPS_NNP ,_, comprising_VBG 4,000_CD shares_NNS of_IN $_$ 100,000_CD each_DT ,_, issued_VBN in_IN five_CD series_NN ,_, the_DT dividend_NN on_IN which_WDT also_RB varies_VBZ under_IN conditions_NNS similar_JJ to_TO the_DT Flex_NNP AMPS_NNP described_VBD above_IN ._.
Together_RB ,_, the_DT ARPS_NNP and_CC the_DT Flex_NNP AMPS_NNP constitute_VBP the_DT preference_NN shares_NNS ,_, which_WDT represent_VBP the_DT non-equity_JJ minority_NN interest_NN ._.
SmithKline_NNP Beecham_NNP plc_NN has_VBZ ,_, in_IN certain_JJ circumstances_NNS ,_, guaranteed_VBN payment_NN of_IN dividends_NNS declared_VBD on_IN the_DT preference_NN shares_NNS ._.
SmithKline_NNP Beecham_NNP plc_NN has_VBZ also_RB agreed_VBN with_IN SBH_NNP Corp_NNP that_IN in_IN certain_JJ circumstances_NNS it_PRP will_MD provide_VB support_NN to_TO SBH_NNP Corp_NNP in_IN relation_NN to_TO the_DT principal_NN ._.
However_RB ,_, any_DT guarantee_NN or_CC support_NN is_VBZ limited_VBN so_RB that_IN in_IN no_DT circumstances_NNS could_MD the_DT holder_NN of_IN preference_NN shares_NNS be_VB in_IN a_DT more_RBR favourable_JJ position_NN than_IN had_VBD they_PRP been_VBN a_DT holder_NN of_IN a_DT preference_NN share_NN in_IN SmithKline_NNP Beecham_NNP plc._NN ._.
The_DT preference_NN shares_NNS represent_VBP a_DT long-term_JJ non-equity_JJ minority_NN interest_NN in_IN the_DT Group_NNP balance_NN sheet_NN in_IN accordance_NN with_IN FRS_NNP 4_CD Capital_NNP Instruments_NNP and_CC UITF_NNP 33_CD Obligations_NNS in_IN capital_NN instruments_NNS ._.
102_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS profit_NN and_CC Other_JJ loss_NN account_NN Total_JJ 29_CD Reserves_NNS reserves_NNS restated_VBN restated_VBN m_FW m_FW m_FW At_IN 31st_CD December_NNP 1999_CD 1,701_CD 2,141_CD 3,842_CD Goodwill_NNP written_VBN back_RB 22_CD Exchange_NNP movements_NNS 23_CD 23_CD UK_NNP tax_NN on_IN exchange_NN movements_NNS 16_CD 16_CD Shares_NNP issued_VBD 148_CD 148_CD profit_NN attributable_JJ to_TO shareholders_NNS 4,106_CD 4,106_CD Dividends_NNS 2,097_CD 2,097_CD Revaluation_NN of_IN goodwill_NN due_JJ to_TO exchange_VB 10_CD 10_CD At_IN 31st_CD December_NNP 2000_CD 1,849_CD 4,155_CD 6,004_CD Goodwill_NNP written_VBN back_RB 356_CD 356_CD Exchange_NNP movements_NNS 151_CD 151_CD Shares_NNP purchased_VBD for_IN cancellation_NN 17_CD 1,274_CD 1,257_CD profit_NN attributable_JJ to_TO shareholders_NNS 3,053_CD 3,053_CD Dividends_NNS 2,356_CD 2,356_CD Revaluation_NN of_IN goodwill_NN due_JJ to_TO exchange_VB 28_CD 28_CD At_IN 31st_CD December_NNP 2001_CD 1,866_CD 3,811_CD 5,677_CD Exchange_NNP movements_NNS 154_CD 154_CD UK_NNP tax_NN on_IN exchange_NN movements_NNS 67_CD 67_CD Shares_NNP purchased_VBD for_IN cancellation_NN 39_CD 2,220_CD 2,181_CD profit_NN attributable_JJ to_TO shareholders_NNS 3,915_CD 3,915_CD Dividends_NNS 2,346_CD 2,346_CD Unrealised_JJ gains_NNS on_IN equity_NN investments_NNS 77_CD At_IN 31st_CD December_NNP 2002_CD 1,905_CD 2,946_CD 4,851_CD Goodwill_NNP arising_VBG on_IN acquisitions_NNS before_IN 1st_CD January_NNP 1998_CD which_WDT has_VBZ been_VBN written_VBN off_RP against_IN other_JJ reserves_NNS amounts_NNS to_TO 6,180_CD million_CD ,_, including_VBG goodwill_NN of_IN 4,840_CD million_CD previously_RB held_VBN as_IN a_DT goodwill_NN reserve_NN which_WDT was_VBD offset_VBN against_IN other_JJ reserves_NNS in_IN 1998_CD ._.
The_DT goodwill_NN written_VBN back_RB in_IN 2001_CD relates_VBZ primarily_RB to_TO the_DT disposals_NNS of_IN Affymax_NNP and_CC part_NN of_IN the_DT Groups_NNS holding_VBG in_IN Quest_NNP Diagnostics_NNPS ,_, Inc._NNP ._.
Goodwill_NNP denominated_VBD in_IN local_JJ currencies_NNS which_WDT is_VBZ subject_JJ to_TO revaluation_NN amounted_VBD to_TO 293_CD million_CD at_IN 31st_CD December_NNP 2002_CD ._.
Goodwill_NN on_IN acquisitions_NNS after_IN 1st_CD January_NNP 1998_CD has_VBZ been_VBN capitalized_VBN ,_, in_IN accordance_NN with_IN the_DT accounting_NN policy_NN set_VBN out_RP in_IN Note_NN 2_CD ._.
Exchange_NNP movements_NNS taken_VBN to_TO reserves_NNS in_IN 2002_CD include_VBP losses_NNS of_IN 1,251_CD million_CD 2001_CD losses_NNS 114_CD million_CD ,_, 2000_CD losses_NNS 84_CD million_CD on_IN foreign_JJ currency_NN loans_NNS less_RBR deposits_NNS ,_, gains_NNS of_IN 1,097_CD million_CD 2001_CD losses_NNS 9_CD million_CD ,_, 2000_CD gains_NNS 71_CD million_CD on_IN the_DT retranslation_NN of_IN net_JJ assets_NNS and_CC nil_NN 2001_CD losses_NNS 28_CD million_CD ,_, 2000_CD losses_NNS 10_CD million_CD on_IN goodwill_NN eliminated_VBN against_IN reserves_NNS ._.
The_DT UK_NNP tax_NN on_IN exchange_NN movements_NNS in_IN the_DT year_NN of_IN 67_CD million_CD 2001_CD nil_NN ,_, 2000_CD 16_CD million_CD credit_NN relates_VBZ to_TO the_DT UK_NNP taxable_JJ element_NN of_IN the_DT foreign_JJ currency_NN loans_NNS less_RBR deposits_NNS taken_VBN to_TO reserves_NNS ._.
Exchange_NNP adjustments_NNS debited_VBD to_TO reserves_NNS cumulatively_RB amount_VB to_TO 1,452_CD million_CD ._.
Other_JJ reserves_NNS include_VBP the_DT merger_NN reserve_NN created_VBN on_IN the_DT merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP amounting_VBG to_TO 1,561_CD million_CD at_IN 31st_CD December_NNP 2002_CD 2001_CD 1,561_CD million_CD :_: 2000_CD 1,561_CD million_CD ._.
Other_JJ reserves_NNS also_RB include_VBP the_DT capital_NN redemption_NN reserve_NN created_VBN as_IN a_DT result_NN of_IN the_DT share_NN buy-back_JJ program_NN amounting_NN to_TO 56_CD million_CD at_IN 31st_CD December_NNP 2002_CD 2001_CD 17_CD million_CD ,_, 2000_CD nil_NN ._.
Total_JJ reserves_NNS amounted_VBD to_TO 4,851_CD million_CD at_IN 31st_CD December_NNP 2002_CD 2001_CD 5,677_CD million_CD ,_, 2000_CD 6,004_CD million_CD ,_, of_IN which_WDT 10,879_CD million_CD 2001_CD 718_CD million_CD :_: 2000_CD nil_NN relates_VBZ to_TO the_DT company_NN and_CC 76_CD million_CD 2001_CD 61_CD million_CD ,_, 2000_CD 28_CD million_CD relates_VBZ to_TO joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS ._.
The_DT profit_NN of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN was_VBD 10,598_CD million_CD 2001_CD 4,331_CD million_CD ,_, 6th_CD December_NNP 1999_CD to_TO 31st_CD December_NNP 2000_CD nil_NN ,_, which_WDT after_IN dividends_NNS of_IN 2,352_CD million_CD 2001_CD 2,356_CD million_CD ,_, 6th_CD December_NNP 1999_CD to_TO 31st_CD December_NNP 2000_CD nil_NN ,_, gave_VBD a_DT retained_VBN profit_NN of_IN 8,246_CD million_CD 2001_CD 1,975_CD million_CD ,_, 6th_CD December_NNP 1999_CD to_TO 31st_CD December_NNP 2000_CD nil_NN ._.
After_IN the_DT cost_NN of_IN shares_NNS purchased_VBN for_IN cancellation_NN of_IN 2,220_CD million_CD 2001_CD 1,274_CD million_CD ,_, 6th_CD December_NNP 1999_CD to_TO 31st_CD December_NNP 2000_CD nil_NN and_CC an_DT unrealised_JJ profit_NN on_IN capital_NN reduction_NN by_IN subsidiary_NN of_IN 4,096_CD million_CD 2001_CD nil_NN ,_, 6th_JJ December_NNP 1999_CD to_TO 31st_CD December_NNP 2000_CD nil_NN ,_, the_DT profit_NN and_CC loss_NN account_NN reserve_NN at_IN 31st_CD December_NNP 2002_CD stood_VBD at_IN 10,823_CD million_CD 2001_CD 701_CD million_CD ,_, 2000_CD -_: nil_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 103_CD 30_CD Legal_NNP proceedings_NNS Even_RB if_IN the_DT FDA_NNP were_VBD to_TO approve_VB the_DT Pentech_NNP ANDA_NNP ,_, GlaxoSmithKline_NNP believes_VBZ that_IN the_DT Pentech_NNP capsule_NN would_MD not_RB be_VB The_DT Group_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ and_CC administrative_JJ substitutable_JJ for_IN Paxil_NNP tablets_NNS ._.
proceedings_NNS ,_, principally_RB product_NN liability_NN ,_, intellectual_JJ property_NN ,_, antitrust_JJ ,_, and_CC governmental_JJ investigations_NNS and_CC related_JJ private_JJ In_IN October_NNP 2000_CD GlaxoSmithKline_NNP led_VBD an_DT action_NN against_IN Synthon_NNP litigation_NN ._.
The_DT most_RBS significant_JJ of_IN these_DT matters_NNS are_VBP described_VBN below_IN ._.
Pharmaceuticals_NNS in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Middle_NNP District_NNP of_IN North_NNP Carolina_NNP for_IN infringement_NN of_IN the_DT Groups_NNS patents_NNS for_IN Intellectual_NNP property_NN paroxetine_NN hydrochloride_NN and_CC paroxetine_JJ mesylate_NN ._.
Synthon_NNP had_VBD In_IN the_DT USA_NNP a_DT number_NN of_IN distributors_NNS of_IN generic_JJ drugs_NNS have_VBP led_VBN led_VBD a_DT 505_CD b_NN 2_CD application_NN a_DT paper_NN NDA_NNP with_IN the_DT FDA_NNP using_VBG applications_NNS with_IN the_DT FDA_NNP to_TO market_VB generic_JJ versions_NNS of_IN paroxetine_JJ mesylate_NN ,_, a_DT different_JJ salt_NN form_NN of_IN paroxetine_NN than_IN that_DT Paxil_NNP Seroxat_NNP paroxetine_JJ hydrochloride_NN prior_RB to_TO the_DT expiration_NN in_IN used_VBN in_IN the_DT marketed_VBN form_NN of_IN Paxil_NNP ._.
Even_RB if_IN the_DT FDA_NNP approves_VBZ the_DT 2006_CD of_IN the_DT Groups_NNS patent_NN on_IN paroxetine_JJ hydrochloride_NN Synthon_NNP application_NN ,_, GlaxoSmithKline_NNP believes_VBZ the_DT Synthon_NNP hemihydrate_NN ._.
The_DT distributors_NNS are_VBP looking_VBG to_TO bring_VB to_TO market_NN compound_NN would_MD not_RB be_VB substitutable_JJ for_IN Paxil_NNP ._.
Brieng_NNP on_IN anhydrate_NN or_CC other_JJ versions_NNS of_IN paroxetine_JJ hydrochloride_NN and_CC in_IN one_CD summary_NN judgement_NN motions_NNS led_VBN by_IN the_DT parties_NNS has_VBZ been_VBN case_NN paroxetine_NN mesylate_NN ._.
The_DT cases_NNS are_VBP complex_JJ but_CC the_DT Group_NNP completed_VBD and_CC those_DT motions_NNS remain_VBP pending_VBG ._.
No_DT trial_NN date_NN has_VBZ believes_VBZ that_IN the_DT generic_JJ anhydrate_NN and_CC other_JJ versions_NNS infringe_VBP been_VBN set_VBN ._.
The_DT Hatch-Waxman_NNP stay_VB on_IN FDA_NNP approval_NN of_IN the_DT Synthon_NNP because_IN they_PRP contain_VBP and_CC or_CC convert_VB to_TO the_DT hemihydrate_JJ form_NN application_NN expires_VBZ in_IN April_NNP 2003_CD ._.
and_CC or_CC infringe_VB other_JJ Group_NNP patents_NNS ._.
In_IN response_NN the_DT Group_NNP has_VBZ led_VBN actions_NNS against_IN all_PDT those_DT distributors_NNS for_IN infringement_NN of_IN Following_VBG the_DT expiration_NN of_IN the_DT data_NNS exclusivity_NN period_NN in_IN Europe_NNP ,_, a_DT various_JJ of_IN the_DT Groups_NNS patents_NNS ._.
marketing_NN authorisation_NN was_VBD issued_VBN to_TO Synthon_NNP BV_NNP Genthon_NNP in_IN October_NNP 2000_CD by_IN regulatory_JJ authorities_NNS in_IN Denmark_NNP for_IN paroxetine_JJ In_IN July_NNP 1998_CD GlaxoSmithKline_NNP led_VBD an_DT action_NN against_IN Apotex_NNP in_IN the_DT mesylate_NN ,_, a_DT different_JJ salt_NN form_NN of_IN paroxetine_NN than_IN that_DT used_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Northern_NNP District_NNP of_IN Illinois_NNP for_IN infringement_NN marketed_VBN form_NN of_IN Seroxat_NNP Paxil_NNP ._.
Marketing_NNP authorisations_NNS have_VBP since_IN of_IN the_DT Groups_NNS patent_NN for_IN paroxetine_JJ hydrochloride_NN hemihydrate_NN ._.
been_VBN granted_VBN in_IN nine_CD other_JJ European_JJ countries_NNS ,_, one_CD further_JJ national_JJ Apotex_NNP had_VBD led_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP approval_NN and_CC eight_CD approvals_NNS under_IN the_DT Mutual_JJ Recognition_NN process_NN with_IN the_DT FDA_NNP seeking_VBG approval_NN to_TO introduce_VB a_DT generic_JJ form_NN of_IN Paxil_NNP ._.
based_VBN on_IN the_DT original_JJ Danish_JJ approval_NN ._.
Generic_JJ products_NNS containing_VBG Following_VBG a_DT trial_NN in_IN February_NNP 2003_CD the_DT judge_NN ruled_VBD that_IN paroxetine_JJ mesylate_NN have_VBP been_VBN launched_VBN in_IN Denmark_NNP ,_, Germany_NNP ,_, GlaxoSmithKlines_NNP patent_NN is_VBZ valid_JJ but_CC not_RB infringed_VBN by_IN Apotexs_NNP The_NNP Netherlands_NNP ,_, Austria_NNP ,_, Ireland_NNP ,_, Sweden_NNP and_CC Italy_NNP ,_, although_IN the_DT product_NN ._.
GlaxoSmithKline_NNP is_VBZ appealing_VBG the_DT ruling_NN of_IN nonproduct_NN in_IN Austria_NNP and_CC Denmark_NNP has_VBZ been_VBN withdrawn_VBN following_VBG the_DT infringement_NN to_TO the_DT US_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP award_NN of_IN patent_NN interim_JJ injunctions_NNS ._.
The_DT Group_NNP has_VBZ initiated_VBN CAFC_NNP ,_, which_WDT hears_VBZ all_DT appeals_NNS from_IN US_NNP District_NNP Courts_NNPS on_IN litigation_NN challenging_VBG the_DT approval_NN by_IN the_DT Danish_JJ Medicines_NNP Agency_NNP intellectual_JJ property_NN matters_NNS ._.
on_IN grounds_NNS that_IN an_DT authorisation_NN should_MD not_RB have_VB been_VBN granted_VBN In_IN June_NNP 1999_CD GlaxoSmithKline_NNP led_VBD an_DT action_NN against_IN Geneva_NNP under_IN the_DT abridged_JJ procedure_NN as_IN paroxetine_JJ mesylate_NN is_VBZ not_RB Pharmaceuticals_NNS ,_, a_DT subsidiary_NN of_IN Novartis_NNP Pharmaceuticals_NNP ,_, in_IN the_DT essentially_RB similar_JJ to_TO Seroxat_NNP ._.
Marketing_NNP authorisations_NNS have_VBP also_RB US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP for_IN been_VBN issued_VBN in_IN eleven_JJ European_JJ countries_NNS for_IN products_NNS containing_VBG infringement_NN of_IN the_DT Groups_NNS patents_NNS for_IN paroxetine_JJ hydrochloride_NN paroxetine_NN hydrochloride_NN anhydrate_NN ,_, another_DT variant_NN of_IN the_DT Groups_NNS following_VBG notice_NN of_IN Genevas_NNP ANDA_NNP ling_NN ._.
That_DT case_NN has_VBZ been_VBN product_NN ._.
Generic_JJ products_NNS containing_VBG the_DT anhydrate_NN are_VBP now_RB on_IN the_DT consolidated_JJ with_IN similar_JJ infringement_NN actions_NNS against_IN other_JJ market_NN in_IN Germany_NNP ,_, Austria_NNP ,_, Denmark_NNP ,_, the_DT Netherlands_NNP ,_, Spain_NNP ,_, generic_JJ companies_NNS that_WDT subsequently_RB led_VBD ANDAs_NNP ._.
GlaxoSmithKline_NNP believes_VBZ that_IN marketing_NN of_IN infringement_NN actions_NNS have_VBP been_VBN brought_VBN based_VBN on_IN patents_NNS issued_VBN either_RB a_DT paroxetine_JJ hydrochloride_NN anhydrate_JJ product_NN or_CC a_DT paroxetine_JJ subsequent_JJ to_TO the_DT original_JJ ling_NN against_IN Apotex_NNP in_IN the_DT Northern_NNP mesylate_NN product_NN by_IN third_JJ parties_NNS in_IN European_JJ countries_NNS infringes_VBZ its_PRP$ District_NNP of_IN Illinois_NNP ._.
The_DT Group_NNP also_RB led_VBD an_DT action_NN against_IN Apotex_NNP patents_NNS and_CC is_VBZ litigating_VBG its_PRP$ position_NN in_IN actions_NNS in_IN many_JJ European_JJ and_CC relating_VBG to_TO those_DT new_JJ patents_NNS in_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP ._.
other_JJ countries_NNS outside_IN the_DT USA_NNP ._.
In_IN June_NNP 2002_CD the_DT European_JJ Patent_NN In_IN December_NNP 2002_CD the_DT judge_NN granted_VBN in_IN part_NN and_CC denied_VBN in_IN part_NN Ofce_NNP Opposition_NNP Division_NNP rejected_VBD an_DT opposition_NN led_VBN by_IN Synthon_NNP summary_NN judgement_NN motions_NNS led_VBN by_IN Apotex_NNP with_IN the_DT result_NN that_IN against_IN the_DT Groups_NNS European_JJ patent_NN covering_VBG a_DT crystal_NN form_NN of_IN issues_NNS of_IN validity_NN and_CC infringement_NN of_IN three_CD of_IN the_DT four_CD new_JJ patents_NNS paroxetine_JJ mesylate_NN that_WDT is_VBZ used_VBN in_IN Synthons_NNP product_NN ._.
That_DT decision_NN will_MD move_VB toward_IN trial_NN ._.
GlaxoSmithKline_NNP has_VBZ petitioned_VBN the_DT District_NNP is_VBZ under_IN appeal_NN ._.
In_IN contrast_NN ,_, following_VBG an_DT action_NN initiated_VBN by_IN Court_NNP to_TO permit_VB an_DT interim_JJ appeal_NN to_TO the_DT CAFC_NNP ._.
The_DT last_JJ to_TO expire_VB Synthon_NNP ,_, a_DT UK_NNP court_NN revoked_VBD the_DT corresponding_JJ UK_NNP patent_NN relating_VBG Hatch-Waxman_NNP stay_VB on_IN FDA_NNP approval_NN of_IN the_DT Apotex_NNP ANDA_NNP expires_VBZ to_TO paroxetine_JJ mesylate_NN in_IN December_NNP 2002_CD ._.
An_DT appeal_NN before_IN the_DT in_IN September_NNP 2003_CD ._.
Court_NNP of_IN Appeal_NNP is_VBZ expected_VBN to_TO commence_NN in_IN May_NNP 2003_CD ._.
In_IN February_NNP 2003_CD the_DT Dutch_JJ court_NN revoked_VBD the_DT corresponding_JJ Dutch_JJ In_IN February_NNP 2003_CD the_DT CAFC_NNP heard_VBD Apotexs_NNP appeal_NN from_IN a_DT decision_NN patent_NN which_WDT decision_NN will_MD also_RB be_VB appealed_VBN ._.
by_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Columbia_NNP denying_VBG Apotexs_NNP request_NN that_IN the_DT FDA_NNP be_VB required_VBN to_TO delist_VB certain_JJ of_IN the_DT In_NNP response_NN to_TO a_DT challenge_NN by_IN BASF_NNP to_TO the_DT Groups_NNS UK_NNP patent_NN for_IN Groups_NNS patents_NNS for_IN Paxil_NNP from_IN the_DT Orange_NNP Book_NNP ._.
The_DT CAFC_NNP has_VBZ not_RB paroxetine_JJ hydrochloride_NN anhydrate_NN in_IN the_DT UK_NNP High_NNP Court_NNP in_IN yet_RB ruled_VBN on_IN that_DT matter_NN ._.
In_IN addition_NN ,_, Apotex_NNP has_VBZ applied_VBN to_TO the_DT July_NNP 2002_CD the_DT Judge_NNP decided_VBD that_IN the_DT patent_NN was_VBD partly_RB valid_JJ and_CC court_NN in_IN the_DT litigation_NN in_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP for_IN an_DT partly_RB invalid_JJ ._.
The_DT claims_NNS held_VBD valid_JJ were_VBD asserted_VBN against_IN Apotex_NNP ,_, order_NN that_WDT GlaxoSmithKline_NNP delist_JJ certain_JJ patents_NNS ._.
Neolab_NNP and_CC Waymade_NNP Healthcare_NNP and_CC an_DT interim_JJ injunction_NN preventing_VBG sale_NN of_IN their_PRP$ version_NN of_IN the_DT product_NN was_VBD granted_VBN in_IN In_IN March_NNP 2000_CD GlaxoSmithKline_NNP led_VBD an_DT action_NN against_IN Pentech_NNP November_NNP 2002_CD ._.
The_DT decision_NN granting_VBG the_DT injunction_NN was_VBD afrmed_VBN Pharmaceuticals_NNS in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Northern_NNP District_NNP of_IN on_IN appeal_NN in_IN early_JJ February_NNP 2003_CD ._.
A_DT full_JJ trial_NN relating_VBG to_TO both_DT alleged_VBD Illinois_NNP for_IN infringement_NN of_IN the_DT Groups_NNS patents_NNS for_IN paroxetine_JJ infringement_NN and_CC alleged_VBD invalidity_NN will_MD take_VB place_NN in_IN June_NNP 2003_CD ._.
hydrochloride_NN ._.
Pentech_NNP led_VBD an_DT ANDA_NNP for_IN a_DT capsule_NN version_NN of_IN Paxil_NNP ,_, asserting_VBG that_IN its_PRP$ compound_NN and_CC presentation_NN do_VBP not_RB infringe_VB the_DT Groups_NNS patents_NNS or_CC that_IN the_DT patents_NNS are_VBP invalid_JJ ._.
104_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 30_CD Legal_JJ proceedings_NNS continued_VBD The_DT 30-month_JJ Hatch-Waxman_NNP stay_NN on_IN final_JJ FDA_NNP approval_NN expires_VBZ April_NNP 2003_CD but_CC final_JJ FDA_NNP approval_NN may_MD also_RB be_VB held_VBN up_RP in_IN view_NN of_IN In_IN May_NNP 2001_CD Geneva_NNP Pharmaceuticals_NNP commenced_VBD an_DT action_NN in_IN the_DT rights_NNS to_TO a_DT 180_CD day_NN marketing_NN exclusivity_NN that_WDT may_MD be_VB held_VBN by_IN US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Virginia_NNP over_IN four_CD Andrx_NNP ._.
patents_NNS recently_RB issued_VBD to_TO GlaxoSmithKline_NNP covering_VBG clavulanic_JJ acid_NN ,_, a_DT key_JJ ingredient_NN in_IN Augmentin_NNP and_CC Timentin_NNP ._.
Geneva_NNP asked_VBD the_DT The_NNP Group_NNP led_VBD an_DT action_NN for_IN infringement_NN of_IN its_PRP$ patents_NNS for_IN court_NN to_TO declare_VB the_DT new_JJ patents_NNS ,_, which_WDT expire_VBP in_IN 2017_CD and_CC 2018_CD ,_, cefuroxime_NN axetil_NN ,_, the_DT active_JJ ingredient_NN in_IN the_DT Groups_NNS Ceftin_NNP antiinvalid_NN ._.
In_IN August_NNP 2001_CD Geneva_NNP extended_VBD its_PRP$ complaint_NN to_TO cover_VB infective_JJ product_NN ,_, against_IN Ranbaxy_NNP Pharmaceuticals_NNP in_IN the_DT US_NNP District_NNP three_CD additional_JJ patents_NNS which_WDT expired_VBD in_IN 2002_CD ._.
In_IN September_NNP 2001_CD Court_NNP for_IN New_NNP Jersey_NNP ._.
A_DT preliminary_JJ injunction_NN was_VBD granted_VBN in_IN Teva_NNP Pharmaceuticals_NNP led_VBD a_DT similar_JJ action_NN challenging_VBG the_DT four_CD favor_NN of_IN the_DT Group_NNP but_CC the_DT CAFC_NNP subsequently_RB vacated_VBD that_DT recently_RB issued_VBN patents_NNS and_CC a_DT patent_NN expiring_VBG in_IN December_NNP 2002_CD injunction_NN and_CC remanded_VBD the_DT case_NN to_TO the_DT District_NNP Court_NNP for_IN a_DT full_JJ that_DT cover_NN Augmentin_NNP ._.
In_IN December_NNP 2001_CD Ranbaxy_NNP Pharmaceuticals_NNP trial_NN on_IN the_DT merits_NNS ._.
Thereafter_RB Ranbaxy_NNP launched_VBD its_PRP$ generic_JJ version_NN led_VBD a_DT further_JJ action_NN challenging_VBG the_DT four_CD patents_NNS expiring_VBG in_IN 2017_CD in_IN March_NNP 2002_CD ._.
The_DT trial_NN is_VBZ scheduled_VBN to_TO begin_VB 8th_JJ July_NNP 2003_CD ._.
The_DT Ranbaxy_NNP and_CC Teva_NNP actions_NNS were_VBD consolidated_VBN with_IN the_DT patent_NN as_IN to_TO which_WDT the_DT Group_NNP claims_VBZ infringement_NN expires_VBZ in_IN the_DT Geneva_NNP case_NN ._.
At_IN December_NNP 2001_CD and_CC March_NNP 2002_CD hearings_NNS on_IN May_NNP 2003_CD ,_, the_DT Group_NNP now_RB seeks_VBZ monetary_JJ damages_NNS based_VBN on_IN Tevas_NNP motions_NNS for_IN summary_NN judgement_NN the_DT trial_NN judge_NN held_VBD that_IN the_DT Ranbaxys_NNPS sales_NNS ._.
The_DT Group_NNP has_VBZ led_VBN a_DT similar_JJ action_NN against_IN Apotex_NNP ,_, Groups_NNS patents_NNS expiring_VBG in_IN 2017_CD and_CC 2018_CD were_VBD invalid_JJ ._.
At_IN the_DT a_DT second_JJ distributor_NN of_IN generic_JJ pharmaceutical_JJ products_NNS ,_, in_IN the_DT US_NNP consolidated_JJ trial_NN in_IN May_NNP 2002_CD ,_, the_DT same_JJ judge_NN ruled_VBD that_IN the_DT District_NNP Court_NNP for_IN the_DT Northern_NNP District_NNP of_IN Illinois_NNP ._.
A_DT preliminary_JJ patents_NNS expiring_VBG in_IN 2002_CD were_VBD invalid_JJ ._.
The_DT FDA_NNP has_VBZ granted_VBN injunction_NN was_VBD granted_VBN in_IN favor_NN of_IN the_DT Group_NNP in_IN June_NNP 2002_CD ._.
Apotex_NNP approval_NN to_TO all_DT three_CD companies_NNS and_CC Lek_NNP Pharmaceuticals_NNP for_IN their_PRP$ subsequently_RB obtained_VBN FDA_NNP approval_NN for_IN their_PRP$ generic_JJ product_NN ._.
The_DT generic_JJ products_NNS and_CC all_DT four_CD are_VBP now_RB marketed_VBN in_IN the_DT USA_NNP ._.
The_DT full_JJ trial_NN with_IN Apotex_NNP was_VBD concluded_VBN in_IN January_NNP 2003_CD ,_, but_CC as_RB at_IN the_DT Group_NNP continues_VBZ to_TO believe_VB that_IN its_PRP$ patents_NNS are_VBP valid_JJ and_CC appealed_VBD date_NN of_IN this_DT report_NN no_DT decision_NN had_VBD been_VBN announced_VBN ._.
the_DT District_NNP Court_NNP decisions_NNS to_TO the_DT CAFC_NNP ._.
The_DT hearing_NN on_IN the_DT appeal_NN In_IN August_NNP 2001_CD the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP was_VBD heard_VBN on_IN 5th_JJ March_NNP 2003_CD but_CC as_IN of_IN the_DT date_NN of_IN this_DT report_NN the_DT Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Reddy-Cheminor_NNP and_CC CAFC_NNP had_VBD not_RB yet_RB ruled_VBN on_IN the_DT appeal_NN ._.
Dr._NNP Reddys_NNP Laboratories_NNPS ,_, alleging_VBG infringement_NN of_IN three_CD patents_NNS for_IN In_IN August_NNP 2002_CD the_DT Group_NNP commenced_VBD proceedings_NNS against_IN ondansetron_NN ,_, the_DT active_JJ ingredient_NN in_IN Zofran_NNP tablets_NNS ._.
FDA_NNP approval_NN Geneva_NNP Pharmaceuticals_NNP and_CC its_PRP$ parent_NN Novartis_NNP AG_NNP ,_, Biochemie_NNP of_IN the_DT ANDA_NNP led_VBN by_IN Reddy_NNP is_VBZ stayed_VBN until_IN the_DT earlier_JJR of_IN January_NNP GmbH_NNP and_CC Biochemie_NNP SpA_NNP before_IN the_DT US_NNP International_NNP Trade_NNP 2004_CD or_CC resolution_NN of_IN the_DT patent_NN infringement_NN litigation_NN ._.
In_IN March_NNP Commission_NNP and_CC in_IN Colorado_NNP state_NN court_NN ,_, alleging_VBG that_IN the_DT 2002_CD the_DT Group_NNP led_VBD a_DT similar_JJ action_NN against_IN Teva_NNP ,_, which_WDT alleged_VBD manufacture_NN and_CC sale_NN in_IN the_DT USA_NNP of_IN Genevas_NNP generic_JJ Augmentin_NNP invalidity_NN or_CC non-infringement_NN of_IN two_CD method_NN of_IN use_NN patents_NNS but_CC product_NN using_VBG a_DT production_NN strain_NN stolen_VBN earlier_RB from_IN not_RB the_DT compound_NN patent_NN expiring_VBG in_IN 2005_CD ,_, in_IN the_DT US_NNP District_NNP Court_NNP GlaxoSmithKline_NNP constitutes_VBZ misappropriation_NN of_IN the_DT Groups_NNS trade_NN for_IN the_DT District_NNP of_IN Delaware_NNP ._.
A_DT trial_NN date_NN of_IN 19th_JJ November_NNP 2003_CD secrets_NNS and_CC unfair_JJ competition_NN ._.
Both_DT proceedings_NNS seek_VBP to_TO prevent_VB has_VBZ been_VBN set_VBN for_IN the_DT Teva_NNP case_NN ._.
A_DT third_JJ ondansetron_NN case_NN ,_, involving_VBG the_DT importation_NN and_CC sale_NN in_IN the_DT USA_NNP of_IN generic_JJ Augmentin_NNP orally_RB disintegrating_VBG Zofran_NNP tablets_NNS ,_, was_VBD commenced_VBN in_IN February_NNP containing_VBG clavulanate_JJ made_VBN using_VBG the_DT stolen_VBN GlaxoSmithKline_NNP 2003_CD against_IN Kali_NNP Laboratories_NNPS in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT production_NN strain_NN :_: the_DT Colorado_NNP action_NN seeks_VBZ damages_NNS as_RB well_RB ._.
Similar_JJ state_NN court_NN actions_NNS have_VBP been_VBN initiated_VBN against_IN Teva_NNP ,_, Lek_NNP In_IN August_NNP 2002_CD the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP and_CC Ranbaxy_NNP ._.
Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Teva_NNP ,_, alleging_VBG Five_CD distributors_NNS of_IN generic_JJ pharmaceutical_JJ products_NNS have_VBP led_VBN infringement_NN of_IN the_DT Groups_NNS compound_VBP patent_NN for_IN lamotrigine_NN ,_, the_DT ANDAs_NNP for_IN sustained_VBN release_NN bupropion_NN hydrochloride_NN tablets_NNS active_JJ ingredient_NN in_IN Lamictal_JJ oral_JJ tablets_NNS ._.
That_DT patent_NN expires_VBZ in_IN July_NNP Wellbutrin_NNP SR_NNP and_CC Zyban_NNP in_IN the_DT USA_NNP ,_, accompanied_VBN in_IN each_DT case_NN 2008_CD ._.
The_DT defendant_NN has_VBZ led_VBN an_DT ANDA_NNP with_IN the_DT FDA_NNP with_IN a_DT with_IN a_DT certication_NN of_IN invalidity_NN of_IN the_DT Groups_NNS patents_NNS ._.
The_DT Group_NNP certication_NN of_IN invalidity_NN of_IN the_DT Groups_NNS patent_NN ._.
FDA_NNP approval_NN of_IN has_VBZ brought_VBN suit_NN for_IN patent_NN infringement_NN against_IN each_DT of_IN the_DT ling_NN that_WDT ANDA_NNP is_VBZ stayed_VBN until_IN the_DT earlier_JJR of_IN January_NNP 2005_CD or_CC resolution_NN parties_NNS ._.
The_DT Group_NNP led_VBD suit_NN against_IN Andrx_NNP Pharmaceuticals_NNP ,_, the_DT first_JJ of_IN the_DT patent_NN infringement_NN litigation_NN ._.
The_DT case_NN is_VBZ in_IN its_PRP$ early_JJ stages_NNS ._.
to_TO le_FW an_DT ANDA_NNP ,_, in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN In_IN October_NNP 2002_CD Pzer_NNP Inc._NNP led_VBD an_DT action_NN against_IN Bayer_NNP AG_NNP and_CC Florida_NNP ._.
In_IN February_NNP 2002_CD the_DT District_NNP Court_NNP Judge_NNP granted_VBD Andrxs_NNP GlaxoSmithKline_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN summary_NN judgement_NN motion_NN and_CC ruled_VBD that_IN its_PRP$ product_NN does_VBZ not_RB Delaware_NNP ,_, alleging_VBG that_IN the_DT manufacture_NN and_CC sale_NN of_IN Levitra_NNP infringe_VBP the_DT Groups_NNS patents_NNS ._.
The_DT Group_NNP has_VBZ appealed_VBN that_DT decision_NN vardenal_NN would_MD infringe_VB a_DT patent_NN newly_RB issued_VBN to_TO Pzer_NNP and_CC to_TO the_DT CAFC_NNP ._.
The_DT oral_JJ argument_NN on_IN the_DT appeal_NN was_VBD held_VBN in_IN asking_VBG that_IN Bayer_NNP and_CC GlaxoSmithKline_NNP be_VB permanently_RB enjoined_VBN ._.
December_NNP 2002_CD but_CC as_IN of_IN the_DT date_NN of_IN this_DT report_NN the_DT CAFC_NNP has_VBZ not_RB The_DT case_NN is_VBZ in_IN its_PRP$ early_JJ stages_NNS ._.
Actions_NNS have_VBP also_RB been_VBN led_VBN against_IN Watson_NNP Pharmaceuticals_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN In_NNP January_NNP 2003_CD Cipla_NNP and_CC Neolab_NNP led_VBD an_DT action_NN in_IN the_DT UK_NNP High_NNP Ohio_NNP ,_, Eon_NNP Labs_NNPS Manufacturing_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Court_NNP ,_, seeking_VBG revocation_NN of_IN one_CD of_IN the_DT Groups_NNS patents_NNS relating_VBG to_TO Southern_NNP District_NNP of_IN New_NNP York_NNP ,_, Impax_NNP Laboratories_NNPS in_IN the_DT US_NNP District_NNP the_DT asthma_NN treatment_NN Seretide_NNP Advair_NNP ._.
This_DT patent_NN ,_, set_VBN to_TO expire_VB in_IN Court_NNP for_IN the_DT Northern_NNP District_NNP of_IN California_NNP and_CC Excel_NNP 2013_CD ,_, including_VBG supplementary_JJ protection_NN certicate_NN protection_NN ,_, Pharmaceuticals_NNP in_IN both_DT the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP relates_VBZ to_TO the_DT combination_NN of_IN the_DT active_JJ ingredients_NNS ,_, salmeterol_NN Jersey_NNP and_CC the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Virginia_NNP ._.
and_CC uticasone_JJ propionate_NN ,_, on_IN which_WDT separate_JJ patents_NNS exist_VBP which_WDT The_DT Watson_NNP case_NN has_VBZ been_VBN settled_VBN ._.
Judges_NNPS granted_VBD summary_NN have_VBP not_RB been_VBN challenged_VBN ,_, providing_VBG patent_NN protection_NN in_IN the_DT UK_NNP judgement_NN of_IN non-infringement_NN in_IN the_DT Impax_NNP and_CC Excel_NNP cases_NNS ,_, both_DT until_IN late_JJ 2005_CD ._.
Several_JJ other_JJ UK_NNP Seretide_NNP patents_NNS ,_, for_IN example_NN of_IN which_WDT are_VBP on_IN appeal_NN to_TO the_DT CAFC_NNP ._.
Summary_JJ judgement_NN was_VBD those_DT relating_VBG to_TO the_DT Diskus_NNP device_NN and_CC the_DT CFC-free_JJ MDI_NNP device_NN denied_VBD to_TO Eon_NNP ._.
On_IN Eons_NNS motion_NN for_IN reconsideration_NN ,_, the_DT judge_NN which_WDT expire_VBP in_IN 2011_CD and_CC 2012_CD respectively_RB ,_, have_VBP not_RB been_VBN confirmed_VBN denial_NN of_IN the_DT summary_NN judgement_NN ._.
No_DT trial_NN date_NN has_VBZ yet_RB challenged_VBN ._.
There_EX has_VBZ been_VBN no_DT challenge_NN to_TO the_DT Groups_NNS patents_NNS been_VBN set_VBN in_IN the_DT Eon_NNP case_NN ._.
At_IN this_DT point_NN Eon_NNP is_VBZ the_DT only_JJ distributor_NN relating_VBG to_TO Seretide_NNP Advair_NNP in_IN the_DT USA_NNP or_CC in_IN other_JJ countries_NNS ._.
with_IN tentative_JJ FDA_NNP approval_NN for_IN its_PRP$ generic_JJ version_NN of_IN the_DT product_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 105_CD 30_CD Legal_NNP proceedings_NNS continued_VBD Following_VBG a_DT report_NN from_IN the_DT Yale_NNP Haemorrhagic_NNP Stroke_NNP Project_NNP that_WDT found_VBD a_DT suggestion_NN of_IN an_DT association_NN between_IN first_JJ use_NN of_IN In_IN February_NNP 2003_CD the_DT Group_NNP received_VBD a_DT paragraph_NN iv_NN notication_NN of_IN phenylpropanolamine_NN PPA_NNP decongestant_JJ and_CC hemorrhagic_JJ non-infringement_NN of_IN a_DT patent_NN relating_VBG to_TO lm_VB coating_NN for_IN Imitrex_NNP stroke_NN ,_, the_DT Group_NNP and_CC most_RBS other_JJ manufacturers_NNS voluntarily_RB sumatriptan_VBP in_IN connection_NN with_IN an_DT ANDA_NNP ling_NN by_IN Ranbaxy_NNP with_IN withdrew_VBD consumer_NN healthcare_NN products_NNS in_IN which_WDT PPA_NNP was_VBD an_DT active_JJ respect_NN to_TO Imitrex_NNP ._.
The_DT paragraph_NN iv_NN notication_NN does_VBZ not_RB extend_VB to_TO ingredient_NN ._.
Since_IN the_DT PPA_NNP product_NN withdrawal_NN the_DT Group_NNP has_VBZ been_VBN the_DT basic_JJ US_NNP patents_NNS for_IN the_DT product_NN which_WDT expire_VBP in_IN 2006_CD and_CC named_VBN as_IN a_DT defendant_NN in_IN numerous_JJ personal_JJ injury_NN and_CC class_NN action_NN 2008_CD ._.
lawsuits_NNS led_VBD in_IN state_NN and_CC federal_JJ courts_NNS alleging_VBG personal_JJ injury_NN or_CC In_IN February_NNP 2003_CD the_DT FDA_NNP website_NN posted_VBD receipt_NN by_IN the_DT agency_NN of_IN increased_VBN risk_NN of_IN injury_NN from_IN use_NN of_IN products_NNS containing_VBG PPA_NNP and_CC an_DT ANDA_NNP ling_NN with_IN respect_NN to_TO Valtrex_NNP ._.
As_IN of_IN the_DT date_NN of_IN this_DT report_NN unfair_JJ and_CC deceptive_JJ business_NN practices_NNS ._.
Plaintiffs_NNS seek_VBP remedies_NNS the_DT Group_NNP has_VBZ not_RB yet_RB received_VBN notice_NN of_IN a_DT paragraph_NN iv_NN notication_NN including_VBG compensatory_JJ and_CC punitive_JJ damages_NNS and_CC refunds_NNS ._.
The_DT of_IN invalidity_NN and_CC or_CC non-infringement_JJ with_IN respect_NN to_TO that_DT product_NN ._.
federal_JJ cases_NNS have_VBP been_VBN consolidated_VBN in_IN a_DT multidistrict_JJ litigation_NN The_DT Groups_NNS US_NNP patent_NN on_IN the_DT active_JJ ingredient_NN in_IN Valtrex_NNP proceeding_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Washington_NNP ._.
The_DT judge_NN responsible_JJ for_IN those_DT proceedings_NNS initially_RB denied_VBD class_NN certication_NN and_CC struck_VBD all_DT class_NN allegations_NNS in_IN the_DT federal_JJ personal_JJ Product_NNP liability_NN injury_NN and_CC consumer_NN refund_NN class_NN actions_NNS but_CC granted_VBN plaintiffs_NNS leave_VBP In_IN 1997_CD the_DT FDA_NNP became_VBD aware_JJ of_IN reports_NNS of_IN cardiac_JJ valvular_JJ to_TO le_FW a_DT renewed_JJ motion_NN to_TO certify_VB a_DT consumer_NN refund_NN class_NN problems_NNS in_IN individuals_NNS for_IN whom_WP fenuramine_VBP or_CC dexfenuramine_VBP consisting_VBG of_IN persons_NNS possessing_VBG PPA-containing_JJ products_NNS at_IN the_DT alone_JJ or_CC in_IN combination_NN of_IN phentermine_NN was_VBD prescribed_VBN as_IN part_NN of_IN time_NN of_IN an_DT FDA_NNP advisory_NN in_IN November_NNP 2000_CD ._.
Subsequently_RB ,_, the_DT a_DT regimen_NN of_IN weight_NN reduction_NN and_CC requested_VBD the_DT voluntary_JJ judge_NN denied_VBD that_IN renewed_VBN motion_NN ._.
The_DT lawsuits_NNS are_VBP in_IN their_PRP$ early_JJ withdrawal_NN of_IN fenuramine_NN and_CC dexfenuramine_NN from_IN the_DT market_NN ._.
stages_NNS and_CC there_EX has_VBZ been_VBN no_DT final_JJ determination_NN as_IN to_TO whether_IN any_DT The_DT reports_NNS of_IN cardiac_JJ valvular_JJ problems_NNS and_CC the_DT subsequent_JJ of_IN the_DT lawsuits_NNS led_VBD in_IN state_NN courts_NNS will_MD be_VB permitted_VBN to_TO proceed_VB as_IN withdrawal_NN of_IN those_DT products_NNS from_IN the_DT market_NN spawned_VBD numerous_JJ class_NN actions_NNS ._.
Class_NN certication_NN has_VBZ been_VBN denied_VBN in_IN California_NNP state_NN product_NN liability_NN lawsuits_NNS led_VBD against_IN the_DT manufacturers_NNS and_CC court_NN and_CC is_VBZ on_IN appeal_NN :_: a_DT motion_NN for_IN class_NN certication_NN is_VBZ still_RB distributors_NNS of_IN fenuramine_NN ,_, dexfenuramine_NN and_CC phentermine_NN ._.
pending_VBG in_IN Pennsylvania_NNP state_NN court_NN ._.
As_IN one_CD of_IN a_DT number_NN of_IN manufacturers_NNS of_IN phentermine_NN ,_, the_DT Group_NNP In_IN August_NNP 2001_CD Bayer_NNP AG_NNP withdrew_VBD Baycol_NNP cerivastatin_NN sodium_NN is_VBZ a_DT defendant_NN in_IN thousands_NNS of_IN lawsuits_NNS in_IN various_JJ state_NN and_CC federal_JJ worldwide_NN in_IN light_NN of_IN reports_NNS of_IN adverse_JJ events_NNS ,_, including_VBG deaths_NNS ,_, district_NN courts_NNS in_IN the_DT USA_NNP ,_, many_JJ of_IN which_WDT have_VBP been_VBN led_VBN as_IN class_NN involving_VBG rhabdomyolosis_NN ._.
GlaxoSmithKline_NNP had_VBD participated_VBN in_IN the_DT actions_NNS ._.
Most_JJS of_IN the_DT lawsuits_NNS seek_VBP relief_NN including_VBG some_DT combination_NN marketing_NN of_IN Baycol_NNP in_IN the_DT USA_NNP pursuant_JJ to_TO a_DT co-promotion_NN of_IN compensatory_JJ and_CC punitive_JJ damages_NNS ,_, medical_JJ monitoring_NN and_CC agreement_NN with_IN Bayer_NNP which_WDT was_VBD the_DT license_NN holder_NN and_CC refunds_NNS for_IN purchases_NNS of_IN drugs_NNS ._.
In_IN 1997_CD the_DT Judicial_NNP Panel_NN on_IN manufacturer_NN of_IN the_DT product_NN ._.
Following_VBG the_DT withdrawal_NN ,_, Bayer_NNP and_CC Multidistrict_NNP Litigation_NNP issued_VBD an_DT order_NN consolidating_VBG and_CC transferring_VBG GlaxoSmithKline_NNP have_VBP been_VBN named_VBN as_IN defendants_NNS in_IN thousands_NNS of_IN all_DT federal_JJ actions_NNS to_TO the_DT District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN lawsuits_NNS led_VBN in_IN state_NN and_CC federal_JJ courts_NNS in_IN the_DT USA_NNP on_IN behalf_NN of_IN Pennsylvania_NNP ._.
That_DT court_NN approved_VBD a_DT global_JJ settlement_NN proposed_VBN by_IN both_DT individuals_NNS and_CC putative_JJ classes_NNS of_IN former_JJ Baycol_NNP users_NNS ._.
A_DT defendant_NN Wyeth_NNP ,_, which_WDT sold_VBD fenuramine_NN and_CC dexfenuramine_NN ._.
number_NN of_IN the_DT suits_NNS allege_VBP that_IN the_DT plaintiffs_NNS have_VBP suffered_VBN personal_JJ The_DT settlement_NN ,_, subsequently_RB confirmed_VBN by_IN the_DT Third_NNP Circuit_NNP Court_NNP injuries_NNS ,_, including_VBG rhabdomyolosis_NN ,_, from_IN the_DT use_NN of_IN Baycol_NNP ._.
Others_NNS of_IN Appeals_NNP ,_, does_VBZ not_RB include_VB any_DT of_IN the_DT phentermine_NN defendants_NNS ,_, claim_VBP that_IN persons_NNS who_WP took_VBD Baycol_NNP ,_, although_IN not_RB injured_VBN ,_, may_MD be_VB including_VBG the_DT Group_NNP ._.
Individual_JJ plaintiffs_NNS may_MD elect_VB to_TO opt_VB out_IN of_IN the_DT at_IN risk_NN of_IN future_JJ injury_NN or_CC may_MD have_VB suffered_VBN economic_JJ damages_NNS class_NN settlement_NN and_CC pursue_VB their_PRP$ claims_NNS individually_RB ._.
Wyeth_NNP from_IN purchasing_VBG and_CC using_VBG Baycol_NNP ._.
Plaintiffs_NNS seek_VBP remedies_NNS including_VBG continues_VBZ to_TO settle_VB individual_JJ state_NN court_NN cases_NNS before_IN trial_NN and_CC the_DT compensatory_JJ ,_, punitive_JJ and_CC statutory_JJ damages_NNS and_CC creation_NN of_IN Group_NNP continues_VBZ to_TO be_VB dismissed_VBN from_IN lawsuits_NNS as_IN they_PRP are_VBP settled_VBN funds_NNS for_IN medical_JJ monitoring_NN ._.
GlaxoSmithKline_NNP and_CC Bayer_NNP by_IN Wyeth_NNP ._.
Corporation_NNP ,_, the_DT principal_JJ US_NNP subsidiary_NN of_IN Bayer_NNP AG_NNP ,_, have_VBP signed_VBN GlaxoSmithKline_NNP has_VBZ received_VBN purported_JJ class_NN action_NN lawsuits_NNS led_VBD an_DT allocation_NN agreement_NN under_IN which_WDT Bayer_NNP Corporation_NNP has_VBZ agreed_VBN in_IN state_NN and_CC federal_JJ courts_NNS in_IN the_DT USA_NNP alleging_VBG that_IN paroxetine_NN to_TO pay_VB 95_CD per_IN cent_NN of_IN all_DT settlements_NNS and_CC compensatory_JJ damages_NNS the_DT active_JJ ingredient_NN in_IN Paxil_NNP is_VBZ addictive_JJ and_CC causes_VBZ dependency_NN judgements_NNS with_IN each_DT party_NN retaining_VBG responsibility_NN for_IN its_PRP$ own_JJ and_CC withdrawal_NN reactions_NNS ._.
Plaintiffs_NNS seek_VBP remedies_NNS including_VBG attorneys_NNS fees_NNS and_CC any_DT punitive_JJ damages_NNS ._.
The_DT federal_JJ cases_NNS have_VBP compensatory_JJ ,_, punitive_JJ and_CC statutory_JJ damages_NNS and_CC the_DT cost_NN of_IN a_DT been_VBN consolidated_VBN in_IN a_DT multidistrict_JJ litigation_NN proceeding_NN in_IN the_DT US_NNP fund_NN for_IN medical_JJ monitoring_NN ._.
In_IN January_NNP 2003_CD a_DT federal_JJ district_NN District_NNP Court_NNP for_IN the_DT District_NNP of_IN Minnesota_NNP ._.
Most_JJS of_IN the_DT lawsuits_NNS are_VBP court_NN judge_NN in_IN California_NNP denied_VBD class_NN action_NN certication_NN although_IN in_IN their_PRP$ early_JJ stages_NNS and_CC there_EX has_VBZ been_VBN no_DT determination_NN as_IN to_TO permitting_VBG counsel_NN for_IN the_DT plaintiffs_NNS to_TO le_DT one_CD more_JJR motion_NN for_IN whether_IN any_DT of_IN the_DT lawsuits_NNS to_TO which_WDT the_DT Group_NNP is_VBZ a_DT party_NN will_MD be_VB certication_NN ._.
Most_JJS of_IN the_DT remaining_VBG lawsuits_NNS are_VBP in_IN their_PRP$ early_JJ permitted_VBN to_TO proceed_VB as_IN class_NN actions_NNS ._.
stages_NNS and_CC there_EX has_VBZ been_VBN no_DT determination_NN as_IN to_TO whether_IN any_DT of_IN GlaxoSmithKline_NNP ,_, along_IN with_IN a_DT number_NN of_IN other_JJ pharmaceutical_JJ the_DT lawsuits_NNS pending_VBG in_IN state_NN or_CC federal_JJ courts_NNS elsewhere_RB will_MD be_VB companies_NNS ,_, has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN a_DT number_NN of_IN permitted_VBN to_TO proceed_VB as_IN class_NN actions_NNS ._.
purported_JJ class_NN action_NN and_CC numerous_JJ individual_JJ personal_JJ injury_NN In_IN the_DT last_JJ decade_NN there_RB has_VBZ been_VBN litigation_NN against_IN the_DT lawsuits_NNS in_IN state_NN and_CC federal_JJ district_NN courts_NNS in_IN the_DT USA_NNP alleging_VBG that_IN manufacturers_NNS of_IN Prozac_NNP and_CC other_JJ sustained_VBN serotonin_NN reuptake_NN thimerosal_NN ,_, a_DT preservative_JJ used_VBN in_IN vaccines_NNS ,_, causes_VBZ inhibitor_NN SSRI_NNP products_NNS such_JJ as_IN Paxil_NNP for_IN homicidal_JJ or_CC suicidal_JJ neurodevelopmental_JJ disorders_NNS and_CC other_JJ injuries_NNS ._.
Plaintiffs_NNS seek_VBP behavior_NN exhibited_VBN by_IN users_NNS of_IN their_PRP$ products_NNS ._.
The_DT Group_NNP has_VBZ remedies_NNS including_VBG compensatory_JJ ,_, punitive_JJ and_CC statutory_JJ damages_NNS received_VBD some_DT such_JJ claims_NNS and_CC lawsuits_NNS with_IN respect_NN to_TO Paxil_NNP ._.
and_CC the_DT cost_NN of_IN a_DT fund_NN for_IN medical_JJ monitoring_NN and_CC research_NN ._.
The_DT None_NN of_IN these_DT are_VBP or_CC purport_VBP to_TO be_VB class_NN actions_NNS ._.
lawsuits_NNS are_VBP in_IN their_PRP$ very_RB early_JJ stages_NNS and_CC there_EX has_VBZ been_VBN no_DT determination_NN as_IN to_TO whether_IN any_DT of_IN the_DT purported_JJ class_NN actions_NNS will_MD be_VB permitted_VBN to_TO proceed_VB as_IN class_NN actions_NNS ._.
106_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 30_CD Legal_JJ proceedings_NNS continued_VBD Antitrust_NNP In_IN November_NNP 2000_CD the_DT US_NNP Federal_NNP Trade_NNP Commission_NNP FTC_NNP staff_NN Following_VBG the_DT voluntary_JJ withdrawal_NN of_IN Lotronex_NNP in_IN the_DT USA_NNP in_IN advised_VBD the_DT Group_NNP that_IN the_DT staff_NN was_VBD conducting_VBG a_DT non-public_JJ November_NNP 2000_CD a_DT number_NN of_IN lawsuits_NNS have_VBP been_VBN led_VBN against_IN the_DT investigation_NN to_TO determine_VB whether_IN the_DT Group_NNP was_VBD violating_VBG Group_NNP in_IN state_NN and_CC federal_JJ district_NN courts_NNS ,_, including_VBG individual_JJ Section_NN 5_CD of_IN the_DT Federal_NNP Trade_NNP Commission_NNP Act_NNP by_IN monopolizing_VBG personal_JJ injury_NN actions_NNS and_CC purported_JJ class_NN actions_NNS asserting_VBG or_CC attempting_VBG to_TO monopolize_VB the_DT market_NN for_IN paroxetine_JJ product_NN liability_NN and_CC consumer_NN fraud_NN claims_NNS ._.
Plaintiffs_NNS seek_VBP remedies_NNS hydrochloride_RB by_IN preventing_VBG generic_JJ competition_NN to_TO Paxil_NNP and_CC including_VBG compensatory_JJ ,_, punitive_JJ and_CC statutory_JJ damages_NNS ._.
A_DT requested_VBD the_DT Group_NNP to_TO submit_VB certain_JJ information_NN in_IN connection_NN number_NN of_IN claims_NNS have_VBP been_VBN settled_VBN ._.
Most_JJS of_IN the_DT remaining_VBG actions_NNS with_IN that_DT investigation_NN ._.
The_DT Group_NNP has_VBZ cooperated_VBN with_IN the_DT staffs_NNS are_VBP at_IN their_PRP$ early_JJ stages_NNS although_IN tentative_JJ trial_NN dates_NNS for_IN some_DT investigation_NN ._.
cases_NNS have_VBP been_VBN set_VBN for_IN early_JJ 2003_CD ._.
Following_VBG public_JJ reference_NN to_TO the_DT FTC_NNP investigation_NN regarding_VBG Paxil_NNP ,_, Government_NNP investigations_NNS purported_JJ consumer_NN class_NN actions_NNS have_VBP been_VBN led_VBN in_IN the_DT US_NNP District_NNP GlaxoSmithKline_NNP has_VBZ received_VBN subpoenas_NNS from_IN the_DT US_NNP Attorneys_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP on_IN behalf_NN of_IN putative_JJ ofce_NN in_IN Boston_NNP ,_, Massachusetts_NNP ,_, requesting_VBG production_NN of_IN classes_NNS of_IN indirect_JJ purchasers_NNS ,_, including_VBG consumers_NNS and_CC third_JJ party_NN documents_NNS for_IN the_DT period_NN from_IN 1991_CD to_TO the_DT present_JJ relating_VBG to_TO any_DT payers_NNS ._.
The_DT plaintiffs_NNS claim_VBP that_IN the_DT Group_NNP has_VBZ monopolised_VBN a_DT repackaging_VBG ,_, relabelling_VBG or_CC private_JJ label_NN arrangements_NNS that_WDT market_NN for_IN Paxil_NNP by_IN bringing_VBG allegedly_RB sham_JJ patent_NN litigation_NN and_CC GlaxoSmithKline_NNP has_VBZ had_VBN or_CC discussed_VBN with_IN third-party_JJ customers_NNS allegedly_RB abusing_VBG the_DT regulatory_JJ procedures_NNS for_IN the_DT listing_NN of_IN during_IN such_JJ period_NN ._.
At_IN issue_NN is_VBZ whether_IN the_DT prices_NNS charged_VBD to_TO such_JJ patents_NNS in_IN the_DT FDA_NNP Orange_NNP Book_NNP ._.
Treble_NNP damages_NNS are_VBP sought_VBN for_IN third_JJ parties_NNS for_IN GlaxoSmithKline_NNP products_NNS must_MD be_VB counted_VBN for_IN alleged_JJ overcharges_NNS owing_VBG from_IN the_DT conduct_NN ._.
The_DT cases_NNS are_VBP at_IN an_DT Medicaid_NNP best_JJS price_NN purposes_NNS ._.
The_DT Group_NNP has_VBZ also_RB received_VBN letters_NNS early_RB stage_NN with_IN no_DT determination_NN as_IN to_TO whether_IN they_PRP will_MD be_VB from_IN the_DT Centers_NNPS for_IN Medicare_NNP &_CC Medicaid_NNP Services_NNPS CMS_NNP stating_VBG permitted_VBN to_TO proceed_VB as_IN class_NN actions_NNS ._.
CMSs_NNS position_VBP that_IN certain_JJ of_IN those_DT prices_NNS should_MD have_VB been_VBN Through_IN the_DT US_NNP pharmaceutical_JJ businesses_NNS of_IN both_DT SmithKline_NNP included_VBD in_IN Medicaid_NNP best_JJS price_NN and_CC requesting_VBG that_IN Beecham_NNP and_CC Glaxo_NNP Wellcome_NNP ,_, the_DT Group_NNP is_VBZ party_NN to_TO a_DT number_NN of_IN GlaxoSmithKline_NNP retroactively_RB adjust_VBP its_PRP$ best_JJS price_NN reports_NNS for_IN antitrust_JJ suits_NNS ,_, certain_JJ of_IN which_WDT have_VBP been_VBN certied_VBN as_IN class_NN actions_NNS ,_, quarters_NNS prior_RB to_TO July_NNP 2000_CD to_TO include_VB those_DT prices_NNS ._.
The_DT Group_NNP is_VBZ instituted_VBN by_IN most_JJS of_IN the_DT nations_NNS retail_JJ pharmacies_NNS and_CC consumers_NNS involved_VBN in_IN discussions_NNS with_IN the_DT US_NNP Attorneys_NNP ofce_NN to_TO resolve_VB in_IN several_JJ states_NNS ,_, alleging_VBG conspiracies_NNS in_IN restraint_NN of_IN trade_NN and_CC these_DT issues_NNS ._.
challenging_VBG the_DT pricing_NN practices_NNS of_IN the_DT Group_NNP ._.
A_DT significant_JJ GlaxoSmithKline_NNP has_VBZ been_VBN responding_VBG to_TO subpoenas_NNS from_IN the_DT number_NN of_IN other_JJ pharmaceutical_JJ companies_NNS and_CC wholesalers_NNS have_VBP Ofce_NNP of_IN the_DT Inspector_NNP General_NNP of_IN the_DT US_NNP Department_NNP of_IN Health_NNP also_RB been_VBN sued_VBN in_IN the_DT same_JJ or_CC similar_JJ litigation_NN ._.
These_DT actions_NNS ,_, and_CC Human_NNP Services_NNPS ,_, the_DT US_NNP Department_NNP of_IN Justice_NNP and_CC the_DT states_NNS except_IN for_IN several_JJ actions_NNS brought_VBN in_IN state_NN courts_NNS ,_, were_VBD of_IN Texas_NNP and_CC California_NNP in_IN connection_NN with_IN allegations_NNS that_WDT consolidated_VBD for_IN pre-trial_JJ purposes_NNS in_IN the_DT District_NNP Court_NNP for_IN the_DT pharmaceutical_JJ companies_NNS ,_, including_VBG GlaxoSmithKline_NNP ,_, have_VBP Northern_JJ District_NNP of_IN Illinois_NNP ._.
The_DT federal_JJ class_NN action_NN component_NN ,_, violated_VBD federal_JJ fraud_NN and_CC abuse_NN laws_NNS such_JJ as_IN the_DT Federal_NNP False_NNP which_WDT includes_VBZ pharmacies_NNS representing_VBG approximately_RB two-thirds_NNS Claims_NNP Act_NNP and_CC ,_, with_IN respect_NN to_TO Texas_NNP and_CC California_NNP ,_, comparable_JJ of_IN total_JJ US_NNP retail_JJ sales_NNS volume_NN ,_, was_VBD settled_VBN by_IN both_DT Glaxo_NNP Wellcome_NNP state_NN laws_NNS as_IN a_DT result_NN of_IN the_DT way_NN certain_JJ drugs_NNS are_VBP priced_VBN and_CC the_DT and_CC SmithKline_NNP Beecham_NNP in_IN 1996_CD ._.
Since_IN that_DT time_NN ,_, the_DT Group_NNP has_VBZ way_NN the_DT Medicare_NNP and_CC Medicaid_NNP programs_NNS reimburse_VBP for_IN those_DT entered_VBN into_IN other_JJ settlements_NNS on_IN satisfactory_JJ terms_NNS ._.
In_IN 2002_CD ,_, the_DT Nevada_NNP and_CC Montana_NNP state_NN attorneys_NNS general_JJ has_VBZ not_RB engaged_VBN in_IN any_DT conspiracy_NN and_CC no_DT admission_NN of_IN each_DT led_VBD a_DT civil_JJ lawsuit_NN in_IN state_NN court_NN against_IN GlaxoSmithKline_NNP wrongdoing_NN was_VBD made_VBN nor_CC included_VBN in_IN the_DT final_JJ agreements_NNS ._.
and_CC several_JJ other_JJ drug_NN companies_NNS ._.
The_DT actions_NNS claim_VBP -_: on_IN behalf_NN In_IN August_NNP 2001_CD the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN of_IN the_DT states_NNS as_IN payers_NNS and_CC on_IN behalf_NN of_IN in-state_JJ patients_NNS as_IN Massachusetts_NNP ruled_VBD the_DT Groups_NNS patent_NN for_IN nabumetone_NN Relafen_NNP consumers_NNS -_: damages_NNS and_CC restitution_NN based_VBN on_IN defendants_NNS invalid_JJ for_IN anticipatory_JJ art_NN and_CC unenforceable_JJ on_IN the_DT grounds_NNS of_IN pricing_NN for_IN an_DT undefined_JJ set_NN of_IN pharmaceutical_JJ products_NNS ._.
The_DT Group_NNP led_VBD an_DT appeal_NN from_IN that_DT decision_NN In_IN the_DT first_JJ quarter_NN of_IN 2003_CD ,_, the_DT County_NNP of_IN Suffolk_NNP ,_, New_NNP York_NNP ,_, in_IN November_NNP 2001_CD ._.
In_IN August_NNP 2002_CD the_DT CAFC_NNP issued_VBD a_DT decision_NN led_VBD an_DT action_NN in_IN federal_JJ court_NN that_WDT also_RB asserts_VBZ claims_NNS against_IN afrming_VBG the_DT District_NNP Courts_NNPS judgement_NN of_IN invalidity_NN but_CC declining_VBG GlaxoSmithKline_NNP and_CC others_NNS relating_VBG to_TO the_DT reported_VBN average_NN to_TO rule_VB on_IN the_DT judgement_NN of_IN inequitable_JJ conduct_NN ._.
Following_VBG the_DT wholesale_JJ price_NN of_IN certain_JJ drugs_NNS covered_VBN by_IN the_DT states_NNS Medicaid_NNP District_NNP Court_NNP decision_NN ,_, antitrust_JJ claims_NNS alleging_VBG competitive_JJ injury_NN program_NN ._.
The_DT New_NNP York_NNP state_NN attorney_NN general_JJ led_VBD a_DT similar_JJ and_CC overcharges_NNS have_VBP been_VBN led_VBN by_IN Teva_NNP ,_, a_DT generic_JJ manufacturer_NN complaint_NN in_IN New_NNP York_NNP state_NN court_NN ._.
In_IN addition_NN ,_, private_JJ payer_NN class_NN of_IN nabumetone_NN ,_, by_IN purported_JJ classes_NNS of_IN direct_JJ purchasers_NNS and_CC action_NN lawsuits_NNS have_VBP been_VBN led_VBN against_IN GlaxoSmithKline_NNP in_IN several_JJ payers_NNS and_CC by_IN individual_JJ groups_NNS of_IN purported_JJ direct_JJ purchasers_NNS ._.
federal_JJ district_NN and_CC state_NN courts_NNS ._.
A_DT number_NN of_IN the_DT federal_JJ cases_NNS The_DT plaintiffs_NNS claims_NNS are_VBP based_VBN on_IN allegations_NNS of_IN fraudulent_JJ have_VBP been_VBN consolidated_VBN in_IN a_DT multidistrict_JJ litigation_NN proceeding_NN in_IN procurement_NN of_IN a_DT patent_NN ,_, wrongful_JJ listing_NN of_IN the_DT patent_NN in_IN the_DT FDA_NNP the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Massachusetts_NNP ._.
Most_JJS of_IN the_DT Orange_NNP Book_NNP and_CC prosecution_NN of_IN sham_NN patent_NN infringement_NN civil_JJ suits_NNS led_VBN by_IN state_NN attorneys_NNS general_JJ and_CC class_NN action_NN plaintiffs_NNS litigation_NN ._.
Those_DT cases_NNS ,_, which_WDT were_VBD originally_RB led_VBN in_IN the_DT US_NNP District_NNP have_VBP been_VBN removed_VBN to_TO federal_JJ court_NN ._.
Some_DT of_IN the_DT removed_VBN cases_NNS ,_, Courts_NNS for_IN the_DT District_NNP of_IN Massachusetts_NNP and_CC the_DT Eastern_NNP District_NNP of_IN including_VBG the_DT Nevada_NNP and_CC Montana_NNP cases_NNS ,_, have_VBP been_VBN consolidated_JJ Pennsylvania_NNP ,_, are_VBP now_RB all_DT pending_VBG in_IN the_DT District_NNP of_IN Massachusetts_NNP into_IN the_DT District_NNP of_IN Massachusetts_NNP proceedings_NNS and_CC steps_NNS have_VBP been_VBN and_CC are_VBP in_IN their_PRP$ early_JJ stages_NNS ._.
There_EX has_VBZ been_VBN no_DT determination_NN as_IN taken_VBN to_TO consolidate_VB the_DT other_JJ removed_VBN cases_NNS there_RB too_RB ._.
Nevada_NNP ,_, to_TO whether_IN the_DT putative_JJ class_NN actions_NNS will_MD be_VB permitted_VBN to_TO proceed_VB Montana_NNP and_CC some_DT of_IN the_DT private_JJ class_NN action_NN plaintiffs_NNS who_WP as_IN class_NN actions_NNS ._.
originally_RB led_VBN in_IN state_NN court_NN are_VBP seeking_VBG to_TO have_VB their_PRP$ cases_NNS remanded_VBD to_TO their_PRP$ respective_JJ state_NN courts_NNS ._.
All_PDT the_DT actions_NNS are_VBP in_IN their_PRP$ early_JJ stages_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 107_CD 30_CD Legal_NNP proceedings_NNS continued_VBD These_DT proceedings_NNS seek_VBP to_TO require_VB the_DT operators_NNS of_IN hazardous_JJ waste_NN facilities_NNS ,_, transporters_NNS of_IN waste_NN to_TO the_DT sites_NNS and_CC generators_NNS of_IN In_IN 2002_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Virginia_NNP hazardous_JJ waste_NN disposed_VBD of_IN at_IN the_DT sites_NNS to_TO clean_VB up_RP the_DT sites_NNS or_CC to_TO found_VBN various_JJ patents_NNS covering_VBG Augmentin_NNP invalid_JJ ._.
The_DT Group_NNP has_VBZ reimburse_VB the_DT government_NN for_IN cleanup_NN costs_NNS ._.
In_IN most_JJS instances_NNS ,_, led_VBD an_DT appeal_NN from_IN that_DT decision_NN ,_, which_WDT is_VBZ still_RB pending_VBG before_IN the_DT GlaxoSmithKline_NNP is_VBZ involved_VBN as_IN an_DT alleged_JJ generator_NN of_IN hazardous_JJ CAFC_NNP ._.
Immediately_RB following_VBG the_DT adverse_JJ trial_NN court_NN decision_NN ,_, waste_NN although_IN there_EX are_VBP a_DT few_JJ sites_NNS where_WRB GlaxoSmithKline_NNP is_VBZ purported_JJ antitrust_JJ class_NN actions_NNS were_VBD led_VBN on_IN behalf_NN of_IN consumers_NNS involved_VBN as_IN a_DT current_JJ or_CC former_JJ operator_NN of_IN the_DT facility_NN ._.
Although_IN and_CC third_JJ party_NN payers_NNS in_IN various_JJ federal_JJ courts_NNS ,_, which_WDT have_VBP now_RB all_DT Superfund_NNP provides_VBZ that_IN the_DT defendants_NNS are_VBP jointly_RB and_CC severally_RB been_VBN transferred_VBN or_CC consolidated_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT liable_JJ for_IN cleanup_NN costs_NNS ,_, these_DT proceedings_NNS are_VBP frequently_RB resolved_VBN Eastern_NNP District_NNP of_IN Virginia_NNP ._.
Plaintiffs_NNS allege_VBP that_IN the_DT Group_NNP on_IN the_DT basis_NN of_IN the_DT nature_NN and_CC quantity_NN of_IN waste_NN disposed_VBN of_IN at_IN the_DT knowingly_RB obtained_VBN invalid_JJ patents_NNS and_CC engaged_VBN in_IN other_JJ site_NN by_IN the_DT generator_NN ._.
GlaxoSmithKlines_NNS proportionate_VBP liability_NN for_IN anticompetitive_JJ conduct_NN to_TO prevent_VB entry_NN of_IN generic_JJ products_NNS in_IN cleanup_NN costs_NNS has_VBZ been_VBN substantially_RB determined_VBN for_IN about_RB 20_CD of_IN violation_NN of_IN the_DT monopolization_NN section_NN of_IN the_DT US_NNP antitrust_JJ laws_NNS ._.
the_DT sites_NNS referred_VBD to_TO above_IN ._.
Plaintiffs_NNS seek_VBP declaratory_JJ and_CC injunctive_JJ relief_NN as_RB well_RB as_IN treble_JJ damages_NNS for_IN the_DT alleged_JJ overcharges_NNS ._.
There_EX has_VBZ been_VBN no_DT GlaxoSmithKlines_NNS potential_JJ liability_NN varies_VBZ greatly_RB from_IN site_NN to_TO site_NN ._.
determination_NN as_IN to_TO whether_IN the_DT putative_JJ class_NN actions_NNS ,_, which_WDT are_VBP While_IN the_DT cost_NN of_IN investigation_NN ,_, study_NN and_CC remediation_NN at_IN such_JJ sites_NNS in_IN their_PRP$ early_JJ stages_NNS ,_, will_MD be_VB permitted_VBN to_TO proceed_VB as_IN class_NN actions_NNS ._.
could_MD ,_, over_IN time_NN ,_, be_VB substantial_JJ ,_, GlaxoSmithKline_NNP routinely_RB accrues_VBZ Separately_NNP ,_, the_DT Group_NNP is_VBZ prosecuting_VBG patent_NN infringement_NN suits_NNS amounts_VBZ related_VBN to_TO its_PRP$ share_NN of_IN liability_NN for_IN such_JJ matters_NNS ._.
against_IN four_CD companies_NNS that_WDT have_VBP led_VBN ANDAs_NNS seeking_VBG permission_NN to_TO sell_VB generic_JJ bupropion_NN Wellbutrin_NNP SR_NNP Zyban_NNP in_IN the_DT US_NNP ._.
In_IN three_CD Tax_NNP matters_NNS of_IN those_DT cases_NNS ,_, summary_NN judgement_NN has_VBZ been_VBN entered_VBN against_IN the_DT Pending_NNP tax_NN matters_NNS are_VBP described_VBN in_IN Note_NN 12_CD ._.
Following_VBG these_DT adverse_JJ rulings_NNS in_IN the_DT patent_NN litigation_NN ,_, a_DT purported_JJ class_NN action_NN on_IN behalf_NN of_IN purchasers_NNS and_CC third_JJ party_NN payers_NNS was_VBD led_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP ,_, alleging_VBG that_IN the_DT Group_NNP engaged_VBD in_IN anticompetitive_JJ conduct_NN ,_, including_VBG prosecution_NN of_IN sham_NN patent_NN infringement_NN litigation_NN ,_, to_TO prevent_VB entry_NN of_IN generic_JJ products_NNS ._.
Plaintiffs_NNS seek_VBP declaratory_JJ and_CC injunctive_JJ relief_NN ,_, as_RB well_RB as_IN treble_JJ damages_NNS for_IN the_DT alleged_JJ overcharges_NNS ._.
Commercial_JJ matters_NNS Otsuka_NNP Pharmaceutical_NNP Co._NNP ._.
Ltd._NNP initiated_VBD arbitration_NN proceedings_NNS in_IN December_NNP 2001_CD concerning_VBG the_DT Groups_NNS unilateral_JJ withdrawal_NN of_IN grepaoxacin_NN Raxar_NNP Vaxar_NNP in_IN October_NNP 1999_CD for_IN safety_NN reasons_NNS ._.
Otsuka_FW alleges_VBZ that_IN the_DT product_NN withdrawal_NN and_CC simultaneous_JJ public_JJ announcement_NN constituted_VBD material_NN breaches_NNS of_IN the_DT license_NN and_CC supply_NN agreements_NNS ._.
The_DT Group_NNP believes_VBZ the_DT underlying_JJ product_NN withdrawal_NN was_VBD consistent_JJ with_IN the_DT terms_NNS of_IN the_DT agreements_NNS and_CC that_IN valid_JJ defences_NNS exist_VBP to_TO the_DT claims_NNS ._.
A_DT UK_NNP arbitration_NN panel_NN has_VBZ been_VBN selected_VBN and_CC met_VBN ._.
The_DT hearing_NN to_TO determine_VB liability_NN ,_, if_IN any_DT ,_, is_VBZ scheduled_VBN for_IN December_NNP 2003_CD ._.
SmithKline_NNP Beecham_NNP Clinical_NNP Laboratories_NNPS indemnities_VBZ In_IN connection_NN with_IN the_DT sale_NN of_IN SmithKline_NNP Beecham_NNP Clinical_NNP Laboratories_NNPS SBCL_NNP to_TO Quest_NNP Diagnostics_NNPS ,_, Inc._NNP the_DT Group_NNP has_VBZ agreed_VBN to_TO indemnify_VB Quest_NNP Diagnostics_NNPS ,_, on_IN an_DT after-tax_JJ basis_NN ,_, with_IN respect_NN to_TO certain_JJ liabilities_NNS arising_VBG from_IN the_DT conduct_NN of_IN the_DT SBCL_NNP business_NN prior_RB to_TO closing_NN ,_, including_VBG governmental_JJ and_CC private_JJ claims_NNS arising_VBG from_IN the_DT US_NNP governments_NNS investigation_NN into_IN SBCLs_NNS billing_NN and_CC marketing_NN practices_NNS ._.
Environmental_NNP matters_VBZ GlaxoSmithKline_NNP has_VBZ been_VBN notied_VBN of_IN its_PRP$ potential_JJ responsibility_NN relating_VBG to_TO past_JJ operations_NNS and_CC its_PRP$ past_JJ waste_NN disposal_NN practices_NNS at_IN certain_JJ sites_NNS ,_, primarily_RB in_IN the_DT USA_NNP ._.
Some_DT of_IN these_DT matters_NNS are_VBP the_DT subject_NN of_IN litigation_NN ,_, including_VBG proceedings_NNS initiated_VBN by_IN the_DT US_NNP federal_JJ or_CC state_NN governments_NNS for_IN waste_NN disposal_NN site_NN remediation_NN costs_NNS and_CC tort_NN actions_NNS brought_VBN by_IN private_JJ parties_NNS ._.
GlaxoSmithKline_NNP has_VBZ been_VBN advised_VBN that_IN it_PRP may_MD be_VB a_DT responsible_JJ party_NN at_IN approximately_RB 27_CD sites_NNS ,_, of_IN which_WDT 11_CD appear_VBP on_IN the_DT National_NNP Priority_NNP List_NN created_VBN by_IN the_DT Comprehensive_NNP Environmental_NNP Response_NNP Compensation_NNP and_CC Liability_NNP Act_NNP Superfund_NNP ._.
108_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 31_CD Acquisitions_NNS and_CC disposals_NNS Details_NNS of_IN the_DT acquisition_NN and_CC disposal_NN of_IN subsidiary_NN and_CC associated_VBN undertakings_NNS and_CC joint_JJ ventures_NNS are_VBP given_VBN below_IN ._.
2002_CD Book_NNP Fair_NNP value_NN Net_JJ assets_NNS Goodwill_NNP Cost_NN of_IN values_NNS adjustments_NNS acquired_VBD capitalized_JJ acquisition_NN Acquisitions_NNS m_VBP m_FW m_FW m_FW m_FW Iter_NNP Sterilyo_NNP 7_CD 4_CD 3_CD 21_CD 18_CD Human_NNP Kft_NNP 10_CD 10_CD 1_CD 11_CD Other_JJ 11_CD 3_CD 4_CD 7_CD 23_CD 30_CD Iter_NNP Sterilyo_NNP During_IN 2002_CD the_DT Group_NNP acquired_VBD Iter-Sterilyo_NNP Group_NNP for_IN an_DT initial_JJ cash_NN consideration_NN of_IN 9_CD million_CD ._.
A_DT further_JJ payment_NN will_MD be_VB payable_JJ during_IN 2003_CD ,_, up_RB to_TO a_DT maximum_NN of_IN 9_CD million_CD ,_, depending_VBG on_IN the_DT financial_JJ performance_NN of_IN the_DT acquired_VBN company_NN during_IN 2002_CD ._.
The_DT net_JJ assets_NNS of_IN Iter-Sterilyo_NNP have_VBP been_VBN incorporated_VBN in_IN the_DT financial_JJ statements_NNS at_IN their_PRP$ provisional_JJ fair_JJ values_NNS ._.
Human_JJ Kft_NNP During_IN 2002_CD the_DT Group_NNP acquired_VBD the_DT vaccine_NN related_VBN assets_NNS of_IN Human_JJ Kft_NNP ,_, a_DT manufacturing_NN business_NN located_VBN in_IN Hungary_NNP ,_, for_IN a_DT cash_NN consideration_NN of_IN 11_CD million_CD ._.
Disposals_NNS SB_NNP Clinical_NNP Laboratories_NNPS A_DT cash_NN refund_NN of_IN 6_CD million_CD was_VBD received_VBN during_IN 2002_CD in_IN respect_NN of_IN indemnified_JJ liabilities_NNS arising_VBG from_IN the_DT SB_NNP Clinical_NNP Laboratories_NNP disposal_NN which_WDT occurred_VBD in_IN 1999_CD ._.
The_DT refund_NN is_VBZ as_IN a_DT result_NN of_IN a_DT successful_JJ case_NN in_IN the_DT US_NNP Court_NNP of_IN Appeal_NNP ._.
SB_NNP Clinical_NNP Iter_NNP -_: Human_JJ Laboratories_NNPS Sterilyo_NNP Kft_NNP Other_JJ Total_NNP Cash_NNP ows_VBZ m_FW m_FW m_FW m_FW m_FW Cash_NN consideration_NN paid_VBD 911_CD 6_CD 26_CD Cash_NN acquired_VBD Net_JJ cash_NN payment_NN on_IN acquisitions_NNS 911_CD 6_CD 26_CD Net_JJ cash_NN proceeds_NNS from_IN disposals_NNS 6_CD 6_CD 2001_CD Book_NNP Fair_NNP value_NN Net_JJ assets_NNS Goodwill_NNP Cost_NN of_IN values_NNS adjustments_NNS acquired_VBD capitalized_JJ acquisition_NN Acquisitions_NNS m_VBP m_FW m_FW m_FW m_FW Block_NNP Drug_NNP 491 352 843 843_CD Shionogi_NNP joint_JJ venture_NN 31_CD 31_CD 31_CD Other_JJ 13_CD 8_CD 5_CD 13 18 535 344_CD 879_CD 13_CD 892_CD Block_NNP Drug_NNP Company_NNP Inc._NNP ._.
In_IN January_NNP 2001_CD ,_, the_DT Group_NNP acquired_VBD Block_NNP Drug_NNP for_IN cash_NN consideration_NN of_IN 843_CD million_CD which_WDT represented_VBD the_DT fair_JJ value_NN of_IN the_DT assets_NNS acquired_VBN ._.
Shionogi_NNP joint_JJ venture_NN During_IN 2001_CD the_DT Group_NNP established_VBD a_DT joint_JJ venture_NN with_IN Shionogi_NNP to_TO develop_VB and_CC commercialise_VB a_DT number_NN of_IN compounds_NNS contributed_VBN by_IN both_DT parties_NNS ._.
The_DT Group_NNP acquired_VBD 50_CD per_IN cent_NN of_IN the_DT equity_NN share_NN capital_NN for_IN a_DT cash_NN consideration_NN of_IN 31_CD million_CD ,_, and_CC has_VBZ committed_VBN to_TO make_VB further_JJ contributions_NNS if_IN certain_JJ development_NN milestones_NNS are_VBP achieved_VBN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 109_CD 31_CD Acquisitions_NNS and_CC disposals_NNS continued_VBD Disposals_NNP Quest_NNP Diagnostics_NNPS ,_, Inc._NNP ._.
In_IN May_NNP 2001_CD the_DT Group_NNP disposed_VBD of_IN 1.5_CD million_CD shares_NNS from_IN its_PRP$ investment_NN in_IN Quest_NNP Diagnostics_NNPS ,_, Inc._NNP for_IN cash_NN proceeds_NNS of_IN 124_CD million_CD ,_, reducing_VBG the_DT Groups_NNS holding_VBG at_IN 31st_CD December_NNP 2001_CD to_TO 23_CD per_IN cent_NN ._.
After_IN recognizing_VBG a_DT charge_NN for_IN goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS of_IN 17_CD million_CD a_DT profit_NN of_IN 96_CD million_CD was_VBD recognized_VBN ._.
Affymax_NNP During_IN 2001_CD the_DT Group_NNP completed_VBD the_DT sale_NN of_IN the_DT Affymax_NNP business_NN to_TO Affymax_NNP Inc._NNP a_DT new_JJ holding_VBG company_NN ,_, for_IN 2.3_CD million_CD non-voting_JJ preference_NN shares_NNS in_IN Affymax_NNP Inc._NNP representing_VBG a_DT value_NN of_IN $_$ 19.6_CD million_CD 13.6_CD million_CD ._.
After_IN recognizing_VBG a_DT charge_NN for_IN goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS of_IN 299_CD million_CD a_DT loss_NN of_IN 301_CD million_CD was_VBD made_VBN ._.
Disposal_NN costs_NNS of_IN 5_CD million_CD were_VBD incurred_VBN in_IN completing_VBG the_DT sale_NN ._.
Tagamet_NNP In_IN February_NNP 2001_CD the_DT Group_NNP sold_VBD Tagamet_NNP in_IN Japan_NNP to_TO Sumitomo_NNP Pharmaceutical_NNP Co._NNP ._.
Ltd._NNP for_IN a_DT cash_NN consideration_NN of_IN 71_CD million_CD ._.
After_IN recognizing_VBG a_DT charge_NN for_IN goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS of_IN 72_CD million_CD a_DT loss_NN of_IN 1_CD million_CD was_VBD recognized_VBN ._.
Quest_NNP Diagnostics_NNPS Affymax_NNP Tagamet_NNP Block_NNP Drug_NNP Shionogi_NNP Other_JJ Total_NNP Cash_NNP ows_VBZ m_FW m_FW m_FW m_FW m_FW m_FW m_FW Cash_NN consideration_NN paid_VBD 843_CD 31_CD 18_CD 892_CD Cash_NN acquired_VBN 45_CD 45_CD Net_JJ cash_NN payment_NN on_IN acquisitions_NNS 798_CD 31_CD 18_CD 847_CD Net_JJ cash_NN proceeds_NNS from_IN disposals_NNS 124_CD 5_CD 71 190 2000_CD Book_NNP Fair_NNP value_NN Net_JJ assets_NNS Goodwill_NNP Cost_NN of_IN values_NNS adjustments_NNS acquired_VBD capitalized_JJ acquisition_NN Acquisitions_NNS m_VBP m_FW m_FW m_FW m_FW GlaxoSmithKline_NNP Pharmaceuticals_NNP SA_NNP 7_CD 71623_CD Acquisition_NNP of_IN other_JJ minority_NN interests_NNS 2_CD 2_CD 2_CD 9_CD 91625_CD GlaxoSmithKline_NNP Pharmaceuticals_NNP SA_NNP During_IN 2000_CD the_DT Group_NNP acquired_VBD a_DT further_JJ 8.7_CD per_IN cent_NN of_IN GlaxoSmithKline_NNP Pharmaceuticals_NNP SA_NNP formerly_RB Polfa_NNP Poznan_NNP SA_NNP in_IN Poland_NNP for_IN a_DT cash_NN consideration_NN of_IN 23_CD million_CD ._.
Goodwill_NN of_IN 16_CD million_CD was_VBD capitalized_VBN and_CC is_VBZ being_VBG amortised_VBN in_IN line_NN with_IN the_DT initial_JJ acquisition_NN in_IN 1998_CD ._.
In_IN May_NNP 2000_CD the_DT Group_NNP sold_VBD two_CD million_CD shares_NNS in_IN Affymetrix_NNP ,_, Inc._NNP for_IN cash_NN proceeds_NNS of_IN 155_CD million_CD ,_, realizing_VBG a_DT profit_NN of_IN 144_CD million_CD ._.
SB_NNP Clinical_NNP Laboratories_NNPS A_DT final_JJ cash_NN settlement_NN of_IN US$_$ 95_CD million_CD 62_CD million_CD was_VBD paid_VBN in_IN October_NNP 2000_CD to_TO complete_VB the_DT sale_NN of_IN SB_NNP Clinical_NNP Laboratories_NNPS ._.
SB_NNP Clinical_NNP GlaxoSmithKline_NNP Laboratories_NNP Affymetrix_NNP Pharmaceuticals_NNP SA_NNP Other_JJ Total_NNP Cash_NNP ows_VBZ m_FW m_FW m_FW m_FW m_FW Cash_NN consideration_NN paid_VBD 23_CD 2_CD 25_CD Cash_NN acquired_VBD Net_JJ cash_NN payment_NN on_IN acquisitions_NNS 23_CD 2_CD 25_CD Net_JJ cash_NN proceeds_NNS from_IN disposals_NNS 62_CD 155_CD 93_CD 110_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 32_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS Fair_NNP value_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS The_DT table_NN on_IN page_NN 111_CD presents_VBZ the_DT carrying_VBG amounts_NNS under_IN UK_NNP Policies_NNS GAAP_NNP and_CC the_DT fair_JJ values_NNS of_IN the_DT Groups_NNS financial_JJ assets_NNS and_CC Discussion_NN of_IN the_DT Groups_NNS objectives_NNS and_CC policies_NNS for_IN the_DT liabilities_NNS at_IN 31st_CD December_NNP 2002_CD and_CC 31st_CD December_NNP 2001_CD ._.
management_NN of_IN financial_JJ instruments_NNS and_CC associated_VBN risks_NNS is_VBZ Debtors_NNS and_CC creditors_NNS due_JJ within_IN one_CD year_NN have_VBP been_VBN excluded_VBN ._.
included_VBN under_IN Treasury_NNP Policies_NNS in_IN the_DT Operating_NN and_CC financial_JJ review_NN and_CC prospects_NNS on_IN page_NN 62_CD ._.
The_DT fair_JJ values_NNS of_IN the_DT financial_JJ assets_NNS and_CC liabilities_NNS are_VBP included_VBN at_IN the_DT amount_NN at_IN which_WDT the_DT instrument_NN could_MD be_VB exchanged_VBN in_IN a_DT Investments_NNP current_JJ transaction_NN between_IN willing_JJ parties_NNS ,_, other_JJ than_IN in_IN a_DT forced_VBN The_DT Group_NNP holds_VBZ a_DT number_NN of_IN equity_NN investments_NNS ,_, frequently_RB in_IN or_CC liquidation_NN sale_NN ._.
The_DT following_VBG methods_NNS and_CC assumptions_NNS were_VBD entities_NNS where_WRB the_DT Group_NNP has_VBZ entered_VBN into_IN research_NN collaborations_NNS ._.
used_VBN to_TO estimate_VB the_DT fair_JJ values_NNS :_: The_DT Group_NNP seeks_VBZ to_TO realize_VB the_DT value_NN in_IN these_DT investments_NNS ,_, which_WDT Equity_NNP investments_NNS market_NN value_NN based_VBN on_IN quoted_VBN market_NN in_IN part_NN the_DT research_NN collaboration_NN helps_VBZ to_TO create_VB ,_, and_CC therefore_RB prices_NNS in_IN the_DT case_NN of_IN listed_VBN investments_NNS :_: market_NN value_NN by_IN certain_JJ of_IN these_DT investments_NNS are_VBP regarded_VBN as_IN available_JJ for_IN sale_NN and_CC reference_NN to_TO quoted_VBN prices_NNS for_IN similar_JJ companies_NNS or_CC recent_JJ are_VBP accounted_VBN for_IN as_IN current_JJ asset_NN investments_NNS ._.
For_IN the_DT purposes_NNS nancing_VBG information_NN in_IN the_DT case_NN of_IN material_NN unlisted_JJ of_IN US_NNP GAAP_NNP all_PDT the_DT current_JJ asset_NN investments_NNS are_VBP classied_VBN as_IN investments_NNS available_JJ for_IN sale_NN ._.
Cash_NN at_IN bank_NN approximates_VBZ to_TO the_DT carrying_VBG amount_NN In_IN 2002_CD ,_, GlaxoSmithKline_NNP hedged_VBD part_NN of_IN the_DT equity_NN value_NN of_IN its_PRP$ Liquid_NN investments_NNS based_VBN on_IN quoted_VBN market_NN prices_NNS for_IN similar_JJ holdings_NNS in_IN its_PRP$ largest_JJS equity_NN investment_NN ,_, Quest_NNP Diagnostics_NNPS ,_, Inc._NNP companies_NNS or_CC recent_JJ nancing_NN information_NN in_IN the_DT case_NN of_IN through_IN a_DT series_NN of_IN variable_JJ sale_NN forward_RB contracts_NNS ._.
These_DT contracts_NNS marketable_JJ securities_NNS :_: approximates_VBZ to_TO the_DT carrying_VBG amount_NN the_DT equity_NN collar_NN are_VBP structured_VBN in_IN five_CD series_NN ,_, each_DT over_IN one_CD in_IN the_DT case_NN of_IN time_NN deposits_NNS because_IN of_IN their_PRP$ short_JJ maturity_NN million_CD Quest_NNP shares_NNS and_CC mature_VB between_IN 2006_CD and_CC 2008_CD ._.
Short-term_JJ loans_NNS and_CC overdrafts_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN because_IN of_IN the_DT short_JJ maturity_NN of_IN these_DT instruments_NNS The_DT Group_NNP has_VBZ liquid_JJ investments_NNS ,_, representing_VBG funds_NNS surplus_NN to_TO Medium-term_JJ loans_NNS market_NN value_NN based_VBN on_IN quoted_VBN market_NN immediate_JJ operating_NN requirements_NNS ,_, which_WDT are_VBP accounted_VBN for_IN as_IN prices_NNS in_IN the_DT case_NN of_IN the_DT Eurobonds_NNS and_CC other_JJ xed_JJ rate_NN current_JJ asset_NN investments_NNS ._.
For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP the_DT borrowings_NNS :_: approximates_VBZ to_TO the_DT carrying_VBG amount_NN in_IN the_DT case_NN investments_NNS are_VBP classied_VBN as_IN available_JJ for_IN sale_NN ._.
The_DT proceeds_NNS from_IN of_IN oating_NN rate_NN bank_NN loans_NNS and_CC other_JJ loans_NNS sale_NN of_IN investments_NNS classied_VBD as_IN available_JJ for_IN sale_NN under_IN US_NNP GAAP_NNP Forward_RB exchange_NN contracts_NNS based_VBN on_IN market_NN prices_NNS and_CC in_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD were_VBD 162_CD million_CD ._.
The_DT exchange_NN rates_NNS at_IN the_DT balance_NN sheet_NN date_NN proceeds_NNS include_VBP the_DT roll-over_NN of_IN liquid_JJ funds_NNS on_IN short-term_JJ deposit_NN ._.
Currency_NNP swaps_NNS based_VBN on_IN market_NN valuations_NNS at_IN the_DT balance_NN The_DT gross_JJ gains_NNS and_CC losses_NNS reected_VBD in_IN the_DT consolidated_JJ profit_NN and_CC sheet_NN date_NN loss_NN account_NN in_IN respect_NN of_IN investments_NNS classied_VBD as_IN available_JJ for_IN sale_NN Equity_NN collar_NN -_: fair_JJ value_NN is_VBZ determined_VBN based_VBN on_IN an_DT option_NN under_IN US_NNP GAAP_NNP were_VBD 44_CD million_CD and_CC 1_CD million_CD ,_, respectively_RB ._.
pricing_NN model_NN Interest_NN rate_NN instruments_NNS based_VBN on_IN market_NN valuations_NNS at_IN the_DT Foreign_JJ exchange_NN risk_NN management_NN balance_NN sheet_NN date_NN The_DT Group_NNP has_VBZ entered_VBN into_IN forward_RB foreign_JJ exchange_NN contracts_NNS Debtors_NNS and_CC creditors_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN in_IN order_NN to_TO swap_VB liquid_JJ assets_NNS and_CC borrowings_NNS into_IN the_DT currencies_NNS Provisions_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN required_VBN for_IN Group_NNP purposes_NNS ._.
At_IN 31st_CD December_NNP 2002_CD the_DT Group_NNP Auction_NNP rate_NN preference_NN stock_NN -_: approximates_VBZ to_TO the_DT carrying_NN had_VBD outstanding_JJ contracts_NNS to_TO sell_VB or_CC purchase_VB foreign_JJ currency_NN amount_NN in_IN the_DT case_NN of_IN oating_NN rate_NN instruments_NNS having_VBG a_DT total_JJ notional_JJ principal_NN amount_NN of_IN 1,937_CD million_CD Flexible_JJ auction_NN market_NN preferred_VBN stock_NN -_: based_VBN on_IN market_NN 2001_CD 7,312_CD million_CD ._.
The_DT majority_NN of_IN contracts_NNS are_VBP for_IN periods_NNS valuations_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
At_IN the_DT end_NN of_IN the_DT year_NN the_DT Group_NNP had_VBD a_DT number_NN of_IN currency_NN swaps_NNS Fair_NNP value_NN of_IN investments_NNS in_IN own_JJ shares_NNS in_IN place_NN in_IN respect_NN of_IN medium-term_JJ debt_NN instruments_NNS ._.
The_DT Group_NNP had_VBD at_IN 31st_CD December_NNP 2002_CD investments_NNS in_IN own_JJ shares_NNS of_IN 2,826_CD million_CD 2001_CD 2,936_CD million_CD with_IN a_DT fair_JJ value_NN of_IN Borrowings_NNS denominated_VBN in_IN ,_, or_CC swapped_VBD into_IN ,_, foreign_JJ currencies_NNS 2,161_CD million_CD 2001_CD 3,229_CD million_CD ._.
The_DT difference_NN between_IN which_WDT match_NN investments_NNS in_IN overseas_JJ Group_NNP assets_NNS are_VBP treated_VBN as_IN the_DT carrying_VBG amount_NN and_CC the_DT fair_JJ value_NN represents_VBZ an_DT unrealised_JJ a_DT hedge_NN against_IN the_DT relevant_JJ net_JJ assets_NNS and_CC exchange_NN gains_NNS or_CC loss_NN of_IN 665_CD million_CD ._.
This_DT valuation_NN shortfall_NN is_VBZ not_RB considered_VBN to_TO losses_NNS are_VBP recorded_VBN in_IN reserves_NNS ._.
represent_VB a_DT permanent_JJ diminution_NN in_IN value_NN in_IN the_DT context_NN of_IN the_DT length_NN of_IN the_DT future_JJ period_NN over_IN which_WDT the_DT related_JJ share_NN options_NNS Interest_NN rate_NN risk_NN management_NN may_MD be_VB exercised_VBN ._.
These_DT To_TO manage_VB the_DT xed_VBN oating_NN interest_NN rate_NN prole_NN of_IN debt_NN ,_, the_DT Group_NNP investments_NNS are_VBP excluded_VBN from_IN financial_JJ instrument_NN disclosure_NN ._.
The_DT had_VBD several_JJ interest_NN rate_NN swaps_NNS outstanding_JJ with_IN commercial_JJ banks_NNS fair_JJ value_NN is_VBZ the_DT market_NN value_NN based_VBN on_IN quoted_VBN market_NN price_NN ._.
The_DT shares_NNS represent_VBP purchases_NNS by_IN Employee_NNP Share_NNP Ownership_NNP Concentrations_NNS of_IN credit_NN risk_NN and_CC credit_NN exposures_NNS of_IN Trusts_NNS to_TO satisfy_VB future_JJ exercises_NNS of_IN options_NNS and_CC awards_NNS under_IN financial_JJ instruments_NNS employee_NN incentive_NN schemes_NNS ._.
The_DT purchases_NNS are_VBP matched_VBN against_IN The_DT Group_NNP does_VBZ not_RB believe_VB it_PRP is_VBZ exposed_VBN to_TO major_JJ concentrations_NNS options_NNS at_IN pre-determined_JJ exercise_NN prices_NNS and_CC the_DT gain_NN or_CC loss_NN to_TO of_IN credit_NN risk_NN ._.
The_DT Group_NNP is_VBZ exposed_VBN to_TO credit-related_JJ losses_NNS in_IN the_DT be_VB recognized_VBN is_VBZ measured_VBN against_IN exercise_NN price_NN rather_RB than_IN event_NN of_IN non-performance_JJ by_IN counterparties_NNS to_TO financial_JJ market_NN value_NN ._.
instruments_NNS ,_, but_CC does_VBZ not_RB expect_VB any_DT counterparties_NNS to_TO fail_VB to_TO meet_VB their_PRP$ obligations_NNS ._.
The_DT Group_NNP applies_VBZ Board-approved_JJ limits_NNS to_TO the_DT amount_NN of_IN credit_NN exposure_NN to_TO any_DT one_CD counterparty_NN and_CC employs_VBZ strict_JJ minimum_NN credit_NN worthiness_NN criteria_NNS as_IN to_TO the_DT choice_NN of_IN counterparty_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 111_CD 32_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS continued_VBD Classication_NNP and_CC fair_JJ values_NNS of_IN financial_JJ assets_NNS and_CC liabilities_NNS The_DT following_JJ table_NN sets_VBZ out_RP the_DT classication_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS and_CC provides_VBZ a_DT reconciliation_NN to_TO Group_NNP net_JJ debt_NN in_IN Note_NN 25_CD ._.
Short-term_JJ debtors_NNS and_CC creditors_NNS have_VBP been_VBN excluded_VBN from_IN financial_JJ assets_NNS and_CC liabilities_NNS ._.
Provisions_NNS have_VBP been_VBN included_VBN where_WRB there_EX is_VBZ a_DT contractual_JJ obligation_NN to_TO settle_VB in_IN cash_NN ._.
2002_CD 2001_CD Carrying_VBG Fair_NNP Carrying_VBG Fair_NNP amount_NN value_NN amount_NN value_NN m_NN m_FW m_FW m_FW Net_JJ debt_NN Liquid_NN investments_NNS 1,256_CD 1,264_CD 1,415_CD 1,418_CD Cash_NN at_IN bank_NN 1,052_CD 1,052_CD 716_CD 716_CD Current_JJ asset_NN financial_JJ instruments_NNS 2,308_CD 2,316_CD 2,131_CD 2,134_CD Sterling_NN notes_NNS and_CC bonds_NNS 1,472_CD 1,559_CD 1,471_CD 1,534_CD 1,472_CD 1,559_CD 1,471_CD 1,534_CD US_NNP dollar_NN notes_NNS ,_, bonds_NNS and_CC private_JJ nancing_NN 978_CD 1,018_CD 729_CD 752_CD Notes_NNS and_CC bonds_NNS swapped_VBD into_IN US_NNP dollars_NNS 498_CD 507_CD 61_CD 53_CD Currency_NN swaps_NNS 21_CD 8_CD Interest_NN rate_NN swaps_NNS 7_CD 1,476_CD 1,497_CD 790_CD 813_CD Notes_NNS and_CC bonds_NNS swapped_VBD into_IN Yen_NNP 106 114 340 346_CD Currency_NNP swaps_NNS 6_CD 18 106 108 340_CD 328_CD Other_JJ medium-term_JJ borrowings_NNS 38_CD 38_CD 49_CD 49_CD Other_JJ short-term_JJ loans_NNS and_CC overdrafts_NNS 1,551_CD 1,551_CD 1,582_CD 1,582_CD Total_JJ borrowings_NNS 4,643_CD 4,753_CD 4,232_CD 4,306_CD Interest_NN rate_NN swaps_NNS 1_CD 10_CD Total_JJ net_JJ debt_NN 2,335_CD 2,438_CD 2,101_CD 2,162_CD Fixed_VBN asset_NN equity_NN investments_NNS 125 129 133 133_CD Current_JJ asset_NN equity_NN investments_NNS 161 232 185 531_CD Other_JJ debtors_NNS due_JJ after_IN 1_CD year_NN 308 308 329 329_CD Other_JJ creditors_NNS due_JJ after_IN 1_CD year_NN 206 206 110 110_CD Provisions_NNS 224 224 105 105_CD Other_JJ foreign_JJ exchange_NN derivatives_NNS 133_CD 133_CD 6_CD 1_CD Equity_NNP collar_NN 78_CD Auction_NN rate_NN preference_NN stock_NN 248 248 276 276_CD Flexible_NNP auction_NN market_NN preferred_VBN stock_NN 311 316 345 355_CD Total_JJ non-equity_JJ minority_NN interests_NNS 559 564 621 631_CD Total_JJ financial_JJ assets_NNS and_CC liabilities_NNS 2,597_CD 2,552_CD 2,296_CD 2,014_CD Total_JJ financial_JJ assets_NNS 3,035_CD 3,196_CD 2,778_CD 3,138_CD Total_JJ financial_JJ liabilities_NNS 5,632_CD 5,748_CD 5,074_CD 5,152_CD Where_WRB appropriate_JJ currency_NN and_CC interest_NN rate_NN swaps_NNS have_VBP been_VBN presented_VBN alongside_IN the_DT underlying_VBG principal_NN instrument_NN ._.
The_DT carrying_VBG amounts_NNS of_IN these_DT instruments_NNS have_VBP been_VBN adjusted_VBN for_IN the_DT effect_NN of_IN the_DT currency_NN and_CC interest_NN rate_NN swaps_NNS acting_VBG as_IN hedges_NNS ._.
The_DT difference_NN between_IN the_DT carrying_VBG amount_NN and_CC the_DT fair_JJ value_NN of_IN equity_NN xed_VBD and_CC current_JJ assets_NNS and_CC liquid_JJ investments_NNS represents_VBZ gross_JJ unrealised_JJ gains_NNS of_IN 75_CD million_CD and_CC 8_CD million_CD ,_, respectively_RB ._.
112_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 32_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS continued_VBD Currency_NNP and_CC interest_NN rate_NN risk_NN prole_NN of_IN financial_JJ liabilities_NNS Financial_JJ liabilities_NNS ,_, after_IN taking_VBG account_NN of_IN currency_NN and_CC interest_NN rate_NN swaps_NNS ,_, are_VBP analyzed_VBN below_IN ._.
Total_JJ financial_JJ liabilities_NNS comprise_VBP total_JJ borrowings_NNS of_IN 4,643_CD million_CD 2001_CD 4,232_CD million_CD ,_, other_JJ creditors_NNS due_RB after_IN one_CD year_NN of_IN 206_CD million_CD 2001_CD 110_CD million_CD ,_, provisions_NNS of_IN 224_CD million_CD 2001_CD 105_CD million_CD and_CC non-equity_JJ minority_NN interest_NN preference_NN shares_NNS of_IN 559_CD million_CD 2001_CD 621_CD million_CD but_CC exclude_VB foreign_JJ exchange_NN derivatives_NNS of_IN nil_NN 2001_CD 6_CD million_CD ._.
Creditors_NNS due_JJ within_IN one_CD year_NN have_VBP been_VBN excluded_VBN ._.
The_DT benchmark_JJ rate_NN for_IN determining_VBG interest_NN payments_NNS for_IN all_DT oating_NN rate_NN financial_JJ liabilities_NNS in_IN the_DT tables_NNS below_IN is_VBZ LIBOR_NNP ._.
Fixed_JJ rate_NN Non-interest_JJ bearing_NN Weighted_NNP Weighted_NNP average_JJ average_JJ Weighted_JJ interest_NN years_NNS for_IN Floating_VBG average_JJ At_IN 31st_CD December_NNP 2002_CD rate_NN which_WDT rate_NN rate_NN years_NNS to_TO Total_JJ Currency_NN m_CD %_NN is_VBZ xed_VBN m_FW m_FW maturity_NN m_NN US_NNP dollars_NNS 471_CD 2.6_CD 0.7_CD 2,974_CD 325_CD 7.8_CD 3,770_CD Sterling_NNP 1,472_CD 6.4_CD 21.5_CD 4_CD 64_CD 1.6_CD 1,540_CD Euro_NNP 64_CD 13_CD 1.3_CD 77_CD Japanese_JJ Yen_NNP 144_CD 0.7_CD 1.2_CD 144_CD Other_JJ currencies_NNS 73_CD 28_CD 3.6_CD 101_CD 2,087_CD 4.2_CD 9.8_CD 3,115_CD 430_CD 6.4_CD 5,632_CD Fixed_VBN rate_NN Non-interest_JJ bearing_NN Weighted_NNP Weighted_NNP average_JJ average_JJ Weighted_JJ interest_NN years_NNS for_IN Floating_VBG average_JJ At_IN 31st_CD December_NNP 2001_CD rate_NN which_WDT rate_NN rate_NN years_NNS to_TO Total_JJ Currency_NN m_CD %_NN is_VBZ xed_VBN m_FW m_FW maturity_NN m_NN US_NNP dollars_NNS 516_CD 6.1_CD 3.2_CD 2,291_CD 131_CD 1.2_CD 2,938_CD Sterling_NNP 1,471_CD 6.5_CD 22.5_CD 45_CD 25_CD 1.3_CD 1,541_CD Euro_NNP 4_CD 7.9_CD 1.0_CD 45_CD 19_CD 0.4_CD 68_CD Japanese_JJ Yen_NNP 340_CD 0.5_CD 1.4_CD 3_CD 1_CD 15.0_CD 344_CD Other_JJ currencies_NNS 134_CD 43_CD 0.2_CD 177_CD 2,331_CD 5.5_CD 15.1_CD 2,518_CD 219_CD 1.0_CD 5,068_CD Currency_NN and_CC interest_NN rate_NN risk_NN prole_NN of_IN financial_JJ assets_NNS Total_JJ financial_JJ assets_NNS comprise_VBP xed_JJ asset_NN equity_NN investments_NNS of_IN 125_CD million_CD 2001_CD 133_CD million_CD ,_, current_JJ asset_NN equity_NN investments_NNS of_IN 161_CD million_CD 2001_CD 185_CD million_CD ,_, liquid_JJ investments_NNS of_IN 1,256_CD million_CD 2001_CD 1,415_CD million_CD ,_, cash_NN at_IN bank_NN of_IN 1,052_CD million_CD 2001_CD 716_CD million_CD ,_, and_CC debtors_NNS due_RB after_IN one_CD year_NN of_IN 308_CD million_CD 2001_CD 329_CD million_CD but_CC exclude_VB foreign_JJ exchange_NN derivatives_NNS of_IN 133_CD million_CD 2001_CD nil_NN ._.
The_DT benchmark_JJ rate_NN for_IN determining_VBG interest_NN receipts_NNS for_IN all_DT oating_NN rate_NN assets_NNS in_IN the_DT table_NN below_IN is_VBZ LIBOR_NNP ._.
Fixed_VBN Floating_VBG Non-interest_JJ At_IN 31st_CD December_NNP 2002_CD rate_NN rate_NN bearing_VBG Total_JJ Currency_NN m_NN m_FW m_FW m_FW US_PRP dollars_NNS 365_CD 1,275_CD 290_CD 1,930_CD Sterling_NNP 20_CD 123_CD 28_CD 171_CD Euro_NNP 41_CD 299_CD 22_CD 362_CD Japanese_JJ Yen_NNP 72_CD 24_CD 33_CD Other_JJ currencies_NNS 23_CD 323 60 406 456_CD 2,022_CD 424_CD 2,902_CD Fixed_NNP Floating_VBG Non-interest_JJ At_IN 31st_CD December_NNP 2001_CD rate_NN rate_NN bearing_VBG Total_JJ Currency_NN m_NN m_FW m_FW m_FW US_PRP dollars_NNS 404_CD 1,050_CD 406_CD 1,860_CD Sterling_NNP 18_CD 17_CD 66_CD 101_CD Euro_NNP 60_CD 168_CD 96_CD 324_CD Japanese_JJ Yen_NNP 7141940_CD Other_JJ currencies_NNS 173_CD 254 26 453 662_CD 1,503_CD 613_CD 2,778_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 113_CD 32_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS continued_VBD Currency_NNP exposure_NN of_IN net_JJ monetary_JJ assets_NNS liabilities_NNS The_DT Groups_NNS currency_NN exposures_NNS that_WDT give_VBP rise_VB to_TO net_JJ currency_NN gains_NNS and_CC losses_NNS that_WDT are_VBP recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN arise_VB principally_RB in_IN companies_NNS with_IN sterling_NN functional_JJ currency_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN overseas_JJ functional_JJ currency_NN ,_, and_CC borrowings_NNS designated_VBN as_IN a_DT hedge_NN against_IN overseas_JJ net_JJ assets_NNS ,_, are_VBP excluded_VBN from_IN the_DT table_NN below_IN ._.
At_IN 31st_CD December_NNP 2002_CD Functional_JJ currency_NN of_IN Group_NNP operation_NN Net_JJ monetary_JJ assets_NNS liabilities_NNS Sterling_NNP US$_$ Euro_NNP Yen_NNP Other_JJ Total_NNP held_VBD in_IN non-functional_JJ currency_NN m_NN m_FW m_FW m_FW m_FW m_FW Sterling_NN 144_CD 14_CD 18_CD 48_CD 188_CD US_NNP dollars_NNS 708_CD 54_CD 1_CD 63_CD 718_CD Euro_NNP 184_CD 6_CD 11_CD 167_CD Japanese_JJ Yen_NNP 10_CD 2_CD 12_CD Other_JJ 354_CD 10_CD 1_CD 1_CD 364 868 160_CD 43_CD 16_CD 122_CD 1,091_CD At_IN 31st_CD December_NNP 2001_CD Functional_JJ currency_NN of_IN Group_NNP operation_NN Net_JJ monetary_JJ assets_NNS liabilities_NNS Sterling_NNP US$_$ Euro_NNP Yen_NNP Other_JJ Total_NNP held_VBD in_IN non-functional_JJ currency_NN m_NN m_FW m_FW m_FW m_FW m_FW Sterling_NN 80_CD 5_CD 1_CD 10_CD 86_CD US_NNP dollars_NNS 329_CD 85_CD 63_CD 477_CD Euro_NNP 147_CD 7_CD 1_CD 153_CD Japanese_JJ Yen_NNP 13_CD 2_CD 11_CD Other_JJ 88_CD 3_CD 1_CD 92_CD 577_CD 70_CD 89_CD 1_CD 52_CD 647_CD Non-equity_JJ Finance_NNP minority_NN Total_JJ Total_JJ Debt_NN leases_NNS interests_NNS Other_JJ 2002_CD 2001_CD Maturity_NN of_IN financial_JJ liabilities_NNS m_VBP m_FW m_FW m_FW m_FW m_FW Within_IN one_CD year_NN or_CC on_IN demand_NN 1,550_CD 1_CD 559_CD 90_CD 2,201_CD 2,602_CD Between_IN one_CD and_CC two_CD years_NNS 421_CD 2_CD 91 514 268_CD Between_IN two_CD and_CC five_CD years_NNS 873_CD 3_CD 121_CD 996_CD 1,183_CD After_IN five_CD years_NNS 1,786_CD 7_CD 128_CD 1,921_CD 1,015_CD 4,630_CD 13 559 430_CD 5,632_CD 5,068_CD 2002_CD Gains_NNS Losses_NNS Net_JJ Hedges_NNP m_FW m_FW m_FW Unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT beginning_NN of_IN the_DT year_NN 56_CD 29_CD 27_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS and_CC recognized_VBN in_IN the_DT year_NN 51_CD 25_CD 26_CD Gains_NNS and_CC losses_NNS arising_VBG before_IN the_DT beginning_NN of_IN the_DT year_NN and_CC still_RB unrecognised_JJ at_IN the_DT end_NN of_IN the_DT year_NN 5_CD 4_CD 1_CD Unrecognised_JJ gains_NNS and_CC losses_NNS arising_VBG in_IN the_DT year_NN 107_CD 3_CD 110_CD Total_JJ unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT end_NN of_IN the_DT year_NN 112_CD 1_CD 111_CD Expected_VBN to_TO be_VB recognized_VBN within_IN one_CD year_NN Expected_VBN to_TO be_VB recognized_VBN after_IN one_CD year_NN 112_CD 1_CD 111_CD Total_JJ unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT end_NN of_IN the_DT year_NN 112_CD 1_CD 111_CD The_DT unrecognised_JJ gains_NNS and_CC losses_NNS above_IN represent_VBP the_DT difference_NN between_IN the_DT carrying_VBG amount_NN and_CC the_DT fair_JJ value_NN of_IN the_DT currency_NN swaps_NNS ,_, interest_NN rate_NN swaps_NNS ,_, equity_NN collar_NN and_CC other_JJ foreign_JJ exchange_NN derivatives_NNS ._.
Committed_VBN facilities_NNS The_DT Group_NNP has_VBZ committed_VBN facilities_NNS to_TO back_VB up_RP the_DT commercial_JJ paper_NN program_NN of_IN 872_CD million_CD 2001_CD 968_CD million_CD of_IN 364_CD days_NNS duration_NN renewable_JJ annually_RB ._.
At_IN 31st_CD December_NNP 2002_CD ,_, undrawn_JJ committed_JJ facilities_NNS totalled_VBD 1,404_CD million_CD ._.
114_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 33_CD Employee_NN costs_NNS 2002 2001 2000_CD m_FW m_FW m_FW Wages_NNS and_CC salaries_NNS 3,876_CD 3,664_CD 3,578_CD Social_NNP security_NN costs_NNS 385 344 383_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS 299 228 244_CD Cost_NN of_IN share-based_JJ incentive_NN plans_NNS 135 147 197_CD Severance_NN costs_NNS arising_VBG from_IN integration_NN and_CC restructuring_NN activities_NNS 228_CD 245_CD 82_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS arising_VBG from_IN integration_NN 17_CD 58_CD 3_CD 4,940_CD 4,686_CD 4,487_CD The_DT Group_NNP provides_VBZ benets_NNS to_TO employees_NNS ,_, commensurate_JJ with_IN local_JJ practice_NN in_IN individual_JJ countries_NNS ,_, including_VBG ,_, in_IN some_DT markets_NNS ,_, healthcare_NN insurance_NN ,_, subsidised_VBN car_NN schemes_NNS and_CC personal_JJ life_NN assurance_NN ._.
Information_NN on_IN Directors_NNS remuneration_NN is_VBZ given_VBN in_IN the_DT Remuneration_NNP Report_NNP on_IN pages_NNS 39_CD to_TO 50_CD ._.
2002 2001 2000_CD The_DT average_JJ number_NN of_IN persons_NNS employed_VBN by_IN the_DT Group_NNP including_VBG Directors_NNS during_IN the_DT year_NN Number_NNP Number_NNP Number_NNP Manufacturing_NNP 36,548_CD 37,154_CD 36,177_CD Selling_NNP ,_, general_JJ and_CC administration_NN 54,810_CD 55,655_CD 55,365_CD Research_NNP and_CC development_NN 14,808_CD 15,090_CD 16,659_CD 106,166_CD 107,899_CD 108,201_CD The_DT average_JJ number_NN of_IN Group_NNP employees_NNS excludes_VBZ temporary_JJ and_CC contract_NN staff_NN ._.
The_DT numbers_NNS of_IN Group_NNP employees_NNS at_IN the_DT end_NN of_IN each_DT financial_JJ year_NN are_VBP given_VBN in_IN the_DT Financial_NNP record_NN page_NN 150_CD ._.
2002 2001 2000_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS m_VBP m_FW m_FW UK_NNP pension_NN schemes_NNS 60_CD 16_CD 16_CD US_NNP pension_NN schemes_NNS 86_CD 70_CD 68_CD Other_JJ overseas_JJ pensions_NNS schemes_NNS 52_CD 57_CD 105_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 61_CD 57_CD 48_CD Post-employment_NN costs_NNS 40_CD 28_CD 7_CD 299 228 244_CD Analysed_NNP as_IN :_: Funded_VBN dened_VBN benefit_NN hybrid_NN schemes_NNS 134_CD 107_CD 82_CD Unfunded_JJ dened_VBN benefit_NN schemes_NNS 34_CD 13_CD 10_CD Dened_VBN contribution_NN schemes_NNS 30_CD 23_CD 97_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 61_CD 57_CD 48_CD Post-employment_NN costs_NNS 40_CD 28_CD 7_CD 299 228 244_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS arising_VBG from_IN integration_NN 17_CD 58_CD 3_CD Included_VBN within_IN the_DT UK_NNP pension_NN costs_NNS above_IN is_VBZ an_DT exceptional_JJ charge_NN of_IN 42_CD million_CD relating_VBG to_TO pension_NN augmentation_NN on_IN redundancies_NNS arising_VBG from_IN the_DT manufacturing_NN restructuring_NN plans_NNS in_IN the_DT UK_NNP ._.
Pensions_NNP Group_NNP undertakings_NNS operate_VBP pension_NN arrangements_NNS which_WDT cover_VBP the_DT Groups_NNS material_NN obligations_NNS to_TO provide_VB pensions_NNS to_TO retired_JJ employees_NNS ._.
These_DT arrangements_NNS have_VBP been_VBN developed_VBN in_IN accordance_NN with_IN local_JJ practices_NNS in_IN the_DT countries_NNS concerned_VBN ._.
Pension_NNP benets_NNS can_MD be_VB provided_VBN by_IN State_NNP schemes_NNS :_: by_IN dened_VBN contribution_NN schemes_NNS ,_, whereby_WRB retirement_NN benets_NNS are_VBP determined_VBN by_IN the_DT value_NN of_IN funds_NNS arising_VBG from_IN contributions_NNS paid_VBN in_IN respect_NN of_IN each_DT employee_NN ,_, or_CC by_IN dened_JJ benefit_NN schemes_NNS ,_, whereby_WRB retirement_NN benets_NNS are_VBP based_VBN on_IN employee_NN pensionable_JJ remuneration_NN and_CC length_NN of_IN service_NN ._.
Some_DT dened_VBD benefit_NN schemes_NNS now_RB also_RB include_VBP dened_VBN contribution_NN sections_NNS and_CC are_VBP described_VBN as_IN hybrid_JJ schemes_NNS in_IN the_DT table_NN ._.
In_IN the_DT majority_NN of_IN cases_NNS the_DT contributions_NNS to_TO dened_JJ benefit_NN schemes_NNS are_VBP determined_VBN in_IN accordance_NN with_IN the_DT advice_NN of_IN independent_JJ ,_, professionally_RB qualied_VBD actuaries_NNS ._.
Formal_JJ ,_, independent_JJ ,_, actuarial_JJ valuations_NNS of_IN the_DT Groups_NNS main_JJ plans_NNS are_VBP undertaken_VBN regularly_RB ,_, normally_RB at_IN least_JJS every_DT three_CD years_NNS ._.
The_DT assets_NNS of_IN funded_JJ schemes_NNS are_VBP generally_RB held_VBN in_IN separately_RB administered_VBN trusts_NNS or_CC are_VBP insured_VBN ._.
Pension_NN costs_NNS for_IN accounting_NN purposes_NNS have_VBP been_VBN assessed_VBN in_IN accordance_NN with_IN independent_JJ actuarial_JJ advice_NN ,_, generally_RB using_VBG the_DT projected_VBN unit_NN method_NN and_CC by_IN spreading_VBG surpluses_NNS or_CC deficits_NNS over_IN the_DT average_NN expected_VBN remaining_VBG service_NN lives_NNS of_IN the_DT respective_JJ memberships_NNS ._.
In_IN certain_JJ countries_NNS pension_NN benets_NNS are_VBP provided_VBN on_IN an_DT unfunded_JJ basis_NN ,_, some_DT of_IN which_WDT are_VBP under_IN a_DT scheme_NN administered_VBN by_IN a_DT trustee_NN company_NN ._.
Where_WRB assets_NNS are_VBP not_RB held_VBN with_IN the_DT specic_JJ purpose_NN of_IN matching_VBG the_DT liabilities_NNS of_IN unfunded_JJ schemes_NNS ,_, a_DT provision_NN is_VBZ included_VBN within_IN provisions_NNS for_IN pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS ._.
The_DT charge_NN against_IN profits_NNS in_IN respect_NN of_IN these_DT benets_NNS is_VBZ the_DT aggregate_NN of_IN the_DT increase_NN over_IN the_DT year_NN in_IN the_DT assessed_VBN liabilities_NNS for_IN members_NNS still_RB in_IN service_NN and_CC the_DT net_JJ movement_NN in_IN provisions_NNS set_VBN up_RP for_IN pensions_NNS in_IN payment_NN ._.
Liabilities_NNS are_VBP generally_RB assessed_VBN annually_RB in_IN accordance_NN with_IN the_DT advice_NN of_IN independent_JJ actuaries_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 115_CD 33_CD Employee_NN costs_NNS continued_VBD Throughout_IN 2002_CD the_DT pension_NN arrangements_NNS in_IN some_DT of_IN the_DT former_JJ Glaxo_NNP Wellcome_NNP companies_NNS and_CC former_JJ SmithKline_NNP Beecham_NNP companies_NNS continued_VBD to_TO be_VB operated_VBN separately_RB ._.
However_RB in_IN some_DT instances_NNS ,_, including_VBG the_DT USA_NNP ,_, the_DT pension_NN arrangements_NNS have_VBP been_VBN merged_VBN ._.
The_DT following_VBG information_NN deals_NNS with_IN each_DT set_NN of_IN arrangements_NNS accordingly_RB ._.
The_DT market_NN value_NN of_IN the_DT assets_NNS of_IN the_DT Groups_NNS funded_VBN dened_VBD benefit_NN pension_NN funds_NNS at_IN the_DT dates_NNS of_IN the_DT latest_JJS actuarial_JJ valuations_NNS ,_, some_DT of_IN which_WDT date_NN back_RB to_TO 1999_CD ,_, was_VBD 6.5_CD billion_CD and_CC the_DT actuarial_JJ value_NN of_IN assets_NNS was_VBD sufficient_JJ to_TO cover_VB approximately_RB 113_CD per_IN cent_NN of_IN the_DT benets_NNS that_WDT had_VBD accrued_VBN to_TO members_NNS after_IN allowing_VBG for_IN future_JJ salary_NN and_CC pension_NN increases_NNS ._.
The_DT UK_NNP dened_VBD benefit_NN pension_NN schemes_NNS account_VBP for_IN approximately_RB 70_CD per_IN cent_NN of_IN the_DT Groups_NNS plans_NNS in_IN asset_NN valuation_NN and_CC projected_VBD benefit_NN terms_NNS and_CC the_DT US_NNP dened_VBD benefit_NN pension_NN schemes_NNS account_VBP for_IN approximately_RB 25_CD per_IN cent_NN of_IN the_DT Groups_NNS plans_NNS in_IN asset_NN valuation_NN and_CC projected_VBD benefit_NN terms_NNS ._.
In_IN December_NNP 2002_CD ,_, the_DT Group_NNP made_VBD special_JJ funding_NN contributions_NNS to_TO the_DT UK_NNP ,_, US_NNP and_CC German_JJ pension_NN schemes_NNS totalling_VBG 320_CD million_CD ._.
The_DT company_NN will_MD review_VB the_DT pension_NN position_NN annually_RB and_CC will_MD make_VB further_JJ contributions_NNS as_IN appropriate_JJ ._.
Pension_NN costs_NNS are_VBP expected_VBN to_TO be_VB higher_JJR in_IN 2003_CD than_IN in_IN 2002_CD as_IN the_DT new_JJ actuarial_JJ valuations_NNS of_IN the_DT UK_NNP and_CC US_NNP schemes_NNS become_VBP available_JJ ._.
UK_NNP In_IN the_DT UK_NNP the_DT dened_VBN benefit_NN pension_NN schemes_NNS operated_VBD for_IN the_DT benefit_NN of_IN former_JJ Glaxo_NNP Wellcome_NNP employees_NNS and_CC former_JJ SmithKline_NNP Beecham_NNP employees_NNS remain_VBP separate_JJ ._.
These_DT schemes_NNS were_VBD closed_VBN to_TO new_JJ entrants_NNS in_IN 2001_CD and_CC subsequent_JJ UK_NNP employees_NNS are_VBP entitled_VBN to_TO join_VB a_DT dened_VBN contribution_NN scheme_NN ._.
The_DT relevant_JJ assumptions_NNS used_VBN in_IN calculating_VBG the_DT pension_NN costs_NNS of_IN both_DT the_DT former_JJ Glaxo_NNP Wellcome_NNP and_CC former_JJ SmithKline_NNP Beecham_NNP UK_NNP dened_VBD benefit_NN schemes_NNS for_IN accounting_NN purposes_NNS are_VBP as_IN follows_VBZ :_: 2002_CD 2001_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN of_IN future_JJ earnings_NNS 4.0_CD 4.0_CD Discount_NNP rate_NN 8.0_CD 8.0_CD Expected_VBN long-term_JJ rate_NN of_IN return_NN on_IN investments_NNS 8.0_CD 8.0_CD Expected_VBN pension_NN increases_NNS 2.5_CD 2.5_CD UK_NNP equity_NN dividend_NN growth_NN 5.0_CD 5.0_CD The_DT regular_JJ cost_NN for_IN the_DT Glaxo_NNP Wellcome_NNP pension_NN arrangements_NNS in_IN 2002_CD was_VBD 62_CD million_CD ,_, which_WDT became_VBD a_DT 14_CD million_CD credit_NN for_IN the_DT financial_JJ statements_NNS ,_, after_IN allowance_NN was_VBD made_VBN for_IN spreading_VBG the_DT surplus_NN disclosed_VBD as_IN a_DT level_NN percentage_NN of_IN salary_NN over_IN the_DT expected_JJ future_NN working_VBG lifetime_NN of_IN the_DT existing_VBG members_NNS some_DT 11_CD years_NNS ._.
The_DT most_RBS recent_JJ triennial_JJ actuarial_JJ valuations_NNS of_IN the_DT Glaxo_NNP Wellcome_NNP schemes_NNS for_IN funding_VBG purposes_NNS were_VBD carried_VBN out_RP as_IN at_IN 31st_CD March_NNP 2000_CD ._.
At_IN that_DT date_NN the_DT assets_NNS of_IN the_DT schemes_NNS represented_VBD 133_CD per_IN cent_NN of_IN the_DT actuarial_JJ value_NN of_IN all_DT benets_NNS accrued_VBN to_TO members_NNS after_IN allowing_VBG for_IN future_JJ salary_NN and_CC pension_NN increases_NNS ._.
The_DT trustees_NNS of_IN the_DT UK_NNP pension_NN schemes_NNS agreed_VBD ,_, at_IN the_DT companys_NNS request_NN ,_, to_TO grant_VB various_JJ benefit_NN improvements_NNS ,_, which_WDT included_VBD a_DT five_CD per_IN cent_NN enhancement_NN in_IN the_DT entitlement_NN of_IN all_DT beneciaries_NNS ._.
After_IN allowance_NN was_VBD made_VBN for_IN these_DT improvements_NNS ,_, the_DT funding_NN level_NN fell_VBD to_TO 123_CD per_IN cent_NN ._.
Following_VBG the_DT valuations_NNS ,_, normal_JJ company_NN contributions_NNS to_TO the_DT schemes_NNS remain_VBP suspended_VBN at_IN least_JJS until_IN the_DT next_JJ formal_JJ valuation_NN ._.
The_DT total_JJ market_NN value_NN of_IN the_DT assets_NNS held_VBN by_IN the_DT schemes_NNS at_IN 31st_CD March_NNP 2000_CD was_VBD 3,670_CD million_CD ._.
The_DT regular_JJ cost_NN for_IN the_DT SmithKline_NNP Beecham_NNP schemes_NNS in_IN 2002_CD was_VBD 17_CD million_CD ,_, which_WDT increased_VBD to_TO an_DT accounting_NN cost_NN of_IN 28_CD million_CD after_IN allowance_NN was_VBD made_VBN for_IN the_DT spreading_VBG of_IN the_DT deficit_NN over_IN the_DT expected_JJ future_NN working_VBG lifetime_NN of_IN current_JJ employees_NNS in_IN the_DT scheme_NN some_DT 11_CD years_NNS ._.
The_DT latest_JJS valuation_NN was_VBD carried_VBN out_RP at_IN 31st_CD December_NNP 1999_CD and_CC at_IN that_DT date_NN the_DT actuarial_JJ value_NN of_IN scheme_NN assets_NNS represented_VBD 90_CD per_IN cent_NN of_IN the_DT actuarial_JJ value_NN of_IN the_DT accrued_JJ service_NN liabilities_NNS based_VBN on_IN the_DT 2002_CD assumptions_NNS ._.
The_DT total_JJ market_NN value_NN of_IN assets_NNS held_VBN by_IN the_DT scheme_NN at_IN 31st_CD December_NNP 1999_CD was_VBD 1,077_CD million_CD ._.
USA_NNP In_IN the_DT USA_NNP the_DT former_JJ Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP dened_VBD benefit_NN and_CC hybrid_JJ schemes_NNS were_VBD merged_VBN during_IN 2001_CD ._.
The_DT relevant_JJ assumptions_NNS used_VBN in_IN calculating_VBG the_DT pension_NN costs_NNS for_IN accounting_NN purposes_NNS are_VBP as_IN follows_VBZ :_: 2002_CD 2001_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN of_IN future_JJ earnings_NNS 5.5_CD 5.5_CD Discount_NNP rate_NN 9.5_CD 9.5_CD Expected_VBN long-term_JJ rate_NN of_IN return_NN on_IN investments_NNS 9.5_CD 9.5_CD Cash_NN balance_NN credit_NN conversion_NN rate_NN 6.5_CD 6.5_CD US_NNP equity_NN dividend_NN growth_NN 7.75_CD 7.75_CD The_DT regular_JJ cost_NN for_IN the_DT US_NNP scheme_NN in_IN 2002_CD was_VBD 64_CD million_CD ,_, which_WDT increased_VBD to_TO an_DT accounting_NN cost_NN of_IN 77_CD million_CD after_IN allowance_NN was_VBD made_VBN for_IN the_DT spreading_VBG of_IN the_DT deficit_NN over_IN the_DT expected_JJ future_NN working_VBG lifetime_NN of_IN current_JJ employees_NNS in_IN the_DT scheme_NN ._.
The_DT latest_JJS valuation_NN was_VBD carried_VBN out_RP at_IN 1st_CD January_NNP 2002_CD and_CC at_IN that_DT date_NN the_DT actuarial_JJ value_NN of_IN scheme_NN assets_NNS represented_VBD 90_CD per_IN cent_NN of_IN the_DT actuarial_JJ value_NN of_IN the_DT accrued_JJ service_NN liabilities_NNS ._.
The_DT total_JJ market_NN value_NN of_IN assets_NNS held_VBN by_IN the_DT scheme_NN at_IN 1st_CD January_NNP 2002_CD was_VBD 1,536_CD million_CD ._.
116_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 33_CD Employee_NN costs_NNS continued_VBD FRS_NNP 17_CD disclosures_NNS The_DT Group_NNP continues_VBZ to_TO account_VB for_IN pension_NN arrangements_NNS in_IN accordance_NN with_IN SSAP_NNP 24_CD Accounting_NNP for_IN Pension_NNP Costs_NNS ._.
Under_IN the_DT transitional_JJ provisions_NNS of_IN FRS_NNP 17_CD Retirement_NNP Benets_NNPS certain_JJ disclosures_NNS are_VBP required_VBN on_IN the_DT basis_NN of_IN the_DT valuation_NN methodology_NN adopted_VBN by_IN FRS_NNP 17_CD ._.
For_IN dened_VBN benefit_NN schemes_NNS the_DT fair_JJ values_NNS of_IN pension_NN scheme_NN assets_NNS at_IN 31st_CD December_NNP 2002_CD are_VBP compared_VBN with_IN the_DT future_JJ pension_NN liabilities_NNS calculated_VBN under_IN the_DT projected_VBN unit_NN method_NN applying_VBG the_DT following_VBG assumptions_NNS :_: UK_NNP USA_NNP Rest_VBP of_IN World_NNP 2002 2001 2002 2001_CD 2002_CD 2001_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN of_IN future_JJ earnings_NNS 3.75_CD 4.0_CD 5.5_CD 5.5_CD 3.0_CD 3.5_CD Discount_NNP rate_NN 5.75_CD 6.0_CD 6.75_CD 7.25_CD 4.75_CD 4.75_CD Expected_VBN pension_NN increases_NNS 2.25_CD 2.5_CD n_VBD a_DT n_NN a_DT 1.5_CD 1.0_CD Cash_NN balance_NN credit_NN conversion_NN rate_NN n_VBD a_DT n_NN a_DT 5.75_CD 6.25_CD n_VBD a_DT n_NN a_DT Ination_NNP rate_NN 2.25_CD 2.5_CD 2.25_CD 3.5_CD 1.5_CD 1.5_CD The_DT expected_VBN long-term_JJ rates_NNS of_IN return_NN on_IN the_DT assets_NNS and_CC the_DT fair_JJ values_NNS of_IN the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT UK_NNP and_CC US_NNP dened_VBD benefit_NN schemes_NNS ,_, together_RB with_IN aggregated_JJ data_NNS for_IN other_JJ dened_VBN benefit_NN schemes_NNS in_IN the_DT Group_NNP are_VBP as_IN follows_VBZ :_: UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Average_JJ At_IN 31st_CD December_NNP 2002_CD Expected_VBN rate_NN Fair_NN Expected_VBN rate_NN Fair_NN expected_VBN rate_NN Fair_NN Fair_NN of_IN return_NN value_NN of_IN return_NN value_NN of_IN return_NN value_NN value_NN %_NN m_CD %_NN m_CD %_NN m_NN m_NN Equities_NNS 8.25_CD 2,523_CD 9.25_CD 804_CD 6.75_CD 172_CD 3,499_CD Property_NN 7.0_CD 53_CD 7.0_CD 5_CD 58_CD Bonds_NNS 4.5_CD 299_CD 6.25_CD 265_CD 4.5_CD 145_CD 709_CD Other_JJ assets_NNS 4.0_CD 137_CD 1.5_CD 240_CD 1.75_CD 9_CD 386_CD Fair_NNP value_NN of_IN assets_NNS 2,959_CD 1,362_CD 331_CD 4,652_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 4,153_CD 1,782_CD 578_CD 6,513_CD 1,194_CD 420_CD 247_CD 1,861_CD Value_NN of_IN schemes_NNS in_IN surplus_NN 11_CD 11_CD Deferred_JJ tax_NN liability_NN 3_CD 3_CD 8_CD 8_CD Value_NN of_IN schemes_NNS in_IN deficit_NN 1,194_CD 420_CD 258_CD 1,872_CD Deferred_JJ tax_NN asset_NN 358_CD 147 97 602 836_CD 273_CD 161_CD 1,270_CD Group_NNP total_JJ 1,262_CD Other_JJ assets_NNS in_IN the_DT UK_NNP and_CC US_NNP schemes_NNS include_VBP the_DT special_JJ contributions_NNS paid_VBN in_IN December_NNP 2002_CD ._.
These_DT will_MD be_VB allocated_VBN to_TO equities_NNS and_CC bonds_NNS in_IN 2003_CD ._.
UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Average_JJ At_IN 31st_CD December_NNP 2001_CD Expected_VBN rate_NN Fair_NN Expected_VBN rate_NN Fair_NN expected_VBN rate_NN Fair_NN Fair_NN of_IN return_NN value_NN of_IN return_NN value_NN of_IN return_NN value_NN value_NN %_NN m_CD %_NN m_CD %_NN mm_NN Equities_NNS 8.5_CD 3,234_CD 9.5_CD 1,220_CD 7.25_CD 193_CD 4,647_CD Property_NN 8.0_CD 54_CD 7.5_CD 3_CD 57_CD Bonds_NNS 5.0_CD 411_CD 7.0_CD 250_CD 5.0_CD 107_CD 768_CD Other_JJ assets_NNS 4.5_CD 70_CD 5.0_CD 12_CD 3.25_CD 10_CD 92_CD Fair_NNP value_NN of_IN assets_NNS 3,715_CD 1,536_CD 313_CD 5,564_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 3,970_CD 1,781_CD 527_CD 6,278_CD 255 245 214 714_CD Value_NN of_IN schemes_NNS in_IN surplus_NN 42_CD 24_CD 66_CD Deferred_JJ tax_NN liability_NN 13_CD 7_CD 20_CD 29_CD 17_CD 46_CD Value_NN of_IN schemes_NNS in_IN deficit_NN 297 245 238 780_CD Deferred_JJ tax_NN asset_NN 89_CD 93 95 277 208_CD 152 143 503_CD Group_NNP total_JJ 457_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 117_CD 33_CD Employee_NN costs_NNS continued_VBD The_DT UK_NNP dened_VBD benefit_NN schemes_NNS also_RB have_VBP dened_VBN contribution_NN sections_NNS with_IN account_NN balances_NNS totalling_VBG 281_CD million_CD at_IN 31st_CD December_NNP 2002 2001 263_CD million_CD ._.
The_DT dened_VBN benefit_NN sections_NNS of_IN the_DT UK_NNP schemes_NNS have_VBP been_VBN closed_VBN to_TO new_JJ members_NNS ,_, and_CC under_IN the_DT projected_VBN unit_NN method_NN of_IN valuing_VBG the_DT pension_NN scheme_NN liabilities_NNS the_DT current_JJ service_NN cost_NN will_MD increase_VB as_IN the_DT members_NNS of_IN the_DT schemes_NNS approach_VBP retirement_NN ._.
The_DT deficits_NNS under_IN FRS_NNP 17_CD reect_NN the_DT different_JJ bases_NNS for_IN valuing_VBG assets_NNS and_CC liabilities_NNS compared_VBN with_IN SSAP_NNP 24_CD ,_, including_VBG the_DT immediate_JJ impact_NN of_IN the_DT fair_JJ values_NNS of_IN assets_NNS at_IN 31st_CD December_NNP 2002_CD ._.
The_DT Group_NNP also_RB operates_VBZ a_DT number_NN of_IN unfunded_JJ post-retirement_JJ healthcare_NN schemes_NNS ,_, the_DT principal_NN one_CD of_IN which_WDT is_VBZ in_IN the_DT USA_NNP ._.
The_DT liability_NN under_IN FRS_NNP 17_CD for_IN the_DT US_NNP scheme_NN has_VBZ been_VBN assessed_VBN using_VBG the_DT same_JJ assumptions_NNS as_IN for_IN the_DT US_NNP pension_NN scheme_NN ,_, together_RB with_IN the_DT assumption_NN for_IN future_JJ medical_JJ ination_NN of_IN 11_CD per_IN cent_NN ,_, reducing_VBG by_IN one_CD per_IN cent_NN per_IN year_NN to_TO five_CD per_IN cent_NN ._.
On_IN this_DT basis_NN the_DT liability_NN for_IN the_DT US_NNP scheme_NN has_VBZ been_VBN assessed_VBN at_IN 766_CD million_CD 2001_CD 787_CD million_CD ,_, which_WDT reduced_VBD to_TO 475_CD million_CD 2001_CD 488_CD million_CD after_IN taking_VBG account_NN of_IN deferred_JJ tax_NN ._.
If_IN the_DT dened_VBN benefit_NN pension_NN and_CC post-retirement_NN benefit_NN schemes_NNS had_VBD been_VBN accounted_VBN for_IN under_IN FRS_NNP 17_CD ,_, the_DT following_JJ amounts_NNS would_MD have_VB been_VBN recorded_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN and_CC statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD ._.
Post-retirement_NN Pensions_NNS benets_VBZ UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW Amounts_NNPS charged_VBD to_TO operating_VBG profit_NN Current_JJ service_NN cost_NN 118_CD 74_CD 32_CD 224_CD 24_CD Past_JJ service_NN cost_NN 28_CD 34_CD 62_CD Curtailments_NNP settlements_NNS 1_CD 1_CD 146_CD 108_CD 33_CD 287_CD 24_CD Amounts_NNS credited_VBD charged_VBN to_TO net_JJ interest_NN Expected_VBN return_NN on_IN pension_NN scheme_NN assets_NNS 293_CD 129_CD 14_CD 436_CD Interest_NN on_IN scheme_NN liabilities_NNS 235_CD 129_CD 22_CD 386_CD 53_CD 58_CD 8_CD 50_CD 53_CD Amounts_NNS recorded_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN scheme_NN assets_NNS 1,024_CD 293_CD 56_CD 1,373_CD Experience_NN gains_NNS losses_NNS arising_VBG on_IN scheme_NN liabilities_NNS 34_CD 3_CD 2_CD 33_CD 95_CD Changes_NNS in_IN assumptions_NNS relating_VBG to_TO present_JJ value_NN of_IN scheme_NN liabilities_NNS 15_CD 57_CD 10_CD 62_CD 124_CD 1,005_CD 353_CD 44_CD 1,402_CD 29_CD Movements_NNS in_IN deficits_NNS during_IN the_DT year_NN deficits_NNS in_IN schemes_NNS at_IN 1st_CD January_NNP 2002 255 245 214_CD 714_CD 854_CD Exchange_NNP adjustments_NNS 37_CD 9_CD 28_CD 85_CD Charged_VBN to_TO operating_VBG profit_NN 146_CD 108_CD 33_CD 287_CD 24_CD Employer_NN contributions_NNS 154_CD 249_CD 61_CD 464_CD 41_CD Other_JJ finance_NN income_NN expense_NN 58_CD 8_CD 50_CD 53_CD Actuarial_JJ loss_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 1,005_CD 353_CD 44_CD 1,402_CD 29_CD deficits_NNS in_IN schemes_NNS at_IN 31st_CD December_NNP 2002_CD 1,194_CD 420_CD 247_CD 1,861_CD 834_CD History_NN of_IN experience_NN gains_NNS and_CC losses_NNS Difference_NN between_IN the_DT expected_VBN and_CC actual_JJ return_NN on_IN scheme_NN assets_NNS m_VBP 1,024_CD 293_CD 56_CD 1,373_CD Percentage_NN of_IN scheme_NN assets_NNS at_IN 31st_CD December_NNP 2002_CD 35_CD %_NN 22_CD %_NN 17_CD %_NN 30_CD %_NN Experience_NN gains_NNS losses_NNS of_IN scheme_NN liabilities_NNS m_VBP 34_CD 3_CD 2_CD 33_CD 95_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2002_CD 1_CD %_NN 1_CD %_NN 11_CD %_NN Total_JJ amount_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS m_VBP 1,005_CD 353_CD 44_CD 1,402_CD 29_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2002_CD 24_CD %_NN 20_CD %_NN 8_CD %_NN 22_CD %_NN 3_CD %_NN 118_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 33_CD Employee_NN costs_NNS continued_VBD If_IN the_DT FRS_NNP 17_CD valuation_NN basis_NN had_VBD been_VBN applied_VBN in_IN the_DT financial_JJ statements_NNS instead_RB of_IN the_DT SSAP_NNP 24_CD valuation_NN basis_NN ,_, the_DT effect_NN on_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN after_IN taking_VBG account_NN of_IN deferred_JJ tax_NN would_MD have_VB been_VBN as_IN follows_VBZ :_: 2001_CD 2002_CD restated_VBN m_FW m_FW m_FW m_FW profit_NN and_CC loss_NN account_NN reserve_NN per_IN balance_NN sheet_NN 2,946_CD 3,811_CD Pension_NN liability_NN under_IN FRS_NNP 17_CD 1,262_CD 457_CD Pension_NN liability_NN under_IN SSAP_NNP 24_CD per_IN balance_NN sheet_NN 39_CD 185_CD 1,223_CD 272_CD Post-retirement_NN healthcare_NN schemes_NNS under_IN FRS_NNP 17 545 519_CD Post-retirement_NN healthcare_NN schemes_NNS provision_NN per_IN balance_NN sheet_NN 378 388 167 131_CD profit_NN and_CC loss_NN account_NN reserve_NN including_VBG pension_NN and_CC post-retirement_JJ healthcare_NN liability_NN 1,556_CD 3,408_CD 34_CD Employee_NN share_NN schemes_NNS The_DT company_NN operates_VBZ share_NN option_NN schemes_NNS ,_, whereby_WRB options_NNS are_VBP granted_VBN to_TO employees_NNS to_TO acquire_VB shares_NNS or_CC ADSs_NNS in_IN GlaxoSmithKline_NNP plc_NN at_IN the_DT grant_NN price_NN ,_, and_CC share_NN award_NN schemes_NNS ,_, whereby_WRB awards_NNS are_VBP granted_VBN to_TO employees_NNS to_TO acquire_VB shares_NNS or_CC ADSs_NNS in_IN GlaxoSmithKline_NNP plc_NN at_IN no_DT cost_NN ,_, subject_JJ to_TO the_DT achievement_NN of_IN performance_NN targets_NNS ._.
The_DT details_NNS given_VBN below_IN relate_VBP to_TO schemes_NNS operated_VBN by_IN GlaxoSmithKline_NNP in_IN 2002_CD and_CC 2001_CD and_CC separately_RB by_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP up_IN to_TO the_DT date_NN of_IN the_DT merger_NN ,_, which_WDT became_VBD schemes_NNS of_IN GlaxoSmithKline_NNP on_IN the_DT merger_NN ._.
Each_DT Glaxo_NNP Wellcome_NNP option_NN outstanding_JJ at_IN the_DT date_NN of_IN the_DT merger_NN was_VBD converted_VBN into_IN one_CD GlaxoSmithKline_NN option_NN ._.
Each_DT SmithKline_NNP Beecham_NNP share_NN option_NN was_VBD converted_VBN into_IN 0.4552_CD of_IN a_DT GlaxoSmithKline_NNP share_NN option_NN and_CC each_DT SmithKline_NNP Beecham_NNP ADS_NNPS option_NN was_VBD converted_VBN into_IN 1.138_CD GlaxoSmithKline_NNP ADS_NNPS options_NNS ,_, with_IN corresponding_JJ adjustments_NNS to_TO the_DT grant_NN price_NN ._.
GlaxoSmithKline_NNP share_NN option_NN schemes_NNS The_DT company_NN operates_VBZ share_NN option_NN schemes_NNS and_CC savings-related_JJ share_NN option_NN schemes_NNS ._.
Grants_NNPS under_IN share_NN option_NN schemes_NNS are_VBP normally_RB exercisable_JJ between_IN three_CD and_CC ten_CD years_NNS from_IN the_DT date_NN of_IN grant_NN ._.
Grants_NNPS under_IN savings-related_JJ share_NN option_NN schemes_NNS are_VBP normally_RB exercisable_JJ after_IN three_CD years_NNS saving_VBG ._.
Options_NNS under_IN the_DT share_NN option_NN schemes_NNS are_VBP normally_RB granted_VBN at_IN the_DT market_NN price_NN ruling_NN at_IN the_DT date_NN of_IN grant_NN ._.
In_IN accordance_NN with_IN UK_NNP practice_NN ,_, the_DT majority_NN of_IN options_NNS under_IN the_DT savings-related_JJ share_NN option_NN schemes_NNS are_VBP granted_VBN at_IN a_DT price_NN 20_CD per_IN cent_NN below_IN the_DT market_NN price_NN ruling_NN at_IN the_DT date_NN of_IN grant_NN ._.
Share_NN option_NN Share_NN option_NN Savings-related_JJ Options_NNS outstanding_JJ schemes_NNS shares_NNS schemes_NNS ADSs_NNS share_NN option_NN schemes_NNS at_IN 31st_CD December_NNP 2002_CD Weighted_NNP Weighted_NNP Weighted_NNP Number_NNP exercise_NN Number_NNP exercise_NN Number_NNP exercise_NN 000_CD price_NN 000_CD price_NN 000_CD price_NN At_IN 27th_JJ December_NNP 2000_CD :_: Converted_VBN from_IN GW_NNP options_NNS 106,748_CD 13.87_CD 8,397_CD 12.34_CD Converted_VBN from_IN SB_NNP options_NNS 35,122_CD 12.81_CD 37,962_CD $_$ 44.10_CD Options_NNPS exercised_VBN 4,275_CD 11.18_CD 62_CD 11.17_CD Options_NNS canceled_VBN 59_CD 13.41_CD At_IN 31st_CD December_NNP 2000_CD 137,595_CD 13.68_CD 37,962_CD $_$ 44.10_CD 8,276_CD 12.34_CD Options_NNS granted_VBN 67,763_CD 17.98_CD 42,034_CD $_$ 51.82_CD 4,443_CD 14.12_CD Options_NNS exercised_VBN 21,332_CD 10.36_CD 4,705_CD $_$ 13.06_CD 3,075_CD 8.48_CD Options_NNS canceled_VBN 4,090_CD 14.68_CD 1,466_CD $_$ 52.40_CD 1,444_CD 15.90_CD At_IN 31st_CD December_NNP 2001_CD 179,936_CD 15.67_CD 73,825_CD $_$ 50.31_CD 8,200_CD 14.13_CD Options_NNS granted_VBN 33,454_CD 11.91_CD 22,991_CD $_$ 37.57_CD 9,793_CD 9.16_CD Options_NNS exercised_VBN 8,857_CD 10.55_CD 1,504_CD $_$ 21.75_CD 398_CD 14.04_CD Options_NNS canceled_VBN 7,061_CD 17.53_CD 4,435_CD $_$ 54.69_CD 4,607_CD 14.41_CD At_IN 31st_CD December_NNP 2002_CD 197,472_CD 15.20_CD 90,877_CD $_$ 47.34_CD 12,988_CD 10.29_CD Range_NNP of_IN exercise_NN prices_NNS 3.61_CD 19.77_CD $_$ 11.68_CD $_$ 61.35_CD 9.16_CD 16.48_CD In_IN order_NN to_TO encourage_VB employees_NNS to_TO convert_VB options_NNS ,_, excluding_VBG savings-related_JJ share_NN options_NNS ,_, held_VBN over_IN Glaxo_NNP Wellcome_NNP or_CC SmithKline_NNP Beecham_NNP shares_NNS or_CC ADSs_NNS into_IN those_DT over_IN GlaxoSmithKline_NNP shares_NNS or_CC ADSs_NNS ,_, a_DT program_NN was_VBD established_VBN to_TO give_VB an_DT additional_JJ cash_NN benefit_NN of_IN ten_NN per_IN cent_NN of_IN the_DT exercise_NN price_NN of_IN the_DT original_JJ option_NN provided_VBD that_IN the_DT employee_NN does_VBZ not_RB voluntarily_RB leave_VB the_DT Group_NNP for_IN two_CD years_NNS from_IN the_DT date_NN of_IN the_DT merger_NN and_CC does_VBZ not_RB exercise_VB the_DT option_NN before_IN the_DT earlier_JJR of_IN six_CD months_NNS from_IN the_DT expiry_NN date_NN of_IN the_DT original_JJ option_NN and_CC two_CD years_NNS from_IN the_DT date_NN of_IN the_DT merger_NN ._.
The_DT cash_NN benefit_NN will_MD also_RB be_VB paid_VBN if_IN the_DT options_NNS expire_VBP unexercised_JJ if_IN the_DT market_NN price_NN is_VBZ below_IN the_DT exercise_NN price_NN on_IN the_DT date_NN of_IN expiry_NN ._.
There_EX has_VBZ been_VBN no_DT change_NN in_IN the_DT effective_JJ exercise_NN price_NN of_IN any_DT outstanding_JJ options_NNS during_IN the_DT year_NN ._.
No_DT further_RBR options_NNS were_VBD granted_VBN between_IN 31st_CD December_NNP 2002_CD and_CC 3rd_CD March_NNP 2003_CD ._.
Share_NN option_NN Share_NN option_NN Savings-related_JJ Options_NNS exercisable_JJ schemes_NNS shares_NNS schemes_NNS ADSs_NNS share_NN option_NN schemes_NNS Weighted_NNP Weighted_NNP Weighted_NNP Number_NNP exercise_NN Number_NNP exercise_NN Number_NNP exercise_NN 000_CD price_NN 000_CD price_NN 000_CD price_NN At_IN 31st_CD December_NNP 2000_CD 106,805_CD 13.36_CD 37,962_CD $_$ 44.10_CD 2,358_CD 6.73_CD At_IN 31st_CD December_NNP 2001_CD 85,601_CD 14.10_CD 32,373_CD $_$ 48.36_CD 289_CD 14.29_CD At_IN 31st_CD December_NNP 2002_CD 72,611_CD 14.33_CD 27,129_CD $_$ 48.89_CD 2,227_CD 13.27_CD GlaxoSmithKline_NNP share_NN award_NN schemes_NNS The_DT Group_NNP operates_VBZ a_DT Performance_NNP Share_NNP Plan_NNP whereby_WRB awards_NNS are_VBP granted_VBN to_TO Directors_NNS and_CC senior_JJ staff_NN at_IN no_DT cost_NN ._.
The_DT percentage_NN of_IN each_DT award_NN that_WDT vests_NNS is_VBZ based_VBN upon_IN the_DT performance_NN of_IN the_DT Group_NNP over_IN a_DT three_CD year_NN measurement_NN period_NN ._.
The_DT performance_NN conditions_NNS consist_VBP of_IN two_CD parts_NNS ,_, each_DT of_IN which_WDT applies_VBZ to_TO 50_CD per_IN cent_NN of_IN the_DT award_NN ._.
The_DT first_JJ part_NN of_IN the_DT condition_NN compares_VBZ GlaxoSmithKlines_NNP Total_NNP Shareholder_NN Return_NN TSR_NNP over_IN the_DT period_NN with_IN the_DT TSR_NNP of_IN companies_NNS in_IN the_DT UK_NNP FTSE_NNP 100_CD Index_NNP over_IN the_DT same_JJ period_NN ._.
The_DT second_JJ part_NN of_IN the_DT performance_NN condition_NN compares_VBZ GlaxoSmithKlines_NNP earnings_NNS per_IN share_NN growth_NN to_TO the_DT increase_NN in_IN the_DT UK_NNP Retail_NNP Prices_NNS Index_NN over_IN the_DT three_CD year_NN performance_NN period_NN ._.
Shares_NNP ADSs_NNP Number_NNP of_IN shares_NNS and_CC ADSs_NNS issuable_JJ Number_NNP 000_CD Number_NNP 000_CD At_IN 27th_JJ December_NNP 2000_CD Converted_VBN from_IN Glaxo_NNP Wellcome_NNP awards_NNS 2,111_CD Converted_VBN from_IN SmithKline_NNP Beecham_NNP awards_NNS 1,623_CD 1,386_CD Awards_NNS exercised_VBN 243_CD At_IN 31st_CD December_NNP 2000_CD 3,491_CD 1,386_CD Awards_NNPS granted_VBD 1,778_CD 1,042_CD Awards_NNS exercised_VBN 2,016_CD 598_CD Awards_NNPS canceled_VBD 72_CD 70_CD At_IN 31st_CD December_NNP 2001_CD 3,181_CD 1,760_CD Awards_NNPS granted_VBD 863_CD 477_CD Awards_NNPS exercised_VBN 728_CD 197_CD Awards_NNPS canceled_VBD 152_CD 97_CD At_IN 31st_CD December_NNP 2002_CD 3,164_CD 1,943_CD Of_IN the_DT above_JJ awards_NNS 29,000_CD relating_VBG to_TO shares_NNS and_CC nil_NN relating_VBG to_TO ADSs_NNS were_VBD exercisable_JJ at_IN 31st_CD December_NNP 2002_CD ._.
120_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 34_CD Employee_NN share_NN schemes_NNS continued_VBD SmithKline_NNP Beecham_NNP share_NN option_NN schemes_NNS At_IN the_DT date_NN of_IN the_DT merger_NN ,_, all_DT SmithKline_NNP Beecham_NNP share_NN options_NNS became_VBD exercisable_JJ ._.
Shares_NNP ADSs_NNP Weighted_NNP Weighted_NNP exercise_NN exercise_NN Number_NN of_IN shares_NNS and_CC ADSs_NNS issuable_JJ under_IN outstanding_JJ options_NNS Number_NN 000_CD price_NN Number_NN 000_CD price_NN At_IN 31st_CD December_NNP 1999_CD 100,429_CD 5.47_CD 42,399_CD $_$ 45.59_CD Options_NNPS granted_VBD 1,448_CD 8.28_CD 560_CD $_$ 67.00_CD Options_NNPS exercised_VBN 20,951_CD 4.30_CD 8,055_CD $_$ 30.09_CD Options_NNPS canceled_VBD 3,769_CD 5.71_CD 1,545_CD $_$ 35.16_CD Converted_VBN to_TO GlaxoSmithKline_NNP options_NNS 77,157_CD 5.83_CD 33,359_CD $_$ 50.18_CD At_IN 31st_CD December_NNP 2000_CD SmithKline_NNP Beecham_NNP Mid-Term_NNP Incentive_NNP Plan_NNP SmithKline_NNP Beecham_NNP adopted_VBD the_DT Mid-Term_NNP Incentive_NNP Plan_NNP MTIP_NNP in_IN 1996_CD ._.
Participations_NNS in_IN the_DT MTIP_NNP were_VBD granted_VBN annually_RB to_TO senior_JJ staff_NN in_IN SmithKline_NNP Beecham_NNP ,_, designating_VBG a_DT target_NN number_NN of_IN shares_NNS for_IN each_DT participant_NN based_VBN on_IN job_NN grade_NN ._.
Following_VBG a_DT three-year_JJ measurement_NN period_NN ,_, the_DT R&N_NNP Committee_NNP reviewed_VBD SmithKline_NNP Beechams_NNP total_JJ shareholder_NN return_NN relative_JJ to_TO the_DT other_JJ companies_NNS comprising_VBG the_DT FTSE_NNP 100_CD Index_NNP ,_, and_CC made_VBD a_DT final_JJ award_NN of_IN a_DT proportion_NN of_IN the_DT target_NN number_NN of_IN shares_NNS ,_, up_RB to_TO 100_CD per_IN cent_NN ,_, depending_VBG on_IN performance_NN ._.
The_DT first_JJ two_CD measurement_NN periods_NNS ended_VBN on_IN 31st_CD December_NNP 1998_CD and_CC 1999_CD and_CC ,_, 100_CD per_IN cent_NN and_CC 97_CD per_IN cent_NN ,_, respectively_RB ,_, of_IN the_DT target_NN number_NN of_IN shares_NNS was_VBD awarded_VBN ._.
Receipt_NN of_IN the_DT award_NN could_MD be_VB deferred_VBN ,_, in_IN which_WDT case_NN the_DT shares_NNS remained_VBD in_IN the_DT MTIP_NNP ._.
As_IN a_DT result_NN of_IN the_DT merger_NN all_DT outstanding_JJ awards_NNS became_VBD payable_JJ at_IN 100_CD per_IN cent_NN of_IN the_DT target_NN number_NN of_IN shares_NNS at_IN the_DT end_NN of_IN each_DT three-year_JJ cycle_NN ._.
Shares_NNP ADSs_NNP Number_NNP of_IN shares_NNS issuable_JJ under_IN the_DT Mid-Term_NNP Incentive_NNP Plan_NNP Number_NNP 000_CD Number_NNP 000_CD At_IN 31st_CD December_NNP 1999_CD 4,836_CD 1,482_CD Awards_NNPS granted_VBD 124_CD 24_CD Awards_NNS exercised_VBN 1,224_CD 259_CD Awards_NNPS canceled_VBD 170_CD 29_CD Converted_VBN to_TO GlaxoSmithKline_NNP awards_NNS 3,566_CD 1,218_CD At_IN 31st_CD December_NNP 2000_CD Glaxo_NNP Wellcome_NNP share_NN option_NN schemes_NNS At_IN the_DT date_NN of_IN the_DT merger_NN ,_, all_DT Glaxo_NNP Wellcome_NNP options_NNS ,_, except_IN for_IN share_NN options_NNS granted_VBN in_IN 2000_CD and_CC savings-related_JJ share_NN options_NNS granted_VBN in_IN 1998_CD ,_, 1999_CD and_CC 2000_CD ,_, became_VBD exercisable_JJ and_CC performance_NN conditions_NNS ,_, where_WRB applicable_JJ ,_, lapsed_VBD ._.
Savings-related_JJ Share_NN option_NN schemes_NNS share_NN option_NN schemes_NNS Total_JJ Weighted_NNP Weighted_NNP Weighted_NNP exercise_NN exercise_NN exercise_NN Number_NN of_IN shares_NNS issuable_JJ under_IN outstanding_JJ options_NNS Number_NN 000_CD price_NN Number_NN 000_CD price_NN Number_NN 000_CD price_NN At_IN 31st_CD December_NNP 1999_CD 83,014_CD 12.74_CD 11,418_CD 9.18_CD 94,432_CD 12.31_CD Options_NNS granted_VBN 35,989_CD 14.81_CD 2,112_CD 16.48_CD 38,101_CD 14.91_CD Options_NNS exercised_VBN 7,956_CD 7.77_CD 4,801_CD 6.72_CD 12,757_CD 7.38_CD Options_NNS canceled_VBN 4,299_CD 12.53_CD 332_CD 11.36_CD 4,631_CD 12.44_CD Converted_VBN to_TO GlaxoSmithKline_NNP options_NNS 106,748_CD 13.87_CD 8,397_CD 12.34_CD 115,145_CD 13.76_CD At_IN 31st_CD December_NNP 2000_CD Glaxo_NNP Wellcome_NNP share_NN award_NN schemes_NNS Glaxo_NNP Wellcome_NNP operated_VBD a_DT Long_JJ Term_NNP Incentive_NNP Plan_NNP and_CC ,_, between_IN 1996_CD and_CC 1998_CD ,_, an_DT Annual_JJ Incentive_NNP Plan_NNP ._.
The_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP granted_VBD awards_NNS over_IN shares_NNS to_TO Directors_NNS and_CC senior_JJ staff_NN at_IN a_DT nominal_JJ cost_NN ._.
The_DT percentage_NN of_IN each_DT award_NN that_WDT vested_VBD was_VBD based_VBN on_IN the_DT performance_NN of_IN Glaxo_NNP Wellcome_NNP over_IN a_DT three-year_JJ period_NN ._.
The_DT Annual_JJ Incentive_NNP Plan_NNP was_VBD a_DT performance_NN bonus_NN consisting_VBG of_IN a_DT basic_JJ award_NN of_IN shares_NNS and_CC a_DT matching_JJ award_NN with_IN a_DT three-year_JJ retention_NN period_NN ._.
As_IN a_DT result_NN of_IN the_DT merger_NN the_DT awards_NNS under_IN the_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP became_VBD payable_JJ in_IN full_JJ and_CC the_DT retention_NN period_NN of_IN the_DT Annual_JJ Incentive_NNP Plan_NNP lapsed_VBD ._.
Number_NN of_IN shares_NNS issuable_JJ under_IN share_NN award_NN schemes_NNS Number_NNP 000_CD At_IN 31st_CD December_NNP 1999_CD 2,364_CD Awards_NNS granted_VBN 826_CD Awards_NNPS exercised_VBN 790_CD Awards_NNPS canceled_VBD 289_CD Converted_VBN to_TO GlaxoSmithKline_NNP awards_NNS 2,111_CD At_IN 31st_CD December_NNP 2000_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 121_CD 34_CD Employee_NN share_NN schemes_NNS continued_VBD Employee_NNP Share_NNP Ownership_NNP Trusts_NNP The_NNP Group_NNP sponsors_VBZ Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS to_TO acquire_VB and_CC hold_VB shares_NNS in_IN GlaxoSmithKline_NNP plc_NN to_TO satisfy_VB awards_NNS made_VBN under_IN employee_NN incentive_NN plans_NNS and_CC options_NNS granted_VBN under_IN employee_NN share_NN option_NN schemes_NNS ._.
The_DT trustees_NNS of_IN the_DT Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS purchase_NN shares_NNS on_IN the_DT open_JJ market_NN with_IN finance_NN provided_VBN by_IN the_DT Group_NNP by_IN way_NN of_IN loan_NN or_CC contributions_NNS ._.
The_DT expected_VBN cost_NN of_IN the_DT obligations_NNS to_TO deliver_VB shares_NNS under_IN the_DT schemes_NNS are_VBP normally_RB spread_VBN over_IN the_DT periods_NNS of_IN service_NN in_IN respect_NN of_IN which_WDT the_DT awards_NNS and_CC options_NNS are_VBP granted_VBN ._.
An_DT accelerated_JJ charge_NN was_VBD made_VBN in_IN 2000_CD in_IN respect_NN of_IN the_DT outstanding_JJ cost_NN of_IN providing_VBG shares_NNS for_IN awards_NNS and_CC options_NNS which_WDT became_VBD exercisable_JJ solely_RB as_IN a_DT result_NN of_IN the_DT merger_NN ._.
Shares_NNP held_VBD for_IN share_NN award_NN schemes_NNS 2002_CD 2001_CD Number_NN of_IN shares_NNS 000_CD 7,055_CD 6,701_CD m_NN m_NN Nominal_JJ value_NN 2_CD 2_CD Cost_NN less_JJR provision_NN 75_CD 58_CD Market_NN value_NN 84_CD 115_CD Shares_NNS held_VBN for_IN share_NN option_NN schemes_NNS 2002_CD 2001_CD Number_NN of_IN shares_NNS 000_CD 174,256_CD 180,708_CD m_NN m_NN Nominal_JJ value_NN 44_CD 45_CD Cost_NN less_JJR provision_NN 2,751_CD 2,878_CD Market_NN value_NN 2,077_CD 3,114_CD The_DT Trusts_NNS also_RB acquire_VB and_CC hold_VB shares_NNS to_TO meet_VB notional_JJ dividends_NNS re-invested_VBD on_IN deferred_VBN awards_NNS under_IN the_DT SmithKline_NNP Beecham_NNP Mid-Term_NNP Incentive_NNP Plan_NNP ._.
The_DT trustees_NNS have_VBP waived_VBN their_PRP$ rights_NNS to_TO dividends_NNS on_IN the_DT shares_NNS held_VBN by_IN the_DT Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS ._.
Option_NN pricing_NN For_IN the_DT purposes_NNS of_IN valuing_VBG options_NNS to_TO arrive_VB at_IN the_DT stock-based_JJ compensation_NN adjustment_NN in_IN the_DT Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS in_IN Note_NN 37_CD ,_, the_DT Black-Scholes_NNP option_NN pricing_NN model_NN has_VBZ been_VBN used_VBN ._.
The_DT assumptions_NNS used_VBN in_IN the_DT model_NN for_IN 2002_CD and_CC 2001_CD are_VBP as_IN follows_VBZ :_: 2002_CD 2001_CD Risk-free_JJ interest_NN rate_NN 4.2_CD %_NN 5.4_CD %_NN 4.5_CD %_NN 5.0_CD %_NN Dividend_NN yield_NN 1.9_CD %_NN 1.8_CD %_NN 1.9_CD %_NN Volatility_NN 33_CD %_NN 33_CD %_NN Expected_VBN lives_NNS of_IN options_NNS granted_VBN under_IN :_: Share_NN option_NN schemes_NNS 5_CD years_NNS 5_CD years_NNS Savings_NNS related_VBN share_NN option_NN schemes_NNS 3_CD years_NNS 3_CD years_NNS 35_CD Related_VBN party_NN transactions_NNS GlaxoSmithKline_NNP held_VBD a_DT 23_CD per_IN cent_NN interest_NN in_IN Quest_NNP Diagnostics_NNPS Inc._NNP throughout_IN 2002_CD ._.
In_IN December_NNP 2002_CD GlaxoSmithKline_NNP and_CC Quest_NNP amended_VBD the_DT terms_NNS of_IN their_PRP$ Global_JJ Trials_NNP Agreement_NNP ,_, which_WDT is_VBZ a_DT long-term_JJ contractual_JJ relationship_NN under_IN which_WDT Quest_NNP is_VBZ the_DT primary_JJ provider_NN of_IN clinical_JJ laboratory_NN testing_NN to_TO support_VB the_DT Groups_NNS clinical_JJ trials_NNS testing_NN requirements_NNS worldwide_VBP ._.
In_IN February_NNP 2002_CD ,_, Mr_NNP Ingram_NNP ,_, then_RB a_DT member_NN of_IN the_DT CET_NNP ,_, purchased_VBD a_DT portion_NN of_IN land_NN being_VBG part_NN of_IN a_DT residential_JJ property_NN owned_VBN by_IN the_DT Group_NNP that_WDT was_VBD adjacent_JJ to_TO Mr_NNP Ingrams_NNP own_JJ residence_NN ._.
The_DT total_JJ sale_NN price_NN was_VBD $_$ 16,500_CD based_VBN on_IN an_DT independent_JJ valuation_NN of_IN the_DT land_NN ._.
The_DT Group_NNP subsequently_RB determined_VBD that_IN retention_NN of_IN the_DT residential_JJ property_NN no_RB longer_RB served_VBD its_PRP$ business_NN needs_NNS and_CC listed_VBN the_DT property_NN for_IN sale_NN ._.
An_DT independent_JJ valuation_NN of_IN the_DT property_NN on_IN 3rd_CD June_NNP 2002_CD valued_VBN it_PRP at_IN $_$ 1,050,000_CD and_CC the_DT property_NN was_VBD offered_VBN for_IN sale_NN through_IN an_DT estate_NN agent_NN ._.
Mr_NNP Ingram_NNP made_VBD the_DT highest_JJS offer_NN for_IN the_DT property_NN and_CC purchased_VBD it_PRP from_IN the_DT Group_NNP for_IN total_JJ consideration_NN of_IN $_$ 1,070,000_CD ._.
36_CD GlaxoSmithKline_NNP plc_NN investment_NN in_IN subsidiary_NN companies_NNS During_IN 2002_CD ,_, GlaxoSmithKline_NNP plc_NN initiated_VBD an_DT internal_JJ reorganisation_NN ,_, as_IN a_DT result_NN of_IN which_WDT the_DT company_NN acquired_VBD direct_JJ investments_NNS in_IN subsidiary_NN companies_NNS which_WDT had_VBD previously_RB been_VBN held_VBN as_IN indirect_JJ investments_NNS ._.
122_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS Summary_NNP of_IN material_NN differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP The_NNP Financial_NNP statements_NNS ,_, analyses_NNS and_CC reconciliations_NNS presented_VBN in_IN Capitalised_JJ interest_NN this_DT Note_NN represent_VBP the_DT financial_JJ information_NN which_WDT would_MD be_VB Under_IN UK_NNP GAAP_NNP ,_, the_DT Group_NNP does_VBZ not_RB capitalize_VB interest_NN ._.
US_NNP GAAP_NNP required_VBN if_IN US_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS US_NNP GAAP_NNP requires_VBZ interest_NN incurred_VBN as_IN part_NN of_IN the_DT cost_NN of_IN constructing_VBG xed_VBN had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
assets_NNS to_TO be_VB capitalized_VBN and_CC amortised_VBN over_IN the_DT life_NN of_IN the_DT asset_NN ._.
The_DT most_RBS significant_JJ difference_NN between_IN US_NNP and_CC UK_NNP GAAP_NNP is_VBZ that_IN ,_, Computer_NNP software_NN under_IN UK_NNP GAAP_NNP ,_, the_DT combination_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC Under_IN UK_NNP GAAP_NNP ,_, the_DT Group_NNP capitalises_VBZ costs_NNS incurred_VBN in_IN acquiring_VBG SmithKline_NNP Beecham_NNP plc_NN has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT merger_NN and_CC developing_VBG computer_NN software_NN for_IN internal_JJ use_NN where_WRB the_DT pooling_VBG of_IN interest_NN while_IN under_IN US_NNP GAAP_NNP this_DT transaction_NN is_VBZ software_NN supports_VBZ a_DT significant_JJ business_NN system_NN and_CC the_DT accounted_VBN for_IN as_IN a_DT purchase_NN business_NN combination_NN with_IN Glaxo_NNP expenditure_NN leads_VBZ to_TO the_DT creation_NN of_IN a_DT durable_JJ asset_NN ._.
For_IN US_NNP GAAP_NNP ,_, Wellcome_NNP acquiring_VBG SmithKline_NNP Beecham_NNP ._.
the_DT Group_NNP applies_VBZ SOP_NNP 98-1_CD Accounting_NN for_IN the_DT Costs_NNS of_IN Computer_NNP Software_NNP Developed_VBD or_CC Obtained_VBN for_IN Internal_NNP Use_NNP which_WDT GlaxoSmithKline_NNP plc_NN was_VBD formed_VBN to_TO give_VB effect_NN to_TO a_DT Scheme_NN of_IN restricts_VBZ the_DT categories_NNS of_IN costs_NNS which_WDT can_MD be_VB capitalized_VBN ._.
Arrangement_NN for_IN the_DT merger_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP plc_NN effective_JJ on_IN 27th_JJ December_NNP 2000_CD ._.
GlaxoSmithKline_NNP plc_NNP Goodwill_NNP and_CC intangible_JJ xed_JJ assets_NNS acquired_VBD the_DT whole_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN Under_IN UK_NNP GAAP_NNP ,_, goodwill_NN arising_VBG on_IN acquisitions_NNS before_IN 1998_CD ,_, and_CC SmithKline_NNP Beecham_NNP plc_NN in_IN exchange_NN for_IN shares_NNS in_IN accounted_VBN for_IN under_IN the_DT purchase_NN method_NN ,_, has_VBZ been_VBN eliminated_VBN GlaxoSmithKline_NNP plc._NN ._.
Upon_IN completion_NN of_IN the_DT merger_NN the_DT former_JJ against_IN shareholders_NNS funds_NNS ._.
Additionally_RB ,_, UK_NNP GAAP_NNP requires_VBZ that_IN shareholders_NNS of_IN Glaxo_NNP Wellcome_NNP held_VBD approximately_RB 58.75_CD per_IN cent_NN on_IN subsequent_JJ disposal_NN or_CC closure_NN of_IN a_DT business_NN ,_, any_DT goodwill_NN and_CC the_DT former_JJ shareholders_NNS of_IN SmithKline_NNP Beecham_NNP held_VBD previously_RB taken_VBN directly_RB to_TO shareholders_NNS funds_NNS is_VBZ then_RB charged_VBN approximately_RB 41.25_CD per_IN cent_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN against_IN income_NN ._.
Beginning_VBG in_IN 1998_CD ,_, the_DT Group_NNP changed_VBD its_PRP$ GlaxoSmithKline_NNP plc._NN ._.
accounting_NN policy_NN for_IN goodwill_NN and_CC intangible_JJ assets_NNS under_IN UK_NNP GAAP_NNP in_IN respect_NN of_IN acquisitions_NNS from_IN 1998_CD ._.
Under_IN UK_NNP GAAP_NNP ,_, As_IN the_DT combination_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP goodwill_NN arising_VBG on_IN acquisitions_NNS from_IN 1998_CD is_VBZ capitalized_VBN and_CC was_VBD accounted_VBN for_IN as_IN a_DT merger_NN under_IN UK_NNP GAAP_NNP ,_, the_DT financial_JJ amortised_VBN over_IN a_DT period_NN not_RB exceeding_VBG 20_CD years_NNS ._.
statements_NNS of_IN GlaxoSmithKline_NNP under_IN UK_NNP GAAP_NNP represent_VBP the_DT combined_VBN Financial_NNP statements_NNS of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Under_IN US_NNP GAAP_NNP ,_, goodwill_NN arising_VBG on_IN acquisitions_NNS prior_RB to_TO Beecham_NNP on_IN a_DT historical_JJ basis_NN for_IN 2000_CD ._.
30_CD June_NNP 2001_CD was_VBD capitalized_VBN and_CC amortised_VBN over_IN a_DT period_NN not_RB exceeding_VBG 40_CD years_NNS ._.
In_IN July_NNP 2001_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP 142_CD Under_IN US_NNP GAAP_NNP ,_, this_DT business_NN combination_NN did_VBD not_RB qualify_VB for_IN Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ._.
SFAS_NNP 142_CD requires_VBZ that_IN pooling_VBG of_IN interests_NNS accounting_VBG and_CC Glaxo_NNP Wellcome_NNP was_VBD goodwill_NN no_RB longer_RB be_VB amortised_VBN over_IN its_PRP$ estimated_VBN useful_JJ life_NN ._.
The_DT determined_VBN to_TO be_VB the_DT accounting_NN acquirer_NN in_IN a_DT purchase_NN acquisition_NN Group_NNP must_MD instead_RB identify_VB and_CC value_VB its_PRP$ reporting_VBG units_NNS for_IN the_DT dated_JJ 27th_JJ December_NNP 2000_CD ._.
Under_IN US_NNP GAAP_NNP the_DT financial_JJ purpose_NN of_IN assessing_VBG ,_, at_IN least_JJS annually_RB ,_, potential_JJ impairment_NN of_IN statements_NNS of_IN GlaxoSmithKline_NNP prior_RB to_TO the_DT merger_NN are_VBP therefore_RB goodwill_NN allocated_VBN to_TO each_DT reporting_VBG unit_NN ._.
Additionally_RB ,_, the_DT Group_NNP those_DT of_IN Glaxo_NNP Wellcome_NNP ._.
reassesses_VBZ the_DT useful_JJ lives_NNS of_IN existing_VBG recognized_VBN intangible_JJ assets_NNS ._.
In_IN view_NN of_IN the_DT proximity_NN of_IN the_DT merger_NN date_NN to_TO the_DT financial_JJ year_NN end_NN Intangible_JJ assets_NNS deemed_VBD to_TO have_VB indefinite_JJ lives_NNS are_VBP no_RB longer_RB date_NN ,_, and_CC the_DT relative_JJ insignicance_NN of_IN any_DT business_NN activity_NN between_IN amortised_JJ ,_, instead_RB they_PRP are_VBP tested_VBN annually_RB for_IN potential_JJ 27th_JJ December_NNP 2000_CD and_CC 31st_CD December_NNP 2000_CD ,_, the_DT accounting_NN impairment_NN ._.
Separate_JJ intangible_JJ assets_NNS with_IN nite_JJ lives_NNS continue_VBP to_TO date_NN of_IN the_DT acquisition_NN was_VBD for_IN practical_JJ purposes_NNS taken_VBN as_RB be_VB amortised_VBN over_IN their_PRP$ useful_JJ lives_NNS ._.
The_DT Group_NNP adopted_VBD SFAS_NNP 142_CD as_IN of_IN 1st_CD January_NNP 2002_CD ._.
The_DT The_DT reconciliation_NN of_IN the_DT consolidated_JJ income_NN statements_NNS and_CC the_DT implementation_NN of_IN SFAS_NNP 142_CD resulted_VBD in_IN no_DT impairment_NN of_IN the_DT consolidated_JJ statements_NNS of_IN comprehensive_JJ income_NN and_CC changes_NNS in_IN Groups_NNS goodwill_NN and_CC an_DT initial_JJ impairment_NN of_IN 173_CD million_CD shareholder_NN equity_NN for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD 127_CD million_CD net_NN of_IN tax_NN on_IN indefinite-lived_JJ assets_NNS ._.
This_DT is_VBZ shown_VBN as_IN correspondingly_RB reect_VB the_DT purchase_NN method_NN of_IN accounting_NN for_IN a_DT cumulative_JJ effect_NN of_IN an_DT accounting_NN change_NN ._.
the_DT acquisition_NN of_IN SmithKline_NNP Beecham_NNP by_IN Glaxo_NNP Wellcome_NNP ._.
The_DT Under_IN UK_NNP GAAP_NNP ,_, costs_VBZ to_TO be_VB incurred_VBN in_IN integrating_VBG and_CC income_NN statement_NN has_VBZ been_VBN presented_VBN in_IN a_DT US_NNP GAAP_NNP format_NN and_CC restructuring_VBG the_DT Wellcome_NNP ,_, SmithKline_NNP Beecham_NNP and_CC Block_NNP Drug_NNP therefore_RB certain_JJ exceptional_JJ items_NNS under_IN UK_NNP GAAP_NNP being_VBG product_NN businesses_NNS following_VBG the_DT acquisitions_NNS in_IN 1995_CD ,_, 2000_CD and_CC 2001_CD divestments_NNS ,_, merger_NN integration_NN costs_NNS and_CC ,_, in_IN addition_NN ,_, the_DT write-off_NN respectively_RB were_VBD charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN post_NN of_IN in-process_JJ research_NN and_CC development_NN have_VBP been_VBN classied_VBN within_IN acquisition_NN ._.
Under_IN US_NNP GAAP_NNP ,_, certain_JJ of_IN such_JJ costs_NNS are_VBP considered_VBN operating_NN profit_NN ._.
in_IN the_DT allocation_NN of_IN purchase_NN consideration_NN thereby_RB affecting_VBG the_DT A_DT consolidated_JJ balance_NN sheet_NN and_CC a_DT consolidated_JJ statement_NN of_IN cash_NN goodwill_NN arising_VBG on_IN acquisition_NN ._.
ows_NNS under_IN US_NNP GAAP_NNP and_CC in_IN US_NNP GAAP_NNP format_NN are_VBP also_RB presented_VBN ._.
Under_IN UK_NNP GAAP_NNP certain_JJ intangible_JJ assets_NNS related_VBN to_TO specic_VB These_DT Financial_NNP statements_NNS reect_VBP both_DT the_DT purchase_NN method_NN of_IN compounds_NNS or_CC products_NNS which_WDT are_VBP purchased_VBN from_IN a_DT third_JJ party_NN accounting_NN for_IN the_DT combination_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP and_CC are_VBP developed_VBN for_IN commercial_JJ applications_NNS are_VBP capitalized_VBN ._.
Beecham_NNP and_CC also_RB other_JJ material_NN adjustments_NNS which_WDT would_MD be_VB Under_IN US_NNP GAAP_NNP ,_, payments_NNS made_VBD for_IN these_DT compounds_NNS or_CC products_NNS required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP for_IN which_WDT are_VBP still_RB in_IN development_NN and_CC have_VBP not_RB yet_RB received_VBN regulatory_JJ the_DT periods_NNS presented_VBN ._.
A_DT summary_NN of_IN the_DT purchase_NN accounting_NN approval_NN are_VBP charged_VBN directly_RB to_TO profit_NN and_CC loss_NN until_IN such_JJ time_NN that_WDT adjustments_NNS and_CC of_IN other_JJ US_NNP GAAP_NNP adjustments_NNS is_VBZ provided_VBN in_IN the_DT they_PRP receive_VBP regulatory_JJ approval_NN ._.
reconciliations_NNS of_IN profit_NN attributable_JJ to_TO shareholders_NNS and_CC of_IN equity_NN shareholders_NNS funds_NNS from_IN UK_NNP to_TO US_NNP GAAP_NNP ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 123_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD As_IN a_DT result_NN of_IN the_DT merger_NN certain_JJ of_IN the_DT Groups_NNS options_NNS vested_VBN immediately_RB requiring_VBG the_DT acceleration_NN of_IN compensation_NN expense_NN ._.
Merger_NN transaction_NN costs_VBZ The_DT amount_NN of_IN stock-based_JJ compensation_NN expense_NN related_VBN to_TO this_DT Glaxo_NNP Wellcome_NNP incurred_VBD total_JJ merger-related_JJ transaction_NN costs_NNS of_IN accelerated_VBN vesting_NN was_VBD 83_CD million_CD in_IN 2000_CD ._.
The_DT disclosures_NNS 66_CD million_CD ,_, excluding_VBG integration_NN and_CC restructuring_NN costs_NNS ._.
Under_IN UK_NNP required_VBN by_IN SFAS_NNP 123_CD are_VBP included_VBN in_IN Note_NN 34_CD ._.
GAAP_NNP these_DT merger_NN transaction_NN costs_NNS were_VBD expensed_VBN as_IN incurred_VBN during_IN 2000_CD ._.
Under_IN US_NNP GAAP_NNP ,_, direct_JJ acquisition_NN costs_NNS of_IN the_DT Additionally_RB ,_, the_DT Group_NNP is_VBZ entitled_VBN to_TO receive_VB a_DT tax_NN deduction_NN for_IN the_DT acquiring_VBG company_NN are_VBP included_VBN as_IN a_DT portion_NN of_IN the_DT purchase_NN amount_NN treated_VBN as_IN compensation_NN under_IN US_NNP tax_NN rules_NNS for_IN employee_NN consideration_NN ._.
stock_NN options_NNS which_WDT have_VBP been_VBN exercised_VBN by_IN US_NNP employees_NNS during_IN the_DT year_NN ._.
Under_IN UK_NNP GAAP_NNP this_DT is_VBZ treated_VBN as_IN a_DT reduction_NN of_IN tax_NN Restructuring_NN costs_NNS expense_NN whereas_IN under_IN US_NNP GAAP_NNP a_DT portion_NN of_IN this_DT amount_NN is_VBZ The_DT requirements_NNS for_IN recording_VBG a_DT provision_NN for_IN restructuring_VBG costs_NNS credited_VBN to_TO equity_NN ._.
are_VBP different_JJ in_IN certain_JJ aspects_NNS under_IN US_NNP GAAP_NNP than_IN under_IN UK_NNP GAAP_NNP ._.
Accordingly_RB ,_, adjustments_NNS have_VBP been_VBN made_VBN to_TO eliminate_VB the_DT Employee_NNP Share_NN Ownership_NNP Trust_NNP ESOT_NNP UK_NNP GAAP_NNP provisions_NNS for_IN restructuring_VBG costs_NNS that_WDT do_VBP not_RB meet_VB US_NNP Under_IN UK_NNP GAAP_NNP shares_NNS of_IN the_DT Groups_NNS stock_NN held_VBN by_IN the_DT ESOT_NNP GAAP_NNP requirements_NNS ._.
are_VBP recorded_VBN at_IN cost_NN ,_, less_JJR a_DT provision_NN representing_VBG the_DT difference_NN between_IN the_DT cost_NN and_CC the_DT option_NN exercise_NN price_NN ,_, and_CC accounted_VBD for_IN Marketable_JJ securities_NNS as_IN xed_JJ asset_NN investments_NNS ._.
Projected_JJ losses_NNS on_IN the_DT exercise_NN of_IN the_DT Marketable_JJ securities_NNS consist_VBP primarily_RB of_IN equity_NN securities_NNS and_CC options_NNS covered_VBN by_IN the_DT shares_NNS are_VBP recorded_VBN through_IN the_DT profit_NN and_CC certain_JJ other_JJ liquid_JJ investments_NNS ._.
Under_IN UK_NNP GAAP_NNP these_DT securities_NNS loss_NN account_NN over_IN the_DT life_NN of_IN the_DT options_NNS ._.
Under_IN US_NNP GAAP_NNP shares_NNS of_IN are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Under_IN US_NNP the_DT Groups_NNS stock_NN purchased_VBN by_IN the_DT ESOT_NNP are_VBP accounted_VBN for_IN within_IN GAAP_NNP these_DT securities_NNS are_VBP available_JJ for_IN sale_NN under_IN Statement_NN of_IN shareholders_NNS equity_NN at_IN cost_NN ._.
Gains_NNS or_CC losses_NNS arising_VBG on_IN subsequent_JJ Financial_NNP Accounting_NNP Standard_NNP No_NNP 115_CD SFAS_NNP 115_CD Accounting_NN for_IN issuance_NN of_IN the_DT shares_NNS to_TO employees_NNS to_TO satisfy_VB share_NN options_NNS are_VBP certain_JJ investments_NNS in_IN debt_NN and_CC equity_NN securities_NNS and_CC are_VBP carried_VBN at_IN recorded_VBN as_IN adjustments_NNS to_TO shareholders_NNS equity_NN ._.
fair_JJ value_NN ,_, with_IN the_DT unrealised_JJ gains_NNS and_CC losses_NNS ,_, net_NN of_IN tax_NN ,_, reported_VBD as_IN a_DT separate_JJ component_NN of_IN shareholders_NNS equity_NN ._.
Derivative_JJ instruments_NNS Statement_NN of_IN Financial_NNP Accounting_NNP Standard_NNP No._NN ._.
133_CD ,_, Accounting_NNP Pensions_NNPS and_CC other_JJ post-retirement_JJ benets_NNS for_IN Derivative_JJ Instruments_NNPS and_CC Hedging_NNP Activities_NNPS SFAS_NNP 133_CD as_IN The_DT key_JJ differences_NNS between_IN UK_NNP SSAP_NNP 24_CD and_CC US_NNP GAAP_NNP in_IN relation_NN amended_VBN by_IN SFAS_NNP 137_CD and_CC SFAS_NNP 138_CD and_CC as_IN interpreted_VBN by_IN the_DT to_TO dened_VBN benefit_NN pension_NN plans_NNS are_VBP :_: Derivatives_NNS Implementation_NNP Group_NNP ,_, was_VBD adopted_VBN by_IN the_DT Group_NNP with_IN under_IN UK_NNP GAAP_NNP the_DT effect_NN of_IN variations_NNS in_IN cost_NN can_MD be_VB effect_NN from_IN 1st_CD January_NNP 2001_CD ._.
SFAS_NNP 133_CD establishes_VBZ accounting_NN and_CC accumulated_VBN at_IN successive_JJ valuations_NNS and_CC amortised_VBN on_IN an_DT reporting_NN standards_NNS for_IN derivative_JJ instruments_NNS ,_, including_VBG certain_JJ aggregate_JJ basis_NN ._.
Under_IN US_NNP GAAP_NNP the_DT amortisation_NN of_IN the_DT derivative_JJ instruments_NNS embedded_VBN in_IN other_JJ contracts_NNS collectively_RB ,_, transition_NN asset_NN and_CC the_DT costs_NNS of_IN past_JJ service_NN benefit_NN referred_VBD to_TO as_IN derivatives_NNS and_CC for_IN hedging_VBG activities_NNS ._.
Under_IN UK_NNP improvements_NNS are_VBP separately_RB tracked_VBN :_: experience_NN gains_NNS losses_NNS GAAP_NNP ,_, some_DT derivative_JJ instruments_NNS used_VBN for_IN hedging_VBG are_VBP not_RB are_VBP dealt_VBN with_IN on_IN an_DT aggregate_JJ basis_NN but_CC amortised_VBD only_RB if_IN recognized_VBN on_IN the_DT balance_NN sheet_NN and_CC the_DT matching_JJ principle_NN is_VBZ outside_IN a_DT 10_CD per_IN cent_NN corridor_NN ._.
used_VBN to_TO match_VB the_DT gain_NN or_CC loss_NN under_IN these_DT hedging_VBG contracts_NNS to_TO the_DT foreign_JJ currency_NN transaction_NN or_CC profits_NNS to_TO which_WDT they_PRP relate_VBP ._.
UK_NNP GAAP_NNP allows_VBZ measurements_NNS of_IN plan_NN assets_NNS and_CC liabilities_NNS to_TO SFAS_NNP 133_CD requires_VBZ that_IN an_DT entity_NN recognize_VB all_DT derivatives_NNS as_IN either_DT be_VB based_VBN on_IN the_DT result_NN of_IN the_DT latest_JJS actuarial_JJ valuation_NN ._.
US_NNP GAAP_NNP assets_NNS or_CC liabilities_NNS in_IN the_DT consolidated_JJ balance_NN sheet_NN and_CC measure_NN requires_VBZ measurement_NN of_IN plan_NN assets_NNS and_CC liabilities_NNS to_TO be_VB made_VBN those_DT instruments_NNS at_IN fair_JJ value_NN ._.
Changes_NNS in_IN fair_JJ value_NN over_IN the_DT at_IN the_DT date_NN of_IN the_DT Financial_NNP statements_NNS or_CC up_RB to_TO three_CD months_NNS period_NN are_VBP recorded_VBN in_IN current_JJ earnings_NNS unless_IN hedge_JJ accounting_NN prior_RB to_TO that_DT date_NN ._.
The_DT Group_NNP does_VBZ not_RB designate_VB any_DT of_IN its_PRP$ derivatives_NNS as_IN The_DT pension_NN adjustment_NN also_RB includes_VBZ the_DT impact_NN of_IN changes_NNS in_IN qualifying_VBG hedge_NN instruments_NNS under_IN SFAS_NNP 133_CD ._.
SFAS_NNP 133_CD prescribes_VBZ minimum_JJ pension_NN liabilities_NNS included_VBD within_IN accumulated_VBN other_JJ requirements_NNS for_IN designation_NN and_CC documentation_NN of_IN hedging_VBG comprehensive_JJ income_NN ._.
relationships_NNS and_CC ongoing_JJ assessments_NNS of_IN effectiveness_NN in_IN order_NN to_TO qualify_VB for_IN hedge_JJ accounting_NN ._.
During_IN 2002_CD ,_, the_DT Group_NNP decided_VBD to_TO align_VB the_DT measurement_NN date_NN for_IN all_DT of_IN its_PRP$ pension_NN plans_NNS to_TO 31st_CD December_NNP as_IN certain_JJ of_IN the_DT The_NNP Group_NNP also_RB evaluates_VBZ contracts_NNS for_IN embedded_VBN derivatives_NNS ,_, and_CC Groups_NNS plans_NNS had_VBD a_DT measurement_NN date_NN for_IN pension_NN assets_NNS and_CC considers_VBZ whether_IN any_DT embedded_VBN derivatives_NNS have_VBP to_TO be_VB bifurcated_VBN ,_, liabilities_NNS of_IN 30th_JJ September_NNP ._.
or_CC separated_JJ ,_, from_IN the_DT host_NN contracts_NNS in_IN accordance_NN with_IN SFAS_NNP 133_CD requirements_NNS ._.
If_IN embedded_VBN derivatives_NNS exist_VBP and_CC are_VBP not_RB clearly_RB and_CC The_DT impact_NN ,_, reected_VBD as_IN a_DT cumulative_JJ effect_NN of_IN an_DT accounting_NN closely_RB related_VBN to_TO the_DT host_NN contract_NN ,_, they_PRP are_VBP accounted_VBN for_IN change_NN ,_, was_VBD a_DT 37_CD million_CD credit_NN ,_, net_NN of_IN tax_NN ,_, to_TO income_NN ._.
separately_RB from_IN the_DT host_NN contract_NN as_IN derivatives_NNS ._.
The_DT disclosures_NNS required_VBN by_IN SFAS_NNP 132_CD are_VBP included_VBN in_IN this_DT Note_NN ._.
Gains_NNS and_CC losses_NNS related_VBN to_TO the_DT fair_JJ value_NN adjustments_NNS of_IN all_DT derivative_JJ instruments_NNS are_VBP classied_VBN in_IN the_DT consolidated_JJ statement_NN Stock-based_JJ compensation_NN of_IN income_NN and_CC cash_NN ows_NNS in_IN accordance_NN with_IN the_DT nature_NN of_IN the_DT Under_IN UK_NNP GAAP_NNP share_NN options_NNS are_VBP accounted_VBN for_IN as_IN equity_NN when_WRB derivative_NN ._.
exercised_VBN ,_, valued_VBN at_IN the_DT issuance_NN price_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP applies_VBZ SFAS_NNP 123_CD Accounting_NN for_IN stock-based_JJ compensation_NN and_CC The_DT fair_JJ value_NN and_CC book_NN value_NN of_IN derivative_JJ instruments_NNS in_IN respect_NN related_VBN accounting_NN interpretations_NNS in_IN accounting_NN for_IN its_PRP$ option_NN plans_NNS of_IN financial_JJ assets_NNS and_CC liabilities_NNS as_IN at_IN 31st_CD December_NNP 2002_CD is_VBZ which_WDT require_VBP options_NNS to_TO be_VB fair_JJ valued_VBN at_IN their_PRP$ grant_NN date_NN and_CC disclosed_VBN in_IN the_DT Classication_NNP and_CC fair_JJ value_NN of_IN financial_JJ assets_NNS included_VBN in_IN profit_NN and_CC loss_NN over_IN the_DT vesting_JJ period_NN of_IN the_DT options_NNS ._.
and_CC liabilities_NNS table_NN in_IN Note_NN 32_CD ._.
124_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Comprehensive_JJ income_NN statement_NN The_DT requirement_NN of_IN SFAS_NNP 130_CD Reporting_NNP comprehensive_JJ income_NN to_TO Valuation_NNP of_IN derivative_JJ instruments_NNS provide_VBP a_DT comprehensive_JJ income_NN statement_NN is_VBZ met_VBN under_IN UK_NNP GAAP_NNP The_NNP fair_JJ value_NN of_IN derivative_JJ instruments_NNS is_VBZ sensitive_JJ to_TO movements_NNS in_IN by_IN the_DT Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS pages_NNS 76_CD to_TO the_DT underlying_VBG market_NN rates_NNS and_CC variables_NNS ._.
A_DT statement_NN of_IN comprehensive_JJ income_NN under_IN US_NNP GAAP_NNP for_IN the_DT fair_JJ value_NN of_IN derivative_JJ instruments_NNS on_IN a_DT periodic_JJ basis_NN ._.
Derivatives_NNS three_CD years_NNS in_IN the_DT period_NN ending_VBG 31st_CD December_NNP 2002_CD is_VBZ presented_VBN including_VBG interest_NN rate_NN swaps_NNS and_CC cross_JJ currency_NN swaps_NNS are_VBP valued_VBN on_IN pages_NNS 126_CD and_CC 127_CD ._.
Under_IN US_NNP GAAP_NNP the_DT statement_NN includes_VBZ the_DT using_VBG standard_JJ valuation_NN models_NNS ,_, counterparty_NN valuations_NNS ,_, or_CC thirdnet_NN impact_NN of_IN gains_NNS and_CC losses_NNS on_IN equity_NN and_CC liquid_JJ investments_NNS and_CC party_NN valuations_NNS ._.
Standard_NNP valuation_NN models_NNS used_VBN by_IN the_DT Group_NNP translation_NN adjustments_NNS ._.
consider_VB relevant_JJ discount_NN rates_NNS ,_, the_DT market_NN yield_NN curve_NN on_IN the_DT valuation_NN date_NN ,_, forward_RB currency_NN exchange_NN rates_NNS and_CC counterparty_NN Recent_JJ Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP risk_NN ._.
All_DT significant_JJ rates_NNS and_CC variables_NNS are_VBP obtained_VBN from_IN market_NN pronouncements_NNS sources_NNS ._.
All_DT valuations_NNS are_VBP based_VBN on_IN the_DT remaining_VBG term_NN to_TO maturity_NN In_IN June_NNP 2001_CD ,_, the_DT FASB_NNP approved_VBD SFAS_NNP 143_CD Accounting_NN for_IN of_IN the_DT instrument_NN ._.
Foreign_JJ exchange_NN contracts_NNS are_VBP valued_VBN using_VBG Obligations_NNS Associated_NNP with_IN the_DT Retirement_NNP of_IN Long-Lived_NNP Assets_NNPS forward_RB rates_NNS observed_VBD from_IN quoted_VBN prices_NNS in_IN the_DT relevant_JJ markets_NNS which_WDT requires_VBZ that_IN the_DT fair_JJ values_NNS of_IN the_DT obligation_NN associated_VBN when_WRB possible_JJ ._.
The_DT Group_NNP assumes_VBZ parties_NNS to_TO long-term_JJ contracts_NNS with_IN the_DT retirement_NN of_IN long-lived_JJ assets_NNS be_VB capitalized_VBN as_IN part_NN of_IN are_VBP economically_RB viable_JJ but_CC reserves_NNS the_DT right_NN to_TO exercise_VB early_RB the_DT cost_NN ._.
This_DT is_VBZ required_VBN to_TO be_VB implemented_VBN by_IN the_DT Group_NNP with_IN termination_NN rights_NNS if_IN economically_RB beneficial_JJ when_WRB such_JJ rights_NNS exist_VBP effect_NN from_IN 1st_CD January_NNP 2003_CD ._.
The_DT Group_NNP does_VBZ not_RB believe_VB the_DT in_IN the_DT contract_NN ._.
adoption_NN of_IN this_DT standard_NN will_MD have_VB a_DT material_NN impact_NN on_IN its_PRP$ results_NNS ._.
Dividends_NNS Under_IN UK_NNP GAAP_NNP ,_, dividends_NNS proposed_VBN are_VBP provided_VBN for_IN in_IN the_DT year_NN in_IN On_IN 1st_CD January_NNP 2002_CD ,_, SFAS_NNP 144_CD Accounting_NN for_IN the_DT Impairment_NN respect_NN of_IN which_WDT they_PRP are_VBP recommended_VBN by_IN the_DT Board_NNP of_IN Directors_NNS or_CC Disposal_NN of_IN Long-Lived_NNP Assets_NNPS was_VBD adopted_VBN by_IN the_DT Group_NNP ._.
for_IN approval_NN by_IN the_DT shareholders_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, such_JJ dividends_NNS SFAS_NNP 144_CD develops_VBZ one_CD accounting_NN model_NN for_IN long-lived_JJ assets_NNS ,_, are_VBP not_RB provided_VBN for_IN until_IN declared_VBN by_IN the_DT Board_NNP of_IN Directors_NNS ._.
including_VBG discontinued_VBN operations_NNS to_TO be_VB disposed_VBN of_IN by_IN sale_NN ._.
It_PRP requires_VBZ that_IN all_DT long-lived_JJ assets_NNS be_VB measured_VBN at_IN the_DT lower_JJR of_IN Deferred_JJ taxation_NN carrying_VBG amount_NN or_CC fair_JJ value_NN less_RBR cost_VBN to_TO sell_VB whether_IN reported_VBN in_IN Under_IN UK_NNP GAAP_NNP the_DT Group_NNP has_VBZ implemented_VBN in_IN 2002_CD FRS_NNP 19_CD continuing_VBG or_CC discontinued_VBN operations_NNS ._.
The_DT adoption_NN of_IN SFAS_NNP 144_CD Deferred_NNP Tax_NNP ._.
This_DT requires_VBZ deferred_JJ tax_NN to_TO be_VB accounted_VBN for_IN on_IN a_DT has_VBZ not_RB had_VBD a_DT material_NN impact_NN on_IN the_DT Groups_NNS financial_JJ full_JJ provision_NN basis_NN ,_, similar_JJ to_TO the_DT requirement_NN for_IN US_NNP GAAP_NNP ,_, rather_RB statements_NNS ._.
than_IN a_DT partial_JJ provision_NN basis_NN as_IN in_IN 2001_CD and_CC earlier_JJR years_NNS ._.
As_IN a_DT consequence_NN the_DT profit_NN attributable_JJ to_TO shareholders_NNS and_CC Equity_NN In_IN April_NNP 2002_CD ,_, SFAS_NNP 145_CD Rescission_NNP of_IN FASB_NNP Statements_NNP no._NN ._.
4_CD ,_, 44_CD shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP and_CC the_DT deferred_JJ tax_NN and_CC 64_CD ,_, Amendment_NNP of_IN FASB_NNP Statement_NNP no._NN ._.
13_CD and_CC Technical_NNP adjustments_NNS under_IN US_NNP GAAP_NNP for_IN prior_RB periods_NNS have_VBP been_VBN restated_VBN ._.
The_DT statement_NN updates_NNS ,_, claries_NNS and_CC There_EX is_VBZ no_DT impact_NN to_TO Net_JJ loss_NN and_CC Shareholders_NNS equity_NN under_IN US_NNP simplies_VBZ existing_VBG accounting_NN standards_NNS ._.
The_DT Group_NNP does_VBZ not_RB GAAP_NNP as_IN previously_RB reported_VBN ._.
The_DT adoption_NN of_IN FRS_NNP 19_CD has_VBZ believe_VB the_DT adoption_NN of_IN this_DT standard_NN will_MD have_VB a_DT material_NN impact_NN eliminated_VBN most_JJS of_IN the_DT differences_NNS for_IN deferred_JJ tax_NN that_WDT previously_RB on_IN its_PRP$ results_NNS ._.
existed_VBD between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ._.
As_IN a_DT result_NN ,_, the_DT SFAS_NNP 146_CD Accounting_NN for_IN Costs_NNS Associated_NNP with_IN Exit_NN or_CC Disposal_NN adjustment_NN now_RB primarily_RB relates_VBZ to_TO the_DT deferred_VBN tax_NN effect_NN of_IN other_JJ Activities_NNS ,_, was_VBD issued_VBN in_IN June_NNP 2002_CD ._.
SFAS_NNP 146_CD requires_VBZ companies_NNS US_NNP GAAP_NNP adjustments_NNS ._.
to_TO recognize_VB costs_NNS associated_VBN with_IN exit_NN or_CC disposal_NN activities_NNS when_WRB they_PRP are_VBP incurred_VBN rather_RB than_IN at_IN the_DT date_NN of_IN a_DT commitment_NN to_TO an_DT Exceptional_JJ items_NNS exit_NN or_CC disposal_NN plan_NN and_CC is_VBZ to_TO be_VB applied_VBN prospectively_RB to_TO exit_NN or_CC Items_NNS classied_VBD as_IN exceptional_JJ under_IN UK_NNP GAAP_NNP do_VBP not_RB meet_VB the_DT disposal_NN activities_NNS initiated_VBN after_IN 31st_CD December_NNP 2002_CD ._.
The_DT Group_NNP denition_NN of_IN extraordinary_JJ under_IN US_NNP GAAP_NNP and_CC are_VBP therefore_RB is_VBZ currently_RB assessing_VBG the_DT impact_NN of_IN this_DT standard_NN ._.
In_IN November_NNP 2002_CD ,_, the_DT FASB_NNP published_VBD Interpretation_NNP no._NNP ._.
45_CD ,_, Consolidated_NNP statement_NN of_IN cash_NN ows_VBZ Guarantors_NNP Accounting_NNP and_CC Disclosures_NNS requirements_NNS for_IN The_DT US_NNP GAAP_NNP cash_NN ow_NN statement_NN reports_NNS changes_NNS in_IN cash_NN and_CC Guarantees_NNS ,_, Including_VBG Indirect_NNP Guarantees_NNP of_IN Indebtedness_NNP of_IN cash_NN equivalents_NNS ,_, which_WDT includes_VBZ short-term_JJ highly_RB liquid_JJ Others_NNS FIN_NNP 45_CD ._.
FIN_NNP 45_CD expands_VBZ on_IN the_DT accounting_NN guidance_NN of_IN investments_NNS with_IN original_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ._.
FIN_NNP 45s_NNS provisions_NNS for_IN initial_JJ recognition_NN and_CC Only_RB three_CD categories_NNS of_IN cash_NN ows_NNS are_VBP reported_VBN :_: operating_VBG measurement_NN should_MD be_VB applied_VBN to_TO guarantees_NNS issued_VBN or_CC modied_VBN activities_NNS including_VBG tax_NN and_CC interest_NN :_: investing_VBG activities_NNS including_VBG after_IN 31st_CD December_NNP 2002_CD ._.
The_DT disclosure_NN requirements_NNS are_VBP effective_JJ capital_NN expenditure_NN ,_, acquisitions_NNS and_CC disposals_NNS together_RB with_IN for_IN financial_JJ years_NNS ending_VBG after_IN 15th_JJ December_NNP 2002_CD ._.
The_DT Group_NNP cash_NN ows_VBZ from_IN available_JJ for_IN sale_NN current_JJ asset_NN investments_NNS :_: does_VBZ not_RB believe_VB that_IN the_DT adoption_NN of_IN FIN_NNP 45_CD will_MD have_VB a_DT material_NN and_CC nancing_NN activities_NNS including_VBG dividends_NNS paid_VBN ._.
A_DT statement_NN impact_NN on_IN its_PRP$ results_NNS ._.
of_IN cash_NN ows_NNS is_VBZ presented_VBN on_IN page_NN 128_CD ._.
In_IN January_NNP 2003_CD ,_, the_DT FASB_NNP published_VBD Interpretation_NNP no._NNP ._.
46_CD Consolidation_NN of_IN Variable_JJ Interest_NN Entities_NNS FIN_NNP 46_CD ._.
Under_IN FIN_NNP 46_CD Cash_NN and_CC cash_NN equivalents_NNS the_DT primary_JJ beneciary_NN of_IN the_DT entity_NN must_MD consolidate_VB certain_JJ Under_IN UK_NNP GAAP_NNP the_DT cash_NN balance_NN includes_VBZ only_RB cash_NN at_IN bank_NN and_CC entities_NNS known_VBN as_IN Variable_JJ Interest_NN Entities_NNS ._.
The_DT measurement_NN other_JJ cash_NN balances_NNS ._.
Under_IN US_NNP GAAP_NNP cash_NN and_CC cash_NN equivalents_NNS principles_NNS will_MD apply_VB to_TO the_DT Groups_NNS 2003_CD Financial_NNP statements_NNS ._.
The_DT include_VBP cash_NN at_IN bank_NN and_CC certain_JJ liquid_JJ investments_NNS with_IN original_JJ Group_NNP does_VBZ not_RB believe_VB that_IN the_DT adoption_NN of_IN FIN_NNP 46_CD will_MD have_VB a_DT maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ._.
material_NN impact_NN on_IN its_PRP$ results_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 125_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD 2002_CD 2001_CD Consolidated_NNP balance_NN sheet_NN under_IN US_NNP GAAP_NNP m_FW m_FW Assets_NNPS Current_JJ assets_NNS Cash_NN and_CC cash_NN equivalents_NNS 1,082_CD 832_CD Marketable_JJ securities_NNS 1,466_CD 1,647_CD Accounts_NNPS and_CC notes_VBZ receivable_JJ 3,657_CD 3,647_CD Inventories_NNS 2,080_CD 2,090_CD Prepaid_NN expenses_NNS 862_CD 744_CD Deferred_JJ income_NN taxes_NNS 1,133_CD 1,242_CD Total_JJ current_JJ assets_NNS 10,280_CD 10,202_CD Goodwill_NNP 18,160_CD 18,102_CD Intangible_JJ assets_NNS 19,961_CD 24,223_CD Property_NN ,_, plant_NN and_CC equipment_NN 6,864_CD 7,015_CD Investments_NNP in_IN afliates_NNS 1,033_CD 1,038_CD Other_JJ assets_NNS 1,055_CD 491_CD Deferred_JJ income_NN taxes_NNS 318_CD 270_CD Total_JJ assets_NNS 57,671_CD 61,341_CD Liabilities_NNPS and_CC Shareholders_NNP equity_NN Current_JJ liabilities_NNS Cash_NN overdrafts_NNS 193_CD 230_CD Accounts_NNPS payable_JJ 715_CD 760_CD Short-term_JJ borrowings_NNS and_CC capital_NN lease_NN obligations_NNS 1,358_CD 1,894_CD Income_NN taxes_NNS 1,449_CD 1,672_CD Dividends_NNS payable_JJ 538_CD 555_CD Deferred_JJ income_NN taxes_NNS 113_CD 113_CD Other_JJ accrued_VBN liabilities_NNS 3,801_CD 3,601_CD Total_JJ current_JJ liabilities_NNS 8,167_CD 8,825_CD Long-term_JJ borrowings_NNS and_CC capital_NN lease_NN obligations_NNS 3,092_CD 2,108_CD Other_JJ liabilities_NNS 4,197_CD 1,747_CD Deferred_JJ income_NN taxes_NNS 6,486_CD 7,692_CD Total_JJ liabilities_NNS 21,942_CD 20,372_CD Minority_NNP interest_NN 807_CD 862_CD Contingent_JJ liabilities_NNS and_CC commitments_NNS Notes_NNS 24_CD and_CC 26_CD Shareholders_NNS equity_NN Common_JJ stock_NN ,_, 0.25_CD per_IN share_NN par_JJ value_NN :_: 10,000,000,000_CD shares_NNS authorised_VBN :_: 6,024,266,345_CD 2002_CD and_CC 6,172,965,989_CD 2001_CD shares_NNS issued_VBN 1,506_CD 1,543_CD Redeemable_JJ preference_NN shares_NNS ,_, 1.00_CD per_IN share_NN par_JJ value_NN :_: 50,000_CD shares_NNS authorised_VBN ,_, nil_NN 2002_CD and_CC nil_NN 2001_CD shares_NNS outstanding_JJ Additional_JJ paid-in_NN capital_NN 43,749_CD 45,532_CD Retained_VBN deficit_NN and_CC cumulative_JJ other_JJ comprehensive_JJ loss_NN 7,266_CD 3,794_CD Treasury_NNP stock_NN 3,067_CD 3,174_CD Total_JJ shareholders_NNS equity_NN 34,922_CD 40,107_CD Total_JJ liabilities_NNS and_CC shareholders_NNS equity_NN 57,671_CD 61,341_CD Certain_NNP items_NNS for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2001_CD have_VBP been_VBN reclassied_VBN for_IN comparative_JJ purposes_NNS ._.
126_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD 2002_CD GlaxoGlaxoSmithKline_NNP US_NNP GAAP_NNP SmithKline_NNP UK_NNP GAAP_NNP adjustments_NNS US_NNP GAAP_NNP Reconciliation_NNP of_IN consolidated_JJ income_NN statement_NN m_NN m_FW m_FW Revenues_NNS 21,212_CD 21,212_CD Cost_NN of_IN sales_NNS 4,609_CD 13_CD 4,596_CD Gross_NNP profit_NN 16,603_CD 13_CD 16,616_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenditure_NN 8,041_CD 347_CD 8,388_CD Research_NNP and_CC development_NN expenditure_NN 2,900_CD 85_CD 2,985_CD Trading_NN profit_NN 5,662_CD 419_CD 5,243_CD Other_JJ operating_NN income_NN expense_NN 111_CD 71_CD 40_CD Amortisation_NNP and_CC impairment_NN of_IN goodwill_NN and_CC intangible_JJ assets_NNS 4,195_CD 4,195_CD Write-off_NN in-process_JJ R&D_NNP acquired_VBD Product_NNP divestments_VBZ 11_CD 7_CD 18_CD Merger_NN transaction_NN costs_NNS Operating_VBG profit_NN 5,562_CD 4,536_CD 1,026_CD Share_NN of_IN profits_NNS losses_NNS of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 75_CD 6_CD 81_CD profit_NN loss_NN on_IN disposal_NN of_IN interest_NN in_IN associate_JJ Disposal_NNP of_IN businesses_NNS 10_CD 10_CD profit_NN before_IN interest_NN 5,647_CD 4,530_CD 1,117_CD Net_JJ interest_NN expense_NN 141_CD 51_CD 192_CD profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 5,506_CD 4,581_CD 925_CD Taxation_NNP 1,461_CD 1,169_CD 292_CD profit_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN 4,045_CD 3,412_CD 633_CD Minority_NNP interests_NNS 110_CD 110_CD Preference_NN share_NN dividends_NNS 20_CD 20_CD Net_JJ income_NN loss_NN before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 3,915_CD 3,412_CD 503_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 90_CD 90_CD Net_JJ income_NN loss_NN 3,915_CD 3,502_CD 413_CD Basic_JJ and_CC diluted_JJ net_JJ income_NN loss_NN per_IN share_NN before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP pence_NN 8.5_CD p_NN Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS per_IN share_NN under_IN US_NNP GAAP_NNP pence_NN 1.5_CD p_NN Basic_JJ and_CC diluted_JJ net_JJ income_NN loss_NN per_IN share_NN after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP pence_NN 7.0_CD p_NN Basic_JJ and_CC diluted_JJ net_JJ income_NN loss_NN per_IN ADS_NNPS before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP $_$ $_$ 0.26_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS per_IN ADS_NNPS under_IN US_NNP GAAP_NNP $_$ $_$ 0.05_CD Basic_JJ and_CC diluted_JJ net_JJ income_NN loss_NN per_IN ADS_NNPS after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP $_$ $_$ 0.21_CD Consolidated_NNP statement_NN of_IN comprehensive_JJ income_NN and_CC 2002_CD changes_NNS in_IN shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP m_NN Shareholders_NNS equity_NN at_IN beginning_NN of_IN year_NN 40,107_CD Net_JJ income_NN loss_NN 413_CD Exchange_NNP movements_NNS on_IN overseas_JJ net_JJ assets_NNS 73_CD Unrealised_JJ loss_NN gain_NN on_IN equity_NN investments_NNS ,_, net_NN of_IN tax_NN 83_CD Unrealised_NNP gain_NN loss_NN on_IN liquid_JJ investments_NNS ,_, net_NN of_IN tax_NN 7_CD Unrealised_NNP gain_NN on_IN derivatives_NNS 61_CD Minimum_NNP pension_NN liability_NN 1,446_CD Cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN principle_NN Comprehensive_JJ loss_NN income_NN 1,121_CD Dividends_NNPS 2,310_CD Shares_NNP purchased_VBD and_CC canceled_VBD 2,220_CD Shares_NNS issued_VBN 56_CD Employee_NNP Share_NNP Ownership_NNP Plan_NNP 58_CD Shares_NNP issued_VBN to_TO purchase_VB SmithKline_NNP Beecham_NNP Other_JJ 352_CD Shareholders_NNS equity_NN at_IN end_NN of_IN year_NN 34,922_CD Certain_NNP items_NNS for_IN the_DT years_NNS ended_VBN 31st_CD December_NNP 2000_CD and_CC 2001_CD have_VBP been_VBN reclassied_VBN for_IN comparative_JJ purposes_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 127 2001 2000_CD Less_RBR SmithKline_NNP GlaxoGlaxoBeecham_NNP SmithKline_NNP US_NNP GAAP_NNP GlaxoSmithKline_NNP pre-acquisition_JJ US_NNP GAAP_NNP GlaxoUK_NNP GAAP_NNP adjustments_NNS SmithKline_NNP UK_NNP GAAP_NNP UK_NNP GAAP_NNP adjustments_NNS SmithKline_NNP restated_VBN restated_VBN US_NNP GAAP_NNP restated_VBD restated_VBN restated_VBN US_NNP GAAP_NNP m_FW m_FW m_FW m_FW m_FW m_FW m_FW 20,489_CD 20,489_CD 18,079_CD 8,520_CD 9,559_CD 4,733_CD 324_CD 5,057_CD 3,962_CD 1,802_CD 32_CD 2,192_CD 15,756_CD 324_CD 15,432_CD 14,117_CD 6,718_CD 32_CD 7,367_CD 8,408_CD 28_CD 8,436_CD 7,136_CD 3,578_CD 65_CD 3,623_CD 2,651_CD 140_CD 2,791_CD 2,526_CD 1,158_CD 28_CD 1,396_CD 4,697_CD 492_CD 4,205_CD 4,455_CD 1,982_CD 125_CD 2,348_CD 37_CD 75_CD 38_CD 274_CD 23_CD 251_CD 3,577_CD 3,577_CD 725_CD 725_CD 6,324_CD 6,324_CD 1,416_CD 1,422_CD 6_CD 121_CD 55_CD 66_CD 4,734_CD 4,144_CD 590_CD 6,024_CD 3,372_CD 7,108_CD 4,456_CD 71_CD 71_CD 57_CD 57_CD 96_CD 117 21 144 144_CD 296_CD 204_CD 92_CD 14_CD 14_CD 4,605_CD 4,057_CD 548_CD 6,211_CD 3,415_CD 7,108_CD 4,312_CD 88_CD 34_CD 54_CD 182_CD 95_CD 87_CD 4,517_CD 4,023_CD 494_CD 6,029_CD 3,320_CD 7,108_CD 4,399_CD 1,333_CD 827_CD 506_CD 1,747_CD 956_CD 17_CD 808_CD 3,184_CD 3,196_CD 12_CD 4,282_CD 2,364_CD 7,125_CD 5,207_CD 97_CD 97_CD 120_CD 99_CD 21_CD 34_CD 34_CD 56_CD 56_CD 3,053_CD 3,196_CD 143_CD 4,106_CD 2,209_CD 7,125_CD 5,228_CD 3,053_CD 3,196_CD 143_CD 4,106_CD 2,209_CD 7,125_CD 5,228_CD 2.4_CD p_NN 145.6_CD p_NN 2.4_CD p_NN 145.6_CD p_VBP $_$ 0.07_CD $_$ 4.43_CD $_$ 0.07_CD $_$ 4.43_CD 2001_CD 2000_CD m_NN m_NN 44,995_CD 7,230_CD 143_CD 5,228_CD 107 88 381 356_CD 1_CD 1_CD 24_CD 5_CD 603_CD 4,783_CD 2,872_CD 1,334_CD 1,274_CD 144 121 501 472_CD 43,919_CD 218_CD 314_CD 40,107_CD 44,995_CD 128_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD 2002 2001 2000_CD Consolidated_NNP statement_NN of_IN cash_NN ows_NNS under_IN US_NNP GAAP_NNP m_FW m_FW m_FW Cash_NN ows_VBZ from_IN operating_VBG activities_NNS Net_JJ income_NN loss_NN 413_CD 143_CD 5,228_CD Adjustments_NNS to_TO reconcile_VB net_JJ income_NN to_TO net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS :_: Depreciation_NN 755 742 427_CD Amortisation_NNP of_IN intangible_JJ assets_NNS 1,781_CD 3,577_CD 735_CD Write-off_NN in-process_JJ R&D_NNP acquired_VBD 6,324_CD Impairment_NN of_IN goodwill_NN ,_, tangible_JJ and_CC intangible_JJ xed_JJ assets_NNS 2,829_CD 253_CD 47_CD Gain_NN loss_NN on_IN sale_NN of_IN xed_JJ assets_NNS and_CC other_JJ productive_JJ assets_NNS 46_CD 99_CD 152_CD Deferred_JJ taxes_NNS 1,216_CD 877_CD 28_CD Stock_NNP compensation_NN 331 162 254_CD Tax_NNP benefit_NN from_IN exercise_NN of_IN stock_NN options_NNS 13_CD 56_CD 9_CD Income_NN in_IN associate_JJ 75_CD 71_CD Loss_NN on_IN sale_NN of_IN associate_NN and_CC investment_NN 5_CD Derivatives_NNS 8_CD 15_CD Other_JJ 41_CD 93_CD Changes_NNS in_IN operating_VBG assets_NNS and_CC liabilities_NNS ,_, net_NN of_IN acquisitions_NNS :_: Increase_VB decrease_NN in_IN inventory_NN 2_CD 550_CD 21_CD Increase_VBP in_IN trade_NN and_CC other_JJ debtors_NNS 72_CD 77_CD 281_CD Increase_VBP in_IN trade_NN and_CC other_JJ creditors_NNS 426 368 444_CD Increase_VBP decrease_NN in_IN pension_NN and_CC other_JJ provisions_NNS 257_CD 80_CD 92_CD Net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS 5,345_CD 4,606_CD 2,536_CD Cash_NN ows_VBZ from_IN investing_VBG activities_NNS Acquisition_NNP of_IN xed_JJ assets_NNS 1,080_CD 1,111_CD 416_CD Acquisition_NNP of_IN intangible_JJ assets_NNS 5_CD 80_CD 76_CD Acquisition_NNP of_IN SmithKline_NNP Beecham_NNP cash_NN received_VBD on_IN acquisition_NN 1,129_CD Acquisition_NNP of_IN other_JJ new_JJ businesses_NNS net_NN of_IN cash_NN acquired_VBN 17_CD 803_CD 24_CD Proceeds_NNS from_IN disposition_NN of_IN xed_JJ assets_NNS and_CC businesses_NNS 61_CD 211_CD 12_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ xed_JJ assets_NNS 6_CD Increase_VBP decrease_NN in_IN equity_NN investments_NNS 10_CD 92_CD 194_CD Net_JJ cash_NN used_VBN in_IN provided_VBN by_IN investing_VBG activities_NNS 1,051_CD 1,685_CD 819_CD Cash_NN ows_VBZ from_IN nancing_VBG activities_NNS Increase_VB decrease_NN in_IN liquid_JJ investments_NNS 34_CD 1,006_CD 235_CD Proceeds_NNS from_IN additional_JJ borrowings_NNS 1,094_CD 973_CD Reduction_NN in_IN debt_NN 89_CD 112_CD 3_CD Purchase_NN of_IN treasury_NN stock_NN 795_CD 471_CD Dividends_NNPS paid_VBD 2,432_CD 2,454_CD 1,334_CD Net_JJ repayment_NN of_IN short-term_JJ loans_NNS 408 718 193_CD Net_JJ repayment_NN of_IN increase_NN in_IN cash_NN overdrafts_NNS 27_CD 38_CD 121_CD Redemption_NN of_IN preference_NN shares_NNS issued_VBN by_IN a_DT subsidiary_NN 457_CD Ordinary_NNP shares_NNS purchased_VBD for_IN cancellation_NN 2,220_CD 1,274_CD Issue_NN of_IN share_NN capital_NN 114 338 121_CD Other_JJ 28_CD 13_CD Net_JJ cash_NN used_VBN in_IN nancing_VBG activities_NNS 4,002_CD 3,483_CD 2,223_CD Net_JJ increase_NN decrease_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 292_CD 562_CD 1,132_CD Exchange_NNP rate_NN movements_NNS 42_CD 15_CD 1_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN year_NN 832_CD 1,379_CD 246_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN year_NN 1,082_CD 832_CD 1,379_CD Supplemental_NNP cash_NN ow_NN information_NN Cash_NN paid_VBN during_IN the_DT year_NN for_IN :_: Interest_NN 215 196 235_CD Income_NN taxes_NNS 1,633_CD 1,717_CD 635_CD Non-cash_JJ investing_NN and_CC nancing_NN activities_NNS Under_IN the_DT purchase_NN acquisition_NN dated_VBN 27th_JJ December_NNP 2000_CD the_DT Group_NNP acquired_VBD all_PDT the_DT outstanding_JJ shares_NNS of_IN SmithKline_NNP Beecham_NNP in_IN exchange_NN for_IN shares_NNS of_IN GlaxoSmithKline_NNP ._.
In_IN conjunction_NN with_IN the_DT acquisition_NN ,_, liabilities_NNS were_VBD assumed_VBN as_IN follows_VBZ :_: Fair_NNP value_NN of_IN assets_NNS acquired_VBN 57,158_CD Fair_NNP value_NN of_IN shares_NNS issued_VBN 43,919_CD Fair_NNP value_NN of_IN liabilities_NNS assumed_VBD 13,239_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 129_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO profit_VB and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
These_DT adjustments_NNS have_VBP been_VBN reected_VBN in_IN the_DT income_NN statements_NNS and_CC balance_NN sheets_NNS presented_VBN in_IN accordance_NN with_IN US_NNP GAAP_NNP ._.
2001 2000 2002_CD restated_VBN restated_JJ profit_NN m_NN m_FW m_FW profit_NN attributable_JJ to_TO shareholders_NNS under_IN UK_NNP GAAP_NNP 3,915_CD 3,053_CD 4,106_CD Less_RBR :_: SmithKline_NNP Beechams_NNP pre-acquisition_JJ profit_NN attributable_JJ to_TO shareholders_NNS under_IN UK_NNP GAAP_NNP and_CC merger_NN alignment_NN adjustments_NNS 2,237_CD US_NNP GAAP_NNP adjustments_NNS :_: Write-off_NN of_IN SmithKline_NNP Beecham_NNP in-process_JJ R&D_NNP acquired_VBD 6,324_CD Capitalised_VBN interest_NN 25_CD 18_CD 15_CD Computer_NN software_NN 20_CD 3_CD 13_CD Purchased_VBN intangibles_NNS 86_CD 140_CD Reversal_NN amortisation_NN of_IN goodwill_NN 18_CD 1,261_CD 559_CD Amortisation_NNP and_CC impairment_NN of_IN intangible_JJ assets_NNS 4,184_CD 2,266_CD 166_CD Recognition_NN of_IN cost_NN of_IN sales_NNS on_IN fair_JJ value_NN step-up_NN of_IN inventory_NN 298_CD Disposal_NNP of_IN purchased_VBN investment_NN 117_CD Product_NNP divestments_NNS 7_CD Loss_NN on_IN disposal_NN of_IN subsidiary_NN 204_CD Pensions_NNS and_CC post-retirement_JJ benets_NNS 138_CD 12_CD 75_CD Stock-based_JJ compensation_NN 331 162 254_CD Provision_NNP against_IN ESOT_NNP shares_NNS 51_CD 108_CD 26_CD Derivative_JJ instruments_NNS 8_CD 15_CD Restructuring_NN 37_CD 182_CD Tax_NNP benets_NNS on_IN exercise_NN of_IN US_NNP stock_NN options_NNS 13_CD 56_CD 9_CD Merger_NN transaction_NN costs_NNS 66_CD Deferred_JJ taxation_NN 1,182_CD 883_CD 20_CD Impairment_NN of_IN equity_NN investments_NNS 8_CD 75_CD Net_JJ income_NN loss_NN under_IN US_NNP GAAP_NNP before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 503_CD 143_CD 5,228_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 90_CD Net_JJ income_NN loss_NN after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 413_CD 143_CD 5,228_CD 2001_CD 2002_CD restated_VBN Equity_NNP shareholders_NNS funds_NNS m_VBP m_NN Equity_NN shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 6,581_CD 7,390_CD US_NNP GAAP_NNP adjustments_NNS :_: Tangible_JJ xed_JJ assets_NNS 49_CD 44_CD Investments_NNP 829_CD 879_CD Product_NN rights_NNS 18,590_CD 22,927_CD Capitalised_VBN interest_NN 175_CD 155_CD Computer_NN software_NN 9_CD 29_CD Goodwill_NNP 17,989_CD 17,928_CD Other_JJ intangible_JJ assets_NNS 438_CD 377_CD Unrealised_JJ gains_NNS on_IN marketable_JJ securities_NNS 113_CD 163_CD Pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS 1,198_CD 299_CD Employee_NNP Share_NNP Ownership_NNP Trust_NNP 2,826_CD 2,936_CD Restructuring_NN costs_NNS 6_CD 46_CD Derivative_JJ instruments_NNS 98_CD 29_CD Dividends_NNPS 754_CD 718_CD Deferred_JJ taxation_NN 5,779_CD 7,037_CD Shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP 34,922_CD 40,107_CD Certain_NNP items_NNS for_IN the_DT years_NNS ended_VBN 31st_CD December_NNP 2001_CD and_CC 2000_CD have_VBP been_VBN reclassied_VBN for_IN comparative_JJ purposes_NNS ._.
During_IN 2002_CD ,_, FRS_NNP 19_CD Deferred_NNP Tax_NNP has_VBZ been_VBN implemented_VBN by_IN the_DT Group_NNP under_IN UK_NNP GAAP_NNP ._.
This_DT FRS_NNP requires_VBZ deferred_JJ tax_NN to_TO be_VB accounted_VBN for_IN on_IN a_DT full_JJ provision_NN basis_NN ,_, rather_RB than_IN a_DT partial_JJ provision_NN basis_NN as_IN in_IN 2001_CD and_CC earlier_JJR years_NNS ._.
This_DT change_NN has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT prior_JJ year_NN adjustment_NN for_IN UK_NNP GAAP_NNP purposes_NNS and_CC comparative_JJ adjustments_NNS to_TO arrive_VB at_IN US_NNP GAAP_NNP have_VBP been_VBN restated_VBN as_RB necessary_JJ ._.
This_DT change_NN had_VBD no_DT impact_NN on_IN US_NNP GAAP_NNP results_NNS ._.
130_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD c_NN The_DT market_NN value_NN of_IN investments_NNS was_VBD included_VBN in_IN the_DT book_NN value_NN of_IN SmithKline_NNP Beechams_NNP net_JJ assets_NNS under_IN US_NNP GAAP_NNP ._.
The_DT increase_NN Acquisition_NNP of_IN SmithKline_NNP Beecham_NNP in_IN investments_NNS related_VBN to_TO increases_NNS in_IN the_DT fair_JJ market_NN value_NN of_IN Under_IN US_NNP GAAP_NNP ,_, the_DT Financial_NNP statements_NNS of_IN GlaxoSmithKline_NNP prior_RB to_TO non-marketable_JJ securities_NNS at_IN 31st_CD December_NNP 2000_CD ._.
Included_VBD the_DT merger_NN are_VBP those_DT of_IN Glaxo_NNP Wellcome_NNP ,_, the_DT US_NNP GAAP_NNP accounting_NN in_IN this_DT amount_NN are_VBP increases_NNS to_TO equity_NN investments_NNS ._.
The_DT acquisition_NN of_IN SmithKline_NNP Beecham_NNP is_VBZ accounted_VBN for_IN investments_NNS were_VBD measured_VBN at_IN fair_JJ value_NN and_CC any_DT excess_NN of_IN the_DT under_IN the_DT purchase_NN method_NN as_IN of_IN the_DT date_NN of_IN the_DT merger_NN ,_, fair_JJ value_NN over_IN the_DT underlying_VBG tangible_JJ assets_NNS and_CC liabilities_NNS was_VBD 27th_JJ December_NNP 2000_CD ._.
recognized_VBN as_IN goodwill_NN within_IN investments_NNS ._.
This_DT goodwill_NN is_VBZ no_RB longer_RB amortised_VBN ,_, but_CC reviewed_VBN annually_RB for_IN impairment_NN ._.
Purchase_NN accounting_NN adjustments_NNS In_IN order_NN to_TO determine_VB the_DT proper_JJ allocation_NN of_IN purchase_NN price_NN d_SYM The_DT fair_JJ value_NN attributed_VBD to_TO pension_NN obligations_NNS reected_VBD the_DT related_VBN to_TO the_DT acquired_VBN assets_NNS of_IN SmithKline_NNP Beecham_NNP under_IN US_NNP recognition_NN of_IN previously_RB unrecognised_JJ actuarial_JJ gains_NNS losses_NNS ,_, GAAP_NNP purchase_NN accounting_NN ,_, the_DT cost_NN of_IN acquisition_NN is_VBZ calculated_VBN prior_RB service_NN costs_NNS and_CC transition_NN amounts_NNS ._.
The_DT amounts_NNS recognized_VBN using_VBG the_DT market_NN value_NN of_IN the_DT shares_NNS issued_VBN ,_, the_DT fair_JJ value_NN of_IN vested_JJ were_VBD based_VBN on_IN actuarial_JJ assessments_NNS at_IN the_DT acquisition_NN date_NN ._.
options_NNS exchanged_VBD and_CC direct_JJ external_JJ acquisition_NN costs_NNS and_CC then_RB e_SYM The_DT fair_JJ value_NN attributed_VBD to_TO other_JJ intangible_JJ assets_NNS related_VBN allocated_VBN to_TO the_DT fair_JJ value_NN of_IN net_JJ assets_NNS acquired_VBN ._.
As_IN a_DT result_NN of_IN the_DT primarily_RB to_TO managements_NNS estimate_NN of_IN the_DT value_NN of_IN product_NN fair_JJ value_NN exercise_NN ,_, increases_NNS in_IN the_DT values_NNS of_IN SmithKline_NNP Beechams_NNP rights_NNS inclusive_NN of_IN their_PRP$ respective_JJ patents_NNS and_CC trade_NN marks_NNS inventory_NN ,_, tangible_JJ xed_JJ assets_NNS ,_, investments_NNS and_CC pension_NN obligations_NNS on_IN existing_VBG products_NNS and_CC of_IN the_DT assembled_VBN workforce_NN ._.
The_DT fair_JJ were_VBD recognized_VBN and_CC fair_JJ market_NN values_NNS attributed_VBD to_TO its_PRP$ other_JJ value_NN of_IN the_DT product_NN rights_NNS was_VBD determined_VBN based_VBN on_IN a_DT intangible_JJ assets_NNS ,_, mainly_RB product_NN rights_NNS inclusive_NN of_IN patents_NNS and_CC discounted_JJ net_JJ future_NN cash_NN ow_NN analysis_NN of_IN SmithKline_NNP Beechams_NNP trade_NN marks_NNS ,_, assembled_VBN workforce_NN and_CC in-process_JJ research_NN and_CC approved_VBD product_NN portfolio_NN which_WDT included_VBD all_DT existing_VBG approved_VBN development_NN ,_, together_RB with_IN appropriate_JJ deferred_VBN taxation_NN effects_NNS ._.
products_NNS within_IN the_DT pharmaceutical_JJ therapeutic_JJ areas_NNS and_CC The_DT difference_NN between_IN the_DT cost_NN of_IN acquisition_NN and_CC the_DT fair_JJ value_NN consumer_NN healthcare_NN product_NN portfolios_NNS ._.
Any_DT supplemental_JJ of_IN the_DT assets_NNS and_CC liabilities_NNS of_IN SmithKline_NNP Beecham_NNP has_VBZ been_VBN products_NNS in_IN the_DT development_NN process_NN which_WDT built_VBD upon_IN existing_VBG recorded_VBN as_IN goodwill_NN ._.
The_DT amount_NN allocated_VBN to_TO in-process_JJ research_NN chemical_NN entities_NNS within_IN existing_VBG areas_NNS and_CC which_WDT were_VBD not_RB and_CC development_NN is_VBZ required_VBN under_IN US_NNP GAAP_NNP to_TO be_VB expensed_VBN subject_JJ to_TO separate_JJ US_NNP Food_NNP and_CC Drug_NNP Administration_NNP approval_NN immediately_RB in_IN the_DT first_JJ reporting_NN period_NN after_IN the_DT business_NN were_VBD also_RB included_VBN ._.
Management_NN based_VBN the_DT estimates_NNS of_IN the_DT combination_NN ,_, which_WDT for_IN GlaxoSmithKline_NNP was_VBD the_DT period_NN ended_VBD weighted_JJ average_JJ useful_JJ life_NN of_IN the_DT product_NN rights_NNS on_IN the_DT future_JJ 31st_CD December_NNP 2000_CD ._.
Fair_NNP value_NN adjustments_NNS to_TO the_DT recorded_JJ period_NN over_IN which_WDT the_DT substantial_JJ majority_NN of_IN the_DT estimated_JJ net_JJ amount_NN of_IN inventory_NN were_VBD expensed_VBN in_IN 2001_CD and_CC additional_JJ future_JJ cash_NN ow_NN value_NN was_VBD expected_VBN to_TO be_VB realized_VBN ._.
The_DT fair_JJ value_NN amortisation_NN and_CC depreciation_NN will_MD be_VB recorded_VBN in_IN respect_NN of_IN the_DT of_IN the_DT assembled_VBN workforce_NN was_VBD reclassied_VBN to_TO goodwill_NN under_IN fair_JJ value_NN adjustments_NNS to_TO tangible_JJ and_CC intangible_JJ assets_NNS and_CC the_DT SFAS_NNP 142_CD in_IN 2002_CD and_CC will_MD be_VB reviewed_VBN annually_RB for_IN impairment_NN ._.
resulting_VBG goodwill_NN over_IN the_DT periods_NNS of_IN their_PRP$ respective_JJ economic_JJ useful_JJ lives_NNS ._.
f_LS The_DT amount_NN of_IN total_JJ consideration_NN allocated_VBN to_TO SmithKline_NNP Beechams_NNP in-process_JJ research_NN and_CC development_NN projects_NNS IPR&D_NNP The_DT adjustments_NNS to_TO the_DT assets_NNS and_CC liabilities_NNS of_IN SmithKline_NNP Beecham_NNP was_VBD estimated_VBN using_VBG current_JJ estimates_NNS of_IN the_DT status_NN and_CC to_TO reect_VB the_DT fair_JJ values_NNS and_CC allocation_NN of_IN the_DT excess_JJ purchase_NN prospects_NNS of_IN its_PRP$ R&D_NNP portfolio_NN ._.
The_DT IPR&D_NNP included_VBD only_RB those_DT consideration_NN over_IN the_DT fair_JJ value_NN of_IN net_JJ assets_NNS acquired_VBN ,_, based_VBN identied_JJ projects_NNS that_WDT had_VBD advanced_VBN to_TO a_DT stage_NN of_IN development_NN on_IN management_NN best_JJS estimates_NNS of_IN fair_JJ value_NN ,_, are_VBP summarised_VBN in_IN where_WRB management_NN believed_VBD reasonable_JJ estimates_NNS of_IN projected_VBN the_DT table_NN opposite_NN and_CC discussed_VBN below_IN :_: cash_NN ows_NNS could_MD be_VB prepared_VBN ._.
This_DT did_VBD not_RB include_VB basic_JJ a_DT The_DT total_JJ assumed_JJ purchase_NN consideration_NN was_VBD calculated_VBN discovery_NN and_CC the_DT portfolio_NN of_IN gene_NN patents_NNS ._.
The_DT reported_VBN IPR&D_NNP by_IN multiplying_VBG the_DT number_NN of_IN GlaxoSmithKline_NNP shares_NNS issued_VBN value_NN was_VBD not_RB intended_VBN to_TO reect_VB the_DT present_JJ value_NN of_IN all_DT to_TO SmithKline_NNP Beechams_NNP shareholders_NNS for_IN all_DT outstanding_JJ development_NN activities_NNS under_IN way_NN ._.
The_DT value_NN allocated_VBN to_TO the_DT SmithKline_NNP Beecham_NNP shares_NNS by_IN the_DT average_JJ fair_JJ value_NN of_IN Glaxo_NNP IPR&D_NNP was_VBD determined_VBN utilising_VBG a_DT risk_NN adjusted_VBN income_NN approach_NN Wellcome_NNP securities_NNS ._.
The_DT average_JJ fair_JJ value_NN of_IN Glaxo_NNP Wellcome_NNP that_WDT included_VBD earnings_NNS discounted_VBN by_IN the_DT appropriate_JJ cost_NN of_IN securities_NNS was_VBD calculated_VBN over_IN a_DT period_NN of_IN four_CD days_NNS prior_JJ capital_NN for_IN the_DT investment_NN ._.
Estimates_NNS of_IN future_JJ cash_NN ows_NNS related_VBN to_TO and_CC subsequent_JJ to_TO the_DT announcement_NN of_IN the_DT merger_NN on_IN to_TO individual_JJ IPR&D_NNP projects_NNS were_VBD based_VBN on_IN existing_VBG estimates_NNS of_IN 17th_JJ January_NNP 2000_CD ._.
The_DT total_JJ assumed_JJ purchase_NN consideration_NN revenues_NNS and_CC contribution_NN margin_NN for_IN the_DT project_NN ._.
also_RB included_VBD the_DT fair_JJ value_NN of_IN SmithKline_NNP Beecham_NNP vested_JJ g_NN Additional_JJ liabilities_NNS related_VBN to_TO restructuring_VBG costs_NNS directly_RB linked_VBN options_NNS exchanged_VBD for_IN vested_JJ options_NNS in_IN GlaxoSmithKline_NNP ._.
to_TO plans_NNS that_WDT were_VBD in_IN place_NN at_IN the_DT date_NN of_IN the_DT acquisition_NN ._.
These_DT The_DT total_JJ number_NN of_IN SmithKline_NNP Beecham_NNP vested_JJ options_NNS was_VBD liabilities_NNS reected_VBD the_DT costs_NNS to_TO close_VB certain_JJ SmithKline_NNP Beecham_NNP multiplied_VBD by_IN the_DT respective_JJ fair_JJ value_NN of_IN each_DT of_IN the_DT ordinary_JJ manufacturing_NN sites_NNS and_CC redundancy_NN costs_NNS ._.
The_DT other_JJ liabilities_NNS shares_NNS and_CC ADR_NNP plans_VBZ determined_VBN at_IN 17th_JJ January_NNP 2000_CD ._.
related_VBN to_TO additional_JJ deferred_VBN tax_NN liabilities_NNS previously_RB not_RB b_NN The_DT increase_NN in_IN fair_JJ value_NN of_IN inventory_NN and_CC xed_VBD assets_NNS was_VBD recognized_VBN ._.
determined_VBN based_VBN on_IN the_DT difference_NN between_IN the_DT carrying_VBG h_NN Deferred_JJ taxes_NNS were_VBD computed_VBN on_IN the_DT excess_NN of_IN fair_JJ value_NN over_IN value_NN and_CC the_DT market_NN value_NN of_IN these_DT assets_NNS ._.
The_DT increase_NN to_TO book_NN value_NN ,_, other_JJ than_IN for_IN goodwill_NN and_CC in-process_JJ research_NN and_CC inventory_NN was_VBD expensed_VBN in_IN 2001_CD ,_, as_IN all_DT inventory_NN was_VBD sold_VBN ._.
The_DT development_NN ,_, using_VBG the_DT applicable_JJ weighted_JJ average_JJ statutory_JJ increase_NN in_IN xed_JJ assets_NNS was_VBD allocated_VBN to_TO its_PRP$ respective_JJ category_NN tax_NN rates_NNS ._.
and_CC is_VBZ being_VBG depreciated_VBN over_IN the_DT remaining_VBG useful_JJ lives_NNS of_IN these_DT assets_NNS ._.
i_FW Goodwill_NNP represents_VBZ the_DT remainder_NN of_IN unallocated_JJ purchase_NN consideration_NN and_CC now_RB includes_VBZ the_DT value_NN originally_RB allocated_VBN to_TO workforce_NN ._.
Goodwill_NN is_VBZ no_RB longer_RB amortised_VBN under_IN SFAS_NNP 142_CD ,_, but_CC rather_RB reviewed_VBN annually_RB for_IN impairment_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 131_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Purchase_NNP accounting_NN adjustments_NNS m_VBP Total_JJ assumed_VBD purchase_NN consideration_NN for_IN outstanding_JJ shares_NNS a_DT 43,919_CD Costs_NNS and_CC fees_NNS of_IN transaction_NN 66_CD Less_RBR :_: Book_NNP value_NN of_IN SmithKline_NNP Beecham_NNP net_JJ assets_NNS US_NNP GAAP_NNP less_JJR goodwill_NN 2,742_CD Excess_NNP fair_JJ value_NN of_IN inventory_NN b_NN 267_CD Excess_NNPS fair_JJ value_NN of_IN tangible_JJ xed_JJ assets_NNS b_NN 15_CD Excess_NNP fair_JJ value_NN of_IN investments_NNS c_NN 1,042_CD Excess_NNP fair_JJ value_NN of_IN pension_NN asset_NN d_SYM 81_CD Fair_NNP value_NN attributed_VBD to_TO other_JJ intangible_JJ assets_NNS e_LS 24,382_CD Fair_NNP value_NN attributed_VBD to_TO workforce_NN now_RB considered_VBN goodwill_NN e_SYM 483_CD Fair_NNP value_NN attributed_VBD to_TO in-process_JJ R&D_NNP projects_NNS f_LS 6,324_CD Additional_JJ liabilities_NNS assumed_VBD g_RB 110_CD Deferred_JJ tax_NN liabilities_NNS related_VBN to_TO purchase_VB price_NN adjustments_NNS h_VBP 7,669_CD Goodwill_NNP i_FW 16,428_CD 132_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD The_DT following_JJ tables_NNS present_JJ details_NNS of_IN the_DT Groups_NNS total_VBP purchased_VBN identiable_JJ intangible_JJ assets_NNS which_WDT are_VBP subject_JJ to_TO amortisation_NN ._.
Accumulated_VBN 31st_JJ December_NNP 2002_CD Gross_NNP amortisation_NN Impairment_NNP Net_NNP m_FW m_FW m_FW m_FW Product_NN rights_NNS 20,120_CD 3,693_CD 2,076_CD 14,351_CD Brands_NNP 1,151_CD 58_CD 1,093_CD Total_JJ 21,271_CD 3,751_CD 2,076_CD 15,444_CD Following_VBG the_DT launch_NN in_IN the_DT USA_NNP of_IN a_DT generic_JJ Augmentin_NNP product_NN ,_, the_DT carrying_VBG value_NN of_IN product_NN rights_NNS relating_VBG to_TO Augmentin_NNP has_VBZ been_VBN reviewed_VBN and_CC an_DT impairment_NN of_IN 1,667_CD million_CD recorded_VBN ._.
The_DT carrying_VBG values_NNS of_IN certain_JJ other_JJ product_NN rights_NNS have_VBP also_RB been_VBN reviewed_VBN and_CC an_DT impairment_NN of_IN 409_CD million_CD recorded_VBN ._.
Fair_NNP values_NNS were_VBD determined_VBN using_VBG a_DT discounted_JJ cash_NN ow_NN model_NN ._.
As_IN discussed_VBN in_IN Note_NN 30_CD Legal_NNP proceedings_NNS ,_, a_DT number_NN of_IN distributors_NNS of_IN generic_JJ drugs_NNS have_VBP led_VBN applications_NNS to_TO market_NN generic_JJ versions_NNS of_IN Paxil_NNP in_IN the_DT USA_NNP prior_RB to_TO the_DT expiration_NN of_IN the_DT Groups_NNS patent_NN ._.
The_DT carrying_VBG value_NN of_IN the_DT Paxil_NNP product_NN rights_NNS under_IN US_NNP GAAP_NNP is_VBZ 3.6_CD billion_CD at_IN 31st_CD December_NNP 2002_CD ._.
The_DT Group_NNP will_MD continue_VB to_TO keep_VB the_DT position_NN under_IN review_NN ._.
Accumulated_VBN 31st_JJ December_NNP 2001_CD Gross_NNP amortisation_NN Impairment_NNP Net_NNP m_FW m_FW m_FW m_FW Product_NN rights_NNS 20,116_CD 1,865_CD 18,251_CD Brands_NNP 1,151_CD 29_CD 1,122_CD Total_JJ 21,267_CD 1,894_CD 19,373_CD The_DT estimated_JJ future_JJ amortisation_NN expense_NN for_IN the_DT next_JJ five_CD years_NNS for_IN purchased_VBN identiable_JJ intangible_JJ assets_NNS subject_JJ to_TO amortisation_NN as_IN of_IN 31st_CD December_NNP 2002_CD is_VBZ as_IN follows_VBZ :_: Year_NN m_NN 2003_CD 1,636_CD 2004_CD 1,629_CD 2005_CD 1,629_CD 2006_CD 1,588_CD 2007_CD 1,574_CD Total_JJ 8,056_CD Carrying_VBG amount_NN of_IN identiable_JJ intangible_JJ assets_NNS which_WDT are_VBP not_RB subject_JJ to_TO amortisation_NN 2002_CD 2001_CD m_NN m_NNP Brands_NNP 4,345_CD 4,850_CD Following_VBG the_DT initial_JJ implementation_NN of_IN SFAS_NNP 142_CD in_IN 2002_CD ,_, the_DT carrying_VBG values_NNS of_IN the_DT brands_NNS determined_VBD to_TO have_VB indefinite_JJ lives_NNS were_VBD reviewed_VBN and_CC an_DT impairment_NN of_IN 173_CD million_CD 127_CD million_CD net_NN of_IN tax_NN was_VBD recognized_VBN ._.
This_DT is_VBZ recorded_VBN as_IN a_DT cumulative_JJ effect_NN of_IN a_DT change_NN in_IN accounting_NN principle_NN ._.
In_IN addition_NN ,_, a_DT 332_CD million_CD charge_NN was_VBD recognized_VBN during_IN 2002_CD as_IN a_DT result_NN of_IN changes_NNS in_IN market_NN conditions_NNS and_CC management_NN forecasts_NNS for_IN certain_JJ brand_NN intangibles_NNS ._.
The_DT following_JJ table_NN presents_VBZ the_DT changes_NNS in_IN goodwill_NN allocated_VBN to_TO the_DT Groups_NNS reportable_JJ segments_NNS during_IN 2002_CD ._.
The_DT carrying_VBG value_NN of_IN the_DT assembled_VBN workforce_NN at_IN 31st_CD December_NNP 2001_CD ,_, net_NN of_IN tax_NN ,_, has_VBZ been_VBN reclassied_VBN into_IN opening_VBG balance_NN of_IN goodwill_NN in_IN accordance_NN with_IN SFAS_NNP 142_CD ._.
At_IN 31.12.01_CD Acquired_VBN Impairment_NNP Exchange_NNP At_IN 31.12.02_CD m_FW m_FW m_FW m_FW m_FW Pharmaceuticals_NNPS 15,670_CD 23_CD 14_CD 15,679_CD Consumer_NN Healthcare_NNP 2,503_CD 22_CD 2,481_CD Total_JJ 18,173_CD 23_CD 36_CD 18,160_CD If_IN the_DT Group_NNP had_VBD accounted_VBN for_IN goodwill_NN and_CC identiable_JJ intangible_JJ assets_NNS that_WDT have_VBP indefinite_JJ lives_NNS under_IN SFAS_NNP 142_CD for_IN the_DT years_NNS ended_VBN 31st_CD December_NNP 2000_CD and_CC 2001_CD ,_, the_DT impact_NN on_IN reported_VBN US_NNP GAAP_NNP results_NNS would_MD have_VB been_VBN as_IN follows_VBZ :_: 2001_CD 2000_CD m_NN m_NN Net_JJ income_NN under_IN US_NNP GAAP_NNP 143_CD 5,228_CD Amortisation_NNP ,_, net_NN of_IN tax_NN :_: Goodwill_NNP 1,475_CD 570_CD Brands_NNP 124_CD Adjusted_JJ net_JJ income_NN under_IN US_NNP GAAP_NNP 1,456_CD 4,658_CD Adjusted_VBN basic_JJ net_JJ income_NN per_IN share_NN pence_NN 24.0_CD 129.7_CD Adjusted_VBN diluted_JJ net_JJ income_NN per_IN share_NN pence_NN 23.8_CD 129.7_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 133_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Earnings_NNS per_IN share_NN under_IN US_NNP GAAP_NNP 2002 2001 2000_CD Weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN millions_NNS millions_NNS millions_NNS Basic_JJ 5,912_CD 6,064_CD 3,591_CD Adjustments_NNS :_: Share_NN options_NNS 22_CD 52_CD 35_CD Diluted_NNP 5,934_CD 6,116_CD 3,626_CD Shares_NNS held_VBN by_IN the_DT Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS are_VBP excluded_VBN from_IN shares_NNS in_IN issue_NN ._.
Taxation_NNP 2001 2000 2002_CD restated_VBN restated_VBN Total_JJ tax_NN expense_NN m_NN m_FW m_FW UK_NNP GAAP_NNP :_: Current_JJ tax_NN expense_NN 1,432_CD 1,386_CD 808_CD Deferred_JJ tax_NN expense_NN 29_CD 53_CD 17_CD Total_JJ tax_NN expense_NN 1,461_CD 1,333_CD 791_CD US_NNP GAAP_NNP :_: Current_JJ tax_NN expense_NN 1,445_CD 1,442_CD 817_CD Deferred_JJ tax_NN expense_NN 1,737_CD 936_CD 9_CD Total_JJ tax_NN expense_NN 292 506 808_CD Deferred_JJ taxation_NN under_IN US_NNP GAAP_NNP Classication_NNP of_IN GlaxoSmithKlines_NNP deferred_VBD taxation_NN liabilities_NNS and_CC assets_NNS under_IN US_NNP GAAP_NNP is_VBZ as_IN follows_VBZ :_: 2002_CD 2001_CD m_NN m_NN Liabilities_NNP Stock_NNP valuation_NN adjustment_NN 113_CD 113_CD Current_JJ deferred_VBN taxation_NN liabilities_NNS 113_CD 113_CD Accelerated_VBN capital_NN allowances_NNS 710_CD 691_CD Product_NN rights_NNS 5,620_CD 6,126_CD Other_JJ timing_NN differences_NNS 156_CD 1,030_CD Total_JJ deferred_VBN taxation_NN liabilities_NNS 6,599_CD 7,960_CD Assets_NNS Intra-Group_JJ profit_NN 487_CD 375_CD Other_JJ timing_NN differences_NNS 646_CD 842_CD Current_JJ deferred_VBN taxation_NN assets_NNS 1,133_CD 1,217_CD Asset_NNP disposal_NN 125_CD 161_CD Pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS 111_CD 221_CD Tax_NNP losses_NNS 93_CD 97_CD Manufacturing_NNP restructuring_NN 52_CD 71_CD Legal_NNP and_CC other_JJ disputes_NNS 124_CD 25_CD Other_JJ timing_NN differences_NNS 63_CD 42_CD Total_JJ deferred_VBN taxation_NN assets_NNS 1,451_CD 1,512_CD Net_JJ deferred_VBN taxation_NN under_IN US_NNP GAAP_NNP 5,148_CD 6,448_CD The_DT difference_NN between_IN the_DT UK_NNP effective_JJ taxation_NN rate_NN and_CC the_DT US_NNP effective_JJ taxation_NN rate_NN is_VBZ primarily_RB related_VBN to_TO the_DT fair_JJ value_NN adjustments_NNS for_IN goodwill_NN and_CC intangibles_NNS related_VBN to_TO the_DT acquisitions_NNS of_IN Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP ._.
134_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Segment_NNP information_NN under_IN US_NNP GAAP_NNP Under_IN UK_NNP GAAP_NNP ,_, the_DT segment_NN information_NN presented_VBN in_IN Note_NN 6_CD includes_VBZ results_NNS of_IN operations_NNS and_CC other_JJ information_NN on_IN a_DT historical_JJ combined_VBN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP basis_NN for_IN 2002_CD ,_, 2001_CD and_CC 2000_CD ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT segment_NN information_NN for_IN results_NNS of_IN operations_NNS for_IN 2002_CD and_CC 2001_CD reect_VB the_DT merged_JJ operations_NNS of_IN GlaxoSmithKline_NNP ,_, while_IN for_IN 2000_CD it_PRP relates_VBZ to_TO Glaxo_NNP Wellcome_NNP only_RB as_IN this_DT period_NN is_VBZ ,_, for_IN practical_JJ purposes_NNS ,_, regarded_VBN as_IN being_VBG prior_RB to_TO the_DT acquisition_NN of_IN SmithKline_NNP Beecham_NNP ._.
Glaxo_NNP Wellcome_NNP operated_VBD in_IN only_RB one_CD segment_NN Pharmaceuticals_NNS ._.
Segment_NN information_NN in_IN respect_NN of_IN assets_NNS relates_VBZ to_TO Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP on_IN a_DT consolidated_JJ basis_NN at_IN 31st_CD December_NNP 2002_CD and_CC 2001_CD as_IN the_DT acquisition_NN of_IN SmithKline_NNP Beecham_NNP by_IN Glaxo_NNP Wellcome_NNP occurred_VBD on_IN 27th_JJ December_NNP 2000_CD ._.
2001 2000 2002_CD restated_VBN restated_VBN Turnover_NN by_IN location_NN of_IN customer_NN m_NN m_FW m_FW USA_NNP 10,807_CD 10,087_CD 4,314_CD Europe_NNP 6,064_CD 5,855_CD 2,959_CD International_NNP 4,341_CD 4,547_CD 2,286_CD External_NNP turnover_NN 21,212_CD 20,489_CD 9,559_CD Turnover_NN by_IN business_NN sector_NN Pharmaceuticals_NNS 17,995_CD 17,205_CD 9,559_CD Consumer_NN Healthcare_NNP 3,217_CD 3,284_CD External_NNP turnover_NN 21,212_CD 20,489_CD 9,559_CD Operating_NN profit_NN loss_NN by_IN business_NN sector_NN Pharmaceuticals_NNS 876_CD 565_CD 4,456_CD Consumer_NN Healthcare_NNP 150_CD 25_CD Operating_NN profit_NN loss_NN 1,026_CD 590_CD 4,456_CD Turnover_NN by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 11,096_CD 10,517_CD 4,494_CD Europe_NNP 10,423_CD 10,704_CD 5,375_CD International_NNP 6,824_CD 7,540_CD 3,370_CD Gross_NNP turnover_NN 28,343_CD 28,761_CD 13,239_CD USA_NNP 168 327 176_CD Europe_NNP 3,873_CD 4,372_CD 2,271_CD International_NNP 3,090_CD 3,573_CD 1,233_CD Inter-segment_NN turnover_NN 7,131_CD 8,272_CD 3,680_CD USA_NNP 10,928_CD 10,190_CD 4,318_CD Europe_NNP 6,550_CD 6,332_CD 3,104_CD International_NNP 3,734_CD 3,967_CD 2,137_CD External_NNP turnover_NN 21,212_CD 20,489_CD 9,559_CD profit_NN before_IN tax_NN by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 418_CD 938_CD 2,850_CD Europe_NNP 795_CD 1,305_CD 670_CD International_NNP 187 223 936_CD Operating_NN profit_NN loss_NN 1,026_CD 590_CD 4,456_CD Share_NN of_IN profits_NNS of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 81_CD 71_CD profit_NN loss_NN on_IN disposal_NN of_IN businesses_NNS and_CC or_CC interest_NN in_IN associates_NNS 10 113 144_CD Net_JJ interest_NN expense_NN 192_CD 54_CD 87_CD profit_NN loss_NN before_IN taxation_NN 925_CD 494_CD 4,399_CD profit_NN loss_NN before_IN taxation_NN 925_CD 494_CD 4,399_CD Taxation_NNP 292 506 808_CD Minority_NNP interests_NNS and_CC preference_NN share_NN dividends_NNS 130_CD 131_CD 21_CD Net_JJ income_NN loss_NN before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 503_CD 143_CD 5,228_CD Cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN principle_NN 90_CD Net_JJ income_NN loss_NN 413_CD 143_CD 5,228_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 135_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD 2002_CD 2001_CD Total_JJ assets_NNS by_IN business_NN sector_NN m_NN m_NN Pharmaceuticals_NNS 46,706_CD 52,391_CD Consumer_NN Healthcare_NNP 10,965_CD 8,950_CD Total_JJ assets_NNS 57,671_CD 61,341_CD Total_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 22,727_CD 25,741_CD Europe_NNP 20,982_CD 20,865_CD International_NNP 11,414_CD 12,256_CD Total_JJ operating_VBG assets_NNS 55,123_CD 58,862_CD Cash_NN and_CC cash_NN equivalents_NNS and_CC marketable_JJ securities_NNS 2,548_CD 2,479_CD Total_JJ assets_NNS 57,671_CD 61,341_CD 2002_CD 2001_CD Total_JJ liabilities_NNS by_IN business_NN sector_NN m_NN m_NN Pharmaceuticals_NNS 16,816_CD 15,757_CD Consumer_NN Healthcare_NNP 5,126_CD 4,615_CD Total_JJ liabilities_NNS 21,942_CD 20,372_CD Total_JJ liabilities_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 8,710_CD 7,971_CD Europe_NNP 9,351_CD 9,112_CD International_NNP 3,881_CD 3,289_CD Total_JJ liabilities_NNS 21,942_CD 20,372_CD 2002_CD 2001_CD Plant_NN ,_, Land_NNP and_CC equipment_NN Computer_NN Assets_NNS in_IN buildings_NNS and_CC vehicles_NNS software_NN construction_NN Total_JJ Total_JJ Tangible_JJ xed_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN m_NN m_FW m_FW m_FW m_FW m_FW USA_NNP 691_CD 379_CD 29_CD 378_CD 1,477_CD 1,611_CD Europe_NNP 1,729_CD 1,833_CD 111_CD 649_CD 4,322_CD 4,210_CD International_NNP 533_CD 370_CD 11_CD 151_CD 1,065_CD 1,194_CD Total_JJ 2,953_CD 2,582_CD 151_CD 1,178_CD 6,864_CD 7,015_CD UK_NNP segment_NN Information_NN is_VBZ given_VBN separately_RB in_IN respect_NN of_IN the_DT UK_NNP ,_, which_WDT ,_, although_IN included_VBN in_IN the_DT Groups_NNS Europe_NNP market_NN region_NN ,_, is_VBZ considered_VBN the_DT Groups_NNS home_NN segment_NN for_IN the_DT purposes_NNS of_IN segmental_JJ reporting_NN ._.
2002 2001 2000_CD m_FW m_FW m_FW Turnover_NN by_IN location_NN of_IN customer_NN 1,366_CD 1,328_CD 474_CD Gross_NNP turnover_NN 4,945_CD 5,388_CD 1,241_CD Inter-segment_NN turnover_NN 3,230_CD 3,753_CD 562_CD Turnover_NN by_IN location_NN of_IN subsidiary_NN 1,715_CD 1,635_CD 679_CD Operating_NN profit_NN 373 321 370_CD Total_JJ assets_NNS 8,253_CD 6,962_CD 136_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Pensions_NNS under_IN US_NNP GAAP_NNP The_NNP SFAS_NNP 132_CD disclosures_NNS for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD and_CC 2001_CD are_VBP provided_VBN in_IN relation_NN to_TO the_DT employees_NNS of_IN GlaxoSmithKline_NNP ._.
For_IN 2000_CD the_DT income_NN statement_NN disclosures_NNS are_VBP provided_VBN in_IN relation_NN to_TO the_DT employees_NNS of_IN Glaxo_NNP Wellcome_NNP only_RB ._.
During_IN 2002_CD ,_, the_DT Group_NNP decided_VBD to_TO align_VB the_DT measurement_NN date_NN for_IN all_DT of_IN its_PRP$ pension_NN plans_NNS ._.
As_IN certain_JJ of_IN the_DT Groups_NNS pension_NN plans_NNS had_VBD a_DT measurement_NN date_NN for_IN pension_NN assets_NNS and_CC liabilities_NNS of_IN 30th_JJ September_NNP ,_, the_DT Group_NNP elected_VBD to_TO change_VB the_DT measurement_NN date_NN for_IN these_DT plans_NNS from_IN 30th_JJ September_NNP to_TO 31st_VB December_NNP ._.
As_IN a_DT result_NN ,_, included_VBD in_IN 2002_CD net_JJ loss_NN is_VBZ a_DT 49_CD million_CD credit_NN to_TO income_NN 37_CD million_CD net_NN of_IN tax_NN ,_, treated_VBN as_IN the_DT cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN principle_NN ._.
The_DT average_JJ number_NN of_IN persons_NNS employed_VBN by_IN the_DT Group_NNP 2002 2001 2000_CD including_VBG Directors_NNS during_IN the_DT year_NN Number_NNP Number_NNP Number_NNP Manufacturing_NNP 36,548_CD 37,154_CD 20,477_CD Selling_NNP ,_, general_JJ and_CC administration_NN 54,810_CD 55,655_CD 30,765_CD Research_NNP and_CC development_NN 14,808_CD 15,090_CD 9,659_CD 106,166_CD 107,899_CD 60,901_CD 2002 2001 2000_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS m_VBP m_FW m_FW UK_NNP pension_NN schemes_NNS 103_CD 26_CD 6_CD US_NNP pension_NN schemes_NNS 67_CD 70_CD 59_CD Other_JJ overseas_JJ pension_NN schemes_NNS 51_CD 70_CD 31_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 78_CD 57_CD 16_CD Post-employment_NN costs_NNS 40_CD 28_CD 7_CD 339 251 119_CD Analysed_NNP as_IN :_: Funded_VBN dened_VBN benefit_NN hybrid_NN schemes_NNS 149_CD 123_CD 57_CD Unfunded_JJ dened_VBN benefit_NN schemes_NNS 48_CD 11_CD 10_CD Dened_VBN contribution_NN schemes_NNS 24_CD 32_CD 29_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 78_CD 57_CD 16_CD Post-employment_NN costs_NNS 40_CD 28_CD 7_CD 339 251 119_CD The_DT disclosures_NNS below_IN include_VBP the_DT additional_JJ information_NN required_VBN by_IN SFAS_NNP 132_CD ._.
The_DT pension_NN costs_NNS of_IN the_DT UK_NNP ,_, US_NNP and_CC major_JJ overseas_JJ dened_VBN benefit_NN pension_NN plans_NNS have_VBP been_VBN restated_VBN in_IN the_DT following_VBG tables_NNS in_IN accordance_NN with_IN US_NNP GAAP_NNP ._.
Pension_NN costs_NNS in_IN 2002_CD of_IN 12_CD million_CD ,_, 2001_CD 17_CD million_CD ,_, 2000_CD 35_CD million_CD in_IN respect_NN of_IN minor_JJ retirement_NN plans_NNS ,_, which_WDT have_VBP not_RB been_VBN recalculated_VBN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN SFAS_NNP 87_CD ,_, have_VBP been_VBN excluded_VBN ._.
2002 2001 2000_CD The_DT net_JJ periodic_JJ pension_NN cost_NN income_NN for_IN the_DT major_JJ retirement_NN plans_NNS comprised_VBN :_: m_VB m_FW m_FW Service_NNP cost_NN 219 194 119_CD Interest_NN cost_NN 388 351 161_CD Expected_VBN return_NN on_IN plan_NN assets_NNS 470 508 253_CD Amortisation_NNP of_IN prior_JJ service_NN cost_NN 20_CD 15_CD 16_CD Amortisation_NNP of_IN transition_NN obligation_NN 6_CD 9_CD 12_CD Recognised_VBN net_JJ actuarial_JJ gain_NN 3_CD 57_CD 70_CD Net_JJ periodic_JJ pension_NN cost_NN income_NN under_IN US_NNP GAAP_NNP 154_CD 14_CD 39_CD Termination_NN benets_NNS and_CC curtailment_NN costs_NNS 56_CD 27_CD Adjustment_NNP for_IN change_NN in_IN accounting_NN principle_NN 62_CD The_DT major_JJ assumptions_NNS used_VBN in_IN computing_VBG the_DT above_JJ pension_NN cost_NN income_NN were_VBD :_: %_NN pa_CD %_NN pa_CD %_NN pa_NN Rates_NNS of_IN future_JJ pay_NN increases_VBZ 4.25_CD 4.5_CD 4.6_CD Discount_NNP rate_NN 6.0_CD 6.25_CD 6.5_CD Expected_VBN long-term_JJ rates_NNS of_IN return_NN on_IN plan_NN assets_NNS 7.75_CD 8.25_CD 7.0_CD In_IN aggregate_JJ ,_, average_JJ international_JJ plan_NN assumptions_NNS did_VBD not_RB vary_VB signicantly_RB from_IN US_NNP assumptions_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 137_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD 2002_CD 2001_CD Change_NNP in_IN benefit_NN obligation_NN m_NN m_NN benefit_NN obligation_NN at_IN beginning_NN of_IN year_NN 6,372_CD 5,560_CD Adjustment_NNP for_IN change_NN in_IN accounting_NN principle_NN 153_CD Amendments_NNP 24_CD 32_CD Service_NNP cost_NN 219_CD 194_CD Interest_NN cost_NN 388_CD 351_CD Plan_NN participants_NNS contributions_NNS 16_CD 30_CD Actuarial_JJ loss_NN 51_CD 114_CD Benets_NNPS paid_VBD 324_CD 260_CD Acquisition_NNP 326_CD Termination_NN benets_NNS and_CC curtailment_NN costs_NNS 35_CD 2_CD Exchange_NNP 174_CD 23_CD benefit_NN obligation_NN at_IN end_NN of_IN year_NN 6,760_CD 6,372_CD benefit_NN obligation_NN at_IN end_NN of_IN year_NN for_IN pension_NN plans_NNS with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS 6,087_CD 2,995_CD 2002_CD 2001_CD Change_NNP in_IN plan_NN assets_NNS m_VBP m_NN Fair_NN value_NN of_IN plan_NN assets_NNS at_IN beginning_NN of_IN year_NN 5,385_CD 6,452_CD Adjustment_NNP for_IN change_NN in_IN accounting_NN principle_NN 383_CD Actual_JJ return_NN on_IN plan_NN assets_NNS 913_CD 1,106_CD Employer_NN contribution_NN 457_CD 82_CD Plan_NN participants_NNS contributions_NNS 16_CD 30_CD Benets_NNPS paid_VBD 324_CD 260_CD Acquisition_NNP 146_CD Termination_NN benets_NNS and_CC curtailment_NN costs_NNS 3_CD Exchange_NNP 146_CD 41_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN 4,855_CD 5,385_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN for_IN pension_NN plans_NNS with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS 4,741_CD 2,484_CD Plan_NN assets_NNS consist_VBP primarily_RB of_IN investments_NNS in_IN UK_NNP and_CC overseas_JJ equities_NNS ,_, xed_VBN interest_NN securities_NNS ,_, securities_NNS linked_VBN to_TO the_DT UK_NNP Retail_NNP Price_NNP Index_NNP and_CC property_NN ._.
At_IN 31st_CD December_NNP 2002_CD UK_NNP equities_NNS included_VBD 2.1_CD million_CD GlaxoSmithKline_NNP shares_NNS 2001_CD 5.3_CD million_CD shares_NNS with_IN a_DT market_NN value_NN of_IN 25_CD million_CD 2001_CD 91_CD million_CD ._.
2002_CD 2001_CD Funded_VBN status_NN m_NN m_NN Funded_VBN status_NN 1,905_CD 987_CD Unrecognised_JJ net_JJ actuarial_JJ loss_NN 1,932_CD 724_CD Unrecognised_JJ prior_JJ service_NN cost_NN 145_CD 152_CD Unrecognised_JJ transition_NN obligation_NN 29_CD 24_CD Other_JJ 3_CD Net_JJ amount_NN recognized_VBN 201 84 2002 2001_CD Amounts_NNS recognized_VBN in_IN the_DT statement_NN of_IN financial_JJ position_NN consist_VBP of_IN :_: m_VB m_FW Prepaid_FW benefit_NN cost_NN 532_CD 353_CD Accrued_VBN pension_NN liability_NN 331_CD 437_CD Additional_JJ required_VBN liability_NN 1,618_CD 373_CD Intangible_JJ asset_NN 172_CD 36_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 1,446_CD 337_CD Net_JJ amount_NN recognized_VBN 201_CD 84_CD 138_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Post-retirement_JJ healthcare_NN under_IN US_NNP GAAP_NNP The_NNP disclosures_NNS for_IN 2002_CD and_CC 2001_CD are_VBP provided_VBN in_IN relation_NN to_TO the_DT employees_NNS of_IN GlaxoSmithKline_NNP ._.
2002 2001 2000_CD Net_JJ healthcare_NN cost_NN m_FW m_FW m_FW Service_NNP cost_NN 23_CD 15_CD 5_CD Interest_NN cost_NN 53_CD 40_CD 13_CD Amortisation_NNP of_IN prior_JJ service_NN cost_NN 2_CD 3_CD 2_CD Net_JJ healthcare_NN cost_NN 78_CD 52_CD 16_CD The_DT major_JJ assumptions_NNS used_VBN in_IN calculating_VBG the_DT net_JJ healthcare_NN cost_NN were_VBD :_: %_NN pa_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN future_JJ healthcare_NN ination_NN 7.0_CD to_TO 5.0_CD 7.0_CD to_TO 5.0_CD 7.8_CD to_TO 4.9_CD Discount_NNP rate_NN 6.75_CD 7.3_CD 7.2_CD The_DT rate_NN of_IN future_JJ healthcare_NN ination_NN reects_VBZ the_DT fact_NN that_IN the_DT benets_NNS of_IN certain_JJ groups_NNS of_IN participants_NNS are_VBP capped_VBN ._.
2002_CD 2001_CD Change_NNP in_IN benefit_NN obligation_NN m_NN m_NN benefit_NN obligation_NN at_IN beginning_NN of_IN year_NN 788_CD 583_CD Adjustment_NNP for_IN change_NN in_IN accounting_NN principle_NN 13_CD Amendments_NNS 1_CD Service_NNP cost_NN 77_CD 15_CD Interest_NN cost_NN 53_CD 40_CD Plan_NN participants_NNS contributions_NNS 9_CD 2_CD Actuarial_JJ loss_NN 24_CD 202_CD Benets_NNPS paid_VBD 50_CD 31_CD Acquisition_NNP 32_CD Curtailments_NNP 2_CD Exchange_NNP 84_CD 12_CD benefit_NN obligation_NN at_IN end_NN of_IN year_NN 830_CD 788_CD Change_NNP in_IN plan_NN assets_NNS Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN beginning_NN of_IN year_NN Employer_NN and_CC plan_NN participants_NNS contributions_NNS 51_CD 31_CD Benets_NNPS paid_VBD 51_CD 31_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN Funded_VBN status_NN Funded_VBN status_NN 830_CD 788_CD Unrecognised_JJ net_JJ actuarial_JJ loss_NN 230_CD 216_CD Unrecognised_JJ prior_JJ service_NN cost_NN 17_CD 20_CD Other_JJ 8_CD Accrued_VBN post-retirement_JJ healthcare_NN cost_NN 617_CD 584_CD 1_CD %_NN decrease_NN 1_CD %_NN increase_NN The_DT impact_NN of_IN a_DT 1_CD per_IN cent_NN variation_NN in_IN the_DT rate_NN of_IN future_JJ healthcare_NN ination_NN would_MD be_VB :_: m_VB m_FW Effect_NN on_IN total_JJ service_NN and_CC interest_NN cost_NN 9_CD 8_CD Effect_NN on_IN provision_NN for_IN post-retirement_JJ benets_NNS 85_CD 71_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 139_CD 38_CD Principal_NN Group_NNP companies_NNS The_DT following_JJ represent_VBP the_DT principal_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS of_IN the_DT GlaxoSmithKline_NNP Group_NNP at_IN 31st_CD December_NNP 2002_CD ._.
Details_NNS are_VBP given_VBN of_IN the_DT principal_JJ country_NN of_IN operation_NN ,_, the_DT location_NN of_IN the_DT headquarters_NN ,_, the_DT business_NN segment_NN and_CC the_DT business_NN activities_NNS ._.
The_DT equity_NN share_NN capital_NN of_IN these_DT undertakings_NNS is_VBZ wholly_RB owned_VBN by_IN the_DT Group_NNP except_IN where_WRB its_PRP$ percentage_NN interest_NN is_VBZ shown_VBN otherwise_RB ._.
All_DT companies_NNS are_VBP incorporated_VBN in_IN their_PRP$ principal_JJ country_NN of_IN operation_NN except_IN where_WRB stated_VBN ._.
Europe_NNP Location_NNP Subsidiary_NNP undertaking_VBG Segment_NNP Activity_NNP %_NN England_NNP Brentford_NNP GlaxoSmithKline_NNP Services_NNPS Unlimited_NNP plc_NN Ph_NNP ,_, CH_NNP s_VBZ formerly_RB GlaxoSmithKline_NNP Services_NNP plc_NN Brentford_NNP SmithKline_NNP Beecham_NNP plc_NN Ph_NNP ,_, CH_NNP e_LS h_FW r_NN d_SYM m_FW p_FW Greenford_NNP Glaxo_NNP Group_NNP Ltd_NNP Ph_NNP h_VBP Brentford_NNP SmithKline_NNP Beecham_NNP Research_NNP Ltd_NNP Ph_NNP m_NN Brentford_NNP SmithKline_NNP Beecham_NNP Investments_NNPS Ltd_NNP Ph_NNP ,_, CH_NNP f_LS Brentford_NNP GlaxoSmithKline_NNP Research_NNP &_CC Development_NNP Ltd_NNP Ph_NNP r_NN d_SYM Brentford_NNP GlaxoSmithKline_NNP Export_NNP Ltd_NNP Ph_NNP e_SYM Brentford_NNP GlaxoSmithKline_NNP UK_NNP Ltd_NNP Ph_NNP m_FW p_FW Greenford_NNP The_DT Wellcome_NNP Foundation_NNP Ltd_NNP Ph_NNP p_VBP Brentford_NNP Wellcome_NNP Limited_NNP Ph_NNP ,_, CH_NNP h_NNP Brentford_NNP SmithKline_NNP Beecham_NNP SWG_NNP Ltd_NNP CH_NNP e_LS m_FW Brentford_NNP Glaxo_NNP Operations_NNP UK_NNP Ltd_NNP Ph_NNP p_VBP Brentford_NNP Glaxo_NNP Wellcome_NNP International_NNP BV_NNP Footnote_NNP iv_VB Ph_NNP ,_, CH_NNP h_NNP Brentford_NNP Glaxo_NNP Wellcome_NNP Investments_NNP BV_NNP Footnote_NNP iv_VB Ph_NNP ,_, CH_NNP h_NNP Stockley_NNP Park_NNP Glaxo_NNP Wellcome_NNP UK_NNP Ltd_NNP Ph_NNP h_VBP m_FW p_FW Brentford_NNP Stafford-Miller_NNP Ltd_NNP CH_NNP m_FW p_FW Austria_NNP Vienna_NNP GlaxoSmithKline_NNP Pharma_NNP GmbH_NNP Ph_NNP m_NN Belgium_NNP Genval_NNP GlaxoSmithKline_NNP SA_NNP formerly_RB GlaxoSmithKline_NNP Belgium_NNP SA_NNP Ph_NNP m_NN Rixensart_NNP GlaxoSmithKline_NNP Biologicals_NNPS SA_NNP Ph_NNP e_SYM r_SYM d_SYM p_FW Rixensart_NNP GlaxoSmithKline_NNP Biologicals_NNP Manufacturing_NNP SA_NNP Ph_NNP e_SYM p_FW Guernsey_NNP St._NNP Peter_NNP Port_NNP S._NNP B._NNP Insurance_NNP Ltd_NNP Ph_NNP ,_, CH_NNP i_FW Denmark_NNP Ballerup_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP A_NNP S_NNP CH_NNP m_FW formerly_RB SmithKline_NNP Beecham_NNP A_NNP S_NNP Brndby_NNP GlaxoSmithKline_NNP Pharma_NNP a_DT s_PRP Ph_NNP m_FW Finland_NNP Espoo_NNP GlaxoSmithKline_NNP Oy_NNP Ph_NNP m_NN France_NNP Marly_NNP le_FW Roi_NNP GlaxoSmithKline_NNP Sante_NNP Grand_NNP Publique_NNP SAS_NNP CH_NNP m_FW Marly_NNP le_FW Roi_NNP Glaxo_NNP Wellcome_NNP Production_NNP SAS_NNP Ph_NNP m_FW p_FW Germany_NNP Buehl_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP GmbH_NNP &_CC Co_NNP KG_NNP CH_NNP m_FW p_FW Munich_NNP SmithKline_NNP Beecham_NNP GmbH_NNP Ph_NNP m_NN Greece_NNP Athens_NNP GlaxoSmithKline_NNP AEBE_NNP formerly_RB Glaxo_NNP Wellcome_NNP AEBE_NNP Ph_NNP h_VBP m_FW p_FW Hungary_NNP Budapest_NNP GlaxoSmithKline_NNP Kft_NNP Ph_NNP ,_, CH_NNP m_NNP Italy_NNP Verona_NNP GlaxoSmithKline_NNP SpA_NNP Ph_NNP m_NN p_NN r_NN d_SYM Milan_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP SpA_NNP CH_NNP h_VBP m_FW Luxembourg_NNP Mamer_NNP GlaxoSmithKline_NNP International_NNP Luxembourg_NNP SA_NNP Ph_NNP ,_, CH_NNP h_NNP Mamer_NNP GlaxoSmithKline_NNP Luxembourg_NNP SA_NNP Ph_NNP ,_, CH_NNP h_VBD 140_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 38_CD Principal_NN Group_NNP companies_NNS continued_VBD Europe_NNP Location_NNP Subsidiary_NNP undertaking_VBG Segment_NNP Activity_NNP %_NN Netherlands_NNP Zeist_NNP GlaxoSmithKline_NNP BV_NNP Ph_NNP m_NN Zeist_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP BV_NNP CH_NNP m_FW Norway_NNP Oslo_NNP GlaxoSmithKline_NNP AS_NNP Ph_NNP m_NN Poland_NNP Poznan_NNP GlaxoSmithKline_NNP Pharmaceuticals_NNP SA_NNP Ph_NNP m_NN p_NN 97_CD Warsaw_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP sp_NN zoo_NN CH_NNP m_NNP Portugal_NNP Lisbon_NNP Farmaceuticos_NNP Lda_NNP Ph_NNP m_NN formerly_RB Instituto_NNP Luso-Farmaco_NNP Lda_NNP Republic_NNP of_IN Carrigaline_NNP SmithKline_NNP Beecham_NNP Cork_NNP Ltd_NNP Footnote_NNP i_FW Ph_NNP p_FW Ireland_NNP Carrigaline_NNP SmithKline_NNP Beecham_NNP Manufacturing_NNP Ltd_NNP Footnote_NNP i_FW Ph_NNP p_FW Spain_NNP Madrid_NNP Glaxo_NNP Wellcome_NNP ,_, SA_NNP Ph_NNP r_NN m_FW p_FW Madrid_NNP SmithKline_NNP Beecham_NNP SA_NNP Ph_NNP m_NN Sweden_NNP Mlndal_NNP GlaxoSmithKline_NNP AB_NNP Ph_NNP m_NN Switzerland_NNP Muenchenbuchsee_NNP GlaxoSmithKline_NNP Investments_NNP Switzerland_NNP GmbH_NNP Ph_NNP ,_, CH_NNP h_NNP Muenchenbuchsee_NNP GlaxoSmithKline_NNP International_NNP Switzerland_NNP GmbH_NNP Ph_NNP ,_, CH_NNP h_NNP Muenchenbuchsee_NNP Glaxo_NNP Wellcome_NNP International_NNP Footnote_NNP i_FW ,_, v_VB Ph_NNP ,_, CH_NNP h_NNP Muenchenbuchsee_NNP GlaxoSmithKline_NNP AG_NNP formerly_RB Glaxo_NNP Wellcome_NNP AG_NNP Ph_NNP m_NN Zug_NNP Adechsa_NNP GmbH_NNP Ph_NNP e_SYM Turkey_NNP Istanbul_NNP GlaxoSmithKline_NNP Ilaclari_NNP Sanayi_NNP five_CD Ticaret_NNP AS_NNP Ph_NNP m_NN p_NN formerly_RB Glaxo_NNP Wellcome_NNP ISAS_NNP USA_NNP USA_NNP Philadelphia_NNP SmithKline_NNP Beecham_NNP Corporation_NNP Ph_NNP ,_, CH_NNP e_LS h_FW r_NN d_SYM m_FW p_FW s_PRP Pittsburgh_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP LP_NNP CH_NNP m_FW p_FW 66_CD Jersey_NNP City_NNP Block_NNP Drug_NNP Company_NNP ,_, Inc_NNP CH_NNP h_VBP m_FW p_FW Wilmington_NNP GlaxoSmithKline_NNP Financial_NNP Inc_NNP Ph_NNP ,_, CH_NNP f_LS Wilmington_NNP SmithKline_NNP Beecham_NNP Holdings_NNP Corporation_NNP Ph_NNP ,_, CH_NNP h_NNP Wilmington_NNP GlaxoSmithKline_NNP Holdings_NNPS Americas_NNPS Inc_NNP Ph_NNP ,_, CH_NNP h_NNP Americas_NNP Bermuda_NNP Hamilton_NNP GlaxoSmithKline_NNP Insurance_NNP Ltd_NNP Ph_NNP ,_, CH_NNP i_FW Canada_NNP Mississauga_NNP GlaxoSmithKline_NNP Inc_NNP Ph_NNP ,_, CH_NNP m_FW p_FW r_NN Asia_NNP Pacic_NNP Australia_NNP Boronia_NNP Glaxo_NNP Wellcome_NNP Australia_NNP Ltd_NNP Ph_NNP m_FW p_FW Dandenong_NNP SmithKline_NNP Beecham_NNP Australia_NNP Pty_NNP Ltd_NNP Ph_NNP ,_, CH_NNP m_NNP China_NNP Hong_NNP Kong_NNP GlaxoSmithKline_NNP Limited_NNP formerly_RB Glaxo_NNP Wellcome_NNP China_NNP Ltd_NNP Ph_NNP m_NN Tianjin_NNP Sino-American_NNP Tianjin_NNP Smith_NNP Kline_NNP &_CC French_NNP Laboratories_NNPS Ltd_NNP Ph_NNP m_NN 55_CD India_NNP Mumbai_NNP GlaxoSmithKline_NNP Pharmaceuticals_NNP Ltd_NNP Footnote_NNP ii_FW Ph_NNP m_FW p_FW 49_CD Nabha_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP Ltd_NNP formerly_RB SmithKline_NNP CH_NNP m_FW p_FW 40_CD Beecham_NNP Consumer_NNP Healthcare_NNP Ltd_NNP Footnote_NNP ii_FW Malaysia_NNP Selangor_NNP GlaxoSmithKline_NNP Pharmaceutical_NNP Sdn_NNP Bhd_NNP Ph_NNP m_NN Darul_NNP Ehsan_NNP New_NNP Zealand_NNP Auckland_NNP GlaxoSmithKline_NNP NZ_NNP Limited_NNP Ph_NNP ,_, CH_NNP m_NNP Pakistan_NNP Karachi_NNP Glaxo_NNP Wellcome_NNP Pakistan_NNP Ltd_NNP Ph_NNP ,_, CH_NNP m_FW p_FW 79_CD Philippines_NNPS Manila_NNP Glaxo_NNP Wellcome_NNP Philippines_NNPS Inc_NNP Ph_NNP m_NN Singapore_NNP Singapore_NNP Glaxo_NNP Wellcome_NNP Manufacturing_NNP Pte_NNP Ltd_NNP Ph_NNP p_VBP Singapore_NNP GlaxoSmithKline_NNP Pte_NNP Ltd_NNP formerly_RB Glaxo_NNP Wellcome_NNP Asia_NNP Pacic_NNP Pte_NNP Ltd_NNP Ph_NNP m_NN South_NNP Korea_NNP Seoul_NNP GlaxoSmithKline_NNP Korea_NNP Ph_NNP m_FW p_FW Taiwan_NNP Taipei_NNP Glaxo_NNP Wellcome_NNP Taiwan_NNP Ltd_NNP Ph_NNP m_NN p_NN Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 141_CD 38_CD Principal_NN Group_NNP companies_NNS continued_VBD Japan_NNP Location_NNP Subsidiary_NNP undertaking_VBG Segment_NNP Activity_NNP %_NN Japan_NNP Tokyo_NNP GlaxoSmithKline_NNP KK_NNP Ph_NNP m_NN p_NN r_NN 85_CD Kobe_NNP Block_NNP Drug_NNP Company_NNP Japan_NNP Inc_NNP CH_NNP m_FW Latin_NNP America_NNP Argentina_NNP Buenos_NNP Aires_NNP GlaxoSmithKline_NNP Argentina_NNP SA_NNP Ph_NNP ,_, CH_NNP m_FW p_FW Brazil_NNP Rio_NNP fide_VBD Janeiro_NNP GlaxoSmithKline_NNP Brasil_NNP Lda_NNP formerly_RB SmithKline_NNP Beecham_NNP Brasil_NNP Lda_NNP Ph_NNP ,_, CH_NNP m_FW p_FW Colombia_NNP Bogota_NNP GlaxoSmithKline_NNP Colombia_NNP SA_NNP Ph_NNP ,_, CH_NNP m_NNP Mexico_NNP Mexico_NNP City_NNP GlaxoSmithKline_NNP Mexico_NNP ,_, SA_NNP fide_VBD CV_NNP Ph_NNP ,_, CH_NNP m_FW p_FW formerly_RB Glaxo_NNP Wellcome_NNP Mexico_NNP ,_, SA_NNP fide_VBD CV_NNP Puerto_NNP Rico_NNP San_NNP Juan_NNP GlaxoSmithKline_NNP Puerto_NNP Rico_NNP Inc_NNP Ph_NNP m_VBD Hato_NNP Rey_NNP SB_NNP Pharmco_NNP Puerto_NNP Rico_NNP Inc_NNP Ph_NNP p_NN Venezuela_NNP Caracas_NNP GlaxoSmithKline_NNP Venezuela_NNP CA_NNP formerly_RB Glaxo_NNP Wellcome_NNP CA_NNP Ph_NNP m_NN p_NN Middle_NNP East_NNP Africa_NNP Egypt_NNP Cairo_NNP Glaxo_NNP Wellcome_NNP Egypt_NNP SAE_NNP Ph_NNP m_FW p_FW 90_CD South_NNP Africa_NNP Midrand_NNP GlaxoSmithKline_NNP South_NNP Africa_NNP Pty_NNP Ph_NNP m_NN p_NN formerly_RB Glaxo_NNP Wellcome_NNP South_NNP Africa_NNP Pty_NNP Ltd_NNP Johannesburg_NNP SmithKline_NNP Beecham_NNP Consumer_NNP Healthcare_NNP Pty_NNP Ltd_NNP CH_NNP m_FW p_FW USA_NNP Location_NNP Associated_NNP undertaking_VBG %_NN USA_NNP Teterboro_NNP ,_, Quest_NNP Diagnostics_NNPS ,_, Inc._NNP ._.
Footnote_NN iii_FW 23_CD New_NNP Jersey_NNP Footnotes_NNP i_FW Exempt_NNP from_IN the_DT provisions_NNS of_IN Section_NN 7_CD of_IN the_DT Companies_NNS Amendment_NNP Act_NNP 1986_CD Ireland_NNP ii_FW Consolidated_NNP as_IN a_DT subsidiary_NN undertaking_NN in_IN accordance_NN with_IN Section_NN 258_CD 4_CD a_DT of_IN the_DT Companies_NNS Act_NNP on_IN the_DT grounds_NNS of_IN significant_JJ inuence_NN iii_FW This_DT holding_NN was_VBD reduced_VBN to_TO 21_CD per_IN cent_NN in_IN February_NNP 2003_CD ,_, following_VBG Quests_NNP acquisition_NN of_IN Unilab_NNP Corporation_NNP iv_NNP Incorporated_NNP in_IN the_DT Netherlands_NNP v_NNP Incorporated_NNP in_IN the_DT Republic_NNP of_IN Ireland_NNP ._.
directly_RB held_VBN wholly_RB owned_VBN subsidiary_NN of_IN GlaxoSmithKline_NNP plc._NNP ._.
Business_NNP segment_NN :_: Ph_NNP Pharmaceuticals_NNP ,_, CH_NNP Consumer_NNP Healthcare_NNP Business_NNP activity_NN :_: d_LS development_NN ,_, e_SYM exporting_VBG ,_, f_SYM finance_NN ,_, h_VBP holding_VBG company_NN ,_, i_FW insurance_NN ,_, m_NN marketing_NN ,_, p_NN production_NN ,_, r_NN research_NN ,_, s_VBZ service_NN Full_NNP details_NNS of_IN all_DT Group_NNP subsidiary_NN and_CC associated_VBN undertakings_NNS will_MD be_VB attached_VBN to_TO the_DT companys_NNS Annual_JJ Return_NN to_TO be_VB led_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
